lipid metabolism, has a strong antiatherosclerotic effect. There is an assumption that apoE has allele-specific antioxidant abilities. The study found a reduced level of ApoE in the blood serum of children with JIA compared with the control group. During adalimumab treatment, a remission of the disease was achieved. According to the results of a second study of the indicators ApoA, ApoB and ApoE, 6 months after the start of biological therapy, an improvement in these indicators was found. Thus, the content of ApoA increased to 118.9 [113.2; 129.4] mg / dl, and the ApoB content decreased to 33.6 [20.8; 49.4] mg / dl. An increase in ApoE to reference values was also noted.

Conclusion: The results of the study indicate the likelihood of a reduction in cardiovascular risk in children with JIA in the treatment of adalimumab.

Disclosure of Interest
None declared

P123
Vaccination coverage in a cohort of patients with juvenile idiopathic arthritis: a single-centre experience
R. Alfani, R. Naderi, A. Vincenzi, F. Viscogliosi, A. Paonessa, A. Catzola, M. Alessio
Pediatric Rheumatology Unit, Mother and Child Department, University of Naples Federico II, Naples, Italy

Introduction: Juvenile idiopathic arthritis (JIA) represents the most common pediatric chronic rheumatic disease. Children with JIA present an increased risk of infections, due to the immune-regulatory effects of disease modifying antirheumatic drugs (DMARDs); many of these infections are vaccine-preventable. Nevertheless, suboptimal vaccinations rates are reported in children with JIA.

Objectives: To evaluate vaccination coverage in a population of children with JIA and to describe the prevalence of the adverse events following immunization (AEFIs) in our cohort.

Methods: A single-centre retrospective study was conducted by reviewing medical records of all JIA patients, diagnosed according to ILAR criteria, admitted to the Pediatric Rheumatology Unit of University of Naples Federico II from January to December 2019. Parents were asked to provide the vaccinations records in form of the vaccination booklet. The occurrence of AEFIs was explored by telephone interviews.
Results: Data were obtained by 121 out of the 212 (57.1%) invited patients (90 females; median age: 12.2 years, interquartile range 9.25-15). The most frequent diagnosis was oligoarticular JIA (69.4%), followed by polyarticular (21.5%), systemic (8.3%), and psoriatic (0.8%) subtypes. Vaccination status was complete in 65 out of 121 of patients (53.3%); anti-diphtheria-tetanus-pertussis (DTP) and anti-polioymelitis was complete in 76% and 72% of eligible cases, respectively; anti-hepatitis B virus in 99.2%; anti-haemophilus influenzae b in 97.5%; anti-measles-mumps-rubella (MMR) 69.4%. The most frequently omitted vaccine is MMR. There was no association between vaccination coverage and age of onset of JIA (p=0.524), gender (p=0.885) or JIA subtype (p=0.298).

The vaccination status differed in a statistically significant manner with respect to JIA treatment: vaccination coverage was complete in 75% (21/28) of patients who underwent solely nonsteroidal anti-inflammatory drugs and/or intra-articular injections of steroids compared to in 68.4% (26/38) of patients treated with methotrexate (MTX) and in 32.7% (18/55) of patients who underwent a biological DMDARs (bDMARDs) treatment (p<0.001). In particular, in the group of patients treated with bDMARDs, coverages for DTP and MMR were 67.3% and 49.1%, respectively.

In regard to non-mandatory vaccinations, 67 patients (55.4%) received the pneumococcal vaccine, 56 meningococcal C (46.3%), 14 meningococcal conjugate (ACW135Y) (11.6%), 6 meningococcal B vaccine (5%). The 15.7% of our population received at least one dose of influenza vaccine. 47.2% of eligible female patients did not receive any human papillomavirus (HPV) vaccine dose, 3.8% 1 dose, 32.1% 2 doses, and 17% 3 doses. 37 AEFls were reported (30.6%): 11 were local reactions (9.1%), 11 fever episodes (9.1%), 2 sleepiness (1.7%). In 3 cases (2.5%), the onset of JIA occurred approximately one month after the vaccine administration and was classified as a ‘coincidental event’, according to WHO AEFl classification.

Conclusion: In our cohort, 46.3% of patients presented an incomplete vaccination status and a low coverage for non-mandatory, though recommended, vaccinations was observed. No serious AEFls were reported. Patients treated with bDMARDs showed the lowest vaccination coverage for live-attenuated vaccines, as expected, but also for non-live vaccines, resulting in a major risk for serious diseases preventable by vaccines. Further communication strategies are therefore needed.

Disclosure of Interest
None declared

P124 Minimal sedation/anxiolysis in children with juvenile idiopathic arthritis undergoing intrarticular injection of corticosteroids
S. M. Orsi,1 M. Gattinara,2 F. Baldo1,3, S. Carbognolo1,3, A. Petaccia1, C. Agostoni1,3, G. Filocamo1, R. Cimaz2, S. Lanni1 on behalf of on behalf of the Pediatric Rheumatology Group of the Milan Area (PRAGMA)
1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; 2ASST G. Pini-CTO; 3University of Milan, 4Department of Clinical Sciences and Community Health, and RECAP-RE, University of Milan, Milan, Italy

Correspondence: S. M. Orsi
Pediatric Rheumatology 2020, 18(Suppl 2):P124

Introduction: Intrarticular corticosteroid injections (IACI) are widely used in the management of patients with juvenile idiopathic arthritis (JIA). General anesthesia can be avoided in case of a small number of joints to inject or in older children. However, pain and anxiety may reduce the patient compliance to IACI, and may compromise the accuracy of the procedure. In order to overcome such problems, the use of appropriate methods of pain and anxiety control is advisable. Accuracy of the procedure. In order to overcame such problems, the use of appropriate methods of pain and anxiety control is advisable.

Objectives: To assess the effectiveness and satisfaction of patients undergoing IACI with the use of topical numbing agent (prilocaine+lidocaine) to the skin over the injection site. Another group of patients (group B) were treated under minimal sedation (Ketorolac/Tramadol or Morphine + Midazolam). The physician was asked to record the degree of motion and pain of the patient during the procedure and the patient (or parents for patients aged less than 4 years) was asked to report the degree of pain and satisfaction on a Visual Analogue Scale (VAS) from 0 to 10.

Results: Twenty-seven patients were enrolled for a total of 30 procedures, 17 and 13 of them in group A and B, respectively. The median age at the procedure was 10 years for group A and 11 years for group B. For group A median pain scores for patients, parents and physicians were 2, 2 and 1.5, respectively. In patients of group B who underwent the IACI under Ketorolac/Tramadol the median pain scores for patients, parents and physicians were 3, 5.25 and 2.5, whereas in patients treated with Morphine median pain scores were 6, 6 and 2, respectively. Overall, we found that pain as reported by the patient/parent were higher with increase in the number of sites injected (and, consequently, duration of procedure) and age of patient. Amount of motion during procedures was overall negligible. The majority of patients/parents was satisfied for the procedures. Only 2 patients treated with Midazolam had psychomotor agitation during the IACI.

Conclusion: IACI in a small number of sites without the use of general anesthesia is well tolerated by patients. The level of pain perceived free of our patients irrespective of the power of the painkiller used, but seems to correlate with the duration of the procedures. It is possible that, in the paediatric age, the psychoemotional component seems to be decisive, with a progressive loss of tolerance with the increase in the number of injected joints.

Disclosure of Interest
None declared

P125 The effect of anti-TNF on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach
Y. Butbul1, A. Keinan2, M. F. Hartmann3, S. A. Wudy4, D. Tiosano5
1Pediatric Rheumatology Service, Ruth Rappaport Children’s Hospital, Rambam Medical Center, Haifa; 2Child and adolescent psychiatry unit, Ha’emek medical center; Afula, Israel; 3Pediatric Endocrinology & Diabetology, Laboratory for Translational Hormone Analytics in Pediatric Endocrinology, Steroid Research and Mass Spectrometry Unit; 4Pediatric Endocrinology & Diabetology, Laboratory for Translational Hormone Analytics in Pediatric Endocrinology, Steroid Research and Mass Spectrometry Unit, Center of Child and Adolescent Medicine , Justus Liebig University, Giessen, Germany; 5Pediatric endocrinology unit, Ruth Rappaport Children’s Hospital, Rambam Medical Center, Haifa, Israel

Correspondence: Y. Butbul
Pediatric Rheumatology 2020, 18(Suppl 2):P125

Introduction: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and is a major cause of functional disability. The chronic inflammatory synovitis and systemic features of JIA are mediated by cytokine products of an activated immune system. Decreased production of adrenal androgens and cortisol production has been observed in RA. Recent studies showed that urinary free cortisol levels in active JIA patients are significantly lower than in remission periods and control groups. Among the cytokines that are involved in the acute phase of the disease, TNFα has a major role.

Objectives: The aim of our study was to evaluate the impact of anti-TNFα on adrenal steroid metabolism by evaluating urinary adrenal steroid hormone metabolites by using GC-MS analysis before and after Etanercept treatment.

Methods: Eleven JIA patients were enrolled into the study, eight females and three males, average age was 12±6.2 years (range 3 to 21 years). The average disease duration was 6.3±5.2 years (range 1.6-18 years) and the duration of Etanercept treatment was 3 ±2.8 years (range 6 months to 10 years). The patients were treated once weekly with Etanercept injection (0.8 mg/kg). Urine was collected 3 times (just before and +1,+3 days following Etanercept injection)
for GC-MS analysis of the steroid hormone metabolites age and sex-matched healthy controls were matched to each patient. Patients were excluded if they were treated with corticosteroids in the preceding 3 months.

Results: Of the 35 metabolites measured, 23 were significantly lower in JIA patients before the Etanercept treatment compared to the healthy control group. One day after the injection only 5 metabolites were still significantly lower in the JIA patients and all the other 30 metabolites normalized and were similar to the control group. Urine metabolite ratios reflecting CYP21 and 11β-HSD2 enzymatic activity indicate that these two enzyme activities were lower in JIA patients. The slowest recoveries noted were for metabolites of DHEAS and OH pregnenolone.

Conclusion: Prior to Etanercept treatment almost all urine adrenal metabolites were significantly lower mainly due to the active inflammatory process. Immediately after the treatment many metabolites raised to normal values as in the control group. The two adrenal enzymes that were found to be affected in JIR are CYP21 and 11β-HSD2. BlockingTN alpha immediately restore adrenal function in JIA.

Disclosure of Interest
None declared

P126
Translation and validation of the MTX intolerance severity score questionnaire for Portuguese version in BRAZIL in juvenile idiopathic arthritis
A.C. Londe1, R. Mariní, S. Appenzeller2
1Child and Adolescent Health Graduate Program; 2Pediatrics, UNICAMP, Campinas, Brazil

Correspondence: S. Appenzeller
Pediatric Rheumatology 2020, 18(Suppl 2):P126

Introduction: Methotrexate Intolerance Severity Score Questionnaire, MISS, is the tool in patients with juvenile idiopathic arthritis (JIA). During therapy, there are frequent reports of discontinuation of MTX, a drug classified as the first choice for the treatment of JIA, either by physicians or patient’s own conduct.

Objectives: Translate and validate the MTX Intolerance Severity Score questionnaire (MISS) to Portuguese of Brazil in patients with JIA.

Methods: The MISS was translated into Portuguese following the “Guidelines for the process of cross-cultural adaptation of self-report measures”. The MISS consists of 4 domains: stomachache, nausea, vomiting, and behavioral complaints. The new version was tested on patients with JIA and relatives, both on the same day. The psychometric properties were analyzed according to the Consensus based Standards for the Selection of Health Measurement Instruments (CO MIN I), analyzing acceptability for each item. Internal consistency using Cronbach’s alpha coefficient and reproducibility assessed by Kappa. We plot the ROC curve to evaluate the discriminant validity of the MISS compared to gold standard (clinical interview).

Results: We included 246 subjects to answer the MISS questionnaire, of these, 138 with JIA in use for least 3 months of MTX (oral/parenteral) and 108 relatives of children. All the subjects answered the MISS with less than 5 minutes and with no difficult of understanding it. The internal consistency of MISS had a Cronbach’s considered good, with coefficient 0.88 (patients) and 0.79 (relatives). The reproducibility between the test (40 patients) and the retest done after 15 days (36 patients - less than 1% of missing data) was almost perfect (kappa >0.8), except item restless (kappa = 0.54). We didn’t use test and retest in relative group. Reliability between patients and families was almost perfect (kappa > 0.8), except stomachache by anticipatory (weak kappa = 0.30), stomachache by association (kappa = 0.54) and restless (kappa = 0.45) when taking MTX; both values considered with moderate kappa. We plot the ROC curve and result was 0.90 (95% CI 0.86 – 0.94) for the JIA patients. We found a cutoff score of 6 denoted the best sensitivity (84% ICC 72.9-89.9) and specificity (80% ICC 70.6-91.4) for the MISS. If we considered total sample (JIA and relative), the result was 0.89 (95% CI 0.80 – 0.95) with score of 6 points denoted sensitivity 82% and specificity 79%. The original MISS version found cutoff MISS score 5 and 6 during the validation, we found a good concordance between both points, with a kappa 0.73 and 0.79, respectively; but the score 5 obtained a sensitivity 77% and specificity with 79% in the ROC curve. Finally, we considered MISS with a score 6 points through of these statistic data and comparing with other studies that used the MISS to measure the MTX intolerance in the literature. We found 96 intolerant patients (69.0%) and 42 tolerant patients (30.4%) of MTX. In intolerant, the median score MISS was 12.82 points SD±5.47, whereas tolerant were 2.42 points SD±1.75. The median score MISS for these both groups were 6.0 points SD±5.6 in 246 subjects.

Conclusion: MISS is a viable and practical tool for the routine clinical, good detection between intolerant and tolerant in MTX treatment in JIA. Children or relatives can complete the questionnaire with no discrepancy.

Disclosure of Interest
None declared

P127
Anti-adalimumab antibodies in patients with juvenile idiopathic arthritis: prevalence rate and clinical relevance
T. Marushiko1, Y. Holubovska1, O. Onurevi1, Y. Marushko2
1Pediatrics-2, Shupyk National Medical Academy of Postgraduate Education; 2Pediatrics of postgraduate education, Bogomolets National Medical University, Kyiv, Ukraine

Correspondence: T. Marushiko
Pediatric Rheumatology 2020, 18(Suppl 2):P127

Introduction: Patients with juvenile idiopathic arthritis (JIA) receive adalimumab treatment. Adalimumab is a monoclonal antibody that blocks TNF-α and is structurally and functionally similar to human IgG1. Nevertheless, there are reports of the development of anti-drug antibodies. The production of these antibodies may be associated with treatment failures (a decrease in the effectiveness of therapy or drug inefficiency that developed over time) and hypersensitivity reactions. To our knowledge, there is currently limited information on the availability of adalimumab antibodies (AAA) in patients with JIA.

Objectives: to evaluate the prevalence rate and the clinical significance of AAA in patients with JIA on adalimumab treatment.

Methods: 26 patients with JIA were examined, 17 of whom had the oligoarticular form of the disease, 7 of them with uveitis, and 9 patients had the polyarticular form of the disease, 3 of them with uveitis. Among them, there were 13 (50%) girls and 13 (50%) boys. The mean age was 11.0 ± 3.4 years; the mean disease duration was 4.1 ± 2.2 years. Patients received adalimumab (at least 1 year before the study) with concomitant administration of methotrexate (MTX) or adalimumab only – 13 children who did not receive MTX for at least 3 months prior to the study as a result of either adverse events of MTX administration (5 patients) or permanent drug remission (8 patients). Before starting adalimumab therapy, all participants were treated with MTX. The mean duration of adalimumab treatment for these patients was 1.8 ± 1.0 years. The serum AAA level of antibodies was determined using the enzyme immunoassay (EIA) method. This method determines both free and bound antibodies to adalimumab at reference values less than 10 AU/mL a and was used every 2 weeks for 3 months. The values were presented as mean ± standard deviation. Data processing and analysis were carried out using Pearson’s chi-squared test and Spearman’s correlation test.

Results: 8 (31%) of the 26 patients enrolled in the study had AAA-positive results. The mean AAA level in positive patients was 40.8 ± 20.1 AU/mL. Further disease relapses tended to occur significantly more often in AAA-positive patients than in AAA-negative ones (χ2 = 5.46, p = 0.019). Thus, 5 of 8 (62.5%) AAA-positive children had at least 1 exacerbation of the disease within 3 months, compared with 3 out of 18 (16.7%) in AAA-negative ones. 7 out of 8 (87.5%) AAA-positives did not take MTX for at least 3 months compared to 6 out of 18 (33.3%) in AAA-negative ones. Thus, AAs are found to be significantly more frequent without concomitant administration of MTX in the treatment of JIA (χ2 = 6.5, p = 0.01). There were no observed adverse events or side effects during adalimumab therapy. No significant correlation was found between the presence of AAA and sex,
JIA form, uveitis presence, antinuclear antibodies high titer, rheumatoid factor, or disease duration.

**Conclusion:** We assume it would be appropriate to evaluate the AAA level in patients with JIA on adalimumab therapy, especially in the case of MTX withdrawal and the disease exacerbation. This gives a valuable advantage for further therapy enhancement.

**Disclosure of Interest**
None declared

---

**P128** Establishment of a registry for juvenile idiopathic arthritis patients in South Australia: focus on patient-reported outcome and experience measures (PROMS/PREMS)

M. Min1, Y.C. Trottie1, C. Boros1

1University of Adelaide Discipline of Paediatrics, Women’s and Children’s Hospital, 2Faculty of Health and Medical Sciences, University of Adelaide; 3Women’s and Children’s Hospital Department of Rheumatology, Adelaide, Australia

**Correspondence:** M. Min

Pediatric Rheumatology 2020, 18(Suppl 2):P128

**Introduction:** Patient outcomes and experiences are key components in the measurement of overall health outcomes in Juvenile Idiopathic Arthritis (JIA) and can be measured by validated patient-reported outcome and experience measures (PROMs and PREMs) questionnaires. There is little information in the published literature regarding the relationship between PROMs and PREMs and clinical disease activity in JIA.

**Objectives:** The objective was to establish a registry for JIA patients in South Australia (SA) and to understand the relationship between PROMs and PREMs and clinical disease activity.

**Methods:** JIA patients attending the Paediatric Rheumatology outpatient clinic at Women’s and Children’s Hospital were invited to participate. After obtaining written informed consent, data regarding demographics, JIA subtype, disease onset, investigation results, medications used and the clinical JIA Disease Activity Score (cJADAS) were documented. Patients/carers completed questionnaires at each clinic visit, namely the Childhood Health Assessment Questionnaire (CHAQ), the Quality of My Life (QoML) and the British Society for Paediatric and Adolescent Rheumatology (BSPAR) PROMs and PREMs Questionnaire. Disease activity states were defined based on cJADAS. Descriptive statistics, Spearman correlations and Kruskal-Wallis tests were used to analyse the data as appropriate.

**Results:** A hundred and twelve patients were recruited (mean age 11.7 ± 4.4 years) in this registry, including n=11 newly diagnosed JIA (9.8%) and n=75 female (67%). The median disease duration was 3.6 years (interquartile range (IQR) 1.2-7.7). N=40, 35.7% patients had oligoarticular onset (oligo) and n=72, 64.3% had polyarticular onset (poly) disease. At the time of recruitment, the median cJADAS for oligo JIA was 0.5 (IQR 0.0-4.7) and for poly JIA was 1.9 (IQR 0.1-5.0). The median quality of life (QoL) was 7.9 (IQR 6.9-9.3) for oligo and 7.6 (IQR 6.4-8.9) for poly JIA. Functional ability was excellent, with a median CHAQ score of 0.1 (IQR 0.0-0.6) for oligo and 0.1 (IQR 0.0-0.7) for poly JIA. Among those patients with established disease (n=101/112, 90.2%), n=20/33, 60.6% of oligo JIA had clinically inactive disease (cJADAS<1), whereas only n=28/88, 41.2% of poly JIA had cJADAS<1.

 Patients with higher cJADAS reported lower QoL (p<0.001) and lower health-related QoL (HRQoL). QoL affected by health or illness (p<0.001). In subgroup analysis, these associations remained significant for oligo and poly JIA. There was a statistically significant positive correlation between CHAQ score and cJADAS (p=0.018 for oligo, p<0.001 for poly), visual analogue pain score and cJADAS (p<0.001 for oligo, p<0.001 for poly).

**Conclusion:** We have successfully commenced the development of a JIA registry in SA and have shown a direct relationship between clinical disease activity and PROMs, such as QoL, HRQoL, CHAQ score and PROM items for our JIA patients.

**Disclosure of Interest**
None declared
Table 1 (abstract P129). Early Risk Factors and The Course Of Juvenile Idiopathic Arthritis

| Closed-ended Questions                                  | Positive answers, n (%) | JADAS, (p) | JADI, (p) | Remission, (p) | Relapse Rate, (p) |
|---------------------------------------------------------|-------------------------|-----------|-----------|---------------|-----------------|
| Have you ever used a cigarette during pregnancy?       | 41 (24)                 | 0.20      | 0.72      | 0.13          | 0.63            |
| Have you had a major illness during pregnancy?         | 14 (8.2)                | 0.2       | 0.4       | 0.97          | 0.92            |
| Did you take any medication during pregnancy?          | 8 (4.7)                 | 0.14      | 0.41      | 0.95          | 0.54            |
| Has the child ever breastfed?                          | 165 (96.5)              | 0.76      | 0.43      | 0.05          | 0.94            |
| Has the child fed with cow’s milk before 12 months of age? | 21 (12.3)              | 0.50      | 0.36      | 0.54          | 0.01            |
| Has the child ever been fed with formula?              | 85 (49.7)               | 0.11      | 0.22      | 0.59          | 0.86            |
| Is the child’s immunization in line with the vaccination schedule? | 155 (90.6)             | 0.63      | 0.92      | 0.10          | 0.24            |
| Has the child gone to preschool?                       | 84 (49.1)               | 0.77      | 0.42      | 0.008         | 0.005           |
| Is there any smoking indoors near the child?           | 107 (62.6)              | 0.11      | 0.71      | 0.80          | 0.93            |

P130

Articular and extra articular manifestations in JIA patients during transition

D. P. de Souza1, R. Marini1, S. Appenzeller2
1 UNICAMP, Campinas, Brazil; 2 Medicine, UNICAMP, Campinas, Brazil

Correspondence: S. Appenzeller
Pediatric Rheumatology 2020, 18(Suppl 2):P130

Introduction: Juvenile idiopathic arthritis (JIA) constitutes the most common rheumatic disease in childhood. Few studies have evaluated the prevalence of activity in patients with JIA when they reach adulthood and how the presence of activity influences a transition.

Objectives: To evaluate the frequency of patients with JIA who reach 18 years of age with joint and extra articular activity.

Methods: A cross-sectional, descriptive study was conducted, including patients with JIA, aged 18 years or older. The variables studied were current age, sex, subtype of the disease and presence of articular and extra articular activity at 18 years old. Disease activity was evaluated by JADAS 78 and remission by preliminary criteria by Wallace.

Results: One hundred and thirty JIA patients were included, 77 (59.24%) of the female sex. Of these, 19 (14.62%) had the systemic form, 25 (19.3%) Oligoarticular form, 19 (14.62%) RF + polyarthritis, 42 (32.3%) FR-Polyarthritis, 5 (3.85%) Psoriatic arthritis, 17 (13.15%) Enthesitis-Associated Arthritis and 3 (2.35%) Undifferentiated arthritis. Of the 130 patients, 89 (68.4%) were inactive at the age of 18. 41 (31.6%) had joint activity and 26 (20%) active uveitis at age 18. No association between subtype of the disease, age of disease-onset, treatment and immunological features were associated with remission at age of 18.

Conclusion: Juvenile rheumatologic diseases frequently continue in adulthood requiring complex regimens of drug treatment, psychological support and complementary therapies. Our data showed that 32% of patients with JIA reached adulthood with disease activity and 20% of the patients had active uveitis, which warns of the vulnerability of young adults with JIA and the importance of a Coordinated Interdisciplinary Transition Program, focusing on orientation and education, patient satisfaction, quality of life and outcomes of the disease.

Disclosure of interest
None declared

P131

Adalimumab trough concentrations are associated with treatment response in patients with juvenile idiopathic arthritis

M. Doeleman1, S. De Roock2, M. El Amrani3, E. van Maarseveen2, N. Wulfraat4, J. Swart4
1 Paediatric Immunology and Rheumatology; 2 Clinical Pharmacy, University Medical Centre Utrecht (UMCU), Utrecht, Netherlands

Correspondence: M. Doeleman
Pediatric Rheumatology 2020, 18(Suppl 2):P131

Introduction: Immunogenicity and low trough concentrations have been associated with adalimumab treatment failure in several studies of paediatric inflammatory diseases, indicating the possible value of therapeutic drug monitoring (TDM). Adalimumab efficacy may be improved by changing dose or treatment intervals based on drug concentrations. However, lack of standardization, assay heterogeneity, and paucity of research hinder the implementation of TDM in clinical practice.

Objectives: To assess the relationship of trough concentrations, immunogenicity and adalimumab response in paediatric patients with JIA.

Methods: Monocentric cohort study of patients ≤18 years with JIA treated with adalimumab due to active arthritis. Clinical data and plasma samples were collected during routine follow-up. Adalimumab trough concentrations were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Anti-adalimumab antibodies were measured in samples with trough concentrations ≤5µg/l. Disease activity was evaluated using the clinical Juvenile Arthritis Disease Activity Score with 71 joint count (cJADAS71). Response to adalimumab was defined as at least 50% reduction of disease activity within 3 months of therapy followed by clinical inactive disease or minimal disease activity after 6 months. The latter was defined as cJADAS71 ≤1.5 and ≤2.5, for oligoarthritis and polyarthritis, respectively, or an active joint count equal to zero when cJADAS71 was unavailable.

Results: 36 adalimumab trough samples were available from 35 JIA patients. Although there was no significant difference in median adalimumab dose, trough concentrations were significantly lower in patients with secondary failure compared to primary failure or an adequate adalimumab response (p-values <0.01). In addition, there were 11 samples with trough concentrations ≤5µg/l, 9 in the group with secondary failure and 2 in the group with adequate adalimumab response (Table 1).

Conclusion: Adalimumab trough concentrations were significantly lower in JIA patients with secondary failure compared to primary failure or an adequate response to adalimumab. Anti-adalimumab antibodies were present in 8 out of 11 samples with trough concentrations ≤5µg/l. Adalimumab trough concentration measurements may identify JIA patients that would benefit from increased doses or shorter treatment intervals. In addition, JIA patients with primary failure and adequate adalimumab trough concentrations may respond better to biologic agents with other therapeutic targets. Although biologic agents have improved disease outcome of patients with JIA,
concentration measurements using reliable and cost-effective methods, such as LC-MS/MS, could further improve efficacy of biologic agents and guide treat-to-target strategies.

Disclosure of Interest
None declared

Table 1 (abstract P131). Characteristics of included JIA patients

| Responders | Primary failure | Secondary failure |
|------------|-----------------|-------------------|
| Patients, n | 16              | 8                 | 12                 |
| MTX, n (%)  | 12 (75)         | 7 (88)            | 5 (42)             |
| MTX dosage (mg/m²/week) | 6.7 (5.3-12.3)  | 12.1 (7.7-12.8)  | 7.3 (5.3-8.4)      |
| ADA dosage (mg/kg/week) | 0.34 (0.31-0.4) | 0.35 (0.31-0.4)  | 0.38 (0.27-0.53)   |
| ADA concentration (mg/l) | 14.94 (10.31-16.19) | 13.37 (10.85-15.99) | 1 (1-5.3)         |
| ADA-Ab-positive | 1/2             | 2 (2-5)           | 1 (1-3)            |
| AIC*        | 0 (0-0)         | 2 (2-5)           | 1 (1-3)            |
| cJADAS71*   | 0.2 (0-0.4)     | 5.5 (3.9-9.2)     | 6.5 (4.9-2)        |

*Significant difference, p-values <0.01. † cJADAS71 was available for 10/16 patients with adequate response, 7/8 with primary failure, and 11/12 with secondary failure. Continuous data are presented as median (interquartile range); ADA: adalimumab; ADA-Ab: anti-drug antibody; AIC: active joint count

P132
Comorbidities in juvenile idiopathic arthritis - important to evaluate patient mental health
E. Berthold1,2, A. Dahlberg1, B. Månsson1, A. Jöud4, R. Kahn2,3
1Department of clinical science Lund, Division of Rheumatology, Lund University; 2Wallenberg Centre for Molecular Medicine; 3Department of clinical science Lund, Division of Pediatrics, Lund University; 4Department of Laboratory Medicine, Lund University, Division of Occupational and Environmental medicine, Lund, Sweden

Introduction: The role of comorbid disease among children with juvenile idiopathic arthritis (JIA) differ, and while the evidence for malignancy is inconclusive (1-5), there seems to be an increased prevalence of comorbid depressive and/or anxiety disorders (6) as well as an increased risk for other autoimmune diseases i.e. type 1 diabetes mellitus (DM1), hypothyroidism and coeliac disease (CD) (7-9).

Objectives: To study the long-term occurrence of comorbid malignancy, psychiatric and autoimmune disease in JIA in a population-based cohort of children with a validated diagnosis of JIA collected over nine years.

Methods: The study cohort comprised of 252 validated cases of JIA diagnosed 2002-2010 in Skåne (10), the southernmost region of Sweden (population 1.24 million; 17.6% aged <16 years, year 2010). ICD-codes registered 1998-2019 for malignant tumours including hematologic malignancies (C00-C97), depression and anxiety disorders (F32, F33, F34.1, F41) and the autoimmune conditions DM1 (E10), hypothyroidism (E03) and CD (K90.0) were collected from the Skåne Health-care Register. Data is descriptively presented as percentage of comorbid disease in the cohort.

Results: No cases of malignant disease were found. Depression or anxiety occurred in 19.8% of the cohort. DM1 was present in 2.8% of the cohort. 5.6% of the patients had comorbid hypothyroidism; no case was due to exogenous substances or complication after infection. CD occurred in 5.2% of the cohort. (Table 1).

Conclusion: In all, 1/5 of the individuals with JIA in this validated population-based cohort were diagnosed with either depression and/or anxiety disorder over a period of 22 years. The presence of a comorbid autoimmune disease in this cohort was, except for a lower proportion of hypothyroidism, in line with previously published results. However, the results need to be compared with the age-matched general population. Knowledge of high-risk comorbidities will contribute to better care for JIA patients, with potential development of new screening routines and our results highlight that it is important to continuously evaluate the patient’s mental health to early detect symptoms of mental illness.

References
1. Zahedi NO, et al. RMD open. 2016;2(1):e000212.
2. Bernatsky S, et al. J Rheumatol. 2011;38(4):760-3.
3. Simard JF, et al. J Rheumatol. Arthritis Rheum. 2010;62(12):3776-82.
4. Nordstrom BL, et al. Arthritis Care Res (Hoboken). 2012;64(9):1357-64.
5. Beukelman T, et al. Arthritis Rheum. 2012;64(4):1263-71.
6. Fair DC, et al. Open Access Rheumatol. 2019;11:237-252.
7. Pohjanko H, et al. Scand J Rheumatol. 2010;39(5):435-6.
8. Schenck S, et al. J Pediatr. 2018;192:196-203.
9. Stagi S, et al. Rheumatology (Oxford). 2005;44(4):517-20.
10. Berthold E, et al. Arthritis Res Ther. 2019;21(1):218.

Disclosure of Interest
None declared

Table 1 (abstract P132), Comorbidities in JIA (n=252)

| Comorbidities | Total (%) |
|---------------|-----------|
| Malignancy    | 0         |
| Depression/Anxiety | 19.8   |
| Diabetes mellitus, type 1 | 2.8     |
| Hypothyroidism | 5.6       |
| Coeliac disease | 5.2      |

P133
Echocardiographic findings of children with juvenile spondyloarthropathies
M. Yildiz1, R. Dedegol2, B. Akdeniz1, A. Adrovic1, F. Haslak1, F. Karagöz2, O. Köker1, S. Sahin1, K. Barut1, F. Oztunc2, O. Kasapcopur1
1Department of Pediatric Rheumatology; 2Department of Pediatric Cardiology, Istanbul University-Cerrahpasa , Istanbul, Turkey

Introduction: Juvenile spondyloarthropathies (JSpA) is an umbrella definition of a group of inflammatory diseases characterized by asymmetric peripheral arthritis (especially in lower extremities), axial skeleton involvement and enthesitis. Although, cardiovascular findings of inflammatory diseases such as juvenile systemic lupus erythematosus, juvenile scleroderma, juvenile dermatomyositis well-documented, it has not been extensively studied in children with JSpA, and there are only few studies in the literature.

Objectives: This cross-sectional study had conducted for evaluating the cardiac functions of the children and adolescents with JSpA.

Methods: Forty patients with JSpA and twenty healthy control were included into the study. Healthy children or adolescents who attended the outpatient clinic for routine control were enrolled in the control group after the informed consent was taken. Patients with history/evidence of congenital heart disease, any rhythm abnormalities, other chronic systemic diseases (including renal, pulmonary diseases, diabetes, etc.), and those taking medications other than JSpA therapy were excluded. Cardiac functions of the patients and healthy controls were evaluated by conventional echocardiography and pulsed-wave tissue Doppler.

Results: Female/male ratio in patient and control groups were 0.6 and 0.81 respectively. The mean ages were 15 ± 3 years in patients with JSpA and 11.9 ± 3.6 years in control group. The mean age at
diagnosis was 12.6 ± 2.9 years and the median follow-up duration was 23 (1-129) months. Tricuspid lateral annulus TDI-PW velocities E/ A’ ratio was significantly lower in patients with JSpA than in healthy controls (1.5 [0.72-4] versus 1.7 [1.2-2.2], p<0.05). Ejection fraction, right ventricle FAC and TAPSE were similar in both groups. Cardiac function parameters of patients were compared according to presence of enthesis, HLA-B27 positivity, morning stiffness, hypertension, medications they were on and erosion/sclerosis on X-ray of pelvis. There were no significant differences between the patients with and without enthesis, HLA-B27 positivity, morning stiffness and erosion/sclerosis on X-ray of pelvis. When cardiac function parameters were compared for magnetic resonance imaging (MRI) findings like bone marrow edema, enthesis, erosion, sclerosis, synovitis; there were no significant differences between groups except for enthesis. Patients with enthesis that is detected on MRI had lower ejection fraction (p<0.05). The correlation analysis that was made for comparing the effect of the disease activity on the cardiac functions; showed significant, moderate correlation between BASDAI score and PW-trans mitral A velocity (r=−0.352, p=0.03) and moderate negative correlation between BASDAI score and TAPSE (r=−0.407, p=0.03). There was significant, moderate negative correlation between follow-up duration and shortening fraction (r=−0.41, p=0.009).

Conclusion: In this cross-sectional study, we are reporting disturbed RV diastolic function with preserved RV systolic function and possible association between MRI confirmed enthesis and lower LV systolic functions. Early identification of cardiac dysfunctions in these patients can help to prevent long-term cardiovascular complications in JSpA before irreversible changes take place.

Disclosure of Interest
None declared

P134

Gender differences in physical fitness related to selection in club-sport activities in JIA

M. Nørgaard1, T. Herlin2
1Department of Physiotherapy; 2Department of Pediatrics, Aarhus University Hospital, 8200 Aarhus N, Denmark

Correspondence: M. Nørgaard
Pediatric Rheumatology 2020, 18(Suppl 2):P134

Introduction: Most studies of physical fitness (PF) in juvenile idiopathic arthritis (JIA) have shown decreased levels of maximal oxygen consumption (VO2max) compared to healthy peers. In JIA, boys have higher PF-levels than girls and younger children have higher levels than adolescents, concurrently with data of healthy peers. Previously, we have shown that more than half of JIA-patients had below normative average of VO2 max. However, most studies focus on physical activity (PA) using accelerometry, 68% of boys and 39% of girls with JIA fulfilled the recommendations of WHO of ≥1 hour of PA per day, which was comparable to normative values (61%/39%). Moreover, patients reporting engagement more than 7 hours per week in club-sports exceeded accelerometry values of healthy peers.

Objectives: To explore the association between PF and specific sport habits in 10 to 16-year-old JIA-patients, related to gender, BMI, disease activity, and pain, and comparing the most fit quartile (Q4) of patients (respectively boys and girls) to the least fit quartile (Q1).

Methods: Sixty patients with JIA performed an indirect ergometer-test of VO2max (Watt max test) and answered the Physical Activity and Sport Questionnaire (PASQ). Objective PA-monitoring for one week was conducted using the GT1M accelerometer. Cut-offs for moderate-high and high intensity PA were set to >1000 and >2500 counts per minute, respectively. Disease activity was assessed with the JADAS-27, current pain and worst pain last week were measured on visual analogue scales (VAS) and in a one-week pain diary using the Faces Pain Scale-Revised (FPS-R).

Results: Girls with JIA (n=36) had lower mean PF than the boys (n=24) (36.5±8.2/43.4±6.73 ml/kg/min), being below normative values, respectively. In both genders the most fit boys and girls (Q4: 49.3-57/40.9-54) had average to well-above normative average PF. The least fit boys (Q1: 33.5-37.4) all had PF-levels well-below normative average. In girls Q1-levels (18.7-30.9) were well-below to below normative average.

We found significant differences between most fit (Q4) and least fit (Q1) patients regarding patient’s global wellbeing (p=0.040) and pain diary (p=0.026). These differences were not significant when separating genders, though differences were more pronounced in girls. The least fit girls (Q1) had significantly higher disease activity (JADAS-27) than the most fit girls (Q4)(p=0.019). The most fit boys and girls (Q4) engaged equally in high intensity sports (soccer: 3/24; 2/36, handball: 0/24; 2/36; gymnastics: 2/24; 4/36, rowing: 1/24; 0/36). However, more boys than girls played soccer (11/24; 3/36), whereas more girls preferred sports of lower intensity (riding: 8/36; 0/24). Eight of 11 boys in soccer and 2 boys in gymnastics or rowing had below average to well-above normative average of PF (Q3+Q4: 41.6-57). Three girls in gymnastics, 2 girls in soccer, and 2 girls in handball were in Q4 (40.9-54) with levels of average to well-above average PF. The third girl in soccer was in Q2 (31-36.3) with levels of well-below to below normative average. None of the riding girls were in Q4 and only 1 was in Q3 (36.3-40.8) (Below average to average normative PF). Comparing accelerometer-monitored values of PA-intensity in girls with low (Q1) and high (Q4) PF, PA-values of Q1 were significantly lower than in Q4. The same tendency was observed in boys, but not to significance.

Conclusion: Our results are in accordance with most other studies of PF in JIA, adding to the knowledge of gender-specific differences in PF and type and behavior in sport activities. It emphasizes the need of regular PF-testing and guidance in high intensity PA and sport in order to improve PF and avoid the risks of inactivity and lifestyle diseases in JIA.

Disclosure of Interest
None declared

P135

The ratio of some cytokines like a marker options and course of juvenile arthritis

O. A. Oshilanska1, N. A. Melanchuk2
1Department of Pediatrics № 1, 2. Department of connective tissue disorders in children, 1.Shupyk National Medical Academy of postgraduate education, 2.State Institute of Pediatrics, Obstetrics and Gynecology, Academy of Medical Sciences of Ukraine; 1.Department of Pediatrics № 1, 2. Department of connective tissue disorders in children, 1.Shupyk National Medical Academy of postgraduate education, Kyiv, Ukraine

Correspondence: O. A. Oshilanska
Pediatric Rheumatology 2020, 18(Suppl 2):P135

Introduction: The leading role in the implementation of inflammation in the human body belongs to cytokines. The study of the role of each of them and their cooperation continues with autoimmune diseases. New data on the importance of chronic inflammation of interleukin 17 (IL-17) have found. The effect of their ratio on the activity of inflammation is not well understood.

Objectives: To study the ratio of some initiating and blocking cytokines of IL-17 in children with juvenile idiopathic arthritis (JIA).

Methods: 40 children with JIA (12 oJIA, 17 pJIA, 1 with positive RF, 6 eJIA, 5 sJIA) were examined during the period of exacerbation of the disease with an assessment of the activity and course of the disease. All cases were additionally studied IL-1B, receptor (IL-17R), IFN-γ in blood serum using linked immunosorbent sandwich method.

Results: The data obtained showed IL-1B was significantly increased only in sJIA (30.15±17.09 pg/ml, significantly (p<0.05) higher than in other JIA (6.71±0.91 pg/ml in oJIA, 8.61±1.11 pg/ml in sJIA). This was detected in 2/3 of the patients, higher (p<0.05) in adolescents (16.69±8.32 pg/ml) compared with children 4-12 y old (6.69±0.86 pg/ml). IFN-γ was increased above normal values (up to 50 pg/ml in healthy children) in all cases of JIA, it could be possible its role in the initiation of outbreak. Maximum values were noted in oJIA, especially in cases with uveitis (7029.2±4750 pg/ml) and were higher (p<0.01) in children 1-3 years old versus adolescents. IL-17R was maximum in pJIA patients (2058936±33.21 pg/ml) and eJIA (22723.65±16022.54 pg/ml).
pg/ml, which also showed the highest the frequency of detection of its increase. It was absent in sJIA (7.5±4.74 pg/ml). The highest values of IL-17R (1849836.4±176751 pg/ml) were in the middle age group. The data obtained suggest the compensatory value of increasing IL-17R and the simultaneous initiation of inflammatory and anti-inflammatory processes during exacerbation of JIA. Assessment of the ratios of stimulating and inhibiting cytokines showed in patients with uveitis, the ratio of IFN-γ/IL-17R (4379.29 ±476.83) was higher than with other JIA (from 60.84 ± 14.92 in oJIA to 105.20±66.01 in pJIA) and IFN-γ/IL-17R (4474.01 ±3899.19 versus from 20.14±11.48 in oJIA to 934.55±931.37 in sJIA). An increase of IL-17R/IL-17R ratio was characteristic only for sJIA (34.12 ±26.17). All of these ratios increased with disease activity (r=0.22-0.37) & they did not reflect the unpleasant course of the disease.

Conclusion: The balance of cytokines determines the direction of the inflammatory process in JIA. The most unfavorable presence of an unpleasant course of the disease.

Analyses for relative abundances of taxa were performed at three taxonomic levels (phyla, families, and genera), and logistic regression with age as a covariate was used for calculations of differences between treated and untreated children, while the Wilcoxon signed-rank test was used for pairwise comparisons. Significance was set to p < 0.05 and corrections for multiple comparisons were made using the Benjamini-Hochberg method.

Results: Analyses showed no significant differences in α-diversity between children treated with MTX or ETN and untreated children, and pairwise comparisons of samples before and during treatment with MTX or ETN also showed no differences. PCoA plots for children treated with MTX or ETN, in comparison with untreated children, did not show any clustering. ANOSIM showed no significant differences between treated and untreated children. PCoA plots were also made for the pairwise comparisons of children sampled before and during treatment, and according to that analysis the community compositions of microbiota did not change in any uniform way during treatment with either MTX or ETN. Furthermore, analyses of relative abundances of specific taxa did not reveal any significant results in any of the comparisons, after adjustment for multiple analyses.

Conclusion: Treatment with MTX or ETN did not alter the composition of fecal microbiota in children with JIA.

Disclosure of Interest
None declared

P136
Treatment with methotrexate and etanercept does not alter the fecal microbiota composition in children with juvenile idiopathic arthritis
A. I. Oman1, J. Dicksveld2, L. Engstrand3, L. Berntson1
1Department of womens and childrens health, Uppsala University; 2Department of Animal Nutrition and Management, Swedish University of Agricultural Sciences, Uppsala; 3Department of Microbiology, Tumour and Cell Biology (MTC), Karolinska Institutet, Solna, Sweden

Correspondence: A. I. Oman
Pediatric Rheumatology 2020, 18(Suppl 2):P136

Introduction: The first-line treatment for juvenile idiopathic arthritis (JIA) is usually methotrexate (MTX), followed by treatment with an anti-tumour necrosis factor alpha (anti-TNF-α) drug, such as etanercept (ETN). The effects of MTX and anti-TNF-α drugs on the fecal microbiota in children with JIA have not been studied previously.

Objectives: To study the effects of MTX and ETN treatments on the fecal microbiota composition in children with JIA.

Methods: In this multicenter, case-control study, 113 fecal samples were collected from 91 children with JIA, with 72 of these samples collected from untreated children (67 of whom were treatment-naive). Samples from 28 children with JIA were collected during treatment with MTX as single treatment and samples from 13 children during treatment with ETN. Of those 13 children, four were treated with ETN as single treatment and nine had a combination of ETN and MTX. We compared 28 children on single treatment with MTX with 57 untreated children (52 treatment-naive), and 13 children on treatment with ETN (nine in combination with MTX) with 62 untreated children (57 treatment-naive). We also did pairwise comparisons of samples taken before any medication was given (n = 22) and samples taken during ongoing treatment with MTX (n = 14) or ETN (n = 8, four in combination with MTX).

The microbiota was characterized by sequencing amplicons from the V3 and V4 regions of the 16S rRNA gene. Alpha diversity of the fecal samples was measured using the Chao-1 index and the Shannon diversity index. To compare these indices between treated children and untreated children, we used a logistic regression model with age at sampling as a covariate. For pairwise analyses, we used the Wilcoxon signed-rank test.

To analyze the community composition of the microbiota, principal coordinate analysis (PCoA) plots based on Bray-Curtis distances were generated for visual comparisons, and analysis of similarity (ANOSIM) was used to test for differences.

P137
Synovial fluid neutrophils from patients with juvenile idiopathic arthritis display a hyperactivated phenotype
M. Metzemaekers1, B. Malengier-Devlees1, K. Yu1, S. Vandendriessche2, P. Matthys1, L. De Somer1, C. Wouters3, P. Proost1
1KU Leuven; 2UZ Leuven, Leuven, Belgium

Correspondence: M. Metzemaekers
Pediatric Rheumatology 2020, 18(Suppl 2):P137

Introduction: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood and an important cause of short-term and long-term disability if patients are not treated appropriately. By definition, JIA clinically presents with peripheral joint inflammation of unknown origin, persisting for at least six consecutive weeks and starting before the age of 16 years. The predominant subtypes, i.e. oligoarthritis (oligo) and polyarthritis (poly) JIA, have long been assumed autoimmune diseases caused by dysregulation of the adaptive immune system, with a central role for autoreactive T cells belonging to the Th1 and Th17 lineages and autoantigens that may include aggrecan, fibrillin, matrix metalloproteinase (MMP)-3 and heat shock proteins. Nevertheless, the original T cell-centered hypothesis has been challenged since it does not cover nor completely explain the full spectrum of immune-pathological phenomena observed in patients.

luien.desomer@uzleuven.be

Objectives: Emerging evidence suggests a potentially important role for neutrophils in JIA pathogenesis. Here, we investigated extensively the phenotypical features of neutrophils present in the peripheral blood and inflamed joints of JIA patients.

Methods: Synovial fluids and parallel blood samples from patients with oligo- or polyJIA and blood samples from healthy children were collected. Multicolor flow cytometry panels allowed for in-depth phenotypical analysis of neutrophils, focusing on the surface expression of adhesion molecules, activation and maturation markers, chemottractant- and Toll-like receptors. Multiplex technology was exploited to quantify pro- and anti-inflammatory cytokines in plasma and synovial fluids.

Results: The vast majority of synovial fluid neutrophils displayed a strongly activated, hypersegmented phenotype with decreased L-selectin (CD62L) expression and increased numbers of nuclear lobes,
upregulation of adhesion molecules CD66b, CD11b and CD15 and downregulation of chemokine receptors CXCR1/2. An elevated percentage of CXCR4-expressing aged neutrophils was detected in synovial fluids from patients. Strikingly, significant percentages of synovial fluid neutrophils showed a profound upregulation of atypical neutrophil markers, including CXCR3, ICAM-1 and HLA-DR.

**Conclusion:** Our data indicate that neutrophils present in inflamed joints of JIA patients are strongly activated cells with elevated pro-inflammatory and antigen presenting potential. This detailed molecular analysis supports the notion that a complex intertwining between these innate immune cells and adaptive immune events drives JIA.

**Disclosure of Interest**
None declared

---

**P138**

The main factors, associated with incomplete vaccination against measles, parotitis, rubella and diphtheria in 170 juvenile idiopathic arthritis patients  
N. Lysibimova¹, I. Fridman², O. Goleva³, S. Khartit¹, M. Kostik³ 
¹Almazov National Medical Research Centre; ²Pediatric Research and Clinical Center for Infection Diseases, Saint Petersburg; ³Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation

**Introduction:** Patients with juvenile idiopathic arthritis (JIA) may have incomplete vaccination against different vaccines that leads to lower protective levels of anti-vaccine antibodies.

**Objectives:** The aim of our study was to evaluate the rate and the main factors of incomplete vaccination against measles, parotitis, rubella and diphtheria in JIA patients.

**Methods:** In the present study were included data 170 JIA/SS patients and 115 girl/boys aged from 2 to 17 years, who received vaccination before the age of 2 years and before JIA onset against measles, parotitis, diphtheria and rubella. Incomplete vaccination means the reduced number of vaccine to age. In all patients the Ig G anti-vaccine antibodies levels were detected with ELISA.

**Results:** The main factors of incomplete vaccination against MMR were: onset age<6 years (OR=7.8 [95%CI:3.2;18.7], p=0.06, Sp=0.86, p=0.000001), JIA duration>3.1 years (OR=4.4 [95%CI:2.0;9.9], Se=0.5, Sp=0.81, p=0.0002), meathotrexate duration>3.1 years (OR=5.7 [95%CI:2.7;12.0], Se=0.74, Sp=0.67, p=0.0000012); biologic treatment (OR=2.5 [95%CI:1.3;4.9], Se=0.64, Sp=0.58) and treatment>1 biologic (OR=3.3 [95%CI:1.1;10.4], Se=0.63, Sp=0.67); for diphtheria were: JIA duration>3.1years (OR=3.4 [95%CI:1.8;6.5], Se=0.55, Sp=0.73, p=0.0002), meathotrexate duration>2.8 years (OR=4.1 [95%CI:2.1;8.1], Se=0.73, Sp=0.61, p=0.00004), biologic treatment (OR=2.4 [95%CI:1.3;4.4], Se=0.59, Sp=0.62).

**Disclosure of Interest**
None declared
TWEAK were analyzed for their potential to predict the 1-year outcome. Demographic and clinical parameters were also recorded. Disease activity was assessed with the clinical Juvenile Arthritis Disease Activity Score (cJADAS10).

**Results:** Two-hundred-sixty-six JIA patients had active disease at baseline, with oligoarthritis and rheumatoid factor-negative polyarthrits representing the largest proportion (72.9%). CRP, ESR, IL-18, S100A8/A9 and S100A12 levels were higher in patients with systemic JIA compared to other JIA categories. Baseline levels of G-CSF, IL-18 and TWEAK were lower in oligoarthritis JIA patients with disease extension within one year. Higher baseline ESR, G-CSF, IL-6, and TNF levels indicated the risk of increased disease activity at 12 months. Additionally, higher levels of ESR, CRP, S100A8/A9, and S100A12 at baseline were associated with the necessity to escalate therapy during the first 12 month of follow-up and subsequent addition of biologic disease-modifying antirheumatic drugs.

**Conclusion:** Our data demonstrate that increased disease activity at baseline, defined through both clinical parameters and biomarker levels is associated with the risk of continued disease activity after 12 months.

**Disclosure of Interest**

None declared

## P140

**Screening for antithyroid antibodies in children with juvenile idiopathic arthritis: a single-centre experience from Southern Italy**

R. Naddeo, C. Esposito, F. Orlando, R. Alfani, V. Disc不解, M. Ale喜

**Pediatric Rheumatology Unit, Mother and Child Department, University of Naples Federico II; Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy**

**Correspondence:** R. Naddeo

**Pediatric Rheumatology 2020, 18(Suppl 2)**

**Introduction:** The prevalence of autoimmune thyroid disorders (AITD) has been reported to be higher in patients with juvenile idiopathic arthritis (JIA) in comparison to the general population. Nevertheless, there is a lack of studies investigating risk factors for AITD development in children with JIA.

**Objectives:** To investigate the co-occurrence of JIA and autoimmune thyroid disorders in southern Italy and to identify potential predisposing factors to anti-thyroid antibodies (ATA) positivity in a JIA population.

**Methods:** A single-centre retrospective study was conducted. All JIA patients admitted to the Pediatric Rheumatology Unit of the University of Naples Federico II, from January 2001 to December 2019, tested for ATA at least once and with a minimum of 6-months follow-up, were included. For each patient, demographic, clinical and laboratory data were extracted from clinical charts. Differences between patients affected by JIA with or without ATA were analyzed.

**Results:** Three hundred thirty JIA patients (247 females; median age 12.5 years, IQR 9.1-16.1) were included in study. Median age at JIA onset was 4 years (IQR 2.2-7.8). Twenty-three patients (7% [95% CI 4.5-10.3]) presented ATA positivity. Twenty-one of them (91.3%) were females. Anti-thyroperoxidase was positive in 18/23 patients (78.2%) while 12 patients presented anti-thyroglobulin positivity (52.1%). Both antibodies were present in 8/23 (34.8%). 19 patients showed while 12 patients presented anti-thyroglobulin positivity (52.1%).

**Conclusion:** A high prevalence of ATA positivity and Hashimoto’s thyroiditis in patients with JIA was found in our wide southern Italian cohort. As expected, a positive family history ofAITD was found to be associated with a higher risk to ATA development during the follow-up. This finding supports the usefulness of an active screening for AITD in JIA children, particularly in patients with relatives affected by thyroid disorders. Notably, patients treated with TNF-alpha inhibitors resulted less likely to develop thyroid antibodies. Further studies are needed to investigate the effect of anti-TNF-alpha therapy on thyroid autoimmunity in JIA.

**Disclosure of Interest**

None declared

## P141

**Which musculoskeletal sites involved can we expect at juvenile idiopathic arthritis (JIA) onset?**

G. Tarantino, A. Uva, D. Pires Marafon, H. Jadoun, A. Aquilani, R. Nicolai, F. De Benedetti, S. Magni Manzoni

1Catholic University of Sacred Heart; 2Sapienza-University; 3Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

**Correspondence:** G. Tarantino

**Pediatric Rheumatology 2020, 18(Suppl 2)**

**Introduction:** The knee is considered by far the joint most frequently affected at JIA onset. Nonetheless, JIA onset may present with unusual musculoskeletal involvement, eventually leading to a delay in the diagnosis and treatment.

**Objectives:** To identify the type and number of musculoskeletal sites affected at JIA onset in consecutive patients seen at the study center in an 8 years period.

**Methods:** Records of patients with new diagnosis of JIA from June 2012 to May 2020 available information in the medical history and standardized joint assessment at diagnosis, were retrospectively reviewed. Systemic JIA subtype according to ILAR classification criteria were excluded. Demographic and clinical features, including the type and number of joints at disease onset and diagnosis, were registered. Data were analyzed through descriptive statistics.

**Results:** Of a total of 333 Caucasian patients included in the study (75.7% females), 241 patients (72.4%) had oligoarthritis, 79 (23.7%) RF-negative polyarthritis, 7 (2.1%) RF-positive polyarthritis, 1 (0.3%) polyarticular arthritis, 5 (1.5%) enthesis-related arthritis (ERA). Antinuclear antibody (ANA) were positive in 188 patients (56.5%). The median age at onset was 4.8 years (IQR 2.3-9.3). At diagnosis 103 (30.9%) patients had only 1 active joint, 143 (43.0%) had 2-4 active joints, 87 (26.1%) had ≥ 5. As expected the knee, the tibiotalar and the wrist were the most frequently affected joints (77.2%, 41.1%, 21.0%, respectively); cervical spine was involved only in patients with polyarthritis (n=13). Notably, of 103 patients with monoarthritis at diagnosis 98 presented with large joints involvement, among which n=2 isolated elbow and n=2 isolated wrist, and 5 with small joints involvement (Table 1). No sufficient data were available regarding the involvement of tendons and bursae, since the standard joint assessment form did not include them. Nonetheless, additional 4 patients, not included in the sample analysis, had isolated tenosynovitis in involvement at diagnosis (n=1 both-sided ulnar extensor tendons; n=2 isolated tenosynovitis of the flexor digiti proprii; n=1 tenosynovitis of 2 flexors digitii proprii).

**Conclusion:** Our study confirms the knee, the tibiotalar and the wrist as the most frequently affected joints at JIA diagnosis. On the other hand, musculoskeletal sites, such as small joints of hands and feet, the hip and the shoulder, usually involved in polyarticular JIA, can be the site of disease presentation in oligo- and also mono-articular JIA. Further, JIA may present with isolated tendon involvement. Our results foster not to delay JIA diagnosis in persistent synovitis occurring
in infrequent joints and to include musculoskeletal sites, other than joints, in the standard articular evaluation. This could be realized by merging clinical and imaging (i.e. ultrasound) musculoskeletal examinations in the same assessment.

Disclosure of Interest
None declared

Table 1 (abstract P141). Number of patients with mono- or oligoarthritis at disease diagnosis according to specific joint involvement

| Joint                  | NAJ=1 (N=103) | NAJ=2-4 (N=143) |
|------------------------|---------------|------------------|
| Temporomandibular joint| 0             | 2                |
| Shoulder               | 0             | 1                |
| Hip                    | 1             | 1                |
| Metacarpophalangeal joint| 0             | 20               |
| Proximal interphalangeal joint| 2 | 31             |
| Distal interphalangeal joint| 2 | 5                |
| Metatarsophalangeal joint| 0             | 6                |
| Toe                    | 1             | 22               |

P142
Combining age at JIA onset, female gender, ANA positivity and family history of autoimmune disease to predict autoimmune thyroid disease in patients with juvenile idiopathic arthritis

L. Baas1, J. van Straalen1, P. Quartier2, V. Panaviane3, J. Anton Lopez4, L. Koné-Paut5, S. Hashad6, V. Keltev7, J. Brunner8, F. Gok9, G. Vega Cornejo10, V. Chasnyk2, S. de Roock1, N. Wulffraat1, J. Swart1, N. Ruperto1

Introduction: Comorbidities occur more often in patients with juvenile idiopathic arthritis (JIA) than in the general population. In adults, the association between rheumatoid arthritis (RA) and other autoimmune diseases, such as autoimmune thyroid disease (AITD) is reported. Little is known about the association between JIA and other autoimmune diseases, like AITD.

Objectives: The purpose of this study is to evaluate the prevalence of symptomatic AITD in JIA patients and to investigate whether there are any factors associated with a higher risk of developing AITD.

Methods: Data of 8,971 patients, classified by the International League of Associations for Rheumatology (ILAR) criteria, were analyzed in a dataset from the worldwide PharmaChild registry. Patients with diagnosed Hashimoto’s thyroiditis, Graves’ disease and non-specified autoimmune thyroiditis were labeled as suffering from AITD. Logistic regression analyses were used and a prediction model was developed.

Results: In this study, the prevalence of symptomatic AITD was 1.1% of all JIA patients. In multivariate analyses, being older at JIA onset (OR= 1.12; 95% CI = 1.05-1.19), female gender (OR = 2.33; 95% CI= 1.32-4.11), ANA positivity (OR= 3.27; 95% CI = 1.78-6.00) and family history of autoimmune disease (OR= 3.07; 95% CI= 1.76-5.37) were significantly associated with developing AITD ever. The final prediction model of developing AITD ever (AUC =0.702; 95% CI= 0.64-0.77) included the predictors age at JIA onset (p<0.001), gender (p= 0.058), ANA positivity (p= 0.001) and family history (p<0.001).

Conclusion: The best predictors for the development of AITD in JIA patients ever shown to be age at JIA onset, female gender, ANA positivity and family history of autoimmune diseases.

Disclosure of Interest
None declared

P143
Methotrexate response subgroups identified in two UK juvenile idiopathic arthritis cohorts

S. J. W. Shoop-Worrall1,2, K. L. Hyrich3,4, L. R. Wedderburn5,6, W. Thomson7,9, N. Geifman8 on behalf of BSPAR-ETN Study, BCRD Study, CLUSTER

1Centre for Health Informatics, 2Centre for Epidemiology Versus Arthritis, The University of Manchester; 3NIHR Manchester BRC, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester; 4Centre for Adolescent Rheumatology Versus Arthritis , UCL, UCLH and GOSH; 5Infection Inflammation and Rheumatology, UCL GOS Institute of Child Health; 6NIHR Great Ormond Street Hospital Biomedical Research Centre, London, 7Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, United Kingdom

Correspondence: S. J. W. Shoop-Worrall

Pediatric Rheumatology 2020, 18(Suppl 2):P143

Introduction: Treatment response in JIA is currently viewed as a binary outcome: response or non-response. However, JIA is a heterogeneous disease and it is likely that different, identifiable subgroups of children and young people (CYP) may demonstrate different patterns of disease following treatment. Identifying these response subgroups can assist the tailoring of stratified treatment approaches in JIA.

Objectives: To identify subgroups of CYP defined by different trajectories of juvenile arthritis disease activity score (JADAS) components following methotrexate (MTX) initiation for JIA.

Methods: MTX-naive CYP with JIA were selected if enrolled prior to January 2018 in the BSPAR Etanercept Cohort Register or the Biologics for Children with Rheumatic Diseases Study at point of starting MTX. JADAS components (active joint count, physician’s global assessment (PGA, 0-10cm), parental global evaluation (PGE, 0-10cm) and standardised ESR (0-10) were calculated based on data collected in the year following MTX initiation.

Multivariate group-based trajectory models were used to explore MTX response clusters across the different JADAS components, which were log1p transformed for analysis. Optimal models were selected based on a combination of model fit (BIC, relative entropy, average posterior probabilities), parsimony and clinical plausibility. Clinical and demographic characteristics and achievement of ACR Pedi 30/90 by six months were compared across identified groups.

Results: Of 658 CYP selected, the majority were female (68%) and of white ethnicity (86%), with RF-negative JIA the most common disease category (35%).

Six subgroups of CYP were identified with differing patterns of disease activity following MTX initiation. Two groups improved across all JADAS components: Fast improvers (11%), and Slow improvers (16%). Persistent PGA (8%), and Persistent PGE (13%) groups maintained one persistent disease feature but otherwise improved. One group relapsed (7%) and a final group had persistent disease overall (44%).

There were no differences in active joint counts at MTX initiation between subgroups and all ILAR categories were represented across
each subgroup. However, CYP in persistent disease and slow improver groups had higher CHAQ, PGA and PGE scores at MTX initiation. Those with persistent disease were also older at MTX initiation.

The majority of CYP fulfilled ACR Pedi 30 response (>60% across every group). ACR Pedi 90 achievement was low at 6 months for slow improvers (30%) and high in the relapse group (68%). Between 41% and 73% achieved ACR Pedi 90 response in groups with persistent disease in one JADAS component.

Conclusion: We identify different patterns of disease activity within CYP initiating MTX, suggesting a simple responder/non-responder analysis at a set point may be over-simplistic. Commonly used response measures did not adequately describe these heterogeneous response patterns. Understanding both clinical factors associated with, and biological mechanisms underpinning, these subgroups would aid stratified medicine in JIA.

Disclosure of Interest
S. Shoop-Worrall: None declared, K. Hyrtch: Speaker Bureau of: Abbvie, L. Wedderburn: Speaker Bureau of: Pfizer, W. Thomson: None declared, N. Geifman: None declared

P144
Pressure pain thresholds in young adults with juvenile idiopathic arthritis
E. D. Arstad1,2, J. M. Iversen3, M. Uglen4,5, M. Glærup6, P. R. Romundstad1,7, T. Sand1,2, M. Rygg2
1Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger; 2Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, Trondheim; 3Bode Municipality, Bodø; 4Department of Neurology and Clinical Neurophysiology, St. Olavs Hospital, Trondheim, Norway; 5Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark; 6Department of Public Health and Nursing, NTNU - Norwegian University of Science and Technology; 7Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway

Correspondence: E. D. Arstad
Pediatric Rheumatology 2020, 18(Suppl 2):P144

Introduction: Despite modern treatment and improved disease control, pain is the most common complaint in juvenile idiopathic arthritis (JIA). Knowledge about pain thresholds and pain sensitivity among young adults with JIA is sparse.

Objectives: To study pressure pain thresholds (PPTs) in young adults with JIA, 16 years after disease onset compared with controls.

Methods: Consecutive newly diagnosed children with JIA and a disease onset between 1997-2004 from Central Norway, were included in this prospective population-based long-term follow-up study. Children with onset 1997-2000 were part of the Nordic JIA cohort1-2. Age- and sex-matched controls were drawn from the National Population Register of Norway. Inactive disease and remission were defined according to Wallace3-4. At the follow-up between 2015-17, data from a clinical examination and blood tests were included in addition to an investigator-blinded quantification of PPTs. A digital algometer was used to manually apply pressure three times with an even rate at the upper and lower limb. PPTs from JIA and controls, and from subgroups of JIA defined by disease status, were compared with multilevel models in STATA.

Results: Among the 96 participants with JIA, 71% were female, median age was 22.7 (IQR 18.7-26.2) years, median disease duration was 16.1 (IQR 14.2-17.1) years, 47% had an oligoarticular disease (persistent or extended), and 45% were in remission off medication. In the control group, 71% were female and median age was 23.5 (IQR 20.2-26.7) years. Results from the multilevel regression model showed significantly lower PPTs among participants with JIA compared to controls (Table 1). In the JIA group, participants with inactive disease had lower PPTs than both JIA in remission off medication and JIA with active disease (Table 1). The results were consistent for both upper and lower limb.

Conclusion: In this long-term follow-up study of young adults with JIA, we found significantly lower PPTs compared to controls. This may indicate that young adults with JIA have altered pain sensitivity possibly due to accumulated earlier pain experiences.

References
1. Nordal E, et al. Arthritis Rheum 2011;63:2809-18
2. Glærup M, et al Arthritis Care Res 2018;72:507-16
3. Wallace CA, et al. J Rheumatol 2004;31:220-4
4. Wallace CA, et al. Arthritis Care Res 2011;63:929-36

Disclosure of Interest
None declared

Table 1 (abstract P144). Pressure pain thresholds in young adults with JIA compared to controls

|                     | Upper Limb kPa (95% CI) | Lower Limb kPa (95% CI) |
|---------------------|-------------------------|-------------------------|
| Control             | 109 (999, 1059)         | 700 (726, 794)          |
| JIA (total group)   | 96 (846, 930)           | 702 (670, 734)          |
| Remission off medication* | 43 (824, 963) | 732 (675, 789) |
| Inactive disease*   | 20 (762, 911)           | 626 (575, 678)          |
| Active disease*     | 33 (842, 979)           | 707 (662, 752)          |

n = number; kPa = kilopascal; CI = confidence interval
*According to Wallace1-4

P145
Renal outcomes of a cohort of paediatric patients with juvenile idiopathic arthritis
M. F. Gicchino, A. Di Sessa, S. Guarino, E. Miraglia del Giudice, A. N. Olivieri, P. Marzullo
University of the Study of Campania Luigi Vanvitelli, Naples, Italy

Correspondence: M. F. Gicchino
Pediatric Rheumatology 2020, 18(Suppl 2):P145

Introduction: Juvenile Idiopathic Arthritis (JIA) represents the most common chronic rheumatic disease in childhood. Non-steroidal anti-inflammatory drugs (NSAIDs) and intra-articular steroids are the first line treatment for JIA. Systemic steroids, disease modifying anti-rheumatic drugs (DMARDs) and biologic drugs are used in children with severe disease. It is not possible at onset of disease to predict when a child can suspend pharmacological treatment, so children affected from JIA have to continue pharmacological treatment for several months or years. Anecdotal reports showed that rarely JIA could present renal involvement due to uncontrolled inflammation or to long exposure to drugs.

Objectives: Because no cohort studies investigating renal injury in children with JIA are available, we designed this kind of study in our population.

Methods: We retrospectively evaluated 110 patients suffering from JIA, JIA diagnosis was made according to ILAR criteria, treatment was assigned with ACR recommendations. For each patient we recorded the type and the duration of pharmacological treatment and the presence of renal injury. Renal injury was defined by the presence of hypertension (systolic and/or diastolic blood pressure >95th percentile for age, sex and height), proteinuria (persistent – confirmation within 3 months– urinary protein/creatinine ratio>0.5 mg/mg for children <2 years old and >0.2 mg/mg for patients >2 years old) or reduced estimated glomerular filtration rate (<90mL/min/1.73m2). Development of renal injury was determined by survival analysis according to Kaplan-Meier method.

Results: All the patients underwent NSAIDs administration for a mean time of 44±12.6 months. 63 patients (57.3%) underwent also MTX administration for a mean time of 47±12.6 months. 34 patients (30.9%) underwent biologic agents with a mean duration of the treatment of 37.8±30.1 months. Among these 34 patients, 30 patients underwent biological agents after administration of NSAIDs and MTX, while only 4 underwent biological agent administration.
without ever undergoing MTX administration. Mean age at the last follow-up was 13.3±5.6 years. The mean duration of JIA was of 84.0±65.4 months. 9 of 110 patients (8.1%) showed renal injury (8 with hypertension and 1 with proteinuria). Patients with renal injury presented longer duration of the disease (152.8±58.2 Vs 77.9±62.7 months; p=0.001), shorter intervals free from JIA relapses (0 (0/1) Vs 12 (6/40); p<0.001), longer duration NSAIDs treatment (80.2±40.9 Vs 41.13±40.5 months; p=0.008)but with similar cumulative NSAIDs dose (270 Vs 252 grams; p=0.83) and higher rate of MTX prescription (100% Vs 53%; p =0.007), longer time of MTX administration (86.0±50.5 Vs 40.5±38.86 months; p=0.005) and higher cumulative MTX dose (4.8%±1.72 grams p= 0.005) compared with the patients without renal injury.

Conclusion: 8% of the children with JIA develop renal injury. The principal risk factor was longer exposure to NSAIDs and MTX for a more severe disease. Probably, the renal damage could be “time dependent” for NSAIDs exposure and “both time and dose dependent” for MTX exposure. Rheumatologists taking care of children with JIA should pay attention also to kidney health, avoiding long-time treatments with NSAIDs and/or MTX possibly preferring biological treatments in case of poor control of the disease. Moreover, in these patients, periodic evaluation of renal function, blood pressure and proteinuria should be warranted.

Disclosure of Interest None declared

P146
Synovial neutrophils have an altered phenotype and impaired effector functions compared to circulating neutrophils in oligoarticular juvenile idiopathic arthritis
S. Arve-Butler1,2, T. Schmidt2,3, A. Mossberg2,3, E. Berthold1,2, B. Gullstrand1, R. Kehr1,2
1Clinical Sciences Lund, Rheumatology; 2Wallenberg Center for Molecular Medicine; 3Clinical Sciences Lund, Pediatrics, Lund University, Lund, Sweden
Correspondence: S. Arve-Butler
Pediatric Rheumatology 2020, 18(Suppl 2):146

Introduction: Juvenile idiopathic arthritis (JIA) is a pediatric rheumatic disease with partially unknown etiology and pathogenesis. Neutrophils are the most common immune cell present in synovial fluid from inflamed joints in oligoarticular JIA, but the role of neutrophils in the immunopathogenesis of oligoarticular JIA has not been investigated.

Objectives: To characterize neutrophil phenotypes and effector functions in the circulation and in the inflamed joint during active arthritis in children with oligoarticular JIA.

Methods: Paired samples of blood and synovial fluid from 17 children with oligoarticular JIA were investigated regarding surface markers, phagocytic ability and oxidative burst. Healthy blood neutrophils exposed to cell-free JIA synovial fluid were investigated for surface markers, phagocytic ability and oxidative burst differences when compared to circulating neutrophils in healthy blood.

Results: Synovial neutrophils had a shifted phenotype, characterized by high surface levels of neutrophil activation markers CD11b and CD66b, and mannose receptor CD206 and decreased levels of adhesion molecule CD62L compared to circulating neutrophils. In comparison to oral cavity neutrophils, synovial neutrophils had higher levels of CD11b and a different overall phenotype, suggesting that the phenotype shift in synovial compared to circulating neutrophils is not dependent on transmigration alone. JIA synovial fluid in itself induced activation of healthy blood neutrophils, measured as increased CD11b levels. Synovial fluid neutrophils had impaired ability to phagocytose opsonized E. coli and to produce oxygen radicals upon neutrophil activation with phorbol-myristate-acetate (PMA) compared to circulating neutrophils. The impaired effector functions in synovial neutrophils was not dependent on the synovial fluid alone, as addition of cell-free synovial fluid to blood neutrophils did not alter phagocytosis and oxidative burst.

Conclusion: JIA synovial fluid neutrophils are activated, have a “polarized” phenotype and impaired effector functions compared to neutrophils in the circulation. This study will help bridge the current knowledge-gap regarding the role of neutrophils in the immunopathogenesis in oligoarticular JIA.

Disclosure of Interest None declared

P147
Withdrawn

P148
JIA-ACR50 response as a predictor of minimal disease activity in patients aged 2–17 years with polyarticular-course JIA treated with abatacept
N. Ruperto1, H. I. Brunner2, A. Berman1, F. Ávila-Zapata1, G. Horneff1, M. Alessio1, M. Becker1, A. Belot1, R. Burgos-Vargas1, A. Boteanu1, C. Goldenstein-Schainer2, L. Scheibel1, M. T. Terrier1, L. Zemel3, R. Wong3, M. Nys4, M. Askelson1, A. Martin1, D. J. Lovell1 on behalf of Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trial Organization (PRINTO)
1PRINTO, Genova, Italy; 2PRCSG, Cincinnati; 3Bristol-Myers Squibb Company, Princeton, United States; 4Bristol-Myers Squibb Company, Braine-l’Alleud, Belgium
Correspondence: N. Ruperto
Pediatric Rheumatology 2020, 18(Suppl 2):148

Introduction: Effectiveness of SC abatacept (ABA) in patients (pts) with polyarticular-course JIA (pJIA) was shown in a 2-year (yr), open-label Phase III international study (NCT01844518).

Objectives: To assess potential predictors of Juvenile Arthritis Disease Activity Score 27-CRP (JADAS27-CRP) minimal disease activity (MDA), inactive disease (ID) and remission.

Methods: Pts with pJIA aged 2–17 yrs received weight-tiered SC ABA (10–<25 kg: 50 mg; 25–<50 kg: 87.5 mg; ≥50 kg: 125 mg) weekly for 40 mos. JIA-ACR30 responders at Mo 4 could receive SC ABA for another 20 mos. Potential predictors of response over 11 time points to Mo 21 were determined with a multivariate logistic regression (MVR) analysis; Mo 4, 13 and 21 data are presented. MVR variables were baseline (BL) age, sex, race, weight, geographic region, CRP, MTX use, prior biologic use, number of active joints and joints with limitation of motion, physician’s global assessment of disease activity, Childhood HAQ-DI (CHAQ-DI), parental assessment of well-being (PaGA) and JIA-ACR50 or JIA-ACR70 responses at Mo 3. Variables were deemed significant if corresponding p values were <0.05 at ≥6 time points. Missing values were imputed as none-responders. BL continuous variable cut-offs (high/low) were determined with receiver-operator curve analysis. Outcomes analysed included JADAS27-CRP MDA (≤3.8), ID (≤1) and remission (JADAS27-CRP ID for ≥6 months) rates. Odds ratios and 95% CIs were computed.

Results: In all treated pts (N=219), median (range) BL characteristics were: age 11.0 (2.0–17.0) yrs, CRP 0.2 (0.1–21.1) mg/dL, CHAQ-DI 1.0 (0.0–2.9) and PaGA 47.2 (0.0–95.8). Variables with the highest number of significant p values (≤0.05) were BL CRP, CHAQ-DI, PaGA and Mo 3 JIA-ACR50 and JIA-ACR70. BL CRP, PaGA and CHAQ-DI were predictive of JADAS27-CRP MDA, ID and/or remission at multiple time points (Mo 13; Table 1). JIA-ACR50 response at Mo 3 significantly predicted achievement of JADAS27-CRP MDA at Mo 13 (Table 1) and Mo 21.

Conclusion: Clinically important JIA-ACR50 response at Mo 3 was predictive of the attainment of JADAS27-CRP MDA status at Mo 13 and Mo 21 in pts aged 2–17 yrs with pJIA treated with SC abatacept.
## Table 1 (abstract P148). ORs (95% CI) for variables potentially predictive of JADAS27-CRP MDA, ID or remission at Mo 13

| Variable   | Cut-off | OR (95% CI) | Remission Cut-off | OR (95% CI) |
|------------|---------|-------------|-------------------|-------------|
| CRP        | >1 vs ≤1| 0.58 (0.23, 1.42) | >0.6 vs ≤0.6 | 0.38 (0.13, 0.76) |
|            |         | 0.83         | 0.78              |             |
| CHAQ-DI    | ≤0.75   | 0.94         | ≤0.75 vs ≤0.75 | 1.18       |
| PaGA       | ≤43.16  | 0.48 (0.21, 1.00) | ≤39 vs ≤39 | 0.81        |
|            |         | 0.75         | 1.24              |             |
|           | ≥43.16  | 1.23         | ≥39 vs ≥39 | 2.73        |
| JIA-ACR50  | Yes vs no | 6.93 (2.20, 21.89) | Yes vs No | 1.65        |
| at Mo 3    |         | 0.47         | 0.12              |             |
|            | No      | 2.47         | 1.10              |             |
| JIA-ACR70  | Yes vs no | 1.53 (0.58, 4.00) | Yes vs No | 3.01        |
| at Mo 3    |         | 1.09         | 0.72              |             |

*Statistically significant (p<0.05).

# Reference
1. Brunner HI, et al. Arthritis Rheumatol 2018;70:1144–1154.

**Disclosure of Interest**
N. Ruperto Consultant for: AbbVie, AstraZeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eli Lilly, EMD Serono, GlaxoSmithKline, F Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, Pharma, Sanofi, Servier, Sinergie, Sobi, Takeda, Employee of: The IRCCS Istituto Giannina Gaslini (IGG), where NR works as a full-time public employee, has received contributions from Bristol-Myers Squibb Company, Eli Lilly, GlaxoSmithKline, F Hoffmann-La Roche, Janssen, Novartis, Pfizer, Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties. The registry is funded by Bristol-Myers Squibb Company, Speaker Bureau of: AbbVie, AstraZeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eli Lilly, EMD Serono, GlaxoSmithKline, F Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, Pharma, Sanofi, Servier, Sinergie, Sobi, Takeda, H. Brunner Consultant for: Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, GlaxoSmithKline, F Hoffmann-La Roche, Novartis, Pfizer, Takeda, UCB, Wyeth (funds paid to employer), Speaker Bureau of: F Hoffmann-La Roche, GlaxoSmithKline, Novartis, A. Berman: None declared, G. Avila-Zapata: None declared, G. Horneff Consultant for: AbbVie, Novartis, Pfizer, Sanofi, Speaker Bureau of: AbbVie, Novartis, Pfizer, Sanofi, M. Alessic: None declared, M. Becker: None declared, A. Belot: None declared, R. Burgos-Vargas: None declared, A. Boteanu: None declared, C. Goldenstein-Scheinberg: None declared, I. Scheibel: None declared, M. T. Terreri: None declared, L. Zemeli: None declared, R. Wong Shareholder of: Bristol-Myers Squibb Company, Employee of: Bristol-Myers Squibb Company, M. Nys Shareholder of: Bristol-Myers Squibb Company, Employee of: Bristol-Myers Squibb Company, M. Askelson Employee of: Bristol-Myers Squibb Company, A. Martini Consultant for: Aurinia, Bristol-Myers Squibb Company, E. Zholobova.

**Introduction:** The JDM working party has 140 active members. Since June 2019, they have been represented by a core group of 7 elected members (Chair: Liza McCann, UK; Secretary: Meredith Wilkinson, UK; Past Chair: Helga Sanner, Norway; Representative for basic science: Judith Wienke, Netherlands; Representative for clinical care / clinical science: Charris Papadopoulou, UK; Representative for education / training & EMERGE: Raquel Campanihlo-Marques, Portugal) and 3 co-opted members (Allied Health Professional Representatives: Sara Röstlund, Sweden and Mette Nørgaard, Denmark; Parent representative, Joanne Swan, Scotland).

**Objectives:** Our aim is to frame our work in line with the PReS pillars – clinical / research, basic science and education / training. We think that part of our role within the PReS Working Group is to help standardise care, facilitate multi-centre research projects and enhance educational opportunities.

**Methods:** The core group meet via teleconference every 2 months with a set agenda incorporating each of the PReS pillars. An update was distributed to all working party members in February 2020, encouraging submission of ideas and/or collaboration on proposed projects.

**Results:** The core group to date has:

- Established and completed a survey to define opinion / use in practice of the SHARE JDM consensus guidelines (Enders FB et al, Ann Rheum Dis 2017). Results of this (n=46) submitted in abstract to PReS 2020; manuscript in preparation.
- Clarified the role of databases / data sharing in JDM across Europe; PReS JDM Working Party and Euromyositis Position Statement available on PReS website.
- Informed members of the EMERGE group of training opportunities / fellowships relating to JDM.
- Produced a summary of research projects and educational resources, available on PReS website.
- Collaborated with the International Myositis Assessment & Clinical Studies Group (IMACS), promoting shared working.

**Work currently in progress includes:**

- Collaborating in the extension of the JDM SHARE consensus for management of JDM in North America (IMACS project).
- Research proposal on sleep in JDM - in development.
- Training package / educational resource on myositis specific antibodies near completion; will be available in PReS website.
- Proposal for a Policy Statement on management of JDM during Covid-19 with a particular focus on transition to adult services.
- Survey of practice in JDM proposed; in early stages of development.

**Conclusion:** The JDM PReS working party provides a platform for collaboration in JDM, incorporating clinical and research issues, basic science and education / training. Ideas and collaborations are welcomed and encouraged within an open membership structure. To join the group, e-mail: meredyth.wilkinson.14@ucl.ac.uk.

**Disclosure of Interest**
None declared.
Methods: 52 children (35 girls and 17 boys), aged from 5 to 17 years were observed. 29 children had JDM, JIA was in 23 children. The level of 25(OH)D in plasma was measured by chemiluminescent immunoassay method. All patients with JDM and 16 (69.5%) JIA patients were taking vitamin D drugs (cholecalciferol 200 IU/day and/or alfacalcidol 0.25 μg). Concentration level 21-30 ng/ml was determined as insufficiency, less than 20 ng/ml as deficiency.

Results: Vitamin D insufficiency was in 50 (94.3%) children of our cohort, including 100% cases in patients with JIA (21 (91.3%) children had a deficit, 4 of them (17.4%) with extra deficit). 25(OH)ID <30 ng/ml was observed in 90% cases in JDM patients, 70% of them with deficit. The average 25(OH)D level in JDM group was significantly higher than in JIA group (21.5±11.87 vs 14.98±9.11 ng/ml).

Conclusion: The overwhelming majority of children with JIA and JDM have an insufficiency or deficiency of vitamin D in comparison with Russian population. Traditional therapy with complex calcium salts drugs and cholecalciferol in low doses is insufficient to achieve the optimal level of vitamin D.

At the same time, vitamin D supplementation in children with JDM is higher than in JIA patients. Perhaps this is partly due to more intensive vitamin D therapy.

Disclosure of Interest
None declared

P151 Favorable clinical response of refractory juvenile dermatomyositis to ruxolitinib

A. Heinen1, A. Schnabel1, N. Brück1, M. Smitka1, C. Wolf1, N. Lucas1, S. Dollinger1, G. Hahn2, C. Guenther2, R. Berner1, M. A. Lee-Kirsch1, C. Schuetz1

1Pediatrics, Technische Universität Dresden, Dresden; 2Pediatric Rheumatology, Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen; 3Department of Radiology, 4Department of Dermatology, TU Dresden, Dresden, Germany

Correspondence: C. Schuetz
Pediatric Rheumatology 2020, 18(Suppl 2):P151

Introduction: Juvenile dermatomyositis (JDM) is a rare systemic inflammatory disorder of childhood associated with vasculopathies and a constitutive type I interferon (IFN) activation. Standard immunosuppression does not always control disease activity and may have serious side effects.

Objectives: JAK1/2 inhibitors were recently shown to be therapeutically effective in patients with monogenic type I interferonopathies. We applied this rationale in a JDM patient with therapy-refractory course and elevated IFN signature.

Methods: A 14-year-old boy with NXP2-positive JDM presented with a relapse almost 10 years into remission. He failed to improve on first-line treatment and was transferred to our center with dysphagia due to severe myositis. His initial Childhood Myositis Assessment Scale (CMAS) score was 6/52. Besides elevation of CK and von-Willebrand antigen, he had a strong IFN signature consistent with the diagnosis of relapsed JDM.

Results: In view of insufficient disease control and the persistent high IFN signature, cyclophosphamide, rituximab and steroid pulses were stopped, and the patient was started on ruxolitinib. During the first three months of ruxolitinib therapy (30 mg/d), the patient experienced increasing muscle strength and significant clinical improvement. He was able to walk short distances and to climb one flight of stairs. At seven months, he is able to ride his bicycle for 10 minutes. His CMAS score improved from 18/52 to 40/52. This was accompanied by a sustained reduction the IFN signature.

Conclusion: The observation of a sustained reduction of the IFN signature under ruxolitinib supports a primary role of constitutive type I IFN activation in JDM pathogenesis. Thus, ruxolitinib should be considered early in the treatment of refractory JDM, not necessarily as second-line therapy.

Disclosure of Interest
None declared

P152 Overlap syndrome of idiopathic inflammatory myopathy with juvenile systemic lupus erythematosus presenting with macrophage activation syndrome

R. L. D. Bragança1, R. P. Silva2, J. P. Mendes2, C. Rocha2, J. L. Barreira1, F. Aguiar1, M. Rodrigues1, I. Brito1

1Serviço de Pediatria, Centro Hospitalar Universitário de São João, Porto; 2Serviço de Pediatria, Centro Hospitalar Entre Douro e Vouga, Feira; 3Unidade de Reumatologia Pediátrica e Jovem Adulto , Centro Hospitalar Universitário de São João, Porto, Portugal

Correspondence: R. L. D. Bragança
Pediatric Rheumatology 2020, 18(Suppl 2):P152

Introduction: Some patients with connective tissue diseases cannot be assigned to a single disease category, presenting characteristics from two or more immune mediated conditions, the so-called overlap syndromes (OS). OS are infrequent in children and their description in literature is limited to some case series.

Objectives: Our aim is to present a rare case of an OS of idiopathic inflammatory myopathy (IMI) with juvenile systemic lupus erythematosus (JSLE) in a child that initially presented with macrophage activation syndrome (MAS).

Methods: A case report is described. Data was extracted from the medical chart of the patient and a literature review was undertaken.

Results: A 7-year-old girl was transferred to our tertiary center after being admitted for prolonged intermittent fevers, abdominal pain, fatigue and polyarthralgias. On examination, there was symmetrical proximal muscle weakness, a vasculitic lower limb rash, facial erythema with eyelid edema (Fig. 1) and oral mucositis. Initial laboratory exams revealed pancytopenia, high muscle enzymes, increased erythrocyte sedimentation rate with moderately elevated reactive C protein, and hypocomplementemia. She also had non-nephrotic proteinuria, without hematuria. Further investigations showed a positive direct antiglobulin test, antinuclear antibodies, anti-double-stranded DNA, anti-Mi 2 and anti-Ku. Serositis (pericardial and pleural effusions, ascitis) and hepatosplenomegaly were present. Lower limb MRI documented diffuse muscle edema. The diagnosis of an overlap syndrome of JSLE and IMI was established. While being treated for constant bacteremia, the patient became ill-appearing, with persistent fevers, worsened cytopenias, low fibrinogen and high ferritin and triglycerides, and a Macrophage Activation Syndrome (MAS) diagnosis was assumed. The patient received antibiotics and intravenous immunoglobulin, followed by methylprednisolone pulses, IV cyclosporine (CYC), hydroxychloroquine and supportive therapy with progressive improvement.

Due to hypertension (possibly related to CYC) and persistent proteinuria a renal biopsy was performed showing class IV lupus nephritis. After achieving clinical stability, CYC was switched to mycophenolate mofetil as an induction treatment, which is ongoing.

Conclusion: IMI with SLE OS is uncommon, and has seldom been described in children. In addition to fulfilling SLE criteria, our patient had clinical, laboratory and imagologic evidence of IMI. The presence of myositis specific antibodies (especially anti-Mi 2) further supports the diagnosis of an OS rather than an atypical presentation of a lupus myopathy. Juvenile dermatomyositis appears to be the IMI subtype - it is associated with anti-Mi 2, and mild heliotrope and eyelid edema are compatible. Facial rash sparing the nasolabial folds is more suggestive of SLE and treatment are paramount.

Disclosure of Interest
None declared
P153
Bilateral knee avascular necrosis in juvenile dermatomyositis: the pitfalls of diagnosis
I. Dabbak, F. Aeschlimann, S. Breton, P. Quartier, B. Baden Meunier
Hôpital Necker, Paris, France
Correspondence: F. Aeschlimann
Pediatric Rheumatology 2020, 18(Suppl 2)P153

Introduction: Skeletal complications seem to be particularly frequent in JDM: bone mineral density loss before treatment initiation seems more frequent than in other inflammatory diseases and vertebral fractures may occur during the first months of CS therapy. Avascular osteonecrosis (AVN) is a rare complication of corticosteroid (CS) use. Rare cases of multifocal AVN in sometimes unusual locations have previously been described in JDM patients, but information about associated myositis-specific autoantibodies was not available in these cases.

Objectives: To report the occurrence and characteristics of knee AVN in juvenile dermatomyositis (JDM) patients

Methods: Retrospective single-center study of JDM patients with knee AVN followed at the national paediatric rheumatology reference center of Necker hospital between January 2013 and December 2019

Results: Three female patients out of the 55 patients of our JDM cohort (5.5%) developed knee AVN over a period of 6 years. Patient A, a 14-year-old girl, was treated with the successive association of CS and mycophenolate mofetil (MMF), methotrexate (MTX) and eventually ruxolitinib due to persistent severe cutaneous ulcerations. Six months after diagnosis, she presented with bilateral knee swelling and pain of both inflammatory and mechanical character. An articular relapse was suspected, but MRI of the knees revealed multiple bilateral epiphyseal, metaphyseal and diaphyseal bone necrosis sites of the femur and tibia (fig. 1A). Patient B, a 14-year-old adolescent, was treated with CS, MTX, and the subsequent addition of MMF and RTX. She presented 6 months after diagnosis with bilateral knee and ankle pain of mechanical character, with minimal knee effusion and normal range of motion. Whole-body MRI showed giant femorobital (fig. 1B) and ankle bone infection sites. Patient C, a 6-year-old girl, was treated with CS, MTX and RTX. Nine months after diagnosis she started complaining of mechanical left-knee pain. There was no swelling and range of motion was normal. MRI showed a focal epiphyseal lesion of the tibia compatible with bone infection. The three patients were positive for anti-MDA5 antibody (3/11 MDA5 positive JDM patients (27%)), while none of the 44 MDA-negative patients had a diagnosis of AVN.

Conclusion: Knee AVN occurred in 5.5% (3/55) patients of our cohort. All of them had severe anti-MDA5-positive JDM, and AVN was diagnosed within the year following the diagnosis. AVN should be considered as an unexpected complication in JDM patients presenting with joint pain. Larger studies are warranted to assess the possible link between its occurrence and the presence of anti-MDA5 autoantibodies.

Disclosure of Interest
None declared

P154
Successful use of cyclophosphamide in calcinosis in juvenile dermatomyositis
K. C. Warrier1, S. Deepak1, S. Rangaraj1
1Pediatric Rheumatology, Nottingham University Hospitals, Nottingham, United Kingdom
Correspondence: K. C. Warrier
Pediatric Rheumatology 2020, 18(Suppl 2)P154

Introduction: Juvenile Dermatomyositis (JDM) is the commonest inflammatory myopathy of childhood. One of the important causes of morbidity in JDM is calcinosis – dystrophic calcification affecting skin, soft tissue and muscles – seen in approximately one-third of patients. The longer duration of active disease, cardiac involvement and presence of certain myositis specific antibodies have been suggested to increase the risk. The complications include secondary infection, panniculitis, and ulceration, in addition to pain and tenderness. The treatment strategies include anti-inflammatory medications, medications affecting calcium and phosphorus metabolism and surgical options, although the results are mixed with limited evidence. Intravenous Immunoglobulin (IVIG), anti-Tumour Necrosis Factor (TNF) agents, Abatacept and Rituximab have all been tried with varying success, in addition to corticosteroids.

Objectives: To describe the clinical and laboratory characteristics of five patients with JDM with calcinosis, who were treated successfully with Cyclophosphamide.

Methods: Retrospective analysis of digital health records.

Results: Four of the five patients were female (80%) and all aged between 6 and 10 years. Four of them had calcinosis at the time of diagnosis, although they may have had symptoms for 12 to 18 months prior to diagnosis. Skin involvement was severe requiring multiple systemic and topical therapeutic agents in four out of the five patients – significantly more affected than the muscles. One patient had amyopathic subtype with normal Childhood Myositis Assessment Score (CMAS) throughout. None of them had cardiac involvement. All had weakly positive Anti-Nuclear Antibodies (ANA); but were negative for myositis antibodies except the patient with most severe skin involvement and calcinosis (patient 2), who was positive for Anti-TIF1gamma antibodies. Two of the three patients with calcinosis at onset had Cyclophosphamide as the second line agent (chosen due to calcinosis) following systemic corticosteroids with complete resolution of the lesions after six cycles at 500mg/m2. One patient responded to Infliximab, which failed to work after 20 months, following which Cyclophosphamide was tried with good response. The other two patients were given Cyclophosphamide after they failed to respond to Rituximab, which did work for muscle disease. One patient had recurrent episodes of calcinosis needing surgical curettage despite initial response to Cyclophosphamide and later IVIG.

Disclosure of Interest
None declared

Gender Female Female Female Female Male
Age 6y 9m 7y 4m 8y 3m 8y (rash responded) 9y 2m (12 – 18m history)
Age at calcification 13y 6m 13y 6m
Site Upper arms, elbows Elbows, Forearm, Elbows, knees
Skin disease Severe Severe Severe Moderate Mild
Muscle Affected – CMAS 28/52 Affected – CMAS 23/52 Amorphopathic – CMAS 44/52 Mild – CMAS 28/52
Other interventions Surgical curettage Surgical excision Complete resolution Complete resolution
Response Stopped new lesions – later flared Stopped new lesions Infliximab (worked for 20 months)
MTX MMF MTX
Other agents tried MTX Rituximab (muscles responded) MTX for skin & calcinosis
Rituximab (muscles responded) MTX
Dapsone Dapsone

Abbreviations
MTX – Methotrexate
MMF – Mycophenolate Mofetil
IVIG – Intravenous Immunoglobulin
HCQ – Hydroxychloroquine

Conclusion: Although Cyclophosphamide does not feature prominently in literature in the management of calcinosis associated with JDM, it has proven to be useful in this cohort of patients, especially when tried early on for calcinosis. Based on our experience, although the numbers are small, Cyclophosphamide is worth trying in patients with calcinosis, after careful discussion with the patient and family about the risks against benefits.

Disclosure of Interest
None declared
Use of mycophenolate mofetil in inflammatory myopathies of childhood

G. C. Varnier1,2, A. Consolato2,3, I. L. Cheng4, A. Silva Riveiro3, C. Pilkington, A. Raveli9,15 on behalf of Juvenile Dermatomyositis Research Group (JDRG)1
1Paediatric Rheumatology, Royal Manchester Children’s Hospital, Manchester, United Kingdom; 2University of Genoa; 3Paediatric Rheumatology, IRCCS G. Gaslini, Genoa, Italy; 4Paediatric Rheumatology, Great Ormond Street Hospital, London, United Kingdom; 5Sechenov First Moscow State Medical University, Moscow, Russian Federation

Introduction: The juvenile idiopathic inflammatory myopathies (JIIM) consist of heterogeneous inflammatory diseases that primarily affect the skeletal muscles, but can potentially also affect the skin and visceral organs. To date, there is still limited evidence regarding the treatment of these rare disorders.

Objectives: To evaluate the efficacy of mycophenolate mofetil (MMF) in the JIIM.

Methods: Patients diagnosed with JIIM and treated with MMF enrolled in the Juvenile Dermatomyositis Research Group (JDRG) in the United Kingdom and under the care of the G. Gaslini Institute (IGG) in Genoa, Italy were included in this study. Data collected included: sex, onset year, onset age, onset type, clinical manifestations, disease duration, disease course and activity, laboratory data and treatment received. Outcomes were muscle strength/endurance, cutaneous and global disease activity, cumulative damage and physical function. Data were retrospectively analysed at time of starting MMF, after 3, 6, 12 months and last clinical follow up.

Results: 29 children were included in this study, 25 were from the UK cohort and 4 were followed at IGG in Italy. Of these 29 patients, 79.3% were diagnosed with juvenile dermatomyositis and the remaining 20.7% were overlap myositis. We observed a significant improvement in the muscle-related outcome measures (Manual Muscle Test-8, 80 from 50% to 83.3%; Childhood Myositis Activity Score = 52 from 53.5% to 88.9%; Disease Activity Score-Muscle from 55.2% to 84.2%) and overall disease activity (Global Visual analogue scale = 0 from 7.1% to 42.1%), and also an improvement of the skin-related outcome measures (Disease activity score-Skin = 0 from 31% to 42.1%; skin visual analogue scale = 0 from 25% to 47.4%). The number of patients with inactive disease significantly improved from 10.3% at baseline, to 68.8% at last study visit.

The corticosteroid dose was significantly reduced from 0.3 to 0.1 mg/Kg/day. No significant side effects were reported.

Conclusion: The use of MMF has shown to be efficacious and safe in children with IIM, especially in patients with refractory muscle disease.

Disclosure of Interest
None declared

Evaluation of disease activity in children with juvenile dermatomyositis: a comparison between electromyography and whole body-magnetic resonance imaging

S. Carbogn1,2, M. Brusamolin1, S. Lanni2, A. Petaccia3, C. Agostoni2,3, R. Cimaz1, G. Filacchino, F. Minoia, A. Cappellani on behalf of on behalf of Pediatric Rheumatology Group of the Milan Area (PRAGMA)
1University of Milan; 2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; 3ASST G. Pini-CTO; 4Department of Clinical Sciences and Community Health, and RECAP-RD, University of Milan, Milan, Italy

Introduction: Juvenile Dermatomyositis (JDM) is the most common pediatric inflammatory myopathy. The Juvenile Dermatomyositis Activity Index (JDMAI) is composed of four clinical items and has been proposed for use in both clinical and research settings. Needle electromyography (EMG) examination is the most informative part of the electro diagnostic study in myopathic disorders. Whole body-magnetic resonance imaging (WB-MRI) allows to reliably visualize the extent of the inflammatory process and to estimate the total disease burden. To date, the role of EMG and WB-MRI in assessing disease activity in JDM is still not fully defined.

Objectives: To perform a comparison between EMG testing and WB-MRI with disease activity score in a group of JDM patients.

Methods: All patients diagnosed with JDM and referred to our Centre between January 2018 and January 2019 were enrolled. Clinical, laboratory and radiological data were collected. A standardized clinical evaluation through manual muscle test (MMT)-8, hybrid MMT/CMAS (hMC) and JDMAI was performed at each visit; laboratory test included muscle enzymes levels; WB-MRI and EMG were performed within one month of the clinic visit. WB-MRI signal intensity was scored using a 0-2 point scale in 42 muscular groups; myofascial and subcutaneous tissue inflammation were assessed on the upper and lower extremities using a 0-1 point scale. The EMG evaluated the presence of fibrillation potentials on four muscles (deltoid and extensor digitorum communis for the upper limb, and vestis medialis and tibias anterior for the lower limb). The degree of fibrillation potentials in every muscle was scored using a 0-2 point scale (0 = no fibrillation potentials; 1 = presence of fibrillation potentials in < 50% of the sites analyzed; 2 = presence of fibrillation potentials in > 50% of the sites analyzed).

Based on JDMAI, visits were grouped as follows: visits of patients in clinically active disease vs visits of patients in clinically inactive disease.

Mann-Whitney U test, Chi-square/Fisher test and Spearman’s rank correlation coefficient were used for statistical analysis.

Results: Thirteen patients were included in the study for a total of 18 visits. WB-MRI score resulted significantly higher for visits of patients with active disease then in those of patients with clinically inactive disease (p 0.011 and 0.007 respectively). No difference was found in EMG scores for both visits of patients with active and inactive disease (p 0.274 and 0.310, respectively). WB-MRI score had a moderate to high correlation with all clinical evaluation tools of muscle strength or disease activity (Spearman’s rank coefficient = 0.61, 0.58, and 0.86 with MMT-8, hMC and JDMAI respectively), while EMG score had a moderate correlation (0.48, 0.42, and 0.62 with MMT-8, hMC and JDMAI respectively).

Conclusion: In this pilot study, WB-MRI seems to better discriminate between active and inactive disease compared to EMG in patients with JDM. Further studies on larger populations of children with JDM could contribute to define the role of EMG and WB-MRI in the assessment of disease activity.

Disclosure of Interest
None declared
Objectives: To evaluate the finds pulmonary by high-resolution Computerized Tomography (HRCT) in accompanying patients in outpatient pediatric rheumatology unit.

Methods: Retrospective study of 62 patients diagnosed with JDM, which are submitted to the examination of image for clinical monitoring of the disease. TCAR tests were observed in approximately 10 years, including repeated CT scans assessed: interstitial pneumoniatia; pneumomediastium; the presence of nodules; opacity in ground glass; fibros elastic stretch marks; sepal thickening; bronquica wall thickening. Two patients were excluded because they had overlap with systemic lupus erythematosus.

Results: HRCT was retrieved for analysis in 62 of patients. We observed interstitial pneumoniatia in 9 (14.51%), showed; nodules/micronodules in 20 (32.25%), opacity in ground glass in 21 (33.87%), fibroatelectasias in 13 (20.96%), sepal thickening in 7 (11.29%), bronchial wall thickening in 10 (16.12%) and pneumomediastium in 1 (1.61%). Findings were observed during the first 2 years of disease in 62 patients.

Conclusion: We conclude that pulmonary involvement in the diseases devolps more frequently during the first two years of the disease. Careful follow-up with HRCT is essential for early diagnosis and adequate treatment.

Disclosure of Interest
None declared

P159
Survey of the use of share JDM recommendations in clinical practise: report of the PRES JDM working group
C. Papadopoulou1, M. G. Wilkinson1, R. Campaniho-Marques2, J. Wienke3, H. Sanner4, F. Bellutti Enders5, A. van Royen-Kerkhof6, L. J. McCann1, on behalf of JDM Working Group

1UCL Great Ormond Street Institute of Child Health, London, United Kingdom; 2Hospital de Santa Maria, CHULN, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; 3University Medical Center, Utrecht, Netherlands; 4Oslo University Hospital, Oslo, Norway; 5University Children's Hospital Basel, UKBB, Basel, Switzerland; 6Wilhelmina Children’s Hospital, University Medical Center, Utrecht, Netherlands; 7Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom

Correspondence: L. J. McCann
Pediatric Rheumatology 2020, 18(Suppl 2):P159

Introduction: The Single Hub and Access point for paediatric Dermatomyositis (JDM)Enders FB et al, Ann Rheum Dis 2017), directed towards healthcare professionals, aims to provide uniform, optimal access to care via evidence-informed consensus on diagnosis/treatment.

Objectives: Audit impact of SHARE guidance, ascertain opinion of Working Group regarding usefulness and if recommendations need to be revised/updated.

Methods: An online survey was written (CHLM) using Survey Monkey®, ratified/piloted by the Working Party core group, then distributed to the JDM working party (n=140) and EMERGE (PReS trainee/young scientist) group (n=150) November 2019-February 2020. Reminders were sent to encourage participation. Results were collated and descriptive analysis performed. Responses were anonymous, but questions were asked regarding clinical role, time of practice and number of JDM cases treated/year.

Results: 46(16%) responses were received from 39 paediatric rheumatologists, 3 adult rheumatologists, 2 physicians with rheumatology interest, 1 internist, 1 parent representative. 31 (67.4%) had ≥10 years’ experience. Number of cases treated/year varied from <5(17.4%) to >30(23.9%). The majority of respondents reported SHARE guidance as important to their practice; 43.5% stated important/incorporated into hospital/national guidelines and 6.5% stated very important/critical for decision-making. Only 5(10.9%) reported not using SHARE guidance. Overall opinion/experience was positive (Table). 33(73.3%) thought the SHARE guidance was relevant to practice as it is, although 21(46.7%) suggested revision/update. Suggestions for revision included biomarkers, myositis antibodies, novel treatments (biologics/ JAK inhibitors), managing resistant disease/calcinosis and addressing mental health. For effect of guidance on clinical practice, 60% reported no change, with only 20% giving a positive answer.

| Survey Question | Yes N (%) | No N (%) | Unsure N (%) | Total N (%) | Comments (abbreviated) |
|-----------------|-----------|----------|--------------|-------------|------------------------|
| Opinion Clear & easy to use | 41 (89.1) | 1 (2.2) | 4 (8.7) | 46 (100) | More on treatment resistant disease! |
| Useful for education & training | 41 (89.1) | 1 (2.2) | 4 (8.7) | 46 (100) | NHSE restricts treatment options for biologics |
| Helps get investigations | 28 (60.9) | 10 (21.7) | 9 (19.6) | 46 (100) | Guidelines for treatment should be written more accurately |
| Helps get treatment | 31 (67.4) | 10 (21.7) | 5 (10.9) | 46 (100) | - No mention for professionals to check mental health in the flow charts (very important in a chronic illness) |

Experience Contains investigations that cannot access in my hospital | 8 (17.4) | 35 (76.1) | 3 (6.5) | 46 (100) | Cannot access TNF blockers |
| Contains treatments that cannot get in my hospital | 4 (8.9%) | 36 (80) | 5 (11.1) | 45 (97.8) | Do not go far enough to help specialists |
| Needs to be revised & updated | 21 (46.7) | 16 (35.56) | 8 (17.8) | 45 (97.8) | - Revision should be done on a regular basis (2-5 yearly) as for all other recommendations/guidelines. JDM does not need it yet. |
| Relevant to my practice as it is | 33 (73.3) | 5 (11.1) | 7 (15.6) | 45 (97.8) | |

Conclusion: According to this survey, SHARE JDM guideline has been implemented widely. Despite not necessarily changing practice, the majority of respondents rate it as important, clear/easy to use and helpful for investigations/treatment. A small number of respondents cannot access investigations/treatments within the guidance, determined by local/national factors. Almost half of all respondents thought the guideline should be updated to include biomarkers, myositis antibodies, new treatments, resistant disease and mental health.

Disclosure of Interest
None declared
Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome of JDM patients

E. Sag1, S. Demir1, T. Bilginer2, B. Talim3, S. Ozen1
1Pediatric Rheumatology; 2Pediatric Pathology Unit, Hacettepe University, Ankara, Turkey.

Introduction: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy of childhood.

Objectives: We aimed to analyse the clinical features, clinical implications of muscle biopsy scores and myositis specific antibodies (MSA), treatment responses and long-term outcomes of our JDM patients.

Methods: JDM patients followed at Hacettepe University, Department of Pediatric Rheumatology between 2000-2020 were included. Patients data were collected retrospectively from patient files.

Results: Fifty-eight (60.3%) JDM patients were included with a mean age of onset 8.1±4.3 years. The mean follow-up period was 5.66±3.59 years. The classical rash (91%; heliotrope rash and/or Gottron’s papules) and muscle weakness (76%) were the most common presenting features. Electromyography was positive in 23/25 patients and muscle MRI revealed myositis in 12/15 patients. 35 patients had presenting features. Electromyography was positive in 23/25 patients

5. Tansley SL, et al.

Conclusion: Recent advances on muscle biopsy scores, muscle imaging with MRI and myositis specific antibodies may provide us valuable informations for the diagnosis, disease course and prognosis of JDM.

References
1. Varsani H, et al. Ann Rheum Dis, 2015. 74(1): p. 204-10
2. Wedderburn LR, et al. Arthritis Rheum. 2007;57(7):1192-1201.
3. Tansley SL, et al. Arthritis Res Ther. 2014;16(6):R138.
4. Tansley SL, et al. Rheumatology (Oxford). 2014;53(12): p. 2204-2208.
5. Tansley SL, et al. J Autoimmun. 2017;84-55:64.
Disclosure of Interest
R. Nicolai: None declared, I. Caiello: None declared, D. Pires Marafon: None declared, S. Rosina: None declared, L. Bracci Laudiero: None declared, F. Liciardi: None declared, A. Ravelli: None declared, F. De Benedetti
Consultant for: Dr. De Benedetti’s Institution received unrestricted research grants from BMS, Pfizer, Abbvie, Novartis, Novimmune, Roche, SOBI, Sanofi, UBC and travel support from Roche, Novartis, Novimmune, SOBI, G. M. Moneta: None declared

P162
Investigating novel mechanisms of T cells in the pathogenesis of juvenile dermatomyositis
L. R. Marshall1, C. T. Deakin1,2,3, E. C. Rosser1,2, D. Eleftheriou1, L. R. Wedderburn1,2,3, on behalf of the UK Juvenile Dermatomyositis Research Group; 1UCL Great Ormond Street Institute of Child Health; 2Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH and GOSH; 3NIHR Biomedical Research Centre at GOSH, London, United Kingdom
Correspondence: L. R. Marshall
Pediatric Rheumatology 2020, 18(Suppl 2):P162

Introduction: Juvenile Dermatomyositis (JDM) is a rare autoimmune disease causing skin and muscle inflammation with an average onset of 7 years of age. At present, JDM aetiology is poorly understood and current treatment options are not evidence based. This highlights the need for research investigating underlying disease pathogenesis. A skewed T helper (Th)17 phenotype in CD4+ T cells resulting in a Th1/17 imbalance has been observed in both child and adult-onset immune-mediated diseases including rheumatoid arthritis, and multiple sclerosis.

Objectives: The aim of this project is to investigate whether a Th1/17 imbalance can be observed in patients with JDM compared to age-sex-matched child healthy controls (CHC).

Methods: Expression of IL-17 and IFN-γ in CD4+ T cells within peripheral blood mononuclear cells (PBMC) from JDM pre-treatment (n=7), JDM on-treatment (n=28) and CHC (n=22) was assessed by flow cytometry after stimulation with PMA/Ionomycin/Brefeldin A (P/I/B) for 4 hours. For secreted cytokine production, isolated CD4+ T cells were isolated by magnetic separation and stimulated with anti-CD3 or anti-CD3/anti-CD28 for 36 hours in the presence of IL-2. Supernatants were collected by magnetic separation and stimulated with anti-CD3 or anti-CD28 for 36 hours. For secreted cytokine production, isolated CD4+ T cells were isolated by magnetic separation and stimulated with anti-CD3 or anti-CD28 for 36 hours in the presence of IL-2. Supernatants were collected by magnetic separation and stimulated with anti-CD3 or anti-CD28 for 36 hours. For secreted cytokine production, isolated CD4+ T cells were isolated by magnetic separation and stimulated with anti-CD3 or anti-CD28 for 36 hours in the presence of IL-2. Supernatants were collected by magnetic separation and stimulated with anti-CD3 or anti-CD28 for 36 hours.

Results: Both intracellular cytokine staining and stimulation experiments to assess secreted cytokine revealed a decreased trend of IFN-γ production in JDM compared to CHC within CD4+ T cells, regardless of treatment status. The JDM CD4+ T cell phenotype was significantly skewed towards a Th17 phenotype (p<0.0016) compared to control ratios after analysis of CD4+IFN-γ+ to CD4+IL-17+ cells within peripheral blood after PMA/Ionomycin stimulation. A Th17 skew was confirmed when analysing surface marker for Th cells (CD3+CD4+CXCR3+CCR6+), Th17 (CD3+CD4+CXCR3+CCR6+) and Treg (CD3+CD4+CD127-CD25hi) subsetting was carried out using flow cytometry and proliferative capacity of T cells was assessed following stimulation by intra-nuclear staining for Ki67 protein. Finally, fluorescence co-staining of JDM muscle biopsies (n=4) to identify Th1 cells (CD3+CD4+IFN-γ+) was performed to assess possible Th1 migration to the primary disease site.

Conclusion: These novel findings show a Th1/17 imbalance in JDM compared to CHC. Whilst results show promising avenues for further investigation there are no definitive explanations for this low Th1 response at present. Future work aims to investigate memory and naive compartments within JDM pre-treatment CD4+ T cells in addition to further testing of cell markers within the muscle. Additionally, other immune and metabolic pathways that may explain this Th17 skew could be targeted to restore IFN-γ loss in JDM patients.

Disclosure of Interest
None declared

P163
An unusual case of macrophage activation syndrome, complicated by thrombotic microangiopathy, with clinical response to IL-1 blockade
K. Mclellan1, I. Shaheen2, P. French3, V. Harkins3, N. Martin1
1Rheumatology; 2Renal; 3Pathology, Royal Hospital for Children, Glasgow, United Kingdom
Correspondence: K. Mclellan
Pediatric Rheumatology 2020, 18(Suppl 2):P163

Introduction: Macrophage activation syndrome (MAS) with associated thrombotic microangiopathy(TMA) is rare, but has been reported1. We present an adolescent with features of MAS and renal impairment with TMA on renal biopsy. Despite partial steroid response, he remained steroid-dependent until addition of an IL-1 blocker with rapid clinical and biochemical improvement.

Objectives: To report this case of an adolescent with MAS and TMA and describe use of IL-1 blockade in his management.

Methods: Retrospective case review

Results: This previously well 14 year old boy presented with 5 weeks malaise, lethargy, poor appetite and 2 weeks dyspnoea and productive cough. There was no history of fever or rash. Similar to other family members, he had a vomiting illness 5 weeks earlier.

He was tachycardic and tachypnoeic, with pleural effusions and significant renal impairment (urea 18mmol/L, creatinine 124μmol/L, anaemia (Hb 10.7g/dL), thrombocytopenia (platelets 75×109/L), raised inflammatory markers (CRP 99mg/L, ESR 80mm/hr, ferritin 1653ng/mL), albumin 19g/L. He received IV co-amoxiclav and albumin/furosamide infusions. He continued to deteriorate; remaining febrile, hypertensive and oliguric, with worsening peripheral oedema, ascites and pleural effusions, requiring oxygen. Echocardiogram and MRI showed pericardial effusion, with thickened pericardium. Non-specific dural thickening identified on MRI brain. Extensive bacterial and viral investigations were negative. Bone marrow identified increased myeloid series with no haemophagocytosis. ANA, ANCA, ADAMTS13 and complement levels (CH100/AP100/terminal complement complex) were normal. Perforin and SAP/XLP1 expression were normal. XIAP/XLP2 expression was reduced, but with no pathogenic variant on sequence analysis XLP type 2 was excluded. No autoinflammatory diagnosis found on genetic testing. VIP3 panel2 identified class 3 variants of unknown significance in IFIH1, LACCI, NLRP6, HTR1A, SCN9A, TGFBR2 and NOTCH3.

On day 9 he was given 600mg/m² methylprednisolone followed by oral steroids. High dose steroids resulted in transient biochemical improvements, but this was not sustained, requiring further IV doses. Chest drains removed high volume inflammatory exudate. Renal biopsy on day 20 showed TMA; abnormal glomeruli, increased mesangial and endocapillary cellularity, fragmented red blood cells within the mesangium, with mesangiolysis and fibrin thrombus. Full body MRI and PET excluded malignancy. MMF, introduced on day 48, was stopped due to worsening cytopenia. IVIG had no apparent effect. Anakinra, started on day 60, had dramatic benefit clinically and biochemically. He reported rapid subjective improvement, renal function and ferritin levels improved and diuretics were stopped.

He was subsequently managed as an outpatient; anti-hypertensives and oral steroids slowly weaned and stopped. 18 months later he had a mild recurrence with an intercurrent infection (ferritin 780ng/mL) which responded to IV methylprednisolone and twice daily anakinra. He responded clinically and biochemically and has remained well since.

Disclosure of Interest
None declared
Macrophage activation syndrome is a preventable life-threatening end point syndrome

I gathered a data of nine patients who were presented to Dev Children’s Hospital as MAS or impending MAS between August 2018 and March 2020. I compared all available clinical and laboratory data of these nine patients in context of HLH-2004 protocol2, Modified 2009 HLH criteria2, 2014 H score for reactive hemophagocytic syndrome and 2016 sJIA-MAS diagnostic criteria5 and 2019 Ferritin:ESR Ratio6.

Results: Table 1

| Parameter | N (%) | Number of Patients |
|-----------|-------|--------------------|
| Fever     | 9 (100%) |                     |
| Rash      | 6 (66.6%) |                     |
| Bleeding manifestations | 2 (22.2%) | |
| Hepatomegaly | 6 (66.6%) | |
| Splenomegaly | 2 (22.2%) | |
| Lymphadenopathy | 3 (33.3%) | |
| CNS dysfunction | 4 (44.4%) | |
| H: <9 gm% | 6 (66.6%) | |
| Neutrophils < 1 * 10^9 / L | 2 (22.2%) | |
| PLT >181 * 10^9 / L | 6 (66.6%) | |
| PLT <=100 * 10^9 / L | 1 (11.1%) | |
| Number of Cytopenias | | |
| 1 lineage | 6 (66.6%) | |
| 2 lineage | 2 (22.2%) | |
| 3 lineage | 1 (11.1%) | |
| SGPT > 48 u/L | 6 (66.6%) | |
| SGPT > 30 | 7 (77.7%) | |
| Triglycerides (mg/dl) >156 mg/dl | 6 (66.6%) | |

Conclusion: The association between MAS and TMA has recently been recognised1. Our case showed clear response to high-dose steroids and achieved sustained remission with IL-1 blockade. This could be a useful therapeutic option for future patients presenting with features of both MAS and TMA.

Disclosure of Interest
None declared.
Table 1 (abstract P164), showed detailed analysis of clinical and laboratory data of our cohort in context of parameters taken from above mentioned criterias (Continued)

| Parameter                           | N (%) – Number of Patients |
|-------------------------------------|-----------------------------|
| >132 mg/dl                          | 7 (77.7%)                   |
| >265 mg/dl                          | 2 (22.2%)                   |
| Fibrinogen (mg/dl)                  |                             |
| ≤360                                | 7 (77.7%)                   |
| ≤250                                | 5 (55.5%)                   |
| ≤150                                | 2 (22.2%)                   |
| Ferritin level (ng/ml)              |                             |
| > 684 -                             | 9 (100%)                    |
| > 500                               | 9 (100%)                    |
| < 2000                              | 2 (22.2%)                   |
| 2000-6000                           | 2 (22.2%)                   |
| < 6000                              | 5 (55.5%)                   |
| Increased Ferritin : ESR Ratio      | 9 (100%)                    |
| Bone Marrow                         | 1 (11.1%)                   |
| Hemophagocytosis³                  |                             |
| LDH (>500IU/L)                      | 7 (77.7%)                   |
| Low Sodium level                   | 3 (33.3%)                   |
| Abnormal PT,aPTT                    | 3 (33.3%)                   |
| Elevated bilirubin                  | 1 (11.1%)                   |
| Decreased albumin                   | 3 (33.3%)                   |
| CRP >40mg/L                         | 6 (66.6%)                   |
| Subtle progressive changes in laboratory parameters rather than actual value | 9 (100%) |
| Responded to Oral /IV steroids      | 9 (100%)                    |

³= Bone marrow examination was performed only in five patients

NK cell function test and CD25 level was not done for any of these patients

Results: Several studies are currently ongoing. A project aimed to establish and validate a risk score for MAS in sJIA patients using routine laboratory parameters of disease activity and severity has already completed the construction phase. Recently, building of a validation cohort comprising data form 182 patients from 10 paediatric rheumatologic centers has been accomplished and is awaiting analysis (Claudia Bracaglia). A second project focused on MAS patients with systemic thrombotic microangiopathy (TMA) has just completed the collection of 27 patients with MAS and TMA from 18 centers in 9 countries and results will soon be published (Francesca Minoia). Furthermore, the MAS/sJIA WP participated in the data collection phase of a project on the development of new criteria for primary HLH (Jan-Inge Henter and AnnaCarin Horne).

A main goal of the WP is to improve clinical care. Within the project Current treatment in sJIA and MAS/secondary hemophagocytic lymphohistiocytosis (sHLH): a PReS/PRINTO survey (Francesca Minoia and Sebastiaan Vastert) the initiators aim to better understand the real-life experience in sJIA and MAS/sHLH treatment in pediatric rheumatology centers. To foster the achievement of a uniform approach, pediatric hemato-oncologists and Intensive Care Unit physicians will be involved, to capture all the different settings in which MAS/sHLH patients may be treated. The project was proposed for the first PReS/PRINTO grant and was ranked second.

Among translational science activities, MAS/sJIA WP members (Sebastiaan Vastert and Claudia Bracaglia) aim to collect biosamples and clinical data from patients with treatment refractory/resistant sJIA, connecting existing large national sJIA cohorts and open for new patients from paediatric rheumatology centers throughout Europe/world (ReSySt study).

A second translational project focuses on the role of viral triggers of MAS and proposes to analyze type I IFN score and IL-18 expression in MAS and MAS risk patients to deepen understanding on type 1 interferons as critical regulators of IL-18 expression (Christoph Kessel).

Finally, the MAS/sJIA WP aims to organize a focused PReS academic course on sJIA and MAS in 2021.

Conclusion: At present, the MAS/sJIA WP is coordinating several clinical and translational research activities. Any proposal for new collaborative projects is highly appreciated.

Claudia Bracaglia, Chair
Francesca Minoia, Secretary and Lead of Clinical Care Pillar
Sebastiaan Vastert, Lead of Training&Education Pillar
Christoph Kessel, Lead of Science&Research Pillar

Disclosure of Interest
None declared

P166
Hemophagocytic lymphohistiocytosis in infancy: a case series
H. Bhaskaran, S. Balan
Department of Clinical Immunology and Rheumatology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Ernakulam, India

Correspondence: H. Bhaskaran
Pediatric Rheumatology 2020, 18(Suppl 2):P166

Introduction: Hemophagocytic lymphohistiocytosis (HLH) is an immunological disorder characterized by clinical signs and symptoms of severe uncontrolled inflammation, due to massive release of inflammatory cytokines. A delay in diagnosis is common, and is one of the factors that determine the poor outcome. HLH is classified into primary (pHLH) and secondary (sHLH). It is important to differentiate between the two as management differs.

Objectives: To describe the clinical and laboratory profile of HLH in infancy.

Methods: The electronic case files of children (age<1 year) diagnosed with HLH at the AIMS, Kochi, Kerala, between January 2012 and December 2019, was retrospectively reviewed and described.

Results: Eight infants, with age range 1.5 months to 7 months, were clinically diagnosed with HLH. All were immunised and had normal
development for age. None had a family history suggestive of HLH. Third degree consanguinity was present in parents of patient no.5 and second degree for patient no.7. Duration of symptoms before presentation ranged from 2 days to 68 days. Duration of follow up with us ranged from 12 days to 192 days, for those who expired.

All, eight of them, had fever, anemia, thrombocytopenia, hyperferritinemia, transaminitis, raised LDH and CRP. Lymphadenopathy was present only in patient no.4. Before starting specific treatment patient no. 7 had Pseudomonas sepsis, patient no.5 had Roseomonas galiardi infection; patient no.3 and 4 were IgM CMV positive but their PCR was negative. Both of them had received prior blood transfusion.

Before making a definitive diagnosis of HLH patients were treated for PUO, sepsis ? cause and acute liver failure. There was a delay in diagnosis for all patients except patient no.7. All of them were treated with HLH 2004 protocol with modification according to clinical status of the patient. Later, broad spectrum antibiotics, antifungals and antivirals were used for all. Anakinra was tried for patient no.5.

Five patients (pHLH) succumbed to sepsis and MODS and three (one pHLH and two sHLH) are continuing follow up. HSCT was not done in any of them. Other clinical features are shown in Table 1.

**Conclusion:** Making a timely diagnosis of HLH is difficult. Differentiating pHLH from sHLH is very important as the management differs. Genetic testing should be done for all infants with HLH. Negative genetic study doesn’t rule out pHLH. The only curative treatment for pHLH is HSCT. sHLH infants, once their primary condition is treated, can have normal survival. Hyperbilirubinemia, splenomegaly, neutropenia, hepatomegaly, tissue hemophagocytes and hypertiglycieridemia were more common in pHLH.

**Disclosure of Interest**

None declared

---

**Table 1 (abstract P166). Clinical and lab characteristics in infantile HLH**

| No | rash | jaundice | Splenomegaly | Hepatomegaly | Neutropenia (<1000/mm³) | Thrombocytopenia (<50,000/mm³) | Hyperferritinemia (>1500 µg/dl) | Hyperfibrinogenemia (>400 mg/dl) | Hypertriglyceridemia (>500 mg/dl) | Hemo- phagocytosis | Mutated |
|----|------|----------|--------------|--------------|-------------------------|-------------------------------|-------------------------------|-------------------------------|--------------------------------|----------------|---------|
| 1  | 1    | 0        | 1            | 0            | 1                       | 0                             | 0                             | 0                             | 1                              | Neg           | 0       |
| 2* | 1    | 0        | 0            | 1            | 1                       | 1                             | 1                             | 0                             | 0                              | Neg           | 0       |
| 3* | 0    | 1        | 1            | 1            | 1                       | 0                             | 1                             | 0                             | 0                              | Neg           | 0       |
| 4* | 0    | 0        | 1            | 1            | 1                       | 1                             | 1                             | 1                             | 1                              | Neg           | 0       |
| 5* | 0    | 0        | 0            | 1            | 1                       | 0                             | 1                             | 0                             | 0                              | Neg           | 0       |
| 6   | 1    | 0        | 0            | 1            | 0                       | 1                             | 1                             | 0                             | 0                              | Neg           | 0       |
| 7   | 1    | 0        | 0            | 1            | 0                       | 0                             | 1                             | 0                             | 0                              | Neg           | 0       |
| 8   | 1    | 0        | 0            | 1            | 1                       | 1                             | 1                             | 1                             | 1                              | Neg           | 0       |

---

**P167**

**Macrophage activation syndrome: 12 years data from an indian center**

P. Pal, J. Bathia, P. P. Giri
Pediatic Rheumatology, Institute of Child Health Kolkata, Kolkata 700017, India

**Correspondence:** P. Pal
Pediatic Rheumatology 2020, 18(Suppl 2):P167

**Introduction:** Macrophage Activation Syndrome (MAS) is a dreaded complication of systemic inflammatory diseases and is most commonly seen in systemic onset juvenile idiopathic arthritis (JIA). Data of patients admitted in the Department of Pediatric Rheumatology, Institute of Child Health, Kolkata diagnosed as having MAS, admitted between July 2008 and April 2020 was tabulated and retrospectively analyzed.

**Objectives:** To evaluate the clinical features, laboratory findings and outcomes in pediatric MAS, assess the response to different pharmacological therapies, and finally to identify possible factors associated with an unfavourable outcome.

**Methods:** The data of patients diagnosed with MAS over the study period was analyzed for the clinical and laboratory features, treatment details, response to therapy and outcome.

**Results:** 35 patients were diagnosed as having MAS. Primary illness was sJIA in 29 (82%), SLE in 5 (14%) and Kawasaki Disease (KD) in 1(4%). All had fever with varying degrees of multi systemic involvement. Hyperferritinemia was universally present. In the absence of Anakinra in India, pulse methylprednisolone with Cyclosporine was used for treating the majority.10 patients (28.5%) expired. Patients on biologics and steroids can present with a silent MAS which may be difficult to diagnose.

**Conclusion:** MAS is a near fatal complication with protean manifestations and multi organ dysfunction. Hyperferritinemia is characteristic, higher values being associated with increased mortality. Patients resistant to steroids and cyclosporine had a poor prognosis. Early recognition with aggressive management forms the backbone of a successful outcome as reflected by improved prognosis over successive years. Late presentations with multiorgan dysfunction are associated with the poorest outcomes.

**Disclosure of Interest**

None declared

---

**P168**

**Life-threatening macrophage activation syndrome with fulminant myocarditis successfully rescued by high dose intravenous Anakinra**

A. Meneghel1, G. Martini1, A. Amigoni2, A. Pettenazzo2, M. Padalino3, F. Zulian1
1Department for Women and Child Health-University Hospital of Padua, Pediatric Rheumatology Unit; 2Department for Women and Child-University Hospital of Padua, Pediatric Intensive Care Unit; 3Department of Cardiac, Thoracic and Vascular Sciences, Pediatric and Congenital Cardiac Surgery, Padua, Italy

**Correspondence:** A. Meneghel
Pediatric Rheumatology 2020, 18(Suppl 2):P168

**Introduction:** Macrophage activation syndrome (MAS) is a rare, potentially life-threatening complication of some rheumatologic diseases1.

**Objectives:** We report the case of a child with systemic onset Juvenile Idiopathic Arthritis (sJIA) complicated by severe MAS and acute myocarditis, needing veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO), successfully rescued by high dose intravenous Anakinra (HDIV-ANA).

**Methods:** Case report’s description

**Results:** A two-year-old boy presented with one month history of fever associated with limping gait, cervical lymphadenopathy and skin rash. Laboratory tests showed elevation of inflammatory markers and ferritin. By exclusion criteria, sJIA was diagnosed and steroid therapy started. After a soft tissue bacterial infection, fever relapsed and laboratory tests were consistent with MAS (day 1): Hb 8.5 g/dL, PLT 44000/mm³; FDP 1522 ug/L, CRP 100 mg/L, ferritin 2200 ug/L. High doses intravenous metilprednisolone and oral Cyclosporin A (CSA) were started. On day 2 he presented a Systemic Capillary Leak Syndrome and acute myocarditis. He was admitted into the pediatric intensive care unit (PICU) where intravenous immunoglobulin and subcutaneous Anakinra (ANA) were added. On day 4, due to an
episode of cardiac arrest, VA-ECMO was started and we tried high dose intravenous ANA (HDIV-ANA, 8 mg/Kg/day q6h). This treatment brought immediate benefit: echocardiography showed progressive resolution of myocarditis so that VA-ECMO was definitely weaned off in six days. Laboratory test showed isolated neutropenia (PMNs 0-100/mm³). Suspecting a iatrogenic cause, HDIV-ANA was gradually reduced to the maintenance dose without benefit. On day 22, ANA was stopped and neutropenia resolved. Analysis of PRF1 gene revealed a mutation (c.[272C>T] p.[Ala91Val]) in heterozygosis. 49 days later, HDIV-ANA was stopped and neutropenia resolved. Analysis of PRF1 gene revealed a mutation (c.[272C>T] p.[Ala91Val]) in heterozygosis. 49 days after admission he was discharged on oral prednisone and CSA. Neither neurological nor other organ consequences related to MAS were revealed a mutation (c.[272C>T] p.[Ala91Val]) in heterozygosis. 49 days after admission he was discharged on oral prednisone and CSA. ACA was restarted with rapid improvement and no side effects reported. A few months later, on tapering down of therapy, he relapsed. ANA was restarted with rapid improvement and no side effects, including neutropenia. Currently, after 12 months, the disease is in clinical remission on medication.

Conclusion: MAS is a rare life-threatening complication of sJIA, triggered by infections in up to one-third of the patients. It is the result of a cytokine storm that lead to a dysregulated inflammatory activation of the immune system, with rapid progression to multiorgan failure. Treatment usually includes high dose corticosteroids and immunosuppressive agents. Recently, the use of selective cytokine inhibitors has been suggested. No standardized guidelines are available to date, but the use of ANA has been already reported, pointing out the need for a higher doses regimen in refractory cases. MAS in our patient appeared after a soft tissue infection which could have act as triggering factor in a patient with sJIA and genetic predisposing pattern. The choice of intravenous administration of ANA was partly due to the generalized edema and partly to the severe discoaugulopathy. Considering the higher doses needed for rapidly suppressing the cytokine storm and ANA pharmacokinetics, we split the daily dose into four administrations. No major adverse events were reported, except for a transient neutropenia, already reported 6.

Based on our experience, HDIV-ANA is a safe and effective treatment for refractory life-threatening sJIA-related MAS. This therapeutic approach may be also considered in the current pandemic COVID-19 emergency where recent evidence showed IL1-driven MAS-like complication triggered by SARS-COV-2 virus as predictor of bad outcome.

Disclosure of Interest
None declared.

P169
Pulmonary involvement as initial manifestation of pediatric Sjögren
C. S. Santos 1, C. Moriano Morales 2, E. Diez Alvarez 3, E. F. Bollo de Miguel 2
1Complejo asistencial universitario de león, LEON; 2Complejo Asistencial Universitario de León, León; 3Complejo Asistencial Universitario tario de León, LEON, Spain
Correspondence: C. S. Santos
Pediatric Rheumatology 2020, 18(Suppl 2):P169

Introduction: Sjögren’s syndrome is a systemic autoimmune disease characterized by dry syndrome and lymphocytic infiltration of the exocrine and extraglandular glands. Pulmonary involvement in primary Sjögren’s syndrome occurs in 9-20% of patients, with very heterogeneous manifestations, and occasionally as an initial manifestation. Diffuse interstitial lung involvement is one of the most characteristic pulmonary manifestations and the most frequent subtypes in lung biopsies are interstitial lymphocytic pneumonia and non-specific interstitial pneumonia. Objectives: 14-year-old girl presented to our hospital because of bilateral interstitial involvement with ground glass areas in lower lobes of both lungs on thorax and abdominal CT scan after for kidney stones follow-up. The patient had grade 1 mMRC dyspnoea and dry cough but denied having symptoms of arthralgia or arthritis, photosensitivity, oral and genital ulcers, Raynaud’s phenomenon or episodes of dry mucosa. She had no history of autoimmune disease nor family antecedents of any autoimmune disease. A physical examination disclosed no finger clubbing or swollen superficial lymph nodes but indicated crackles on pulmonary auscultation. Laboratory work showed elevated acute phase reactants, positive rheumatoid factor, positive antinuclear antibodies (1/40), positive cytoplasmic antineutrophil antibodies (1/320) and IgG and IgA hypergammaglobulinemia. An examination for autoantibodies were negative for anti-SS-A, anti-SS-B, anti Jo-1, anticytomegolivire and anti-scl-70 antibodies. Iontophoresis with pilocarpine and 6-minute walk test was also normal. Pulmonary function tests demonstrated a mild restrictive impairment and a reduced percent diffusion capacity for carbon monoxide of 55%. Fibreoptic bronchoscopy showed acute inflammation in bronchial mucosa. Flow cytometry of bronchoalveolar lavage and cytology showed lymphohyphositis with a 15% of CD4 and 85% of CD8 lymphocytes in bronchoalveolar lavage fluid. Finally, a transbronchial lung biopsy lead to a definitive diagnosis, showing mixed interstitial inflammation and lymphocytic follicular hyperplasia with formation of germinal centers, suggestive of a lymphoid interstitial pneumonia of unreleased autoimmune etiology. Throughout time, the patient reported progression of her symptoms with increasing dyspnœa, persistent dry cough, xerostomia and arthralgia. Schimrer and Rose Bengal dye test were negative, and a salivary gland biopsy showed interstitial plasmacytosis and no IgG4 plasma cells expression which suggested Sjögren’s disease. A high resolution computerized axal tomography was requested, suggesting organizing pneumonia in the context of Sjögren’s disease.

Methods: Several studies indicate that lung involvement in Sjögren’s is more frequent in advanced stages of the disease and rarely as an initial manifestation. Sjögren’s syndrome in paediatric is rare and the subtype of secondary Sjögren’s is the most common. The course is longer, and the symptoms are more heterogeneous than in adulthood. The diagnosis in children is delayed, because children less frequently report dryness and frequently present with extra-glandular clinical features suggestive of other autoimmune diseases. A systematic review on primary Sjögren’s syndrome in male and paediatric population reported a 2.4% of pulmonary involvement in paediatric patients. Pulmonary involvement is associated with an increase in the mortality of patients with Sjögren’s, therefore, it is essential to periodically monitor patients with respiratory symptoms, making an early diagnosis and treatment of the disease.

Results:
Conclusion: We present a case of a patient with childhood Sjögren’s disease with atypical onset of disease with lung involvement.

Disclosure of Interest
None declared.

P170
A frontal bone osseous lesion: an unusual presentation of childhood sarcoidosis
S. Blackstock, S. Compeyrot-Lacassagne
Paediatric Rheumatology, Great Ormond Street Hospital, London, United Kingdom
Correspondence: S. Blackstock
Pediatric Rheumatology 2020, 18(Suppl 2):P170

Introduction: Sarcoidosis is a multi-system disorder. Little is known about its pathogenesis. In children, the early onset sarcoidosis phenotype including Blau syndrome is more often seen. The diagnosis of sarcoidosis is confirmed by demonstrating a typical non-caseating granuloma on a biopsy specimen. Other granulomatous diseases should be excluded, in particular mycobacterial infections, Crohn’s disease and immunodeficiencies. The clinical presentation may vary depending on the organs involved and the age of the patient.

Objectives: We are reporting the case of a boy with a presentation of bone sarcoidosis at a young age. This is a rare phenotype in children.

Methods: Clinical details were retrospectively collated using routine clinical records. Confirmation of diagnosis was confirmed with bone biopsy.

Results: A 5 year old non-identical twin boy of Ghanaian descent born in the UK had a slowly growing, painless frontal bone mass which started to develop from 7 months of age. He was developmentally normal, with no history of fever, rashes or joint pains. Examination findings revealed frontal bossing while the remainder of the musculoskeletal examination was normal. There was no evidence of rashes, hepatosplenomegaly and ocular examination was normal.

Disclosure of Interest
None declared.
The patient was initially referred for neurosurgical review with suspected fibrous dysplasia, after an initial MRI scan of the head revealed abnormal marrow signal and expansion of the frontal bone, with no soft tissue swelling. However, the CT scan of the calvarium was not suggestive of fibrous dysplasia. Consequently, bone biopsy was performed demonstrating inflammation with granuloma formation. He was referred to Infectious Diseases and Rheumatology. There was no travel history and no TB contact. Quantiferon TB was negative. Infectious work-up was negative especially for mycobacterial infections.

Rheumatology work-up identified on skeletal survey another bone location: a well-defined lytic lesion in the right distal fibula that was biopsied. Infection cultures and PCR were negative. Histopathology identified fibrous tissue and poorly formed granulomas. Laboratory investigations revealed a mild microcytic anaemia with iron deficiency and eosinophilia. He had normal serum calcium and vitamin D and his ESR was 25 mm/hr. ANA, ANCA and rheumatoid factor were negative, and complement C3 and C4 were normal. His serum Angiotensin Converting Enzyme (ACE) level was raised at 125 nmol/ml/min (normal <40 nmol/ml/min). Investigations revealed mild renal impairment with normal urinary tests including normal calcium, protein and tubular proteins. Ultrasound of the kidneys was normal. Chest X-ray was normal. Lung function was performed and was normal. DLCO couldn’t be performed due to low lung volume.

Vascular and inflammation genetic panel identified a variant in the NEMO gene. Functional studies excluded NEMO deficiency and patient did not display any of the clinical features. However, a pattern of dysregulated T cells response was identified. He was treated with oral steroids and methotrexate. The oral steroids were successfully weaned off. He has been successfully treated with Methotrexate 10mg s/c to initially stabilise disease with no bone growth, and had no significant side effects.

Repeat MRI 2 years later showed increased burden of disease with other newly affected sites however, including the right femoral diaphysis and signal changes in the left tibial metaphysis. Based on the MRI and increasing musculoskeletal pain, decision was made to escalate to anti-TNF (adalumumab) with good clinical response. Conclusion: Bone sarcoidosis is rare in children but this should be considered in the differential diagnoses when granulomatous inflammation is identified on histopathology. Response to steroids and methotrexate is usually good but some patients will need escalation to anti-TNF.

Disclosure of Interest
None declared

Table 1 (abstract P171). showed characteristics of five children with persistent MSK night pains

| Age (years)/ Sex | 7/M | 4/F | 5/F | 2.5/M | 2.5/F |
|------------------|-----|-----|-----|-------|-------|
| Joint involvement | Hip | Hip | Elbow | Knee | Elbow |
| MSK pain | Thigh | Thigh | Calf | Ankle | Thigh |
| Fever | + | + | + | - | + |
| Persistent Limp | + | + | + | + | - |
| Organomegaly | + | - | - | - | + |
| Lymphadenopathy | + | - | - | - | + |
| HB (gryn/l) | 9 | 6.7 | 8 | 8 | 6 |
| TLC(/cumm) | 7560 | 9300 | 9800 | 6500 | 30,300 |
| Platelet (/l) | 1,52,000 | 1,90,000 | 3,21,000 | 1,65,000 | 7,22,000 |
| ESRI(mm/hr) | 42 | 46 | 81 | 45 | 53 |
| CRP(mg/L) | 56 | 35 | 65 | 34 | 125 |
| LDH(U/L) | 708 | 300 | 321 | 456 | 461 |
| Final Diagnosis | NHL ALL ALL ALL | Multisystem | LCH |

Abbreviations: MSK=musculoskeletal, NHL= non Hodgkin lymphoma , ALL= acute lymphoblastic leukemia, LCH = langerhans cell histiocytosis, LDH=lactate dehydrogenase
Complete remission of auricular relapsing polychondritis by treatment with adalimumab and methotrexate

M. Tsim1, K. Stefanakis1, V. Derventzoglou1, E. Tsitsami1
1Pediatric Rheumatology Unit, First Department of Pediatrics, School Of Medicine, University Of Athens, Children’s Hospital “Aghia Sofia”, Athens, Greece

Introduction: Relapsing polychondritis (RP) is a rare disease with wide spectrum, ranging from isolated auricular chondritis, to life threatening cardiopulmonary manifestations. Even isolated auricular inflammation may result in significant morbidity due to collapse of the external ear canal leading to conductive deafness and to significant deformity. On the other hand auricular chondritis may represent the inaugural symptom of a more aggressive, systemic disease. In children RP is rarer than in adults and often has a more severe course and more frequent involvement of the respiratory tract. Heart valve damage may develop silently with significant morbidity and mortality. Isolated auricular involvement may be complicated with sensorineural or conductive deafness and significant structural damage. First line treatment is corticosteroids. There are conflicting reports on the efficacy of DMARDs and TNF inhibitors

Objectives: To report the clinical picture of isolated auricular relapsing polychondritis and the response to anti-TNFa treatment with adalimumab

Methods: Case presentation

Results: A 9-year-old girl was reported to the pediatric rheumatology unit by the ENT department due to 4 recurrent episodes of bilateral ear (more severe left) inflammation, with painful violaceous edema of the pinna of the ear. After 15 months of treatment, in an effort to prolong the intervals of adalimumab administration, bilateral auricular chondritis relapsed. After 24 months of MTX and 21 months of adalimumab administration inflammation was put in complete remission. The following year no flares or involvement of other systems were observed, under methotrexate and adalimumab treatment.

Conclusion: In this patient isolated auricular relapsing polychondritis was unresponsive to NSAIDs. Steroids and methotrexate greatly improved inflammation but did not induce complete remission. Complete remission was achieved by addition of adalimumab to methotrexate treatment, which also allowed for steroids discontinuation.

Disclosure of Interest
None declared

First ever single center study revealing spectrum of rheumatic diseases in 114 children from an Indian State of Gujarat

D. B. Pandya, on behalf of Dr Mehul Mitra, Pankaj Buch, Sonal Shah, Harsh Dobariya, Jay Virani, Jay Dhirvani, Nishant Dharandiya, Nayan Kalavadia, Hitesh Bhambhani, Rakesh Patel
Pediatric Rheumatology & Immunology, Dev Children’s Hospital, Rajkot, India

Introduction
There is very limited information and awareness about pediatric rheumatic and immunodeficiency diseases amongst primary physicians1,2,3 in Gujarat and to make this matter even worse, we are not having a single exclusive pediatric rheumatology and immunology centre for a population of around 60 million.

Objectives
To guesstimate a status of children with rheumatic and immunodeficiency diseases in Gujarat and spectrum of these diseases at Dev Children’s Hospital.

Methods
I gathered a retrospective data of 174 patients who attended Dev Children’s Hospital’s Rheumatology department from January 2019 and January 2020. Out of these, 114 children with confirmed diagnosis of inflammatory rheumatic diseases and suspected primary immunodeficiencies were included. Patients with non-inflammatory musculoskeletal(MSK) pains and non-rheumatic diseases causing MSK pains were excluded. My collected data included referral details, demographics, clinical presentation, laboratory results and diagnosis.

Results
Majority of the cases were referred by pediatricians, orthopedicians, hemat-o-oncologist and general physicians. Main reasons for referral were joint involvement , undiagnosed fever , multisystem disease and elevated inflammatory markers. Many physicians had put a diagnosis like rheumatoid/rheumatic arthritis, autoimmune disease or connective tissue disease. Almost 80% of patients had been evaluated with RF, ASO titer, ANA and joint imaging irrespective of clinical pattern by their primary physicians before referral. Fever , MSK involvement, extreme fatigue, constitutional symptoms, skin and mucosal involvement were prominent complaints noted by me. Family history of rheumatic, primary immunodeficiency (PID) or consanguinity was found in 1/3 of patients. Anemia of chronic disease, elevated ESR and thrombocytosis were almost universal laboratory findings in our cohort.

Conclusion
Rheumatic diseases in children are not anymore rare but due to lack of expertise and awareness , these children are not getting diagnosed. Many cases were advised unnecessary rheumatological investigations even before referral. Prolonged fever, MSK involvement, skin manifestations, fatigue, constitutional symptoms and unexplained multisystem features with systemic inflammation mainly elevated ESR are found to be very sensitive features to suspect rheumatological problems. The frequency of various rheumatic conditions can be depicted as Infections > Vasculitis > JIA > CTDs > PID in our cohort.

Trial registration identifying number
1. Review.Indian J Pediatr2010 Sep;77(9):993-6.doi: 10.1007/s12098-010-0134-x. Epub 2010 Sep 3.

The Place of Pediatric Rheumatology in India
Sujata Sawhney1, Prudence Manners2
1. Journal of Natural science, Biology & Medicine-2018

Clinico-epidemiological profile of pediatric rheumatology disorders in Eastern India PratapKumarPatra, ManishKumar
Department of Pediatrics, All Institute of Medical Sciences, Patna, Bihar, India

3. International Journal of Advanced Medical Health & Research (IJPMER)
Pediatric rheumatology: An under-recognized subspecialty in India
Year : 2017 | Volume : 4 | Issue : 2 | Page : 47-53
AkhilaKavirayani1, SumaBalan2

18(Suppl 2):82 Page 26 of 111
1 Department of Paediatric Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
2 Department of Paediatric Rheumatology, Amrita Institute of Medical Sciences, Kochi, Kerala, India
4. Research Article: Pediatric Rheumatology: Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus

Alberto Martini, Angelo Ravelli, Tadej Avci, Michael W. Beresford, Ruben Burgos-Vargas, Ruben Cuttica, Norman T. Ilowitz, Raju Khubchandani, Ronald M. Laxer, Daniel J. Lovell, Ross E. Petty, Carol A. Wallace, Nico M. Wulftraat, Angela Pistorio, Nicolinco Ruperto and for the Pediatric Rheumatology International Trials Organization (PRINTO)

Disclosure of Interest
None declared

Table 1 (abstract P173). Showed demographics and spectrum of pediatric rheumatic diseases in our cohort

| Age N(%) | Sex | Stomach & Auto inflammatory syndromes |
|---|---|---|
| Age <5 | Years | Age >10 |
| 48(42%) | 37(34%) | 27(24%) |

Group of Conditions N(%) |

| Vasculitis | Juvenile idiopathic arthritis (JIA) |
|---|---|
| 27 | 24% |

| Infections | cf Juvenile idiopathic arthritis (JIA) |
|---|---|
| 29 | 25% |

| Brucella > | ANA >ve JIA |
|---|---|

| Screening | Suspected Primary Immune Deficiencies |
|---|---|
| 2 of 3 | 10 |

| Type | Primary Immune Deficiencies |
|---|---|
| 1 | 17 |

Macrophage activation syndrome was seen to be associated with sJIA in 4 patients, SLE in 2 patients, PID in 1 patient and brucellosis in 2 patients (Abbreviations: PSRA=Post Streptococcal Reactive Arthritis, ARF=Aureus Rheumatic Fever, ReA=Reactive Arthritis, ESRA= esphesities-spondylitis related arthritis, APECED= Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, IPEX=Immuno dysregulation-polyendocrinopathy-candidiasis-ectodermal dystrophy, sJIA= Systemic Juvenile idiopathic arthritis, JIA= Juvenile idiopathic arthritis, sSLE = Systemic lupus erythematosus, PsA = Psoriatic arthritis, MRSA = Methicillin-resistant Staphylococcus aureus, TBI = Tuberous sclerosis, CRMO = Cervical radiculomyelopathy, ENU = Enuresis nocturna, DCD = Developmental coordination disorder, PMS = Premenstrual syndrome, ALT = Alanine aminotransferase, AST = Aspartate aminotransferase, GGT = Gamma-glutamyltransferase, ALP = Alkaline phosphatase, BUN = Blood urea nitrogen, Cr = Creatinine, WBC = White blood cells, ALT = Aspartate aminotransferase, AST = Aspartate aminotransferase |

P174 Parasites and arthritis: an unheard duo among children
S. Pellizzari1, E. Giacomelli, A. Maggolo, E. Tadidotto, G. Melotti1, G. Aiello1, M. Maschio1, F. Caldonazzi2, S. Pieropan1
1Pediatric, Azienda Ospedaliero Universitaria Integrata, Verona; 2Pediatrics, Ospedale di Rovereto, Rovereto (TN), Italy

Correspondence: S. Pellizzari
Pediatric Rheumatology 2020, 18(Suppl 2):P174

Introduction: Based on literature reports, arthritis is a rare manifestation of parasitic infection and it occurs more frequently in adults with Giardia lamblia, Strongyloides stercoralis, Schistosoma mansoni and Toxocaridae infestations. Reports of this symptom in children are extremely rare. Enterobius vermicularis is the most common helminthic parasite in the Italian general population. It is usually asymptomatic or associated with mild and heterogeneous manifestations, including diffuse or perianal itching, restless sleeping, discomfort, gastrointestinal symptoms and arthralgia, with frequent evidence of peripheral eosinophilia.

Objectives: A cohort of pediatric patients evaluated in the Pediatric Rheumatology Medical Clinic of Verona from 2010 to 2020, affected by mono- and polyarthritis during parasitic infestation was described in this study with the aim of reporting clinical, instrumental and laboratory data, including research of parasites in order to raise awareness of this clinical entity in children and promote its systematic description.

Methods: Patients who presented joint pain or clinical signs of arthritis and evidence of parasitic infestation by scotch tape test or stool examination were selected among Pediatric Rheumatology patients of Verona Day Hospital from 2010 to 2020. The following indicators were considered: articular manifestations at onset, presence of eventual systemic symptoms associated, laboratory test abnormalities, elapsed time between onset and diagnosis, response to treatment and eventual relapse. Patients presenting signs of joint inflammation underwent an ultrasound examination.

Results: We selected 14 patients of prevalent age at onset of 7,71 years (2-14 years), male-to-female ratio 8:6. The majority of patients (86%) presented a symmetric polyarthritis, exclusively involving the lower extremities in 54% of the cases. At onset of the articular manifestation, 78% of the patients presented one or more associated symptoms, such as diffuse or anal itching (30%), gastrointestinal symptoms (abdominal pain 43%) and a less specific symptomatic including headache (21%), fatigue (14%) and dermatitis or skin rash (21%). The laboratory tests, performed by nearly all patients (93%), showed eosinophilia in 92% of the cases, presence of antinuclear antibodies (ANA) (38%) and elevated inflammation markers (0,08%). Ultrasound was performed in 64% of the patients and showed synovial thickening and synovitis in all cases and joint effusion in 44% of the cases. Stool examination and scotch tape test repeated on 3 consecutive samples resulted positive for E. vermicularis in 93% of the cases and for Dientamoeba fragilis in one patient. After eradication therapy with repeated doses of mebendazole and pyrantel pamoate every 2-4 week for all cohabitants and pets, all the patients showed a significant reduction of symptoms and subsequent normalisation of test results. In 2 cases re-infestation occurred with recurrence of articular symptoms and treatment was restarted with benefit, as long as needed until complete eradication.

Conclusion: The study suggests that intestinal parasitic infestations are an under-reported cause of joint pain and arthritis in children. Indeed, parasites should be considered in the differential diagnosis in patients that present joint pain or signs of arthritis with clinical and laboratory findings suggestive of parasitic infestation. A re-infestation should also be excluded in case of recurrence of articular symptoms. A concomitant parasitic infestation should furthermore be excluded in chronic polyarthritis requiring immunosuppressant therapy, due to risk of disseminate infestation.

Disclosure of Interest
None declared

P175 Outcomes of mothers with rheumatic diseases and follow-up of with a focus on autoimmunity and neurodevelopment
K. V. Jirón Mendiola1, S. Jiménez Hernández2, F. García Rodríguez3, A. V. Villareal Treviño4, M. E. Romero López5, E. S. Barriga Maldonado6, L. Barbosa7, C. Skinner8, F. Hernández9, Y. Medina4, M. de la O7, D. Galarza Delgado9, N. Rubio Pérez6
1Reumatología Pediátrica; 2Reumatología; 3OYO; 4Pediatría, Hospital Universitario ‘Dr. José E. González’, Monterrey, Nuevo León, Mexico

Correspondence: K. V. Jirón Mendiola
Pediatric Rheumatology 2020, 18(Suppl 2):P175

Introduction: Autoimmune rheumatic diseases (ARD) predominantly affect women of childbearing age, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) being the most prevalent. Maternal ARD have been associated with early and late abortions, premature births, and low birth weight babies, which will subsequently have repercussions on their neurological development.

Objectives: The aim of this study is to describe the birth outcomes of newborns born to women with rheumatic disease, and the impact of their neurological development.

Methods: A prospective study from July 2017 to April 2020, from children born to women with ARD treated at our center. Sociodemographic and clinical characteristics of newborns and their
Ankle tenosynovitis in Poncet's disease

L. R. Campos¹, K. L. Baptista², J. Caldas², V. Orenbuch³, I. Gomes³, C. A. A. Cardoso³, C. Canella³

¹Pediatric Rheumatology, Department of Pediatrics; ²Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói - Rio de Janeiro, Brazil; ³Department of Maternal and Child; ⁴Department of Radiology, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói - Rio de Janeiro, Brazil

Correspondence: L. R. Campos
Pediatric Rheumatology 2020, 18(Suppl 2):P176

Introduction: Musculoskeletal manifestations of TB account for 10–19% of the cases of extrapulmonary form (1,2). Poncet’s disease is a reactive arthritis associated with active TB, with no evidence of TB in the joints, bones or tendons (3). The typical manifestation is symmetric polyarthritis(4).

Objectives: Report a rare case of ankle tenosynovitis in Poncet’s disease.

Methods: Case report and literature review.

Results: A 10-year-old female patient was referred to the rheumatology clinic at our hospital with a previous history of fever of 39°C (102.2°F), loss of appetite, and acute polyarthritis of wrist, knees, and ankles. At that time, laboratory exams revealed a hemoglobin of 11.1 g/dL, C reactive protein 78.6 mg/L, and antistreptolysin O titers of 400 UI/mL (normal range <200UI/mL). Clinical symptoms were relieved only after using NSAIDs. After 6 months, the patient returned to our hospital with a 7-month history of weight loss and claudication related to pain and daily morning stiffness (15 minutes) on her right ankle. New laboratory findings demonstrated positive antinuclear antibodies 1:320, negative rheumatoid factor, and alpha-1-acid glycoprotein of 171 mg/dL (normal range: 44-113mg/dL). Clinical signs suggestive of chronic arthritis with exuberant swelling of the ankles were observed on physical examination (figure A). She was screened for tuberculosis (TB) and had a positive (18mm) tuberculin skin test (figure B). Chest CT revealed infiltrative soft tissue mass in the posterior mediastinum, with homogeneous contrast enhancement (figure C). Magnetic resonance imaging of both ankles was performed and demonstrated bilateral and symmetrical tibiotalar arthritis and prominent tenosynovitis of extensors, flexors, and fibularis tendons (figure D). Right ankle synovial biopsy revealed no granulomas and joint fluid culture was negative for Mycobacterium tuberculosis, confirming reactive arthritis (Poncet’s) and tenosynovitis, that may follow mycobacterial infection with no infective agent in the joints.

Conclusion: To our knowledge, there is no report of Poncet’s disease associated with inflammatory tenosynovitis, showing the particularity of this case. The patient’s symptoms resolved after two months of anti-TB therapy.

Disclosure of Interest
None declared

Table 1 (abstract P175). RA=Rheumatoid Arthritis, APS=Antiphospholipid Syndrome, SLE=Systemic Lupus Erythematosus, AIJ=Juvenile Idiopathic Arthritis, AV=Arthroventricular

| ARD                  | n=42 | Abnormal                      | Newborn                  |
|----------------------|------|-------------------------------|--------------------------|
| RA                   | 14   | 1 (2.3 %)                     | Polycythemia             |
| SLE                  | 5    | 0                             | Normal                   |
| SJOGREN              | 3    | 1 (2.3 %)                     | Patent ductus arteriosus |
| APS                  | 9    | 1 (2.3 %)                     | Cyanogenic heart disease |
| Asymptomatic         | 2    | 1 (2.3 %)                     | Neonatal lupus AV block  |
| SLE + APS            | 1    | 0                             | Normal                   |
| Dermatomyositis       | 1    | 0                             | Normal                   |
| Others               | 7    | 7 (16.6%)                     | Normal                   |

P177
Camptodactyly-arthropathy-coxa vara-pericarditis syndrome: a rare and misdiagnosed condition

L. R. Campos¹, J. L. Baptista¹, L. Ferreira², L. Lima³, C. Canella³, A. Serfaty⁴

¹Pediatric Rheumatology, Department of Pediatrics; ²Pediatrics; ³Department of Radiology, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói - Rio de Janeiro, Brazil; ⁴Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Correspondence: L. R. Campos
Pediatric Rheumatology 2020, 18(Suppl 2):P177

Introduction: CACP is characterized by congenital or early-onset camptodactyly (usually bilateral); non-inflammatory arthropathy (more frequently in the wrists, knees, ankles, elbows, and hips); coxa vara (reduction of the angle between the neck and shaft of the femur); and non-inflammatory pericardial effusion (a late manifestation, less frequently reported). Recognizing the radiological aspects of this syndrome and differentiating it from JIA is crucial since CACP has no effective treatment and JIA is usually treated with NSAIDs and methotrexate (2, 3).

Objectives: To report a rare case of CACP syndrome mimicking JIA.

Methods: Case report and literature review.

Results: A 5-year-old male patient presented with arthropathy characterized by painless progressive swelling and restricted movement of the hands, hips, knees, and ankles since the first year of life. He had a family history of camptodactyly from his paternal grandfather. On physical examination, symmetric camptodactyly of the hands and feet was observed (A). He had no history of rash or weight loss and inflammatory markers were unremarkable. The echocardiogram was normal. The pelvic radiograph showed a widening of the joint space and bilateral coxa vara. Magnetic resonance imaging (MRI) of the hips (B) and knees (C) was performed and depicted large joint effusions (arrows, B and C) with normal synovial thickness and mild synovial enhancement in all joints, without bone marrow edema-like signal. A synovial biopsy of the knee was performed and revealed mild synovial hyperplasia without inflammatory cells. The patient was diagnosed with camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP – OMIM 208250), a recently described genetic disorder with no gender predominance identified to date (1).

Conclusion: An important differential diagnosis of CACP is juvenile idiopathic arthritis (JIA), a painful inflammatory chronic arthritis that can cause not only joint effusions due to synovial inflammation, but...
also contractures resembling camptodactyly when not effectively treated.

Disclosure of Interest: None declared

P178
Features of childhood Sjogren’s syndrome: a literature review based cohort
A. Marino1, M. Romano2, T. Giani3, C. Gaggiano4, S. Costi5, R. Singh6, J. Mehta7, S. Lieberman8, R. Cimaz9
1Department of Pediatrics, Desio Hospital, Desio, 2ASST G.Pini-CTO, Milano, 3Pediatric Rheumatology, Meyer Children’s Hospital, Florence, 4Department of Pediatrics, University of Siena, Siena, 5University of Milan, Milano, Italy, 6Northwestern University, Evanston, 7Division of Rheumatology, Children’s Hospital of Philadelphia, Philadelphia, 8Department of Pediatrics, University of Iowa, Iowa City, United States

Introduction: Sjogren’s syndrome (SS) is an autoimmune chronic disease characterized by inflammation of exocrine glands, but it can affect other organs as well.

Objectives: To describe childhood SS (cSS) features by reviewing pediatric published cases with individual data.

Methods: We conducted a literature review of cSS (age < 18 years). Eligible papers were identified through a Medline search of English language articles published in the PubMed database until February 2020. Statistical analysis was performed in order to detect associations between clinical/laboratory features.

Results: Two-hundred-forty patients were identified (191 female); the median age at disease onset was 10 years (range 3 months-17 years). Main clinical features are shown in Table 1. The most frequently reported clinical SS-specific feature was parotitis (134/198 patients; bilateralunilateral=2:5:1); fewer patients had sicca symptoms (89/159 with dry eyes; 85/144 with dry mouth).

Conclusion: Parotitis was the most frequently reported feature, a wide range of clinical manifestations in children with SS has been reported so far. A better knowledge of cSS features will help to pave the way for the development of cSS specific diagnostic criteria.

Table 1 (abstract P178). Clinical features of cSS cohort

| SS features | Positive pts | Percentage (% of available data) |
|-------------|--------------|---------------------------------|
| Parotitis   | 134          | 67.7                            |
| Dry eyes    | 89           | 56.0                            |
| Dry mouth   | 85           | 59.0                            |
| Arthritis   | 59           | 72.8                            |
| Fever       | 52           | 70.3                            |
| Rash        | 42           | 64.6                            |
| CNS involvement | 40     | 85                              |
| Renal involvement | 31   | 59                              |
| Raynaud phenomenon | 14 | 58.3                          |

Introduction: Pachydermodactyly (PDD) is a rare benign fibromatosis, characterized by progressive painless swelling of soft tissue of proximal interphalangeal (PIP) joints without inflammation signs. Generally PDD affects PIP joints of the fingers, rarely of the thumb. The involvement is typically symmetrical, in few cases unilateral. It usually occurs more frequently in young males. Etiology is unknown, but it arises from mechanical stimulation of periarticular skin (i.e repetitive rubbing, interlacing, and cracking of fingers). PDD has been considered in the differential diagnosis of arthritis (i.e. juvenile idiopathic arthritis, JIA) and many syndromes (i.e. progressive pseudorheumatoid dysplasia). Prognosis is good with cessation of mechanical stimulation.

Objectives: The aim of this study, is to improve our knowledge about this problem leading to a correct diagnosis. We describe a cohort of outdoor pediatric patients attending the Rheumatology Pediatric Medical Clinic in Verona.

Methods: A retrospective analysis was conducted in the Pediatric Rheumatology Day Hospital of Verona from January 2014 to April 2020. We selected six patients with painless swelling of soft tissue of PIP joints. Male-to female ratio was 1:1. Prevalent age at diagnosis was 11 years. Among all cases, only one practiced sport (16%), in particular canoeing. All cases had painless swelling of soft tissue of PIP joints of fingers, bilateral in 66% of the cases. Associated symptoms were paresthesia and functional limitation (33%), tic (16%), anxiety disorders (16%) and repetitive mechanical movements (i.e rubbing and interlacing of fingers) (33%). None of our patients had findings of articular inflammation. Laboratory tests were completely normal objective and strumental for all reported cases, in particular all inflammatory markers were normal.

Results: Half of the evaluated patients had previously consulted a medical specialist (16% orthopaedist, 33% rhumatologist). Ultrasonography was performed in 33% of patients and it was negative for joint damage in all cases. The hand MRI, performed in 66% of cases, excluded the presence of arthropathic or osteopathic lesions with exclusively swelling of the periarticular soft tissue. For 50% of the patients a genetic test for Progressive pseudorheumatoid dysplasia (gene WISP3) was conducted and it resulted negative in all cases. In one patient the exclusion of the diagnosis of JIA was complicated by concomitant knee pain and suprapatellar effusion on
Correspondence: Hospital IRCCS, Rome, Italy

Introduction: Fibrodysplasia ossificans progressiva (FOP) is the most catastrophic form of heterotopic ossification (HO), due to activating mutations in the ACVR1/ALK2 gene, and ongoing intracellular signaling through the bone morphogenic protein (BMP) pathway. Painful soft tissue swellings usually appear by the age of 3-4 years, but the typical bilateral greater toe deformity can be noted at birth. Average life expectancy is 45 years. Currently, there is no proven effective treatment. The recurrent paroxysmal appearance of inflammatory lumps (local erythematous tender swellings, which partially respond to anti-inflammatory agents), accompanied by elevated inflammatory markers during flares, suggest that FOP may be an auto-inflammatory disease. The episodic formation of bone, often following a trivial injury, suggests that innate immune-related triggers induce tissue transformation through the BMP pathway. Moreover, interleukin-1 (IL-1β), a well-known mediator of the innate immune system, has been linked to HO and mineralization in mesenchymal stem cells derived from human bone marrow. We hypothesized that treating FOP patients with anti-IL-1 agents could help ameliorate the progression of this devastating disease. We report our experience treating two FOP patients with anakinra and canakinumab.

Objectives: To decrease the frequency of FOP paroxysms, and/or limit the symptoms and extent of residual lesions, by using anti-IL-1 agents.

Methods: Patients’ data and blood IL-1 levels were analyzed to characterize the efficacy of anti-IL-1 treatments in ameliorating the natural progression of FOP.

Results: A 13.5 year old boy and a 5 year old girl were diagnosed with FOP, both clinically and genetically (the typical R206H mutation was found). Various treatments, including high-dose corticosteroids, pamidronate infusions, celecoxib, monteleukast and sirolimus, did not change the course of the disease. Both patients are receiving canakinumab (the male patient was initially treated with anakinra). The male patient has been treated for over 2 years. Flare rate was markedly reduced from one new lump every 8 days to approximately one every 25 days (Figure 1). The lumps involved in almost all of these flares are the same: at the left scapular base and within the sternocleidomastoid muscle. The female patient has been treated for a year, and has not experienced any HO flares during canakinumab treatment.

Temporarily withholding canakinumab in both patients, led to serious flares 8 weeks after the last dose. Notably, while undetectable levels of IL-1β (<0.125 pg/ml) were found in the three plasma samples obtained from the male patient during treatment with anakinra or canakinumab, high levels (up to 21.52 pg/ml, about 90-fold higher compared to average levels measured in healthy controls) were found in his plasma samples collected during the flare (Figure 2). In contrast, IL-18 and IL-6 plasma levels, measured before, during and after withholding treatment, were comparable or slightly higher than those observed in healthy controls (Figure 3A, B).

Conclusion: We report here, for the first time, that anti-IL-1 agents were found efficacious in treating two FOP patients. We also found markedly increased IL-1β levels during flares, which normalized following the treatment. We suggest a role for IL-1β in the pathogenesis of this disease. Although it is too soon to conclude whether FOP may be included under the umbrella of auto-inflammatory syndromes, anti-IL-1 agents can be effective in ameliorating the natural progression of FOP.

Disclosure of Interest: None declared

P180
Treating two fibrodysplasia ossificans progressiva patients with interleukin-1 inhibitors

R. Haviv1, V. Moshe2, F. De Benedicti3, G. Prencipe3, N. Rabinowicz2, Y. Uziel1

1Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center, Sackler School of Medicine, Tel Aviv University; 2Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel; 3Division of Rheumatology, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy

Correspondence: R. Haviv

Pediatric Rheumatology 2020, 18(Suppl 2):P180

Introduction: Fibrodysplasia ossificans progressiva (FOP) is the most catastrophic form of heterotopic ossification (HO), due to activating mutations in the ACVR1/ALK2 gene, and ongoing intracellular signaling through the bone morphogenic protein (BMP) pathway. Painful soft tissue swellings usually appear by the age of 3-4 years, but the typical bilateral greater toe deformity can be noted at birth. Average life expectancy is 45 years. Currently, there is no proven effective treatment. The recurrent paroxysmal appearance of inflammatory lumps (local erythematous tender swellings, which partially respond to anti-inflammatory agents), accompanied by elevated inflammatory markers during flares, suggest that FOP may be an auto-inflammatory disease. The episodic formation of bone, often following a trivial injury, suggests that innate immune-related triggers induce tissue transformation through the BMP pathway. Moreover, interleukin-1 (IL-1β), a well-known mediator of the innate immune system, has been linked to HO and mineralization in mesenchymal stem cells derived from human bone marrow. We hypothesized that treating FOP patients with anti-IL-1 agents could help ameliorate the progression of this devastating disease. We report our experience treating two FOP patients with anakinra and canakinumab.

Conclusion: We report here, for the first time, that anti-IL-1 agents were found efficacious in treating two FOP patients. We also found markedly increased IL-1β levels during flares, which normalized following the treatment. We suggest a role for IL-1β in the pathogenesis of this disease. Although it is too soon to conclude whether FOP may be included under the umbrella of auto-inflammatory syndromes, anti-IL-1 agents can be effective in ameliorating the natural progression of FOP.

Disclosure of Interest: None declared

P181
Genetic syndromes mimicking rheumatologic diseases

U. Kaya Akca1, P. O. Simsek Kiper2, G. Urel Demir2, E. Sag1, G. E. Utine2, M. Alikasifoglu3, K. Boduroglu2, Y. Bilginer1, S. Ozen1

1Department of Pediatric Rheumatology; 2Department of Pediatric Genetics, 3Department of Medical Genetics, Hacettepe University Faculty of Medicine, Ankara, Turkey

Correspondence: U. Kaya Akca

Pediatric Rheumatology 2020, 18(Suppl 2):P181

Introduction: Musculoskeletal symptoms are one of the common reasons for applying to rheumatology departments in general practice. Although inflammatory causes are generally considered in the foreground, it is known that non-inflammatory causes including genetic diseases may also be responsible. The absence of signs of inflammation (morning stiffness, redness, tenderness) and normal inflammatory markers in laboratory findings may support non-rheumatologic diseases.

Objectives: To present genetic disorders that can mimic rheumatologic symptoms and to answer when genetic diseases should be considered in the differential diagnosis in patients presenting with rheumatological complaints.

Methods: We retrospectively evaluated 60 patients who applied to Hacettepe University pediatric rheumatology department with musculoskeletal complaints between January 2015 and December 2019 and had been consulted to genetics department. The rate and degree of consanguinity, clinical diagnosis, indication for consultation, accompanying musculoskeletal and other findings had been recorded. The diagnosis of genetic diseases were based on physical examination, radiological evaluations and genetic analysis.

Results: A total of 60 patients, 19 boys (31.6%), with a mean age 12.46 ± 1.41 years were included in the study. The rate of consanguinity was 25.0%. The most frequent referral to the genetic department was the presence of skeletal anomalies (n:12) such as camptodactyly, clinodactyly, and bone shortness accompanying joint findings. Other causes include short stature (n:4), joint deformity (n:5), joint hyperlaxity (n:10), dysmorphic findings such as atypical facial appearance (n:9), accompanying diseases that may be part of a syndrome (n:11), genetic diagnosis suspicion according to the results
of radiological examination (n:4) and joint findings without clinical and laboratory signs of inflammation (n:5). Distribution of joint involvement in 20 patients with genetic disease were hands, knees, and hips respectively. In the laboratory evaluation of patients presenting with joint swelling and arthralgia, acute phase reactants (erythrocyte sedimentation rate and C-reactive protein concentrations) were within normal reference values. One third of the patients (33.3%) had a final diagnosis of a genetic disease. The diagnoses of these patients were as follows; CACP (camptodactyly, arthropathy, coxa vara deformity and pericarditis) syndrome (n:3), trichorhinophalangeal syndrome (n:1), progressive pseudorotoid dysplasia (n:2), LIDS syndrome (n:1), SM syndrome (n:1), H syndrome (n:1), SPENCO (spondylochondrodyplasia, n:3), and nonspecific connective tissue disease (n:8).

Conclusion: Genetic syndromes with musculoskeletal findings are often unrecognized and misdiagnosed as rheumatologic diseases leading to unnecessary procedures and treatments. Summarizing the genetic diagnosis spectrum that can be detected in these patients will increase the awareness of physicians.

References
1. Sills J. Non-inflammatory musculoskeletal disorders in childhood. Archives of disease in childhood. 1997;77(1):71-5.
2. Al-Mayouf SM. Non-inflammatory disorders mimic juvenile idiopathic arthritis. International Journal of Pediatrics and Adolescent Medicine. 2018;5(1):1-4.

Disclosure of Interest: None declared

P182 Infectious triggers of erythema nodosum in children
A. Akhenbekova, S. Akilbekov, G. Tashenova
Faculty of Medicine and Health Care, Al-Farabi Kazakh National University, Almaty, Kazakhstan

Introduction: The aim of the study was to study the role of etiological triggers on the clinical course and severity of erythema nodosum in children.

Objectives: 65 children with nodular erythema aged from 3 years to 15 years were monitored. The examination included General clinical research, C-reactive protein (CRP), antistreptolysin, rheumatoid factor, antinuclear factor (ANF) with method of immunofluorescence. To determine the etiological factor, bacteriological studies of nasopharyngeal swabs, Epstein-Barr virus, fotal studies for intestinal diseases, diagnoses for Listeriosis, Yersiniosis, Chlamydia were conducted.

Results: According to the results of observation, the disease was more common in the age group of 7-11 years (65%), to a lesser extent among children in the group of 12-15 years (35%), less often in the group of 3-7 years (5%). When examining infectious agents, zoonotic infection was detected in 41% (Listeria monocytogenes, Yersinia enterocolitica). Clinical course of nodular erythema in this group was characterized by an expressed activity of the inflammatory process with multiple elements in the lower and upper extremities, joint syndrome, increased ESR to 45±2.8 mm per hour, CRP 28±5 mg/l. The disease was preceded by an episode of acute infection with an increase in body temperature, intoxication, in some cases with short-term intestinal syndrome, pharyngitis. The rashes were persistent and recurrent, with a slow regression of laboratory activity. Streptococcal etiology of nodular erythema was detected in 37% of cases. There was an increase in ESR to 25±3.8 mm per hour, CRP 15±2.7 mg/l, a significant increase in antistreptolysin on average 480±34% IU/ml, with an increase in individual cases to 870 IU/ml. In 13% of cases, erythema nodosum developed after an intestinal infection. Among the pathogens were identified Sh. disenteria, E. coli, Yersinia enterocolitica, enterovirus. The disease was characterized by moderate activity, a good response to etiological therapy and a short course of NSAIDs. An interesting fact was the development of nodular erythema in 4% of cases caused by the Epstein-Barr virus in groups of children from 3 to 7 years and 7-9 years. They had clinic picture with normothermia, no symptoms of intoxication, periodically occurring elements of nodular erythema on the shins, no blood changes. Therapy aimed at eliminating the virus gave a positive result and did not require specific anti-rheumatic therapy. In 5% of cases, the etiology of nodular erythema was not defined.

Conclusion: The clinical course of nodular erythema in children depends on the infectious agent that was the trigger of the pathological process. The higher activity and duration of the disease is caused by zoonotic infection, which requires more active anti-inflammatory therapy with corticosteroids, which may be associated with the activation of autoimmunity. This group of children was taken for further observation as a group at risk of developing systemic connective tissue disease. Changes in the etiological structure of nodular erythema and treatment tactics require further study.

Disclosure of interest
None declared

P183 Pediatric Sjögren syndrome: an Italian case series
M. Romano, T. Giani, A. Marino, C. Gaggiorno, G. Filocamo, I. Pontikaki, R. Cimaz
Department of Pediatric Rheumatology Group of the Milan Area

1Pediatric Rheumatology, ASST-G.Pini-CITO, Milan, Italy; Milan; 2AOU Meyer, Florence; 3Department of Pediatrics, Desio Hospital, ASST Monza, Desio, Monza; 4Clinical Pediatrics, Department of Molecular Medicine and Development, University of Siena, Siena; 5Pediatric Rheumatology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 6Pediatric Rheumatology, ASST-PINI-CITO, Milan, Italy; 7Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

Correspondence: M. Romano
Pediatric Rheumatology, 2018(18(Suppl 2)):P183

Introduction: Sjögren syndrome (SS) is a chronic autoimmune disorder characterized by inflammation of the lacrimal and salivary glands leading to oral and ocular dryness. Childhood SS is rare and poorly defined and underdiagnosed owing to the lack of child-specific diagnostic or classification criteria.

Objectives: The purpose of this study is to describe 12 cases with pediatric SS in order to better clarify the characteristics of the disease in the pediatric age.

Methods: We retrospectively reviewed medical records of patients (pts) with pediatric SS referring to three Italian pediatric rheumatology centers. Due to lack of childhood validated SS-specific criteria, physician diagnosis was the only inclusion criteria.

Results: We collected data on 12 pts (9 females). The mean age of disease onset is 10.0 yrs (median 10.2, range 4-17). The mean age of diagnosis is 11.83 (median 11.45, range 6-18). The follow up period varied from 0.1 to 9.3 yrs (mean 3.95, median 5.0). The most common manifestations were articular involvement (mainly with arthralgia) (9/12 pts) and parotid/salivary glands swelling (8/12 pts). Xerostomia and xerophthalmia were found in 6/12 pts and in 4/12 respectively. Vaginal dryness was reported only by one pt. Fever and fatigue occurred in 3/12 and 7/12 pts respectively. We also recorded 3 cases of circulating immune complexes manifestations in 3 pts, purpura (n=2) and glomerulonephritis (n=1). We observed an endocrine involvement in 3 pts (1 metabolic syndrome, 2 autoimmune thyroiditis). Abdominal pain was found in 4/12 pts. All pts were positive for autoantibodies (positivity for ANA or anti-SSA or anti-SSB or FR) at presentation. RF test results were available in 8 pts, all positive. Positive ANA (titer>1/320) and anti-SSA were present in 10/12 pts and in 9/12 respectively. Hypergammaglobulinemia (range 1.6-8.04 g/dl) was found in 8/11 pts (1 NA).

Abnormal Schirmer test was observed in the half of cases (6/12). Minor salivary gland biopsy was performed in 10 pts resulting in histological evidence of focal lymphocytic salaladenitis in 9/10. Sonographic evaluation of salivary glands was abnormal in all of the patients (10/10).
Methods: We retrospectively studied patients observed in our disorders with onset in the first year of life.

Objectives: PR disorders presenting in the first year of life.

Disclosure of Interest
None declared

P184
Withdrawn

P185
Rheumatological disorders presenting in the first year of life
T. L. Marques, A. Marinhas, J. Nascimento, P. Estanqueiro, M. Salgado 1
1Pediatrics Department, Centro Hospitalar do Baixo Vouga, Aveiro; 2Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra; 3Pediatric Rheumatology Unit, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

Correspondence: A. Marinhas
Pediatric Rheumatology 2020, 18(Suppl 2):P185

Introduction: Improving our understanding of pediatric rheumatological (PR) patient population is crucial for pediatric rheumatologists to know rheumatic disease epidemiology and to raise awareness leading to early detection. We didn’t find studies of PR disorders presenting in the first year of life.

Objectives: The aim of this study is to assess the prevalence of PR disorders with onset in the first year of life.

Methods: We retrospectively studied patients observed in our Pediatric Rheumatology Unit between January 1st of 1987 and December 31st of 2019. We defined acute (<2 weeks), subacute (2 and <6 weeks) and chronic (≥6 weeks).

Results: A total of 3751 patients were observed in 32 years. Diseases’ onset occurred in the first decade of life in 2290 patients (61%) and in the first year of life in 158 (4.2%). Among the latest group, chronic inflammation was the most frequent group of diagnosis (30%), followed by recurrent inflammation (23%), acute inflammation (11%), infection (9%), infiltrative/ degenerative disorders (8%) and subacute inflammation (3%). The remaining patients (16%) were diagnosed with other disorders classified as miscellaneous. Among chronic inflammation group, 14 patients were diagnosed with juvenile idiopathic arthritis (4 systemic); 14 had neonatal lupus and one patient had polyarteritis nodosa. Among recurrent inflammation group, 13 patients were later diagnosed with PFAPA (periodic fever, aphthous stomatitis, pharyngitis and adenitis). 8 were diagnosed with Behçet disease and 6 had an autoinflammatory disorder. Acute vasculitis was diagnosed in 13 patients (9 Kawasaki disease and 4 acute hemorrhagic edema of infancy). Among infectious diseases group, there were two cases of congenital syphilis with arthritis and two cases of osteomyelitis secondary to BCG vaccination.

Conclusion: Rheumatological diseases presenting in the first year of life are not exceptional. Although many patients didn’t have a definitive diagnosis at the beginning of the symptoms, many of them were later diagnosed with rheumatic disorders, mostly chronic inflammation (30%), which requires early diagnosis, specific treatment and long-term follow-up. Rheumatic diseases must be considered as differential diagnosis in the first year of life in order to avoid delayed intervention and long term disabilities and sequelae.

Disclosure of Interest: None declared

References
1. Buonoseno D, Macchiariulo G, Supino MC, et al. Laboratory biomarkers to facilitate differential diagnosis between measles and Kawasaki disease in a pediatric emergency room: A retrospective study. Mediterranean journal of hematology and infectious diseases. 2018;10(1):xe2018033.
2. Lagou P, Korovessi P, Panagoulia E, Tsagris V, Kostaridou S. A rare case of measles-associated hemophagocytic lymphohistiocytosis in an infant. Cur- eus. 2020.
An increasing trend in the incidence of scurvy has been reported in the last years, especially in children with food selectivity associated to autism. Still, a diagnostic delay in the identification of scurvy is common, due to non-specific clinical features mimicking rheumatological, hematologic or infectious conditions.

**Objectives:** To describe clinical features of 5 patients with scurvy, referred to two pediatric Rheumatology Units in Southern Italy, from July 2018 to December 2019.

**Methods:** Case reports

**Results:**
- P1 was a 4-year-old boy presenting limp and bilateral hyperemic tibial swellings for a week. He suffered from autism spectrum disorder and, since the third year of life, he developed marked food selectivity. Joint assessment was normal. Laboratory tests showed elevated erythrocyte sedimentation rate (ESR) level (75 mm/h). Main causes of erythema nodosum were excluded. Vitamin C level resulted greatly reduced: 1.5 μmol/l (26.1-84.69). Supplemental therapy was started with clinical resolution.
- P2 was a 5-year-old boy, with autism spectrum disorder, malnutrition and severe food selectivity, admitted to our Unit for refusal to bear weight and bruises in lower limbs. The auxological evaluation showed a strongly dystrophic aspect. Coagulation profile and main organ function markers were normal. At nutritional biochemical parameters evaluation, iron and Vitamin C deficiencies were detected (vitamin C: 2 μmol/l); hence he started oral vitamin C therapy, with prompt clinical response.
- P3 was a 7-year-old boy with autism spectrum disorder, admitted to our Unit for lameness and difficulty in walking for a month. At clinical examination, a mottled skin at lower limbs was noted. Joint examination was normal. Auxological parameters and main blood tests were adequate for age. Given the presence of food selectivity, he underwent serum vitamin C dosage (11 μmol/L); hence he started oral vitamin C therapy, with rapid clinical improvement.
- P4 was a 2 years old boy who was referred for coxalgia and fever. At clinical examination, pale skin, gingival hyperemia, and pain in mobilization of the left hip were present. Microcytic anemia was detected, but main organ and inflammatory markers were normal. No evidence of infection was present. X-ray of femur and knee showed morpho-structural alteration of the distal metaphysis bilaterally. A low intake of fruit and vegetables was reported; hence, dosage of vitamin C was performed, resulting reduced (2.5 μmol/L). He started Vitamin C oral therapy with clinical response.
- P5 was a 13-year-old girl with behavioral disorder and intellectual disability, admitted for fever and right knee swelling which appeared two days after a right leg burning. C-reactive protein and ESR were elevated and ultrasound exam confirmed intra-articular knee effusion. Suspecting a septic arthritis, antibiotic therapy was started with laboratory normalization and partial clinical improvement. Considering the persistence of knee swelling after nine days of intravenous antibiotic therapy, the presence of gingival hyperemia and history of food selectivity, vitamin C dosage was practiced (12 μmol/l). Oral vitamin C was administered with complete clinical resolution.

**Conclusion:** Although scurvy is considered a disease of the past, it still occurs nowadays. Food selectivity associated to autism is a major risk factor for vitamin C deficiency in childhood. Rheumatologists should take into account the diagnosis of scurvy in the diagnostic approach of musculoskeletal disorders in children, especially when development disorders are present.

**Disclosure of Interest**
None declared

---

**P187**

The musculoskeletal manifestations of scurvy: a diagnostic challenge for the rheumatologist

T. Lastella¹, R. Naddeo¹, F. Orlando², C. Porfíto¹, F. Mozzillo¹, M. Amico¹, M. Alessio¹
¹Pediatric Rheumatology Unit, Mother and Child Department, University of Naples Federico II; ²Rheumatology Unit, Department of Pediatrics, Santobono-Pausilipon Children’s Hospital, Naples, Italy

**Correspondence:** T. Lastella

**Pediatric Rheumatology** 2020, 18(Suppl 2):P187

**Introduction:** An increasing trend in the incidence of scurvy has been reported in the last years, especially in children with food selectivity associated to autism. Still, a diagnostic delay in the identification of scurvy is common, due to non-specific clinical features mimicking rheumatological, hematologic or infectious conditions.

**Objectives:** To describe clinical features of 5 patients with scurvy, referred to two pediatric Rheumatology Units in Southern Italy, from July 2018 to December 2019.

**Methods:** Case reports

**Results:**
- P1 was a 4-year-old boy presenting limp and bilateral hyperemic tibial swellings for a week. He suffered from autism spectrum disorder and, since the third year of life, he developed marked food selectivity. Joint assessment was normal. Laboratory tests showed elevated erythrocyte sedimentation rate (ESR) level (75 mm/h). Main causes of erythema nodosum were excluded. Vitamin C level resulted greatly reduced: 1.5 μmol/l (26.1-84.69). Supplemental therapy was started with clinical resolution.
- P2 was a 5-year-old boy, with autism spectrum disorder, malnutrition and severe food selectivity, admitted to our Unit for refusal to bear weight and bruises in lower limbs. The auxological evaluation showed a strongly dystrophic aspect. Coagulation profile and main organ function markers were normal. At nutritional biochemical parameters evaluation, iron and Vitamin C deficiencies were detected (vitamin C: 2 μmol/l); hence he started oral vitamin C therapy, with prompt clinical response.
- P3 was a 7-year-old boy with autism spectrum disorder, admitted to our Unit for lameness and difficulty in walking for a month. At clinical examination, a mottled skin at lower limbs was noted. Joint examination was normal. Auxological parameters and main blood tests were adequate for age. Given the presence of food selectivity, he underwent serum vitamin C dosage (11 μmol/L); hence he started oral vitamin C therapy, with rapid clinical improvement.
- P4 was a 2 years old boy who was referred for coxalgia and fever. At clinical examination, pale skin, gingival hyperemia, and pain in mobilization of the left hip were present. Microcytic anemia was detected, but main organ and inflammatory markers were normal. No evidence of infection was present. X-ray of femur and knee showed morpho-structural alteration of the distal metaphysis bilaterally. A low intake of fruit and vegetables was reported; hence, dosage of vitamin C was performed, resulting reduced (2.5 μmol/L). He started Vitamin C oral therapy with clinical response.
- P5 was a 13-year-old girl with behavioral disorder and intellectual disability, admitted for fever and right knee swelling which appeared two days after a right leg burning. C-reactive protein and ESR were elevated and ultrasound exam confirmed intra-articular knee effusion. Suspecting a septic arthritis, antibiotic therapy was started with laboratory normalization and partial clinical improvement. Considering the persistence of knee swelling after nine days of intravenous antibiotic therapy, the presence of gingival hyperemia and history of food selectivity, vitamin C dosage was practiced (12 μmol/l). Oral vitamin C was administered with complete clinical resolution.

**Conclusion:** Although scurvy is considered a disease of the past, it still occurs nowadays. Food selectivity associated to autism is a major risk factor for vitamin C deficiency in childhood. Rheumatologists should take into account the diagnosis of scurvy in the diagnostic approach of musculoskeletal disorders in children, especially when development disorders are present.

**Disclosure of Interest**
None declared

---

**P188**

Interstitial lung disease in patients with rheumatic diseases

E. Atalay¹, B. Ozsezen², D. D. Erozo², E. Sag¹, U. K. Akca¹, S. Demir¹, M. K. Cuceoglu¹, H. U. Ozcelik³, N. Kiper⁴, E. Yalcin⁵, N. Emiralioglu⁶, D. A. Tural⁷, B. Sunman⁸, E. D. Batu¹, Y. Bilginer¹, S. Ozen¹
¹Pediatric Rheumatology, ²Pediatric Pulmonology, Hacettepe University, Ankara, Turkey

**Correspondence:** E. Atalay

**Pediatric Rheumatology** 2020, 18(Suppl 2):P188

**Introduction:** Pulmonary involvement of systemic autoimmune and autoinflammatory diseases mostly occurs as pleural involvement and rarely as interstitial lung disease.

**Objectives:** The aim of this study is to retrospectively examine the demographic, clinical, laboratory findings, and clinical follow-up of patients diagnosed with interstitial lung disease during the course of rheumatic diseases.

**Methods:** Patients diagnosed with interstitial lung disease based on clinical and radiological findings or lung biopsy at Departments of Pediatric Rheumatology and Pulmonology in Hacettepe University, between 2005-2020 were included in the study. Data were recorded retrospectively from the patient files.

**Results:** There were 13 patients with systemic rheumatic disease who were diagnosed with interstitial lung disease during the course of the disease. Seven (53.8%) of these patients were female and 6 (46.2%) were male. The median age at the diagnosis of the rheumatic disease was 8 years. Primary rheumatic diseases were as follows: systemic juvenile idiopathic arthritis (JIA) (n=4; 30.8%), systemic sclerosis (n=2; 15.4%), mixed connective tissue disease (n=2; 15.4%), juvenile dermatomyositis (n=1), sarcoidosis (n=1), granulomatous polyangiitis (GPA) (n=1), Sting-associating vasculopa-thy with onset in infancy (SAVI) (n=1), and oligoarticular JIA (n=1). Respiratory symptoms were present in 6 (46.2%) patients at the time of primary diagnosis. In other patients, the time period between the diagnosis of the rheumatic disease and the onset of the respiratory symptoms ranged from 1 to 12 years. Cough, the most common symptom, was present in 10 (76.9%) patients. Six patients manifested with cough and sputum. Six (46.2%) patients had shortness of breath and one patient had hemoptysis. On the physical examination of one patient, rales and clubbing were detected. High resonance computerized tomography (HRCT) was performed in all patients. HRCT findings were as follows: lymphadenopathy in 8 patients (61.5%), ground glass appearance in 10 patients (76.9%), consolidation in one patient, pleural effusion in one patient, pulmonary nodule in 4 patients (30.8%), fibrosis in one patient, cystic lesions in 3 patients (23.1%), sepal thickening in 5 patients (38.5%), bronchiectasis in one patient, and reverse halo sign in one patient. In echocardiographic examination, only one patient had pulmonary hypertension. Three patients underwent open lung biopsy, and diagnosis was made with pathological examination of the lung tissue. Of these three patients, two (15.4%) had lymphocytic interstitial pneumonia (LIP), and one patient had chronic inflammation and focal fibrosis. Infectious lung disease was not detected in any patient. Ten patients (76.9%) had interstitial lung disease associated with rheumatic disease, one patient had pulmonary hemorrhage, one patient had pulmonary involvement of GPA, one patient had pulmonary involvement of sarcoidosis. There was no statistically significant difference between the first and last spirometry and DLCO values during the follow-up period. Mortality was 7.5% (1/13) in this cohort.
Conclusion: Although pulmonary complications of rheumatic diseases are rare in childhood, they can cause significant morbidity and mortality.

References
Cunningham Jaffe A, Young LR. Children's interstitial and diffuse lung disease. Lancet Child Adolesc Health 2019; 3: 568–77
Richardson AE, Warrier K, Vyas H. Respiratory Complications of the rheumatological diseases in childhood. Arch Dis Child 2016; 101:752-758

Disclosure of Interest
None declared

P189
Assessment of lipid profile in children with paediatric rheumatic diseases
S. I. Nasfel1, S. I. M. Abouzeid2, S. M. Elify3, A. Zeiton4
1Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, Ismailia; 2Paediatrics, Portfoad General Hospital, Portsaid; 3Paediatrics, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Correspondence: S. I. Nasfel
Pediatric Rheumatology 2020, 18(Suppl 2):P189

Introduction: Dyslipidemias are well-recognized risk factors for cardiovascular diseases (CVD) and are very common in patients with autoimmune rheumatic diseases. Lipid profile disorders are one of the most studied problems in adult patients with rheumatic diseases. However, few studies addressed this problem in paediatric rheumatic diseases patients.

Objectives: To assess the lipid profile in children with paediatric rheumatic diseases

Methods: Ninety patients diagnosed with pediatric rheumatic diseases were included. Exclusion criteria were patients previously treated with lipid lowering drugs, history of diabetes mellitus, thyroid disease and familial hyperlipidaemia. After fulfilling the inclusion criteria, detailed history was taken. Data included age, sex, weight, body mass index (BMI), and duration of disease. Fasting lipid profiles were measured after overnight fasting and consumption of normal diet for previous 2 days (without fat restriction). Fasting lipid profiles included total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL) and high density lipoprotein cholesterol (HDL). Normal values were considered according to reference values. Disease activity was classified according to clinical assessment and laboratory tests like ESR, CRP, complement levels and anti-ds DNA titres.

Results: The study included 90 children, suffering from rheumatic diseases. Out of them, 13 were males and 77 were females. Sixty-seven patients had juvenile idiopathic arthritis (JIA) of them, 48 patients Polyarticular type, 16 patients systemic onset type and 3 patients oligoarticular type. Twenty children were diagnosed with Juvenile systemic lupus erythematosus (JSLE), 2 children with Vasculitis (henoch schonlein purpura) and 1 child with juvenile scleroderma. Mean age was 11.58±3.6 years. Mean age at diagnosis was 7.2±3.13 years. Mean disease duration was 3.6±1.2 years. Mean BMI was 20.55±8.42 Kg. Twenty-nine patients had active disease while sixty-one patients had inactive disease. Mean TC was 170.65±51.38 mg/dl, mean LDL was 88.45±15.1 and mean TG was 88.15±26.1 mg/dl. The most common lipid abnormality was disturbed HDL, it was found in 29 patients followed by disturbed TC in 22 patients. Abnormal triglycerides was found in 22 patients and abnormal LDL in 16 patients. 14.9% of JIA patients had abnormal TC, 40.3% had abnormal LDL, 11.9% had abnormal HDL and 20.9% had abnormal TG. Sixty percent of JSLE patients had abnormal TC levels, 10% had abnormal HDL level, 40% had abnormal LDL and 40% had abnormal TG levels. Presence of JSLE and JIA was significantly associated with abnormal TC (p=0.001*), abnormal HDL (p=0.005*), abnormal LDL (p=0.01*) and abnormal TG (p=0.07).

Active disease was significantly associated with abnormal TC, HDL, and TG levels (p=0.04*), (p=0.03*) and (p=0.04*) respectively. Multivariate analysis of the factors affecting abnormal cholesterol level revealed that SLE is a significant predictor of abnormal cholesterol level. Presence of JSLE increase risk of abnormal cholesterol 9 times more than cases without JSLE. The overall percent predicted was 80%. Active disease is a significant risk factor for abnormal TG with increased risk of abnormal TG by 3.2 among cases with active disease than cases with inactive disease. The overall percent predicted was 75.6%.

Conclusion: children with rheumatic diseases showed significant lipid profile abnormalities. Abnormal TC, HDL and TG are significantly associated with active disease. Presence of JSLE increase risk of abnormal cholesterol. Active disease is a significant risk factor for abnormal TG. Therefore, lipid levels should be monitored regularly and managed in patients with paediatric rheumatic diseases to minimize the longterm risk of CVD.

Disclosure of Interest
None declared

P190
Definitions and concepts of muscular skeletal pain - what do physicians know?
V. L. Martins1, M. Fernandes1, F. Costa2, A. Vaz1, M. Salgado1
1Hospital Pediátrico de Coimbra; 2Centro Hospitalar e Universitario de Coimbra, Centro Hospitalar Universitario de Coimbra, Coimbra, Portugal
Correspondence: V. L. Martins
Pediatric Rheumatology 2020, 18(Suppl 2):P190

Introduction: Musculoskeletal pain (MSP) is the most frequent reason for seeking health care in adult and paediatric rheumatology. Semiological accuracy and the use of a standardized language will allow correct communication, avoiding ambiguities in definition and interpretation that may culminate in diagnostic errors. At least 82 concepts / definitions and clinical situations associated with musculoskeletal pain are known.

Objectives: Evaluate physicians’ knowledge of the most used definitions of MSP in order to improve patient attendance.

Methods: Non-experimental, cross-sectional and descriptive study. A confidential survey was conducted online, aimed at residents and attendings who deal with musculoskeletal pain. Were addressed with the definitions of arthralgia, arthritis, myalgia, allodynia and hyperesthesia (between five to seven options) with only one correct answer.

Correct definitions: arthralgia (pain localized to the joint or periarticular structures, as a only manifestation); arthritis (Criterion one or criterion two: 1 - Joint swelling or intra-articular effusion / 2 - Limitation of joint mobilization associated with at least one of the following: a) Pain b) Tenderness c) Swelling d) Heat); myalgia (pain with muscular origin or referred to muscle, regardless of its etiology); allodynia (pain resulting from usually non-painful stimulus); hyperesthesia (coexistence of allodynia plus hyperalgesia - exaggerated responses to tactile and thermal nociceptive and nonnociceptive stimuli). The study took place between September and October 2018.

Results: A total of 193 physicians participated, 71.5% (138) attendings and 28.5% (55) residents. Distribution by specialty: Paediatrics 51.3% (99), Rheumatology 14% (27), General and Family Medicine (GFM) 14% (27), Orthopedics 8.8% (17), Paediatric Rheumatology 4.2% (8), Physical and Rehabilitation Medicine (PRM) 2% (4), other specialties 5.7% (11). Overall, the correct answers to each assessed item have the following distribution: isolated arthralgia 41.5% (80), arthritis 17.6% (34), myalgia 54.9% (106), allodynia 61.1% (118), hyperesthesia 64.8% (125). By specialty, the percentage of correct answers is shown in table 1.

Conclusion: The low percentage of correct answers, allows us to conclude that many physicians are unaware of the correct concepts / definitions related to MSP and do not evaluate the musculoskeletal system routinely, or in an appropriate way. This tendency must be counteracted through continuous medical training.

Disclosure of Interest: None declared
Table 1 (abstract P190) Concept and percentage of correct answers by specialty

| Specialty       | Isolated arthralgia | Arthritis | Myalgia | Allodynia | Hyperesthesia |
|-----------------|---------------------|-----------|---------|-----------|---------------|
| Paediatrics     | 51.5% (51)          | 18.2% (18)| 46.5% (46)| 50.5% (50)| 59.6% (59)    |
| Rheumatology    | 77.8% (21)          | 25.9% (7) | 55.6% (15)| 81.5% (22)| 77.8% (21)    |
| GFM             | 25.9% (7)           | 7.4% (2)  | 77.8% (21)| 66.7% (18)| 70.4% (19)    |
| Paediatric      | 75.0% (6)           | 50.0% (4) | 50.0% (4) | 75.0% (6) | 50.0% (4)     |
| Orthopedics     | 29.4% (5)           | 5.9% (1)  | 58.8% (10)| 70.6% (12)| 58.8% (10)    |
| PRM             | 25.0% (1)           | 0.0% (0)  | 75.0% (3) | 75.0% (3) | 75.0% (3)     |
| Overall         | 41.5% (80)          | 17.6% (34)| 54.9% (106)| 61.1% (118)| 64.8% (125)   |

P191

Pure red cell aplasia, type 1 diabetes and poly arthritis in a 2.5 years old girl with a syndromic face - a new disease

D. B. Pandya on behalf of Dr Nishant Dhansandya and Dr I.P. Keshrani
Paediatric Rheumatology & Immunology, Dev Children's Hospital, Rajkot, India

Correspondence: D. B. Pandya
Pediatric Rheumatology 2020, 18(Suppl 2):P191

Introduction

The association of pure red cell aplasia (PRCA) with thymoma led to the discovery of the autoimmune mechanisms involved in the pathogenesis of this rare disease. Till date many adult case reports have revealed a strong link between PRCA and autoimmune diseases, endocrine disorders, rheumatic diseases, autoinflammation and immune dysregulation. 1-5

Objectives

To stimulate a search for the genetic and immunological roots for a 2.5 years old girl with syndromic face, pure red cell aplasia, type 1 diabetes and polyarthropathy.

Methods

This is a story of a 2.5 years old girl with pure red cell aplasia, type 1 diabetes and polyarthropathy. She was normal till 7 months of age. At the age of 8 months, she was diagnosed with type 1 diabetes. She was evaluated by her paediatrician in view of generalised hypotonia, deformed pinna, low set ears, midfacial hypoplasia, blue sclera, umbilical hernia and retracted eyelids. She had multiple episodes of seizures during next few months. To me, she was presented with one year history of polyarthropathy involving right knee, bilateral ankles, fingers and toes. Further examination revealed haemolytic facies and hepatosplenomegaly. I was not able to make out any facial dysmorphism mentioned earlier by her paediatrician.

Results: Table 1

Conclusion

Early age of onset, pure red cell aplasia, autoimmune and endocrine manifestations with some doubtful facial dysmorphism inspired me to suspect some known or unknown immune dysregulation syndrome in this child. Genetic analysis would be the best possible option in this scenario if financial condition permits.

Disclosure of Interest: None declared

Table 1 (abstract P191) showed available investigation reports

| Test                        | Result          |
|-----------------------------|-----------------|
| Haemoglobin (11.5-14.5 gm/dl)| 3.6             |
| RBC Count (4.5-5.3 mill/cumm)| 1.16            |
| PCV (33-43%)                | 10.4            |
| WBC count(4000-12000 cells/ cumm) | 9100          |
| ANC (1800-6800 cells/cumm)  | 5551            |
| ALC (1100-4700cells/cumm)   | 3185            |
| Platelet count (150,000- 450,000/ul) | 5,62,000     |
| MCV (76-90 Fl)              | 89.8            |
| Peripheral smear            | Normocytic Normochromic RBCs |
| Reticulocyte count (0.8-2%) | 0.5%            |
| Absolute reticulocyte count (0.02-0.1 * 10^6 cells/ul) | 0.0005 |
| ESR (0-20 mm/hr)            | 135             |
| CRP (0-5 mg/L)              | 1.1             |
| HBA1c (<5.6%)               | 12.6            |
| TSH (0.45-4.5 microU/ml)    | 4.04            |
| Free T4 (0.91-1.44 ng/dl)   | 1.24            |
| Bone Marrow Examination     | Normocellular marrow with markedly reduced erythropoiesis and occasional lymphoid aggregates |
| ANA by IF                   | Negative        |
| RF                          | Negative        |
| GAD antibody                | Negative        |
| MR Brain                    | Normal          |
**P192**

**Inflammatory arthritis complicating galactosialidosis: a case report and review of the literature**

F. Verkuij1, A. M. Boschin1, P. A. Strujs1, R. Hemke1, J. M. van den Berg1

1Pediatric Immunology, Rheumatology and Infectious Diseases; 2Radiology and Nuclear Medicine; 3Pediatric Metabolic Diseases; 4Orthopedic Surgery, Amsterdam UMC, location AMC, Amsterdam, Netherlands

**Correspondence:** F. Verkuij

Pediatric Rheumatology 2020, 18(Suppl 2):P192

**Introduction:** Galactosialidosis (GS) is a rare inherited lysosomal storage disorder (LSD) which is characterized by a defect in the lysosomal glycoprotein catabolism. Here we report, for the first time, a case of a child affected by GS who presented with recurrent episodes of extensive joint inflammation in both knees. Knowledge on GS related inflammatory joint pathology is lacking, which hampers evaluation of possible mechanisms that could give an explanation for the significant arthritic joint abnormalities as observed in our patient.

**Objectives:** The aim of this study is to describe the clinical presentation as well as the laboratory, radiologic and microscopic features of this extremely rare presentation of GS. Furthermore, we conduct a literature review on LSD’s complicated by arthritis in order to evaluate potential mechanisms that could explain the extensive inflammatory joint swelling observed in our patient.

**Methods:** In this study we present a 12-year-old Turkish boy who was diagnosed with GS (late infantile form) at 17 months of age. From the age of 8 years, the boy presented with episodes of inflammatory joint pathology of the knee. Informed consent was obtained. Alongside the case report, a literature review using Medline was conducted. An extensive list of known LSD’s was combined with the terms: “arthritis”, “joint inflammation”, “synovitis” and “synovial inflammation”. Cases in which joint inflammation was based on a probable cause other than the underlying LSD were excluded.

**Results:** In the present case, owing to comprehensive examinations (i.e. laboratory tests, imaging and microscopic examination) multiple possible causes for the recurrent inflammatory joint pathology could be rejected (i.e. no signs of infectious arthritis, reactive arthritis, osteoarthritis, arthritis secondary to a malignancy or crystal induced arthritis). A diagnosis which could explain the clinical picture is the JIA subtype: ANA negative oligo-articular JIA. However, microscopic examination showed numerous foamy macrophages with extensive vacuolization in the synovial tissue of the inflamed joint, which is not associated with JIA. Given the evidence of storage products within the macrophages of the inflamed synovial tissue and no conclusive diagnosis, GS itself should be considered as the primary cause for the recurrent arthritis.

An in-depth literature review using Medline for data on inflammatory joint pathology in LSD’s showed that 7 LSD subtypes (i.e. Fabry disease, Farber lipogranulomatosis, Gaucher disease type 1, Mucopolysaccharidosis IX, a-Mannosidosis, Fucosidosis and Cystinosis) could present with disease related arthritis. Multiple potential arthritic mechanisms secondary to storage product accumulation in LSD’s have been described, such as: dysregulation of innate immunity and increased upregulation of numerous pro-inflammatory proteins.

**Conclusion:** Given the evidence of storage products within macrophages of the inflamed synovial tissue and the absence of other etiological clues, our hypothesis is that GS itself is the primary cause for the inflammatory joint pathology in our patient. Although, GS cannot be linked directly to joint inflammation, lysosomal defects have been associated to pro-inflammatory effects that possibly could result in arthritic disease. Future identification of other patients with GS is required to support the hypothesis of an arthritic clinical phenotype of GS and to assess underlying pathophysiology.

**Disclosure of Interest:** None declared

**P193**

**Recurrent oral ulcers—a novel mutation**

S. Guha

Pediatric, VIMS, Saltlake, Kolkata, India

Pediatric Rheumatology 2020, 18(Suppl 2):P193

**Introduction:** A 1 year old male infant presented with h/o recurrent oral ulcers and fever since 6 months of age. Provisional diagnosis were: 1. Cyclic neutropenia. 2. Infantile behcet. 3. A2O Haploinsufficiency

**Objectives:** To establish cause of recurrent fever and oral ulcers, to rule out immune deficiency

**Methods:** Blood sent for: Complete blood count, primary immune deficiency work up which included immunoglobulin levels, flow cytometry for lymphocytes subsets and phagocytic defects

**Results:** Thinking of cyclic neutropenia, a complete blood count was done twice a week for 6 weeks. There was no evidence of neutropenia. Primary immune deficiency work up was negative. Genetic analysis was sent to rule out A2O haploinsufficiency. However clinical exome sequencing showed homozygous deletion of MAGT1 gene.

**Conclusion:** So this was a case of MAGT1 deficiency.

The infant showed homozygous deletion and later on may be complicated with recurrent EBV infection and lymphomas. MAGT1 deficiency is an x linked immunodeficiency characterized by CD4 lymphopenia, and defective T cell activation. These individuals have recurrent viral infections especially with Epstein Barr virus. They also have associated lymphoproliferative diseases especially lymphoma. Sometimes magnesium salts may prove useful in treatment. The index case is on magnesium and doing well. Though the usual age of presentation is 3 to 45 years, our patient presented very early. Later on they may have viral skin infections like molluscum, sinopulmonary infections and viral pneumonia.

The main aim of presentation is to recognize immune deficiency early in life and not to ignore them 2. treat them accordingly

**Disclosure of Interest:** None declared

**P194**

**Withdrawn**

**P195**

**Joint pain in children and adolescents: occurrence, causes and age profile**

A. Kozhevnikov1,2, N. Pozdeeva1, M. Nikitin1, A. Moskalenko1, Y. Proshchenko1, G. Novik1

1H Turner National Medical Research Center for Children’s Orthopedics and Trauma Surgery; 2St. Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation

**Correspondence:** A. Kozhevnikov

Pediatric Rheumatology 2020, 18(Suppl 2):P195

**Introduction:** Joint pain (JP) is a relatively common complaint among children and adolescents. A painful joint in children for many years continues to maintain the status of the most common symptom of juvenile arthritis. However this symptom should not always be interpreted as a manifestation of rheumatic diseases.

**Objectives:** The aim of current review is to debate of the structure in children with the chief complaint of JP.
Methods: We retrospectively analysed our series of 600 children which attending outpatient department with complaint about pain lasting longer than two months in one or more joints. The clinical, instrumental and laboratory pictures were collected. Special attention was paid to certain aspect of medical complaints, a complete and accurate history and physical examination. Different categories as possible etiologies of JP in children were systematize and detailed.

Results: All children were divided into several groups based on their anatomical and physiological characteristics of osteoarticular system: the first group consisted of 240 children under 6-7 years old, the second group – 220 children 7-12 years old, the third group – 140 children over 12 years old.

Research suggests that more preschool children were experience bilateral lower extremity pain by “post-walk genesis” due to natural hypermobility, immaturity of sensory innervation of the joints and imbalance of the leg muscles (e.g. growing pains). The second most common cause of JP was associated with intra - or postinfectious factor (viral, streptococcal and chronic focal of infection). The frequency of juvenile arthritis and other rheumatic diseases in children of this age group did not exceed 10%. Special attention was paid to fever, chills, malaise, nightpain and constitutional symptoms with changes in blood lab tests to exclude osteomyelitis (inc specific cause), malignancies manifestation and other bone tumors (less 5%).

The most common causes of joint pain of school-age children were hypermobility syndrome and enthesopathy (primary, secondary). Secondary enthesopathy were result of changes in nutrition, rapid growth and excessive exercise. Also enthesopathy were manifestation of endocrine, gastrointestinal or infectious diseases. The proportion of children with the onset of chronic inflammatory arthropathy also did not exceed 10%. Hypermobility child’s syndrome was characterized by harmless pain (inc low back pain), linked to physical activity (less morning stiffness).

Over the past decade, we’ve seen a gradual increase in the number of children (95% were girls) with knee pain by diagnosed patellofemoral and mediopatellar plica syndromes, patellar tendinitis or idiopathic cause. In most cases children was complicated by syndrome of increased anxiety. The share of true chronic inflammatory arthropathies, including spondylitis, in children of this age group did not exceed 10%. Fibromyalgia were diagnosed less 5%.

Conclusion: Despite continuous improvements in examination technique and image quality there is no universal test to diagnose the cause of chronic childhood arthralgia. Age features, individual nature of pain perception, the high frequency of incomplete and transient forms of arthropathy, cases atypical joint diseases have been intriguing problems for diagnostic pathology. Assessment of statistical significance (Group A = 7.4 years; Group B = 9.3 years; p = 0.019), which means that in Group A more often than in Group B first complaints appear in the age between 1 to 10 while in Group B more often than in Group A it happens in the age between 11 to 16.

2. There was a statistically significant difference in the means between Groups A and B in time between the onset of first complaints and the first visit to a rheumatologist (p = 0.03).

Also in favor of this conclusion speaks the fact that in Group A the number of visits to a rheumatologist in the same year when the first complaints appear is almost 2 times higher than in Group B. 56% of cases in Group A consulted the rheumatologist the same year when the first complaints appeared in comparison to Group B where only 31% of patients did the same.

Below is the table with distribution of cases by the number of years between the first complaints onset and the first visit to a rheumatologist in both groups:

| Number of years | Group A (%) | Group B (%) |
|-----------------|-------------|-------------|
| 0               | 56%         | 31%         |
| 1               | 24%         | 30%         |
| 2               | 10%         | 16%         |
| 3               | 7%          | 7%          |
| 4               | 2%          | 5%          |
| 5               | 2%          | 7%          |
| 6               | 0%          | 0%          |
| 7               | 0%          | 3%          |
| 8               | 0%          | 0%          |

Conclusion: In children with arthritides, the first pain complaints appear at an earlier age (an average of 7.4), and in Group B (an average of 9.3). Patients with arthritis more often visit a rheumatologist earlier (within 1 year after the first complaints) than those with non-inflammatory genesis of pain complaints.

Disclosure of Interest: None declared

P197
Can artificial intelligence help with diagnosing growing pain?
E. D. Batu1, 2, F. Akal3, S. G. Karadağ3, F. Demir3, N. Aktay Ayaz4, B. Sözeri5
1Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine; 2Department of Pediatrics, Division of Rheumatology, Ankara Training and Research Hospital, University of Health Sciences; 3Department of Computer Engineering, Hacettepe University, Ankara; 4Department of Pediatrics, Division of Rheumatology, Kanuni Sultan Süleyman Training and Research Hospital, University of Health Sciences; 5Department of Pediatrics, Division of Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

Correspondence: E. D. Batu

Pediatric Rheumatology 2020, 18(Suppl 2):P197

Introduction: A significant part of patients in rheumatologist’s practice is children and teenagers with complaints of pain. The further volume of examination and the choice of treatment course depends on the capability of the rheumatologist to define the inflammatory and non-inflammatory genesis of pain. That makes the problem of differential diagnosis very important.

Objectives: To conduct a comparative analysis of patients with a principal pain complaint to determine if there are significant differences in the groups with the inflammatory and non-inflammatory pain genesis.

Methods: The retrospective study included children who consulted a rheumatologist in the outpatient clinic in the period 2018-2020 without preliminary selection (n = 176). Of them there were selected children with principal pain complaint (n = 120). According to the diagnosis, the children were divided into 2 groups: those who have inflammatory genesis of pain (A, n = 59) and those with non-inflammatory genesis of pain (B, n = 61). The group A included children with such diagnoses as: reactive, poststreptococcal and juvenile idiopathic arthritides. The group B included children with arthralgia, chronic pain syndrome, orthopedic pathology, fibromyalgia.

Results: 1. Groups A and B differ in the average age of the first complaints onset (t-criterion for equality of means) with a high degree of statistical significance (Group A = 7.4 years; Group B = 9.3 years; p = 0.019). Which means that in Group A more often than in Group B first complaints appear in the age between 1 to 10 while in Group B more often than in Group A it happens in the age between 11 to 16.

2. There was a statistically significant difference in the means between Groups A and B in time between the onset of first complaints and the first visit to a rheumatologist (p = 0.03).

Also in favor of this conclusion speaks the fact that in Group A the number of visits to a rheumatologist in the same year when the first complaints appear is almost 2 times higher than in Group B. 56% of cases in Group A consulted the rheumatologist the same year when the first complaints appeared in comparison to Group B where only 31% of patients did the same.

Below is the table with distribution of cases by the number of years between the first complaints onset and the first visit to a rheumatologist in both groups:

| Number of years | Group A (%) | Group B (%) |
|-----------------|-------------|-------------|
| 0               | 56%         | 31%         |
| 1               | 24%         | 30%         |
| 2               | 10%         | 16%         |
| 3               | 7%          | 7%          |
| 4               | 2%          | 5%          |
| 5               | 2%          | 7%          |
| 6               | 0%          | 0%          |
| 7               | 0%          | 3%          |
| 8               | 0%          | 0%          |

Conclusion: In children with arthritides, the first pain complaints appear at an earlier age (an average of 7.4), and in Group B (an average of 9.3). Patients with arthritis more often visit a rheumatologist earlier (within 1 year after the first complaints) than those with non-inflammatory genesis of pain complaints.

Disclosure of Interest: None declared
Introduction: The most common cause of recurrent musculoskeletal pain is growing pain (GP) in children. Differential from rheumatic diseases could be challenging in some cases since there are no diagnostic criteria for GP.

Objectives: To analyze GP characteristics in a large cohort of patients in comparison with other non-inflammatory and inflammatory diseases causing limb pain, and to simplify the GP’s diagnosis process by using machine learning (ML) techniques.

Methods: This is a multicenter cross-sectional study. From February 2019 through August 2019, patients with GP and diseased controls were enrolled at the pediatric rheumatology units of three centers from Turkey. The gold standard for diagnosis of GP was the expert opinion.

A total of 398 patients with growing pain were enrolled (157 from Ankara Training and Research Hospital, Ankara; 128 from Umraniye Research and Training Hospital, Istanbul; and 113 from Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey). The control group consisted of 254 patients with diseases causing limb pain other than GP; 212 of these had inflammatory diseases (e.g., juvenile idiopathic arthritis), while the etiology of limb pain was non-inflammatory in 42 patients (e.g., trauma).

Once the data obtained from the participating hospitals as an Excel table, we performed exploratory data analysis. Consequently, columns with the missing value rate of more than 20% were removed. Inferential imputation methods were used to complete the rest of the missing values. Afterward, correlations among columns were investigated, and collinearity was removed. Finally, the data set used in this study consisted of 632 rows and 29 columns. We refer to columns as features as in ML vocabulary. Next, we developed several ML models by using a 10-fold cross-validation method with algorithms frequently used in similar problems in literature.

Results: The female-to-male ratio was 1.3, and the median age was 102 (22-213) months in the GP group (n=398). The pain was bilateral (86.2%), localized at lower extremities (89.7%), nocturnal (74%), and led awakening at night (60.8%) in the majority of GP patients. The pain was not daily (58.4%) and was exacerbated by increased physical activity during the day (57.3%) in more than half of the patients. History of arthritis, trauma, morning stiffness, limping, limitation of activities, and school abstinence were more prevalent among diseased controls than GP patients (p<0.001 for others). Hypermobility and pes planus were more frequent in the GP group than controls (p<0.001 and p=0.02, respectively). Anemia, leukocytosis, thrombocytosis, and elevated acute phase reactants were more prevalent among diseased controls than GP patients (p<0.013 for thrombocytosis and p<0.001 for the rest).

Our experiments with different ML models revealed that the Random Forest (RF) algorithm provided with 0.98 accuracy, 1.0 sensitivity, and 0.97 specificity in our test set.

Conclusion: In our cohort, GP was bilateral, localized at lower extremities, nocturnal, and led awakening at night, which were consistent with the previous reports. Our cohort is the largest cohort of children with GP. We also developed an ML model to identify GP patients based on clinical features. The results show that our RF model can be used to facilitate diagnosing GP disease. To the best of our knowledge, this is the first study that attempts to diagnose GP in children by using ML techniques.

Disclosure of Interest: None declared

P199Structural and functional status of the bone tissue in children during growth spurt

N. Osman, T. Frolova, N. Stenkova, I. Siniaieva
Kharkiv National Medical University, Kharkiv, Ukraine

Correspondence: N. Osman
Pediatric Rheumatology 2020, 18(Suppl 2):P198

Introduction: It is a well-known fact that the period of intensive growth in children is associated with the processes of active bone mass accumulation and coincides with them in time. One of the most distinctive indicators of an increase in the disease incidence among children for the recent decade (+105.3%) can be found in the skeletal disorders resulting from disrupted calcium metabolism and vitamin D deficit. The latter is widespread in Ukraine as it is observed in 92% of schoolers.

Objectives: Establish the specifics of the structural and functional status of the bone tissue in children during the growth spurt, taking account of the degree of vitamin D3 sufficiency.

Methods: The examination covered 147 children aged 9-17 who were divided into three groups depending on the presence of the growth spurt (GS) and its intensity: group 1 - 35 children who had become 8-12 cm taller for the year in question; group 2 – 32 children who had become taller by 12 cm or more, group 3 – 80 children who had experienced no growth spurt. Inclusion criteria were the following: no chronic somatic or endocrine pathologies, no musculoskeletal disorders or mineral homeostasis disruptions; physical exertion corresponding to their age; the children had not been taking any complexes of vitamins and minerals, including vitamin D3 for 6 months before the examination.

The examination included analysis of the medical history, general clinical examination and assessment of physical development (WHO “Child Growth Standards”, 2007). Additional tests included ELISA aimed at determining the 25(OH)D3 level as well as Ultrasound densitometry (Sonost -2000, Korea) and X-ray densitometry (DXA) (HOLOGIC QDR W Explorer, USA). Z-score ≤ -2 was used as a criterion determining reduced bone mineral density (BMD) (The International Society For Clinical Densitometry, 2013).

Results: Reduced BMD was found in 51.42% of the children in 1st group, 62.5% of the children in the 2nd group and 35.0% of the children in the control group. All the children under examination experienced a deficiency of 25(OH)D3 (M.F. Holick at all, 2011). In the children of the 1st group, the average 25(OH)D3 level reached 38.87±9.96 nmol/L. In the children of the 2nd group, the average 25(OH)D3 level was 42.58±8.99 nmol/L. In the 3rd group, the 25(OH)D3 level reached 40.68±9.29 nmol/L on average.

Spearmian’s correlation showed that in groups 1 and 2 there was no interrelation between the levels of 25(OH)D3 and BMD, in group 3, it revealed a positive relation between the 25(OH)D3 level and BMD (r=0.45).

Conclusion: Children aged 9-17 showed deficiency of vitamin D3 reaching 100% which had no correlation with the presence or intensity of the growth spurt. In children who experienced growth spurt, a reduced BMD proved more frequent and correlated with the spurt intensity, however, it did not depend on sufficiency of vitamin D3. Therefore, during the growth spurt, disrupted mineralization of the bone tissue was influenced not only by the vitamin D deficit but also by the correlation between the bone tissue mineralization rate and intensity of growth in the children.

Disclosure of Interest: None declared

P199Patient perspectives on living with sJIA or Still’s disease: impact on quality of life

R. Sinha, K. Durrant, M. C. Marques, N. Tennermann, P. Reardon, J. Toussreau, S. Angenevar, S. Lapidus, G. S. Schulte, F. Dedeoglu
1SJIA Foundation, National Organization; 2Autoinflammatory Alliance, San Francisco; 3Boston Children’s Hospital, Boston; 4Autoinflammatory Alliance, National Organization, United States; 5KASZ/VASZ, ENCA, National Organization, Netherlands; 6Hackensack Meridian, Hackensack; 7Cincinnati Children’s Hospital, Cincinnati, United States

Correspondence: R. Sinha
Pediatric Rheumatology 2020, 18(Suppl 2):P199

Introduction: Systemic juvenile idiopathic arthritis (sJIA) and Adult-onset Still’s disease (AOSD) are related arthropathies with features of autoinflammation and onset in children and adults, respectively. Due to their chronic course, we hypothesized that sJIA and AOSD have the impact on quality of life (QOL). We also hypothesized that children with sJIA, adults diagnosed with sJIA as children, and adults with AOSD have differing effects on QOL.

Objectives: To investigate patient-reported factors underlying the negative impact of sJIA and AOSD on QOL.
Methods: A self-reported 25 question online survey on QOL of patients with sJIA and AOSD was developed by the non-profit organizations, the Autoinflammatory Alliance, KAI/SZ/VAISZ, ENCA and sJIA Foundation in English and translated to Dutch. Respondents were recruited by convenience sampling through online social media posts. Data on flares, triggers, family history, and correlation of symptoms with labs were collected in addition to detailed information on QOL during and in-between flares.

Results: Between 2017 and 2019, there were 109 responses; 54 were from parents of children with sJIA, 18 from adults with sJIA, and 37 from adults with AOSD. Interestingly, adults (whether diagnosed with sJIA or AOSD) were more likely to report pain, fatigue, joint swelling or arthritis, nausea & vomiting, and diarrhea during flares than children. Adults were also more likely to describe flares >one month. 80% of patients reported being “greatly” or “severely” limited during flares. Between flares, 20% reported being “greatly” or “severely” limited while 59% were “somewhat” limited. 80% felt their condition affected their studies, job, and career, including 66% of children with sJIA, 100% of adults with sJIA, and 92% with AOSD.

Conclusion: Children and adults with sJIA and AOSD report high levels of QOL limitation and effect on family, school, work, and career, both during and between flares. Our qualitative data emphasizes the importance of QOL limitation and effect on school, work, and career, both during and between flares.

Disclosure of Interest: None declared

P200
Reducing fatigue in paediatric rheumatic conditions: a systematic review
K. Kant-Smits, M. van Brussel, J. Van Der Net
Center for Child Development, Exercise and Physical literacy, University Medical Center Utrecht; Wilhelmina Children’s Hospital, Utrecht, Netherlands

Correspondence: J. Van Der Net

Pediatric Rheumatology 2020, 18(Suppl 2):P200

Introduction: Although fatigue is a generic and profound symptom among children and adolescents with Paediatric Rheumatic Conditions (PRCs), intervention studies designed for reducing fatigue in PRCs are limited.

Objectives: To systematically review contemporary evidence regarding the efficacy of interventions intended to reduce fatigue in patients with PRCs.

Methods: Comprehensive electronic searches were performed in PubMed/ MEDLINE, Embase, Web of Science and Cinahl. Risk of bias was assessed using the ‘Revised Cochrane risk-of-bias tool for randomized trials’ and ‘Quality Assessment Tool for Before-After Studies With No Control Group’ for respectively studies with and without a control group. Level of evidence was assessed according to the rating system of Proper et al.

Results: Eight out of 385 studies were included for review with a total of 213 participants (age range 5-23 years). Applied interventions included exercise therapy, prednisolone therapy, vitamin-D supplementation, psychological therapy and a transition programme. Fatigue was assessed with self-reported questionnaires in all included studies. Four studies displayed a small but significant positive effect, one study a small non-significant positive effect and three studies found no effects in reducing subjective fatigue. Five studies showed a high risk of bias and three studies showed a moderate risk of bias.

Conclusion: Insufficient evidence is provided to substantiate the efficacy of current interventions to reduce fatigue in PRCs. The low number of studies, non-comparable interventions, risk of bias and inclusive outcomes of the included studies denote future research should focus more on understanding the underlying mechanisms of fatigue. Identification and development of and need to effective multifactorial interventions to reduce complaints of fatigue in children and adolescents with PRCs is warranted.

Disclosure of Interest: None declared

P201
Quality of life in juvenile idiopathic arthritis patients in Latvia
A. Barsuka1, I. Saulite2, K. Pudane1, S. Feierabend1, I. Rumba-Rozenfeld2
1University of Latvia; 2Children’s Clinical University Hospital, Riga, Latvia

Correspondence: A. Barsuka

Pediatric Rheumatology 2020, 18(Suppl 2):P201

Introduction: Dimensions of health related quality of life (HRQoL) includes both physical and psychosocial well-being and reveals how health status influence on the patient’s well-being. Juvenile idiopathic arthritis can be a reason for children’s low indicators of quality of life. The objective of the study was to analyse health related quality of life in Juvenile idiopathic arthritis patient comparing to their parents opinion’s and healthy children’s answers about their health related quality of life.

Methods: In this study, juvenile idiopathic arthritis patients aged 8 to 17 years old and their parents were surveyed at the Children’s Clinical University Hospital outpatient department. The participants voluntarily filled KIDSCREEN - 52 questionnaire. Survey includes 10 HRQoL dimensions such as physical, psychological and social life well-being. Control group consisted of 100 healthy children. Statistical analysis was performed using Mann–Whitney U-test (SPSS Statistics 22). The level of statistical significance was set at p < 0.05.

Results: In total 111 participants were included in the study : 62 Juvenile idiopathic arthritis (JIA) patients, and 49 their parents. The mean age of the patients was 13.7 ± 2.3 years. Significant differences were found between patients and healthy children in such HRQoL survey categories like “Autonomy” and “Financial resources” (p < 0.05). Although quality of life in children’s with Juvenile idiopathic arthritis was lower than in healthy children in HRQoL survey categories “Self perception” (p < 0.05). After analyzing data no significantly differences were found between patients and parents’ assessment scores in HRQoL survey categories (p > 0.05).

Conclusion: Juvenile idiopathic arthritis has a moderate negative influence on HRQoL survey categories “Self perception”, “Autonomy” and “Financial resources” (p < 0.05) according KIDSCREEN-52 questionnaire. The evaluation of children and their parents’ opinions in their children’s quality of life did not differ significantly. We need to continue study about children’s with Juvenile idiopathic arthritis quality of life.

Disclosure of Interest: None declared
“Tomato face” – the visible / invisible implications of JDM from a child and young person’s perspective

P. Livermore1, C. T. Deakin1, L. R. Wedderburn2,3,6
1NIHR BRC BRC, 2ORCHID, GOSH; 3ICH/UCL, UCL; 4NIHR BRC GOSH, Great Ormond Street Children’s Hospital; 5Centre for Adolescent Rheumatology Versus Arthritis at UCL UCL and GOSH, UCL, ICH, GOS, London, United Kingdom

Correspondence: P. Livermore
Pediatric Rheumatology 2020, 18(Suppl 2):P202

Introduction: Juvenile Dermatomyositis (JDM) is often first identified by parents and carers as the red facial rash develops. The rash can progress and lead to young people being misdiagnosed with eczema, scarlet fever or psoriasis. However, over time the obvious signs of JDM can become “invisible” as treatment calms the rashes and masks the outward signs of JDM, until a flare occurs, when the rashes can be a marker for disease activity or progression. As part of a larger study, children around the United Kingdom were asked to discuss their views on whether they wanted people to be able to see their JDM.  

Objectives: To understand the implications for children and young people from having a disease that has visible and invisible phases and whether they want others to see their JDM, or not.

Methods: Children and young people around the United Kingdom who were already consented and enrolled into the UK Juvenile Dermatomyositis Cohort and Biomarker Study were asked to complete a bespoke questionnaire. There was a mix of open and closed questions, and it was administered in paper format to all children and young people between the ages of 8 and 19 years of age for self-completion, either on the paper forms, or via a secure web-based software system. The questionnaires were administered at the end of 2018. Numeric data were described and qualitative data were analysed using standard content analysis.

Results: 246 questionnaire packs were sent out, with 127 (52%) being returned. Of these 4 could not be used due to practical reasons, such as only demographic data being completed, which left a sample of 123. 98 (80%) of the 122 who responded said other people could not see their JDM, with only 11 (9%) saying it was visible and 13 (11%) saying they did not know if others can see it. 1 did not respond to the question as said their JDM has gone away. They were then asked whether it was a good or bad thing for others to be able to see their JDM or for others not to be able to see it. 41 young people left comments as to why it was a good thing, 36 left comments as to why it was a bad thing and 14 left comments as to why they said don’t know, table 1 presents the top ranked response for the three multi-choice answers.

Conclusion: This study has highlighted the disparity between young people wanting others to see their JDM so that they gain more understanding and empathy from those around them, but equally, wanting their JDM to be invisible, so that they feel the same as their peers. Whilst many paediatric rheumatic conditions are in fact invisible, our data illustrate that JDM often gives children and young people a taste of both visible and invisible phases of disease activity. As one young person said “it’s not good, nor bad – it’s good that it’s invisible sometimes so I can blend in without the disabled stereotype. However, sometimes it needs to be seen so I can be understood and not challenged”.

Disclosure of Interest: None declared

Table 1 (abstract P202) Presenting the top coded theme for each ranked answer

| Answer Option | Theme                                                                 | Number |
|---------------|-----------------------------------------------------------------------|--------|
| Good          | So others can understand                                               | 23     |
|               | So I can be the same as others                                         | 10     |
|               | Both/neither                                                          | 4      |
| Bad           | Makes me embarrassed                                                  | 14     |
|               | I get treated negatively                                               | 11     |
|               | It means I don’t get any leeway or understanding                       | 5      |
| No answer     | Don’t mind                                                            | 6      |
|               | Neither                                                               | 4      |
|               | Don’t know                                                            | 4      |

A novel multidimensional assessment tool for clinical care of patients with juvenile fibromyalgia syndrome

E. Drago1, M. Mazzoni1, M. Macciò2, C. Lavarello2, M. Sansone3, R. Russo4, E. Pescio5, A. Ronchetti6, A. Raveli7, C. Malatta1
1Clinica Pediatrica e Reumatologia, IRCCS Gianna Gaslini; 2Università degli studi di Genova; 3Child Neuropsychiatry Unit, IRCCS Gianna Gaslini; 4Clinical Psychology Unit, AMRI Onlus; 5UCF Medicina Fisica e Riabilitazione, IRCCS Gianna Gaslini, Genova, Italy

Correspondence: E. Drago
Pediatric Rheumatology 2020, 18(Suppl 2):P203

Introduction: Juvenile fibromyalgia syndrome (JFS) is a chronic disabling condition characterized by widespread musculoskeletal pain in combination with several somatic symptoms including fatigue, non restorative sleep, headaches. Although 2-6% of school age children are estimated to suffer from JFS, patients often go undiagnosed for years; in addition, recommendations for the treatment and validated outcome measures for JFS are currently lacking.

Objectives: 1) To describe clinical features of JFS patients followed at our Centre 2) To develop a new multidimensional outcome measure for the assessment of patients with JFS in standard clinical care.

Methods: We included 43 patients diagnosed with JFS according to the 2010 criteria of the American College of Rheumatology. All patients were administered the Juvenile Fibromyalgia Multidimensional Assessment Report (J-FIMAR) which includes comprehensive patient self-report questionnaire and numerical rating scales to measure pain, fatigue, sleep quality, physical function, psychological state, health-related quality of life, satisfaction with illness course. The J-FIMAR has been devised according to the Outcome measure in Rheumatology (OMERACT) guidelines. Discriminant ability of the multidimensional tool was evaluated by testing it in a control group including healthy controls and patients affected by active juvenile idiopathic arthritis (JIA). The psychosocial consequences of chronic pain were evaluated by using the Children Depression Index (CDI) and the Multidimensional Anxiety Scale for Children (MASC). The objective sleep quality was measured by overnight polysomnography.

Results: Table 1 shows characteristics and the most represented somatic symptoms in our cohort of JFS patients at the study enter. Polysomnography was performed in 21 patients with sleep disturbance; 8/21 (38.1%) showed an electroencephalographic pattern of alpha wave intrusion in slow wave sleep (SWS). The presence of objective sleep disorders was significantly correlated to CDI score rs = -0.775 (p<0.0001) and MASC 0.61 (p=0.005). From November 2016 to April 2020 J-FIMAR was completed by 43 JFS patients (F 35 (81.4%), median age 14.7 years [7.1-17.6], median disease duration 1.9 years [0.1-7.8]) in 125 visits. All patients filled out the questionnaire in a short time (<15 minutes) and considered it simple.
and easy to understand. JFS patients showed significantly higher score for pain, fatigue, poor physical function and measure of psychological distress than healthy controls and JIA patients (p<0.05 for each item).

Conclusion: JFS patients presented significantly higher pain experience, functional disability, and impaired quality of life than patients with active JIA. A relevant percentage of JFS patients experience sleep disturbances, which were correlated with mood and anxiety disorders. Our multidimensional tool was feasible and able to quantify global JFS severity. This multidimensional tool, by measuring the main domains affected by the disease, could be promising to individualize treatment strategy and to test its efficacy.

Disclosure of Interest: None declared

Table 1 (abstract p203). See text for description

| Condition                        | Number | Percentage |
|----------------------------------|--------|------------|
| Widespread musculoskeletal pain  | 38     | 88.4%      |
| Fatigue                          | 37     | 80%        |
| Headache                         | 27     | 62.8%      |
| Concentration or Memory Problems | 22     | 55%        |
| Sleep disturbance                | 22     | 51.7%      |
| Anxiety and/or depression        | 17     | 39.5%      |
| Irregular School attendance      | 15     | 34.9%      |
| IBS and abdominal pain           | 11     | 25.6%      |
| Body mass index >25              | 12     | 27.9%      |
| Family history of fibromyalgia   | 11     | 25.6%      |

P204 Fatigue in children and teens with autoinflammatory disease

S. Angevare1,2,3, K. Durrant3, R. Beesley1,4
1ENCA, Zurich, Switzerland; 2KAISZ, Amersfoort, Netherlands; 3Autoinflammatory Alliance, San Fransico, United States; 4Juvenile Arthritis Research, Tonbridge, United Kingdom

Correspondence: S. Angevare
Pediatric Rheumatology 2020, 18(Suppl 2):P204

Introduction: Fatigue is a subjective state of overwhelming, sustained exhaustion and decreased physical and mental capacity, which is not relieved by rest. Fatigue is the most common complaint in children and teens with an autoinflammatory disease, besides the disease related flares. The purpose for this study was to show that fatigue is a serious issue for children and young people with autoinflammatory diseases. We hypothesized that age, gender and/or the type of autoinflammatory disease could have differing effects on the fatigue experience.

Objectives: We aimed to investigate fatigue in children and young people (CYP) with autoinflammatory disease, including how this affected them on a daily basis.

Methods: CYP with autoinflammatory diseases were invited to complete an online survey, providing details about their fatigue and how it affected them. The survey was developed by the non-profit organizations Autoinflammatory Alliance and KAISZ/VAISZ, in English. Respondents were recruited by convenience sampling through online social media posts. Data on age, gender and disease were collected in addition to information on their experience of fatigue on school and social interaction.

A total of 114 CYP (age range 7-18 years) with an autoinflammatory disease responded to the survey (52% female).

Results: The majority of respondents (81%) reported experiencing both mental and physical fatigue. Respondents were asked how much their fatigue affected them, on a scale of 0 to 10; overall, the mean fatigue score was 6.6. However, younger people aged 15 or over reported a significantly higher impact than those aged 11-14 years (mean 7.5, p=0.012). Different autoinflammatory diseases were surveyed: CRMO 25%, CAPS 20%, PFAPA 12% also Unclassified SAID (uSAID) with 23%.

In the open-response portion of the survey, 81% of respondents reported that fatigue was physical, as well as mental, in their experience. Most (69%) reported that some thought their fatigue in the past; 29% had found their teachers had doubted them, 26% had friends who doubted them, and 24% reported that they felt their doctors had doubted them. Children and young people also felt a number of activities made their fatigue worse (table 1).

Conclusion: CYP with autoinflammatory diseases experience physical and mental fatigue. Health professionals and teachers should listen to patients reporting fatigue, validate their experience, and help find ways to support them. Identifying resources to help the patients with fatigue, and referrals to therapy and mental health resources as needed may help the patients to better cope and manage their chronic disease. Further studies will include patient engagement in designing questionnaires about all aspects of life and autoinflammatory disease will help our understanding of these complex conditions and how they affect patients.

Disclosure of Interest: None declared

Table 1 (Abstract P204). Proportion of respondents reporting what they felt makes their fatigue worse.

| Activity                  | Total | %   |
|---------------------------|-------|-----|
| School                    | 77    | 20% |
| Extracurricular activities| 76    | 20% |
| Sports                    | 72    | 19% |
| Social interaction        | 62    | 16% |
| Family activities         | 50    | 13% |
| Medication                | 16    | 4%  |
| Don’t know                | 16    | 4%  |
| Nothing                   | 8     | 2%  |
| Total                     | 377   |     |

P205 Psychological involvement in young people with chronic rheumatological disease: what input do patients need?

O. Ogundiran1,2, A. Leahy1,2, L. Hennessy3, S. Hartfree4, S. Small5, B. Davidson1, A. De Schutter3, H. De Graaf6
1Faculty of Medicine, University of Southampton; 2Paediatric Rheumatology; 3University Hospital Southampton, Southampton, United Kingdom

Correspondence: O. Ogundiran
Pediatric Rheumatology 2020, 18(Suppl 2):P205

Introduction: Paediatric rheumatological diseases increase the risk of co-morbid mental health disorders and symptoms, yet the optimum psychological intervention to address mental health symptoms in this patient group has not been established.

Objectives: This study set out to establish patient and parent views on the suitability of different interventions that seek to support the mental health of patients with paediatric rheumatological diseases.

Methods: Patients with inflammatory diseases and their parents attending the Paediatric Rheumatology Department or Young Adult Clinic (YAC) at the University Hospital Southampton were invited to take part in the study. Questionnaires and semi-structured interviews, developed with paediatric psychologists, and a medical anthropologist, were used to examine the experience of emotional difficulties amongst patients and views on suitability of different intervention formats. Patients and their parents were invited to complete the questionnaires however only patients were invited to take part in the interviews. Interviews were audio recorded and transcribed verbatim by the interviewer. Codes were generated inductively from the interview transcripts and manually grouped into themes. 
Quantitative data from completed forms were analysed descriptively using SPSS and Excel. Qualitative data from extended answer responses and patient interviews were thematically analysed.

Results: 72 patients, (IQR of age in years 12.25 – 17.00) and 47 parents (IQR of age in years 12.00 – 15.25) completed questionnaires. 80% of patients reported experiencing at least one emotional difficulty, related to their rheumatological condition. Sleeping problems (49.3%) and anxiety (46.5%) were the most commonly reported symptoms in patient participants. 91.4% of patient participants agree or strongly agree that intervention deliverers should understand their condition. 50% of patients and 64.4% of parents reported psychologists as suitable interventionists for emotional difficulties followed by paediatric rheumatologists (29.4% and 57.8%, respectively).

Five patients were interviewed. Key themes from the interviews include experience with emotional difficulties (e.g. anxiety around taking medication and the effect of disease on future life); variety of interventions (e.g. educational and psychological support to overcome emotional challenges related to disease), and awareness of available support.  

Conclusion: This study highlighted there are high levels of emotional difficulties in paediatric rheumatology patients. Psychologists and paediatric rheumatologists are deemed the most suitable interventionists by participants. Patients demonstrate a need for emotional and educational support to overcome emotional difficulties associated with their rheumatological disease.

Disclosure of Interest: None declared
rheumatologist. She showed generalized fatigue, increased tightness of skin on her face as well as her upper and lower extremities, limitation of range of motions of most joints, and an abnormal handgrip. Laboratory tests revealed the following: low CBC at HGB 9.6, ANA 1:1280 positive and antids DNA was negative. ENA was negative. SCL-70 was positive, holter ECG showed ventricular arrhythmia. EMG revealed myopathy, high resolution chest showed fibrosing alveolitis worse than the first one, PFT was decreased. A diagnosis of diffuse systemic sclerosis (JSS) was made, and cyclophosphamide IV was administrated for 6 months. Methotrexate 15mg/m²/week SC was initiated, well as a low dose of steroids for 3 months, along with B blocker tab and an omeprazole capsule; however, there was no improvement. In April 2019, she started using Tocilizumab infusion once per month accompanied with methotrexate SC and MMF tab, and the effects of therapy have been very good.

Conclusion: JSS is a rare condition characterized with internal organ involvement. Tocilizumab represents an efficient treatment option for patients unresponsive to standard treatment.

Disclosure of Interest: None declared

P208
How the adult criss works in pediatric jSSc patients - results from the juvenile scleroderma inclusion cohort

J. Klotsche1, I. Foeldvari2, O. Kasapcopur3, A. Adrovic3, K. Torok3, V. Stanevicha3, J. Anton1, E. Marrani3, W.-A. Sifuentes-Giraldo3, M. T. Terreri3, F. Sztajnbok3, C. Battaglotti3, L. Berntson3, D. Elefteriou3, G. Horneff3, F. Nuruozzan3, N. Helmus3

1German Rheumatism Research Center, Berlin; 2Hamburg Center for Pediatric and Adolescent Rheumatology, Am Schoen Klinik Eilbek; 3JSSc Collaborative Group, Hamburg, Germany

Correspondence: I. Foeldvari
Pediatric Rheumatology 2020, 18(Suppl 2):P208

Introduction: The Composite Response Index in Systemic Sclerosis (CRISS) was developed by Dinesh Khanna as a response measure in patients with adult systemic sclerosis. CRISS aims to capture the complexity of systemic sclerosis and to provide a sensitive measure for change in disease activity. The CRISS score is based on a two-step approach. First, significant disease worsening or new-onset organ damage is defined as non-responsiveness. In patients who did not fulfill the criteria of part one, a probability of improvement is calculated for each patient based the Rodnan Skin Score (mRSS), percent predicted forced expiratory volume in 1 second (FEV1%), and the Health Assessment Questionnaire Disability Index (HAQ-DI). A probability of 0.6 or higher indicates improvement.

Objectives: To validate the CRISS in a prospectively followed cohort of patients with juvenile systemic sclerosis (JSSc)

Methods: Data from the prospective international inception cohort for JSSc was used to validate the CRISS. Patients with an available 12-months follow-up were included in the analyses. Clinically improvement was defined by the anchor question about improvement (much better or little better versus almost the same, little worse or much worse) in patients overall health due to scleroderma since the last visit provided by the treating physician.

Results: Forty seven JSSc patients were included in the analysis. 74.2% had diffuse subtype. The physician rated the disease as improved in 34 patients (72.3%) since the last visit. No patient had a renal crisis or new onset of left ventricular failure during the 12-months follow-up. Three patients (3.4%) each had a new onset of worsening of lung fibrosis and new onset of pulmonary arterial hypertension. In total, 6 patients resulted in a rating of not improved based on the CRSS in part I. The mRSS, FEV1%, CHAQ and PGA significantly improved during the 12 months follow-up in patients who were rated as improved. The predicted probability based on the CRISS S algorithm resulted in an area under curve of 0.77 predicting the anchor question of improvement. In summary, 33 (70.0%) patients were correctly classified by the adult CRISS score resulting in an overall area under curve of 0.7.

Conclusion: The CRISS score was evaluated in a pediatric JSSc cohort for the first time. It showed a good performance. However, it seems that the formula of part II of the CRISS score needs a calibration to pediatric JSSc patients.

Disclosure of Interest: None declared

P209
Description of the characteristics of the nailfold capillary structure in healthy children: a pilot study

H. Adiguzel Dundar1, A. Adrovic2, S. Demir3, F. Demir3, F. Calmack3, N. Akty Ayaz3, B. Sozeri4, Y. Bilginer5, O. Kasapcopur2, E. Unsal2

1Department of Pediatrics, Pediatric Rheumatology Unit, Dokuz Eylul University Faculty of Medicine, Izmir; 2Department of Pediatrics, Pediatric Rheumatology Unit, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Istanbul; 3Department of Pediatrics, Pediatric Rheumatology Unit, Hacettepe University Faculty of Medicine, Ankara; 4Department of Pediatrics, Pediatric Rheumatology Unit, Health Sciences University, Umranie Training and Research Hospital; 5Department of Pediatrics, Pediatric Rheumatology Unit, Istanbul University Çapa Medical Faculty, Istanbul, Turkey

Correspondence: H. Adiguzel Dundar
Pediatric Rheumatology 2020, 18(Suppl 2):P209

Introduction: Nailfold capillaroscopy is the best method for the early diagnosis of connective tissue diseases, especially systemic sclerosis, and evaluation of microcirculation in children and adolescents. Although there are many studies to identify normal capillaroscopic findings in healthy adults, there are limited number of studies for normal reference ranges by age and gender in the children and adolescents.

Objectives: The aim is to define and standardize the nail bed capillary properties in healthy Turkish children and adolescents.

Methods: This multicenter cross-sectional pilot study included 118 healthy children and adolescents from 5 pediatric rheumatology centers. Using the Dino-Lite CapillaryScope 200 Pro / MEDLAN Pro capillaroscopy device, two images of 1mm radial and ulnar edge were obtained from the 4th fingernail bed of the non-dominant hand at 200x magnification. Capillary density, capillary morphology (i.e., capillary tortuosity, capillary crossing, giant capillary, capillary meandering and branched capillary), microhemorrhage and avascular area were the parameters. Also 3 consecutive capillaries from each image; capillary length, capillary width, apical loop, arterial and venous width, and distance between capillaries were measured. The children included in the study were classified according to their age; Group 1: 5-7 years, Group 2: 8-10 years, Group 3: 11-14 years, and Group 4: 15-18 years old.

Results: A total of 336 images were obtained from 118 healthy children included in the study and 708 capillary measurements were made. Capillary density was significantly higher in Group 4 than in Groups 1 and 2. Arterial width was significantly lower in Group 1 as compared to Group 3 and 4, and in Group 2 as compared to Group 4. Apical loop width and capillary distance were significantly lower in Group 1 compared to Group 2 and 3 and 4. There was no significant difference between the age groups in terms of capillary length and venous width. There was no difference between the groups in terms of capillary morphology. In total 336 image evaluations, capillary tortuosity was <50% in 67.8%, and > 50% in 4.2%, and capillary crossing were <50% in 52.5% and > 50% in 3.4%. While the enlarged capillary was 4.7% and the avascular area was 4.2%, capillary branching, capillary meandering, microhemorrhage, and giant capillary were not detected in any case. There was a good level of agreement between the researchers, as 20 cases with 120 capillaries were evaluated with a good level of agreement (Table 1).

Conclusion: This is the first study to evaluate capillary morphology in healthy Turkish children. This study also adds that some special forms such as enlarged capillary and avascular area, which is always named as pathological in adult age, can be seen in healthy children. These data will be guiding in capillaroscopic studies in various patient groups, particularly in children with collagen vascular diseases.
Disclosure of Interest: None declared

Table 1 (Abstract P209). Evaluation of compatibility between the researchers for capillary density / mm, capillary length, capillary width, arterial width, venous width, apical width and intercapillary distance measurements.

| Measure                  | ICC (%) | Confidence Interval (%) | p |
|--------------------------|---------|--------------------------|---|
| Capillary density        | 96.1    | 0.944-0.975              | <0.001 |
| Capillary length         | 94.3    | 0.895-0.974              | <0.001 |
| Capillary width          | 90.6    | 0.866-0.937              | <0.001 |
| Arterial width           | 90.7    | 0.868-0.938              | <0.001 |
| Venous width             | 89.6    | 0.853-0.930              | <0.001 |
| Apical loop width        | 91.1    | 0.874-0.941              | <0.001 |
| Capillary distance       | 94.3    | 0.918-0.962              | <0.001 |

ICC: Interclass correlation coefficient

P210
Is there a different presentation of juvenile systemic diffuse and limited subset? data from the juvenile scleroderma inception cohort. www.juvenile-scleorderma.com
I. Foeldvari

Introduction: Juvenile systemic sclerosis (JSSc) has a prevalence of 3 per 1 000 000 children. There are limited data regarding the clinical presentation of JSSc. The Juvenile Systemic Sclerosis Inception Cohort (JSScIC) is the largest multinational registry that prospectively collects information about JSSc patients.

Objectives: To assess if there is a difference in the clinical characteristics in diffuse and limited subtype JSSc patients at the time of inclusion in the JSScIC.

Methods: Patients were included, if they fulfilled the adult ACR/EULAR classification criteria for systemic sclerosis, if they presented the first non-Raynaud symptom before 16 years of age and were younger than 18 years of age at time of inclusion. Patients’ characteristics at time of inclusion were evaluated.

Results: Until December 2019 hundred fifty patients were included, 83% of them being Caucasian and 80% female. The majority had the diffuse subtype (72%) and 17% of all JSSc had overlap features. The mean age of first presentation of Raynaud’s phenomenon was 9.8 years in the diffuse subtype (dJSSc) and 10.7 years in the limited subtype (lJSSc) (p=0.197). The mean age at first non-Raynaud’s symptom was 10.0 years in the dJSSc and 11.2 years in the lJSSc (p=0.247). Mean disease duration at time of inclusion was 3.4 years in the dJSSc and 2.4 years in the lJSSc group. Significant differences were found between the groups regarding mean modified Rodnan skin score, 18.2 in the dJSSc vs 6.2 in the lJSSc (p=0.02); presence of Gottron’s papule (dJSSc 30% vs lJSSc 13%, p=0.43); presence of telangiectasia (dJSSc 42% vs 18% lJSS, p=0.01); history of ulceration (dJSSc 42% vs 18% lJSS, p=0.008); 6 Minute walk test below the 10th percentile (dJSSc 85% vs lJSS 54%, p=0.044), total pulmonary involvement (dJSSc 49% vs lJSS 31%, p=0.045), cardiac involvement (lJSSc 17% vs dJSSc 3%, p=0.002).

P211
The comparison of the HLA-B27-positive and HLA-B27-negative patients with juvenile idiopathic arthritis in the single center R. Raupov

Introduction: Juvenile spondyloarthropathies (JSA) are the group of diseases with axial involvement in childhood. EULAR and ASAS classifications are known for diagnosis of JSA, the last one is less sensitive. The 70% of patients are HLA-B27 positive and have sacroiliitis or cervical involvement in the onset or developing of the disease. There’s limited information about seronegative JSA in childhood.

Objectives: To compare the patients with JIA depending on HLA-B27 positivity. To identify the rate of axial involvement depending HLA-B27 positivity.

Methods: 308 patients with JIA were tested for HLA-B27. They were divided into 2 groups: 1) HLA-B27 positive and 2) HLA-B27 negative.

Results: 100 patients (32.5%) were HLA-B27 positive and all of them are fulfilled the EULAR criteria of enthesitis-related arthritis (ERA). The group 2 consists of 208 patients (67.5%). There’s no statistical difference between both groups in active joint count, ANA-positivity and uveitis frequency, the rate of use methotrexate and time before biologics. No difference in axial cervical spine 12 (10.1%) vs 21 (10.1%) (p=0.613) and sacroiliac joints 18 (18.0%) vs 23/207 (11.1%) (p=0.097) involvement was observed. HLA B27(+) patients often received pulse therapy with methylprednisolone due to increased inflammatory activity and severe arthritis (22% vs 11.1%, p=0.011). Other parameters are listed in Table1.

Conclusion: patients with HLA-B27 positivity were characterized by male predominance, more often hip involvement, higher laboratory activity and the need for more frequent use biologics. The rate of axial involvement wasn’t different in HLA-B27 positive and negative patients, that needs further study and creating more accurate classification criteria for JSA.

Disclosure of Interest: None declared
**Table 1 (abstract P211). The difference between HLA-B27 positive and negative arthritis**

| Parameters              | HLA B27+ (n=100) | HLA B27- (n=208) | p     |
|-------------------------|------------------|------------------|-------|
| Onset age, years        | 9.3 (6.4–11.8)   | 6.1 (3.5–10.3)   | 0.0001|
| ESR, mm/h               | 16.0 (4.0–30.0)  | 5.0 (3.0–14.0)   | 0.0002|
| CRP, g/l                | 2.2 (0.2–15.7)   | 0.8 (0.0–5.2)    | 0.016 |
| PLT, x10^9/l            | 336.0 (257.0–430.0) | 303.5 (255.0–366.5) | 0.034 |
| Males, n (%)            | 66 (66.0%)       | 93 (44.7%)       | 0.001 |
| Hip arthritis           | 34 (34.0%)       | 41 (19.7%)       | 0.007 |
| Knee arthritis          | 56 (56.0%)       | 155 (74.5%)      | 0.002 |
| Sulfasalazine           | 42/64 (65.6%)    | 34/156 (21.8%)   | 0.001 |
| Biologics               | 61 (61.0%)       | 82 (39.4%)       | 0.001 |

**P212**

Cross-sectional study of fecal calprotectin in children with various forms of arthritis and non-inflammatory musculoskeletal disorders: a single centre experience

L. Lamot1,2, A. Kovacevic1, M. Miller3, M. Lamot1, N. Nikolac Gabaj3, M. Vidovi1, M. Harjaček1,2

1Pediatrics, Sestre milosrdnice University Hospital Center; 2Pediatrics, University of Zagreb School of Medicine; 3Clinical Chemistry, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Introduction: Although gut is increasingly recognized as origin and/or target of inflammation in adult onset spondyloarthritis (SpA), the incidence of gut involvement in juvenile SpA (jSpA) patients is still largely unknown, mostly due to the lack of reliable non-invasive tests.

Objectives: We performed a cross-sectional study of fecal calprotectin (fCAL), a surrogate marker of gut inflammation, in patients with jSpA, other forms of juvenile idiopathic arthritis (JIA) and non-inflammatory (NI) conditions.

Methods: fCAL was measured by commercially available assay in stool samples of enthesitis related (ErA), psoriatic (PsA) and patients with other JIA subtypes (oligo- and poly- articular) who fulfilled ILAR criteria, as well as in children withNI causes of musculoskeletal pain (NI-MSD), regardless of the gastrointestinal (GI) symptoms (Table 1). fCAL was compared among different groups of patients and correlated with demographic data, clinical characteristics, treatment modalities and disease activity measured by jSpADA. The values were also dichotomized to <50 mg/kg, 50-200 mg/kg, and >200 mg/kg, which was regarded as normal, slightly increased and increased, respectively. Ileocolonoscopy was performed in one patient.

Results: The median fCAL levels were highest in ErA patients (p=0.04). There was no significant difference in fCAL concentration between ErA patients with inactive (jSpADA ≤1) or active (jSpADA ≥1) disease (39.7 vs 30.9, p=0.66). In all patients, NSAID use was not associated with increased fCAL (20 vs 23, p=0.18), although weak correlation was found with the duration of the use (r=0.25, p=0.03). No correlation was observed between fCAL level and age at the time of sampling, duration of the disease, CRP or ESR, number of active joints and/or enthesis, physician global assessment, morning stiffness, uveitis, back mobility, abdominal pain, diarrhea, B27 presence in a patient or a family and disease activity in ErA and other JIA patients measured by jSpADA and JADAS, respectively. Microscopic gut inflammation was observed in one ErA patient with fCAL concentration of 839 mg/kg.

Conclusion: Our study has shown that fCAL levels are significantly higher in ErA patients compared to other JIA (p=0.03) and/or NI-MSD (p=0.03) patients. Moreover, almost a third of patients with ErA had levels of fCAL above the range regarded as normal, which adds to the number of evidences for a gut inflammation in this particular type of JIA. In addition, the fCAL levels were higher in those with axial involvement, which further supports the association of gut and axial inflammation in children with ErA. Although endoscopy remains a gold standard for the diagnosis of gut inflammation, fCAL can help to select children with ErA who might benefit from this invasive procedure, regardless of the GI symptoms, as shown in one patient with the highest fCAL concentration in our study. Moreover, fCAL levels seems not to be influenced by disease characteristic and/or concomitant therapy intake. Therefore, fCAL should be a part of diagnostic workup in children with any type of JIA, but most importantly in those with ErA.

Disclosure of Interest: None declared

**P213**

The features of the juvenile idiopathic arthritis in Sakha Republic (Yakutia)

F. Vinokurova1, V. Argunova2, P. Sleptssova2, T. Burtsvea1,3, M. Kostik4

1Yakut science center of complex medical problems; 2Republic hospital № 1 - National center of Medicine, Pediatric center; 3North-Eastern Federal University, Yakutsk; 4SAINTPETERSBURG STATE PEDIATRIC MEDI CAL UNIVERSITY, Saint-Petersburg, Russian Federation

Introduction: Juvenile idiopathic arthritis (JIA) is not uncommon disease among aboriginals in Sakha Republic (Yakutia) - SR(Y), which can be related to high spreading of HLA B27 antigen. Adult aboriginals of SR(Y) have ankylosing spondylitis several times higher than Caucasians. According the epidemiological studies HLA B27 antigen distributes in 33% of healthy aboriginals. The aim of our study was to describe features of JIA in aboriginals of SR(Y).

Methods: In the retrospective study were included 184 JIA patients before age 18 consisted of 155 SR(Y) aboriginals, 26 Caucasians and 3 mixed (Yakutia and Caucasians) whom have been living in SR(Y). We compare data of clinical course and compare aboriginals with Caucasians.

Results: The JIA prevalence in aboriginals is approximately 137/100 000 children and 30/100 000 in Caucasians. Clinical features describes in the table. HLA B27 distributed in aboriginals with JIA two times higher than in Caucasians and in healthy aboriginals. Positive family history in HLA B27 related diseases in 78 (53.1%) of aboriginals compare to 8 (36.4%) in Caucasians. ANA positivity was only in 4/53 (7.6%) that is less than in other populations. Euvetis is in 16 (10.5%) of aboriginals, usually associated with HLA B27 rather than ANA-positivity. Biologics received 44.5% of JIA aboriginals, 91.3% received TNF-a inhibitors. HLA B27 presented in all JIA
categories, 48.7% in oligoarthritis, in 42.9% of RF(-) polyarthritis, in 50% of RF(+) polyarthritis, 66.7% of systemic JIA, 71.3% of enthesis-related arthritis and in 40% of psoriatic arthritis patients. 70.3% of biologic users had HLA B27 antigen (p=0.028).

| Parameter                  | Aboriginals (n=155) | Caucasians (n=26) | p |
|----------------------------|---------------------|-------------------|---|
| Males, n (%)               | 92 (58.6)           | 10 (71.4)         | 0.047 |
| HLA B27, n (%)             | 87/145 (60.0)       | 6/20 (30.0)       | 0.012 |
| JIA categories             |                     |                   |    |
| Oligoarthritis             | 39 (25.1)           | 6 (23.1)          | 0.13 |
| Polyarthritis, RF (-)      | 25 (16.1)           | 4 (15.4)          | 7   |
| Polyarthritis, RF (+)      | 2 (1.3)             | 0 (0.0)           |     |
| Systemic                   | 4 (2.6)             | 4 (15.4)          | 0.001 |
| Enthesitis-related arthritis | 79 (51.0)     | 10 (38.5)         |     |
| Psoriatic arthritis        | 6 (3.9)             | 2 (7.7)           |     |

Conclusion: Aboriginals in SR(Y) have higher prevalence of JIA, HLA B27 antigen, enthesis-related category of JIA and juvenile ankylosing spondylitis, increased family history of rheumatic diseases, especially arthritis and have higher requirement in biologic medicine (anti-cytokine antibodies) for arthritis control compared to Caucasians.

Disclosure of Interest: None declared

Table 1 (abstract P214). Patient and disease characteristics at inception and at one year follow-up. First line indicates initial assessment and second line (in bold) follow up assessment

| Patient Characteristics | Gender | Age (years) | CRP (mg/L) | SI involvement | Physician global assessment | Spinal Pain (VAS 0-10 scale) | CHAQ | JSpA |
|-------------------------|--------|-------------|------------|----------------|-----------------------------|-----------------------------|------|-----|
| Patient 1               | male   | 16          | 5          | 4.5            | 1.5                         | 1.0                         | 0.5  | 0.5 |
| Patient 2               | male   | 17          | 45         | 8              | 7                           | 2                           | 0.5  | 0.5 |
| Patient 3               | female | 15          | 76         | 5              | 1.3                         | 1                           | 1    | 1   |
| Patient 4               | male   | 17          | 19         | 5              | 4                           | 2                           | 0.5  | 0.5 |

Disclosure of Interest: None declared

P214
Achieving inactive disease in era with secukinumab following TNF inhibitors failure; a real-life, dual-center experience
S. Papailiou1, M. Omoufriou2, F. Dasoula1, M. N. Tsolia1, D. N. Martis1,2
1Second Department of Paediatrics, ‘P. & A. Kyriakou’ Children’s Hospital, National and Kapodistrian University of Athens, Athens, Greece; 2Rheumatology Unit, Department of Paediatrics, ‘Makarios III’ Children’s Hospital, Nicosia, Cyprus

Correspondence: S. Papailiou
Pediatric Rheumatology 2020, 18(Suppl 2) P214

Introduction: TNF-inhibitors (TNFi) have greatly improved the clinical outcome of patients with Enthesitis-Related Arthritis (ERA), there is however a minority of patients who fail to respond to standard treatment.

Objectives: We describe the efficacy and safety results of a secukinumab (monoclonal antibody neutralizing interleukin-17A) compassionate use in patients with active ERA following failure of disease remission by TNFi.

Methods: In this case-series, 4 patients diagnosed with ERA (based on ILAR criteria) with a mean age of 16.2 years (range 15-17) received secukinumab 150 mg subcutaneously at weekly intervals and each 4 weeks thereafter for a total period of 18 months. All patients showed mild/no improvement to treatment with adalimumab (TNFi) received for at least six months. Clinical response was assessed at weeks 24, 52, 76(JSpADA). Safety and tolerability were also assessed at the same key time points during the course of the study.

Results: Clinical and demographic data were collected. The JSpADA response rate was 70% at week 24, which was sustained and further improved until week 76. Secukinumab was effective in multiple clinical outcomes including physician’s global assessment of disease activity, CHAQ score and CRP level (table 1). Secukinumab was well-tolerated with a safety profile consistent with reports in adult studies.

Disease duration, prior use of NSAIDS, age and gender did not affect the clinical outcome. There have been no reports of uveitis, psoriasis, IBD or any new-onset autoimmune disease. No major adverse events were reported.

Conclusion: This was a retrospective study regarding secukinumab effectiveness in patients with ERA who failed TNFi treatment, showing optimistic results. Secukinumab is usually effective in inducing and maintaining remission in Ankylosing Spondylitis and psoriatic patients and thus long-term therapy is recommended. Overall, biologic-naive patients demonstrate a swift and sustained response to biologics (TNFi); however not all patients who receive TNFi will reach a state of inactive disease. Further studies are required to address the effectiveness of secukinumab treatment in patients with ERA, with the aid of appropriate disease-associated risk-assessment markers. Our study demonstrated that secukinumab is safe and effective in ERA patients, provided it is initiated promptly following TNFi failure. In addition, prolonging the duration of treatment in clinical remission prior to attempting discontinuation may show favorable results in contrast to other studies endeavoring earlier discontinuation. Minimizing exposure to TNFi especially within the case of partial response or no response may lead to decreased adverse events and costs. In addition, secukinumab provided sustained improvement in the signs and symptoms of ERA patients through 18 months, with no new or unexpected safety signals.

Disclosure of Interest: None declared

P215
Impact of anti-tumor necrosis factor therapy on spondyloarthritis research consortium of Canada sacroiliac joint inflammation score in children with enthesis-related arthritis
M. Katsicas1, C. Anoni2, G. Villarreal1, M. Galeano1
1Immunology & Rheumatology, 2Radiology, HOSPITAL DE PEDIATRIA GARRAHAN, Buenos Aires, Argentina

Correspondence: M. Katsicas
Pediatric Rheumatology 2020, 18(Suppl 2) P215

Introduction: Enthesitis-related arthritis (ERA) is a category of Juvenile idiopathic arthritis considered to be a form of Juvenile Spondyloarthritis (jSpA). Tumor necrosis factor (TNF)-blocking strategies have proven to be effective in the treatment of jSpA. The Spondyloarthritis Research Consortium of Canada sacroiliac joint score (SPARC CC- SIS), measures inflammation in sacroiliac joints (SJ). It has been used in adults as a tool to assess response to anti-TNF agents, however, limited experience exists in jSpA cohorts.

Objectives: To evaluate effectiveness of anti-TNF treatment in SJ inflammation in a cohort of patients with ERA using SPARC CC-SIS. To quantify the effect size of TNF-blockers on SJ inflammation. To

Table 1 (abstract P215). Patient and disease characteristics at inception and at one year follow-up. First line indicates initial assessment and second line (in bold) follow up assessment

| Characteristic | Gender | Age (years) | CRP (mg/L) | SI involvement | Physician global assessment | Spinal Pain (VAS 0-10 scale) | CHAQ | JSpA |
|---------------|--------|-------------|------------|----------------|-----------------------------|-----------------------------|------|------|
| Patient 1     | male   | 16          | 5          | 4.5            | 1.5                         | 1.0                         | 0.5  | 0.5 |
| Patient 2     | male   | 17          | 45         | 8              | 7                           | 2                           | 0.5  | 0.5 |
| Patient 3     | female | 15          | 76         | 5              | 1.3                         | 1                           | 1    | 1    |
| Patient 4     | male   | 17          | 19         | 5              | 4                           | 2                           | 0.5  | 0.5 |
evaluate potential predictor variables of Magnetic Resonance Imaging (MRI) SIJ remission

Methods: Retrospective review of prospectively collected data. We included patients with ERA (according to ILAR criteria) continuously treated with anti-TNF agents for ≥ 12 months who had at least two MRIs of the sacroiliac joints performed before starting anti-TNF therapy (baseline) and during the follow up ( > 12 months after anti-TNF treatment). SI joints were examined using T1-weighted images, T2 fast-suppressed and short-tau inversion recovery. The SPARCC-SIS was scored by two pediatric radiologists. SPARCC-SIS assessed the presence, depth and intensity of bone marrow edema (BME) on consecutive six slices in the iliac and sacrum bones. Scoring is composed by: BME (0-48), BM intensity (0-12), BM depth (0-12). Maximum: 72. MRI SIJ remission was defined as SPARCC-SIS score ≤ 2. Magnitude of change on MRI SIJ score was assessed. Treatment with TNF-blockers and exposure time were recorded. Outcome measures were collected: pain score (0-10), wellbeing according to the patient using a visual analogue scale (VASp, 0-10), disease activity according to the physician (VASphy, 0-10), JADAS-10, JSpADA. Functional capacity was assessed by CHAQ. Statistical analysis included: Intraclass Correlation Coefficient (ICC) for readers, magnitude of change using Cohen’s d test, comparisons by Wilkoxon Signed Rank test and McNemar test.

Results:
Twelve (75% male) patients fulfilled inclusion criteria. Median (range) age at start of TNF-blocker therapy was 10.5 years (6-15) and disease duration 8 years (4-14). Presence of HLA-B27 positive 33%. Anti-TNF therapy consisted of: etanercept (7, two of them were later switched to adalimumab) and adalimumab (5). Median (range) exposure to anti-TNF was 30.5 months (12-60). All patients had evidence of SIJ inflammation at baseline on MRI. SPARCC-SIS at baseline was (median±SD) = 36±16.87. SPARCC-SIS over time (post treatment) was 12±7.44. Magnitude of change on score (Cohen’s d: 1.84, r: 0.68). MRI SIJ remission was achieved on 33%. ICC for concordance between readers= 0.73. Outcome measures are shown in table1.

There was no significant association between exposure time to anti-TNF treatment and MRI SIJ remission. Neither predictor variables on MRI SIJ remission were found.

Conclusion: Anti-TNF blockers showed to be effective in reducing MRI SIJ inflammation. Magnitude of change in SIJ inflammation had a large effect size. One third of patients achieved MRI SIJ remission on TNF-agents

Disclosure of Interest: None declared

Table 1 (abstract P215). See text for description

| Category | Number (%) |
|----------|------------|
| Oligoarticular JIA | 19 (20.2%) |
| Polyarticular RF negative JIA | 10 (10.6%) |
| Polyarticular RF positive JIA | 6 (6.4%) |
| Psoriatic arthritis | 3 (3.2%) |
| Systemic JIA | 9 (9.6%) |
| Undifferentiated JIA | 10 (10.6%) |
| Enthesitis related arthritis | 37 (39.4%) |
| Sacroilitis | 29 (27.8%) |
| Low Back Pain Treatment other than NSAIDs | 66 (70.2%) |
| DMARDs | 54 (57.4%) |
| Prednisolone | 4 (4.3%) |
| Intra-articular steroid | 8 (8.5%) |
| Biologics | 18 (19.1%) |

Discussion: In Hong Kong ERA is the most prevalent JIA subtype. A striking 78% develop sacroilitis early in the course. This is somewhat different from what being suggested by a recent Taiwanese cohort, in which only 16% has sacroilitis. It was not mentioned in their study how SIJ was assessed. The possible difference in SIJ assessment may explain the discrepancy.

Biologics, instead of DMARDs, is indicated when the sacroilitis fails to respond to NSAIDs. The finding of such a sizable number of sacroilitis in ERA may have an impact on treatment algorithm and resource justification in the future.

Conclusion: ERA is the predominant JIA subtype in Hong Kong. Sacroilitis development are common and probably early.

References

1. Glenup M, Rypdal V, Arstad ED et al. Arthritis Care Res (Hoboken). 2020;72(4):507-516
2. Shih YJ, Yang YH, Lin CY et al. Pediatr Rheumatol Online 2019;17:58
3. Ringold S, Angeles-Han ST, Beukelman T et al. Arthritis Care Res (Hoboken). 2019;71(6):717-734

Disclosure of Interest: None declared
P217

Enthesitis-related arthritis: is there a relationship between structural hip damage and ultrasound synovitis?

K. Zouaoui, H. Ferjani, K. Maatallah, L. Ben ammar, D. Kaffel, W. Hamdi
Rheumatology, Kassab Institute of orthopedics, Ksar Said, Tunis, Tunisia

Correspondence: K. Zouaoui
Pediatric Rheumatology 2020, 18(Suppl 2):P217

Introduction: Juvenile idiopathic arthritis (JIA) includes all inflammatory joint damage starting before the age of 16, lasting more than or equal to 6 weeks and with no identifiable cause. Enthesitis-related arthritis (ERA) accounts for 15-20% of all JIAs. Hip involvement is particularly important in this disease as it represents a major functional prognostic factor.

Objectives: The objective of our study is to clarify the correlation between the presence of a structural hip damage on X-Ray and the presence of synovitis on hip ultrasound.

Methods: This is a monocentric retrospective study, 35 patients with ERA were enrolled (ILAR Criteria). We have identified the epidemiological, clinical and radiological characteristics. The damage of hip was assessed by the Bath Ankylosing Spondylitis Radiology Index hip (BASRI) score.

Results: Our study included 35 patients, 91.4% of whom were male. The average age at diagnosis was 13.08 years [6-16]. At the time of inclusion, 88, 5% of patients had coxitis, 77, 1% of which had bilateral coxitis. The median time to onset of coxitis from the onset of ERA was 0,2 years [0-3,4]. Nearly 60% of patients had destructive coxitis. The average BASRI was 2,57 [0,4]. The ultrasound performed in 17 patients had demonstrated synovitis in 6 cases (n = 6) and effusion in 3 cases. There was no statistically significant correlation between the BASRI Hip Score and hip synovitis (p = 0.053).

Conclusion: According to our study, there was no correlation between structural hip damage assessed by BASRI and ultrasound synovitis in ERA. These two examinations must be complementary and if necessary supplemented by an MRI in order to better document the involvement of the hip.

Disclosure of Interest: None declared

P218

Spider bite mimicking pyoderma gangrenosum in sJIA: a case report

M. C. Maggio1, S. Giordano2, F. Cardella3, G. Corsello4
1PROMISE "G. D’Alessandro", University of Palermo; 2U.O.C. of Paediatric Infectious Diseases, Paediatric COVID Center, Children Hospital "G. Di Cristina", 3Paediatric Clinic, Children Hospital "G. Di Cristina", ARNAS, Palermo; 4Department PROMISE "G. D’Alessandro", University of Palermo, Palermo, Italy

Correspondence: M. C. Maggio
Pediatric Rheumatology 2020, 18(Suppl 2):P218

Introduction: Several paediatric patients manifest conditions commonly misdiagnosed as spider bites, which however, can include other arthropods bites; bacterial, viral, and mycotic infections; vasculitis; dermatological diseases; miscellaneous conditions as drug reactions, chemical injuries.

Objectives: In Italy, spiders which are likely to be associated with severe toxin mediated tissue damage are uncommon, especially in urban zones. However, a minor trauma may be a precipitating factor for pyoderma gangrenosum particularly over the legs, in association with inflammatory bowel disease, haematologic diseases and Juvenile Idiopathic Arthritis (JIA).

Methods: We describe a 11-years old boy with pyoderma gangrenosum complicated spider bite in association with systemic JIA (sJIA). The patient was in clinical remission after the start of the sJIA, occurred two months before, still treated with tapering doses of steroids and canakinumab, with the normalization of inflammatory parameters (CRP, ESR, SAA, ferritin) and clinical manifestations. Only a mild arthritis of the knee persisted and for this reason he was still treated with steroids. Furthermore, he developed hyperglycemia, requiring insulin treatment. The first dermatological manifestation which he referred was a red dot of the leg skin. In a few days, the erythema enlarged, involving an area of 7 x 7 cm, with oedema, pain, and blisters, evolving in a necrotic lesion, with purulent exudate, surrounded by a haemorrhagic zone.

Results: Haematological controls revealed neutrophilic leucocytosis, increased CRP and procalcitonin. He started treatment with intravenous administration of ticoplanin plus ceftriaxone, with no resolution of the clinical manifestations and the reduction of leucocytosis, CRP, procalcitonin.

A culture swab was performed and was positive for Pseudomonas Aeruginosa, confirmed by PCR on the culture. He started ciprofloxacin and surgical curettage of the lesion, with the resolution of the lesion and the normalization of biochemical parameters.

Conclusion: The aspect of the lesion and its evolution were evocative of a spider bite suggested by anamnestic records, complicated by a pyoderma gangrenosum secondary to Pseudomonas Aeruginosa. The underlying disease, the immune suppressive treatment, with steroids and biological drugs, the hyperglycaemic pattern of the patient allowed the severe evolution of the spider bite.

Children in treatment with immune suppressive and/or biologic drugs are at high risk of infections. Skin lesions, as arthropods bites, can be a facility for superinfection, with possible haematological and systemic diffusion.

Disclosure of Interest: None declared

P219

Application of preliminary PRINTO classification criteria for sJIA in an Indian cohort

D. B. Pandya, on behalf of Dr Jay Virani, Dr Harsh Dobariya, Dr Harsh Bala, Dr Hitshe Bhambhani, DrAmbish Panara and Dr Vinod Bhadukya
Pediatric Rheumatology & Immunology, Dev Children’s Hospital, Rajkot, India

Correspondence: D. B. Pandya
Pediatric Rheumatology 2020, 18(Suppl 2):P219

Introduction

The strict application of the ILAR requirement for the presence of documented arthritis for the diagnosis of sJIA, early in the disease course, may result in unnecessary delays in initiating appropriate treatment. In preliminary PRINTO classification criteria for sJIA, this mandatory requirement of documented arthritis has been modified.

Objectives

To measure performance of preliminary PRINTO classification criteria for sJIA in our Indian cohort.

Methods

I gathered a data of seven sJIA patients who attended dev children's hospital between Jan 2019 and Jan 2020. My data included demographics, clinical presentation, laboratory parameters and outcome of these patients. All these patients were diagnosed at an early stage by clinical judgement irrespective of fulfilment of ILAR criteria. I applied preliminary PRINTO classification criteria for all.

Results

Average age of selected children (4 girls and 3 boys) was 5.1 years.

Conclusion

A preliminary PRINTO classification criteria for sJIA has been validated in our cohort. There are many raised inflammatory markers in most of these patients other than WBC count. These markers should be considered to be added in supportive laboratory criteria to be more specific towards the diagnosis. It is important to add PID in exclusion list especially in a case of sJIA with MAS at onset.

Trial registration identifying number

1.R.E. Petty, T.R. Southwood, P. Manners, et al., International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001, J. Rheumatol. 31 (2) (2004) 390–392. 2. Second revision, New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus Alberto Martini, Angelo Ravelli, Tadej Avcin, Michael W. Beresford, Ruben Burgos-Vargas, Ruben Cuttica, Norman T. Ilowite, Raju Khubchandani, Ronald M. Laxer, Daniel J. Lovell, Ross E. Petty, Carol A. Wallace, Nico M. Wulffraat, Angela Pistorio, Nicolino Ruferto and for the Pediatric Rheumatology International Trials Organization (PRINTO)
The Journal of Rheumatology February 2019, 46 (2) 190-197; DOI: https://doi.org/10.3899/jrheum.180168

3. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Sebastian FN Bode,1,2 Sandra Ammann,1,3 Waleed Al-Herz,4 Mihaela Batanescu,1,3,5 Christopher C. Dvorak. Haematologica. 2015 Jul; 100(7): 978–988. doi: 10.3324/haematol.2014.121608

Disclosure of Interest: None declared

Table 1 (abstract P219). Showed performance of preliminary PRINTO classification criteria for sJIA in our cohort

| sJIA | Preliminary PRINTO Classification Criteria | No of patients fulfilled respective criteria |
|------|--------------------------------------------|--------------------------------------------|
|      |                                           | N (total=7) (%)                            |
| **Mandatory criterion** | Fever of unknown origin that is documented to be daily, quotidian; fever that rises >/= 39 C once a day and returns to | 7 (100%) at diagnosis |
| **Major criteria** | 1. Evanescent (nonfixed) erythematous rash | 6 (86%) at diagnosis |
|      | 2. Arthritis | 2 (28%) at diagnosis |
|      | 3. Arthralgia lasting 2 weeks or longer (in absence of arthritis) | 3 (43%) at diagnosis |
|      | 4. Leukocytosis (>/= 15,000/mm3) with neutrophilia | 7 (100%) at diagnosis |
| **Minor Criteria** | 1. Generalized lymph node enlargement and/or hepatomegaly and/or splenomegaly | 3 (43%) at diagnosis |
|      | 2. Serositis | 3 (43%) at diagnosis |
|      | 3. Arthralgia lasting 2 weeks or longer (in absence of arthritis) | 3 (43%) at diagnosis |
|      | 4. Leukocytosis (>/= 15,000/mm3) with neutrophilia | 7 (100%) at diagnosis |
| **Exclusions/ruled out in our cohort** | EBV | 3 (43%) |
|      | Autoimmune conditions | 2 (28%) |
|      | Monogenic auto-inflammatory condition- CAPS | 3 (43%) |
|      | PID | 1 (1-4%) |
| **Common laboratory parameters** | Anemia of chronic disease (age matched) | 7 (100%) |
|      | Platelet count (> 5 lakhs/ul) | 5 (71%) |
|      | ESR (>80mm/hr) | 5 (71%) |
|      | CRP (>60mg/L) | 6 (86%) |
|      | Ferritin (>500ug/dl) | 2 (28%) |
| **Medicines used in our cohort** | Oral Naproxen with oral steroids | 7 (100%) |
|      | SC Methotrexate | 5 (71%) |
|      | IV Methyprednisolone | 1 (1-4%) |
|      | IV Tocilizumab | 2 (28%) |
|      | IV Ig (in one case of suspected incomplete KD) | 1 (1-4%) |
| **Final Outcome** | Death (due to MAS) | 1 (1-4%) |
|      | Monocylic course | 2 (28%) |
|      | Chronic persistent course | 4 (57%) |

Abbreviations: PRINTO: Paediatric Rheumatology International Trail Organization, sJIA: systemic juvenile idiopathic arthritis, ILAR: International League of Associations for Rheumatology, EBV: Epstein-Barr-virus, CAPS: Cryopyrin Associated Periodic Syndromes, KD: Epstein-Barr-virus, MAS: Macrophage Activation Syndrome, PID: Primary Immunodeficiency Disease

P220

Allogenic hematopoietic stem cell transplantation for refractory childhood rheumatic diseases

C. Beaullifs,1, C. Proulx2, A. Blincoe1, P. Teira3, H. Bittencourt3, S. Cellot2, M. Duval3, M-P. Morin1, J. J. De Bruycker1, J. Couture1, K. Samaan1, H. Decaluwe1, F. Touzot1, E. Haddad1, J. Barsalou1

1Pediatric Rheumatology and Immunology; 2Pediatrics; 3Pediatric Hemato-Oncology, CHU Sainte-Justine, Université de Montréal, Montreal, Canada

Correspondence: C. Beaullifs

Pediatric Rheumatology 2020, 18(Suppl 2):P220

Introduction: Patients with refractory rheumatic diseases face poor quality of life, long-term sequelae and life-threatening complications. With advances in allogenic hematopoietic stem cell transplantation (allo-HSCT), this procedure becomes an interesting therapeutic option, allowing patients to achieve complete remission (CR) and withdrawal of most medications.

Objectives: Report two cases of allo-HSCT performed in children with refractory rheumatic diseases at a tertiary care paediatric hospital since 2017.

Methods: Patients’ demographics, disease course, allo-HSCT course and outcome are described. A review of the literature was performed, and clinical outcomes were compared to our local experience. Patients/parental consent was obtained from both subjects.

Results: Two patients with systemic-onset juvenile idiopathic arthritis (sJIA) underwent allo-HSCT. Patients’ characteristics are shown in Table 1. Both had failed multiple lines of immunosuppressive treatments and experienced severe disease and treatment-related complications. Both experienced early complications following HSCT but recovered without major sequelae. Patient 1 is in CR off all immunosuppressive medications at 2.6 years post-HSCT. Patient 2 experienced a disease flare at 11 months post-HSCT. He received one pulse of methylprednisolone and was started on tofacitinib. At 1.3 years post-HSCT, he is now in CR on tofacitinib monotherapy, which represents a significant improvement from his pre-HSCT status. Engraftment was excellent with most recent chimerism at 100% (2.6 years post-HSCT) and 95% (1.1 years post HSCT), for Patient 1 and 2, respectively. Allo-HSCT is reported as a treatment option in very few paediatric JIA patients. In a recently described cohort of 16 JIA patients who underwent allo-HSCT (11/16 had sJIA), CR was shown in Table 1. Both had failed multiple lines of immunosuppressive treatments and experienced severe disease and treatment-related complications. Both experienced early complications following HSCT but recovered without major sequelae. With current TRM rates < 10 %, allo-HSCT should be considered as an alternative therapeutic option early in the course of severe paediatric rheumatic diseases refractory to conventional treatments as it is currently the only curative treatment. The decision to proceed to allo-HSCT should not be delayed since it increases TRM, and allo-HSCT does not correct disease and treatment’s sequelae. With current TRM rates < 10 %, allo-HSCT should be considered sooner after failure of conventional lines of treatment, and not only in patients with no other therapeutic options. Our data may suggest that full donor chimerism is necessary in some patients to maintain CR off immunosuppression.

Conclusion: Allo-HSCT should be considered as an alternative therapeutic option early in the course of severe paediatric rheumatic diseases refractory to conventional treatments as it is currently the only curative treatment. The decision to proceed to allo-HSCT should not be delayed since it increases TRM, and allo-HSCT does not correct disease and treatment’s sequelae.

Methods: Patients’ demographics, disease course, allo-HSCT course and outcome are described. A review of the literature was performed, and clinical outcomes were compared to our local experience. Patients/parental consent was obtained from both subjects.

Results: Two patients with systemic-onset juvenile idiopathic arthritis (sJIA) underwent allo-HSCT. Patients’ characteristics are shown in Table 1. Both had failed multiple lines of immunosuppressive treatments and experienced severe disease and treatment-related complications. Both experienced early complications following HSCT but recovered without major sequelae. Patient 1 is in CR off all immunosuppressive medications at 2.6 years post-HSCT. Patient 2 experienced a disease flare at 11 months post-HSCT. He received one pulse of methylprednisolone and was started on tofacitinib. At 1.3 years post-HSCT, he is now in CR on tofacitinib monotherapy, which represents a significant improvement from his pre-HSCT status. Engraftment was excellent with most recent chimerism at 100% (2.6 years post-HSCT) and 95% (1.1 years post HSCT), for Patient 1 and 2, respectively. Allo-HSCT is reported as a treatment option in very few paediatric JIA patients. In a recently described cohort of 16 JIA patients who underwent allo-HSCT (11/16 had sJIA), CR was shown in Table 1. Both had failed multiple lines of immunosuppressive treatments and experienced severe disease and treatment-related complications. Both experienced early complications following HSCT but recovered without major sequelae. With current TRM rates < 10 %, allo-HSCT should be considered sooner after failure of conventional lines of treatment, and not only in patients with no other therapeutic options. Our data may suggest that full donor chimerism is necessary in some patients to maintain CR off immunosuppression.

Reference:

1. J MF, Ladomenou F, Carpenter B, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood advances 2018;2(7):777-86.

Disclosure of Interest: None declared
Table 1 (abstract P220). sJIA patients characteristics and evolution post-HSCT

| Sex | Patient 1 | Patient 2 |
|-----|-----------|-----------|
| Age at baseline, years | 5 | 8 |
| Duration at HSCT, years | 2 | 3 |
| Disease type | MUD | MRD |
| Time to stop IS post-HSCT, months | 14 | Ongoing |
| Disease outcome (years post-HSCT) | CR off IS (2.6) Relapsed at 11 months; CR on Tofacitinib (1.3) |

F: Female; IS: Immunosuppression; M: Male; MUD: Matched Unrelated Donor; NSAID: Non Steroidal Anti-Inflammatory Drugs

**P221**
The role of Intra-Articular Glucocorticoid Injections (IAGI) in Systemic Juvenile Idiopathic Arthritis (sJIA): a single center experience
A. Uva1, G. Tarantino2, D. Pires-Marafon3, A. Aquilani3, H. Jadoun3, R. CA

**Introduction:** IAGI are a safe and widespread treatment option in patients with JIA. Little is known about the benefits of IAGI in sJIA. **Objectives:** The aim of the study is to explore whether IAGI can spare the amount of systemic glucocorticoids (GC) in achieving remission of arthritis in sJIA.

**Methods:** Records of patients with sJIA at the study center were retrospectively reviewed. All sJIA patients at their first assessment of arthritis (baseline) and treated with systemic GC (with or without c/ bDMARDs) were included and divided into two groups: group A comprised children who were also treated with IAGI within the first five months of arthritis occurrence; group B the others. Patients with disease onset before 2015 or treated for more than 3 months before accessing to the study center were excluded. Demographic and clinical features, administration of intravenous (IV) GC pulses from baseline to six months from arthritis occurrence (T6), total amount of systemic GC (mg/kg), remission of arthritis and achievement of clinical inactive disease (CID, according to Wallace criteria) at T6 were registered and compared in the two groups.

**Results:** From a total of 23 sJIA patients at first assessment of arthritis at the study center, 11 were excluded because of treatment before 2015 (n=2), treatment for more than 3 months before coming to the study center (n=6), no systemic GC (n=2) or follow-up less than six months from IAGI (n=1). Twelve patients were included in the study. In group A (n=6, F 83.3%) IAGI was performed in a median of 3.8 months (range 1.6-4.9) from baseline, with a median of 12 injected sites/IAGI procedure (range 2-26), including 30 large joints, 19 small joints and 24 tendon sheaths. Triamcinolone hexacetonide and methylprednisolone acetate were injected in large joints and small joints-tendon sheaths, respectively. Children in group B (n=6, F 33.3%) presented arthritis of large joints (2 wrists, 2 knees, 1 ankle, 1 elbow). In both groups 4/6 (66.7%) patients received IV GC pulses from baseline to T6. Table 1 shows demographic features at baseline and clinical assessment at T6 of the two groups.

**Conclusion:** Our study represents the first attempt to define the role of IAGI in children with sJIA. Despite a clear trend in sparing systemic GC in achieving remission in children with sJIA treated also with IAGI, our results highlight the complexity of sJIA features presentation and treatment. This limits the possibility of comparing the therapeutic strategies in our cohort. Nonetheless, IAGI appear to represent an efficacious option in sJIA, particularly in those patients with widespread articular involvement. Prospective randomized studies may further explore this benefit.

**Disclosure of Interest:** None declared

**Table 1 (abstract P222).** Demographic features at baseline and clinical assessment at T6 in sJIA patients with arthritis.

| Group A (IAGI; N=6) | Group B (No IAGI; N=6) |
|---------------------|-----------------------|
| Age at baseline, years, median (range) | 3.5 (1.0-7.9) 7.4 (0.8-15.1) |
| Concomitant systemic treatment at baseline, n (%) | 3 (50.0) 5 (83.3) |
| Systemic treatment (apart from GC) baseline-T6, n (%) | 6 (100) 6 (100) |
| Systemic GC baseline-T6, n (%) | 5 (83.3) 6 (100) |
| Cumulative systemic GC baseline-T6 (mg/Kg), median (range) | 54 (21-147) 102 (54-200) |
| Triamcinolone hexacetonide (mg/kg), median (range) | 2.7 (1.1-6.7) - |
| Methylprednisolone acetate (mg/kg), median (range) | 4.8 (1.1-8.0) - |
| Remission of arthritis at T6, n (%) | 5 (83.3) 6 (100) |
| CID at T6, n (%) | 4 (66.7) 5 (83.3) |

**P222**
Coxarthrosis risk factors in systemic and Non-Systemic Juvenile Idiopathic Arthritis
L. Sorokina1, I. Avrušin2, R. Raupov3, N. Garipova4, M. Gharabaghtyan5, S. Khrypov6, E. Isupova7, E. Gaidar8, A. Santimov2, I. Chikova2, M. Dubko5, V. Masalova5, T. Likhacheva2, S. Snegireva2, M. Kostik9

**Introduction:** Hip involvement in juvenile idiopathic arthritis (JIA) is an alarming sign for patients and physicians. It can lead to coxarthrosis (CA), severe loss of function and decreased quality of life, and may require total hip arthroplasty (THA).

**Objectives:** To compare the frequency of hip involvement, progression to CA and a requirement for THA in patients with systemic and non-systemic JIA categories.

**Methods:** 753 JIA patients aged 2 to 17 years included in the retrospective study. JIA was diagnosed by ILAR criteria. Patients divided into two groups: systemic-onset JIA (n=58) and non-systemic, included other JIA categories (n=695). We compared demographic and clinical data, frequency and character of hip damage (coxitis, CA and THA), and treatment regimens too, especially, corticosteroid (CS) administration.

**Results:** The data presented in table 1. Patients with sJIA developed CA earlier than non-systemic 13.7 (9.5; 15.4) vs 15.2 (13.5; 16.4) years.
Objectives: To analyze the drug survival of canakinumab in patients with systemic juvenile idiopathic arthritis (sJIA) was demonstrated.

Methods: Medical records from sJIA patients treated with canakinumab (CAN) were analyzed retrospectively from the National Medical Research Center of Children’s health, Moscow, Russia.

Results: Seventy-four patients presenting with sJIA were included in this observation, with a median age at treatment initiation of 8.2 (interquartile range, IQR 3.9 -12.7) years and a median disease duration of 5.3 (IQR 2.9-10.7) years. Most patients (66/74) had been treated previously with one or more biologic agents for sJIA, 44/74 patients have received cDMARDs. As of 30 March of 2020, the median time of follow up was 97.3 (37.4-153.8) months, with all patients being followed for at least 6 months. The most patients (66/74) were previously treated with other biologic drugs. Eleven (11/74) patients stopped treatment with canakinumab, three of them - because of achievement of remission. Two patient stopped treatment within 6 months from therapy start: due to primary inefficacy (1) and allergic reaction (1). Five (5/11) patients were co-administered with cDMARDs, other 5 – with oral GC, and 6 subjects had been previously exposed to other biologic drugs. Whole 5 patients stopped therapy due to secondary inefficacy: 2 patients were switched on TOC, other children were switched on ETA (1), RIT (1), ADA (1). There were 1 death recorded because of MAS, not associated with receiving CAN.

Conclusion: Our results have shown an excellent survival of the IL-1 inhibitor CAN. Survival was not affected by the concomitant use of cDMARDs. These data underline the effectiveness of CAN in sJIA patients as monotherapy.

Disclosure of Interest: E. Krekhova: None declared, E. Alexeeva Speaker Bureau of: Novartis, Pfizer, Sanofi, MSD and Roche, T. Dvoryakovskaya Speaker Bureau of: Novartis, Pfizer, MSD and Roche, A. Mamutova Speaker Bureau of: Novartis, K. Isayeva: None declared, R. Denisova Speaker Bureau of: Novartis, MSD and Roche, A. Chomahidze: None declared, A. Fetisova: None declared, O. Lomakina: None declared, K. Chibisova: None declared, M. Gautier: None declared, D. Vankova: None declared, I. Kriulin: None declared, M. Shingarova: None declared.

P223 Drug survival for IL-1 inhibitor canakinumab: data from a single-center observation

E. Krekhova1,2, E. Alexeeva1,2, T. Dvoryakovskaya1,2, A. Mamutova1, K. Isayeva1, R. Denisova1, A. Chomahidze1, A. Fetisova1, O. Lomakina1, K. Chibisova1, M. Gautier1, D. Vankova1, I. Kriulin2, M. Shingarova1,2

Rheumatology, National Medical Research Center for Children’s Health, Moscow, Russian Federation

Correspondence: E. Alexeeva
Pediatric Rheumatology 2020, 18(Suppl 2):P223

Introduction: The efficacy of canakinumab for treatment patients with systemic juvenile idiopathic arthritis (sJIA) was demonstrated before. Our aims was to describe canakinumab drug survival based on data from a single-center observation.

Objectives: To analyze the drug survival of canakinumab in patients with sJIA treated at the National Medical Research Center of Children’s health, Moscow, Russia.
Introduction: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex auto-inflammatory disease with significant morbidity including fever, rash, serositis and articular problems. With the availability of interleukin-1 (IL-1) and IL-6 inhibitor treatment, morbidity has significantly reduced and the outcome for sJIA patients has improved. However, differences in access to care and differences in treatment strategies between countries in and outside of Europe remain a concern.

Objectives: The Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) consortium aimed to develop best practices for paediatric rheumatic diseases in order to decrease differences in care between European countries. Here, we present the final results of the literature review and a series of consensus meetings on defining overarching, diagnostic and therapeutic recommendations for diagnosis and treatment of sJIA.

Methods: The SHARE methodology has been previously published, including the use of the EULAR standardized operating procedure for developing best practice recommendations. As per these guidelines, a methodologist provided supervision during the process and consensus meetings.

A systematic literature search of Medline, Embase and Cochrane databases was performed in 2013 and again in November 2019. Results were used to develop and support recommendations on diagnosis, treatment and complications of systemic JIA. These recommendations were presented in an online survey to a task-force of expert paediatric rheumatologists to assess potential agreement and enable rewording. The participating experts convened in 3 consensus meetings (Genoa 2014, Barcelona 2015 and Utrecht 2020) to develop the recommendations. Making use of the Nominal Group Technique, recommendations were proposed, discussed and voted on. Recommendations that reached ≥80% were accepted.

Results: The 2-step systematic literature review included 98 papers on sJIA. Quality and grade of evidence was assessed and a categorized overview was used as backbone during the consensus meeting. In total, 15 recommendations were developed and accepted: 4 overarching principles, 3 diagnostic recommendations and 8 recommendations on management of sJIA and its complications. Recommendations were presented with accompanying level of evidence (LoE), strength of recommendation (SoR) and percentage of agreement (PoA). In addition, adherence to the 2018 EULAR Treat-to-Target principles on JIA was confirmed by the expert panel.

Conclusion: These SHARE best practice recommendations for sJIA are based on the best available evidence and expert opinion, and provide guidance for the diagnosis and management of sJIA, aiming to improve the outcome for all sJIA patients in Europe and beyond.

Disclosure of Interest: A. Leek: None declared, J. Anton Consultant for: SOBI, Roche, Novartis, Speaker Bureau of: SOBI, Roche, Novartis, T. Avcin Consultant for: AbbVie, Octapharma, Takeda, Alexion, F. De Benedetti Consultant for: Institutional grants from AbbVie, SOBI, Novimmune, Novartis, Roche, Pfizer, Abbvie, SOBI, Novimmune, Novartis, Roche, Pfizer, Employee of: Family member SOBI employee, V. Boom: None declared, C. Bracaglia Consultant for: SOBI and Novartis, P. Brogan Consultant for: SOBI, Roche, Novartis; UCB, institutional grants from SOBI, Roche, Novartis, A. Consolaro Speaker Bureau of: AbbVie, T. Constantin: None declared, P. Dolezalova Consultant for: SOBI, Novartis, Sanofi Genzyme, D. Eleftheriou: None declared, H. Foster Consultant for: Unrestricted educational grants from Pfizer, SOBI, Sanofi-Genzyme, C. Hinze Consultant for: Novartis, I. Kone-Paut: None declared, K. Minden Consultant for: Abbvie, Sanofi, gsk, Roche, F. Mina Consultant for: SOBI, P. Quartier Consultant for: consultation or speaking fees from AbbVie, Bristol-Myers Squibb, Chugai-Roche, Lilly, Novartis, Novimmune, and Swedish Orphan Biovitrum, A. Ravelli Consultant for: SOBI, Novartis and Roche, N. Ruperto Consultant for: consultancy or speakers fee from: Abl Lynx, Astrazeneca-Medimmune, Aurinia, Biogen, Boehringer, Bristol Myers and Squibb, Centrional Global, Domain Therapeutics, Eli-Lilly, EMD Serono, Glaxo Smith and Kline, Hoffmann-La Roche, Idorsia, Janssen, Merck, Novartis, Pfizer, R-Pharma, Sanofi, Servier, Sinerig, and SoBi, J. Swart Paid Instructor for: SOBI, Y. Uziel Speaker Bureau of: Pfizer, Abbvie, H. Wittkowski Speaker Bureau of: Novartis, Shire/Takeda and CSL-Behring. C. Wouters Consultant for: institutional grants from Roche, Novartis, SoBi, GSK, M. Zajc Avramovitz: None declared, N. Wulfraat Consultant for: SoBi, Novartis, Roche, institutional grants from SoBi, S. Vastert Consultant for: SOBI, Novartis, unrestricted institutional grant SOBI

P224 Effect of dose and duration of glucocorticoid treatment on prognosis of Systemic Juvenile Idiopathic Arthritis

A. Paç Nısaarıncı, S. Özdemir Cicek, ın, M. Basıl2, S. Doğantan1, N. N. Taşkıncı1, M. H. Poyrazoğlu1
1Pediatric Rheumatology, Erciyes University Faculty of Medicine, Kayseri, Turkey
2Biostatistics, Abant Izzet Baysal University Faculty of Medicine, Bolu, Turkey

Correspondence: S. Özdemir Cicek
Pediatric Rheumatology 2020, 18(Suppl 2):P224

Introduction: Systemic Juvenile idiopathic arthritis(sJIA) is characterised with high level of inflammation, high disease activity, and risk of development of macrophage activation syndrome that is high life threatening condition. Due to all of these reasons, the rate of glucocorticoid usage is very higher in sJIA than other JIA subtypes. Although the cessation of glucocorticoid was recommended as soon as possible, there is no consensus on the duration and dosage of glucocorticoid treatment.

Objectives: We aimed to investigate to effect of dose and duration of glucocorticoid treatment on sJIA disease prognosis.

Methods: Forty two patients diagnosed with sJIA and had duration of disease upper than 2 years were involved in this study. Demographic, clinic, laboratory data, and treatments were collected from patients records. Affecting factors which were patients clinical, laboratory findings, treatment options, dose and duration of steroid treatments were evaluated on the duration of achieving remission period (period of active disease) and duration of remission period with cox regression analysis.

Results: Half of patients had monophasic course. Age at diagnosis: HR(95% CI): 1.095 (1.006-1.192), p: 0.036, platelet values; HR (95% CI): 0.997 (0.995-0.999), p: 0.008, duration of steroid treatment;HR (95% CI): 0.837 (0.754-0.929), p: 0.001 were determined as risk factors on duration of achieving remission period (period of active disease) with multivariate cox regression analysis (table). There was no determined risk factors on duration of remission period.

Conclusion: In our preliminary study showed that duration and dose of glucocorticoid treatment did not change prognosis and disease course. The best dose and duration of the treatment should be evaluated further studies.

Disclosure of Interest: None declared
Table 1 (abstract P225). Factors Affecting on the Duration of Achieving Remission Period

| Variables                  | Univariate Cox Regression | Multivariate Cox Regression* |
|----------------------------|---------------------------|-------------------------------|
|                            | n | H    | (95% CI) | P    | n | H    | (95% CI) | P    |
| Age at diagnosis            | 42 | 1.008 (1.015-1.008) | 0.191 | 1.006 (1.009-1.000) | 0.030 |
| Gender                     | 96 | 0.980 (0.933-1.035) | 0.965 |
| Features at first flare     | 42 | 0.904 (0.594-1.363) | 0.317 |
| Fever                      | 42 | 1.451 (0.316-6.770) | 0.672 |
| Serositis                  | 5  | 0.332 (0.003-14.724) | 0.949 |
| Rash                       | 23 | 1.064 (0.342-3.583) | 0.909 |
| Joint involvement          | 38 | 0.606 (0.217-1.629) | 0.294 |
| Morning stiffness           | 9  | 0.440 (0.169-1.206) | 0.157 |
| Lymphadenopathy            | 6  | 1.003 (0.665-3.338) | 0.970 |
| Hepatomegaly               | 10 | 2.059 (0.963-4.574) | 0.052 |
| Macrophage activating syndrome | 14 | 1.108 (0.578-2.125) | 0.757 |
| Patient/parent VAS         | 42 | 0.886 (0.549-1.400) | 0.619 |
| Oral steroid               | 40 | 1.002 (0.777-1.293) | 0.987 |
| Trigliserid (mg/dL)        | 17 | 1.000 (0.998-1.002) | 0.999 |
| Fibrinojen (mg/dL)         | 17 | 1.001 (0.997-1.004) | 0.711 |
| BUN (mg/dL)                | 42 | 1.000 (0.995-1.006) | 0.892 |
| CRP (mg/L)                 | 42 | 1.000 (0.995-1.006) | 0.925 |
| ESR (μm/h)                 | 42 | 1.000 (0.995-1.006) | 0.902 |
| PGA                        | 42 | 1.000 (0.995-1.006) | 0.902 |
| Macrophage activation syndrome | 14 | 1.108 (0.578-2.125) | 0.757 |
| Patient/parent VAS         | 42 | 0.886 (0.549-1.400) | 0.619 |
| Oral steroid               | 40 | 1.002 (0.777-1.293) | 0.987 |
| Trigliserid (mg/dL)        | 17 | 1.000 (0.997-1.004) | 0.711 |
| Fibrinojen (mg/dL)         | 17 | 1.000 (0.995-1.006) | 0.925 |
| Liveromegaly               | 17 | 1.000 (0.995-1.006) | 0.925 |
| Hepatomegaly               | 10 | 2.059 (0.963-4.574) | 0.052 |
| Macrophage activating syndrome | 14 | 1.108 (0.578-2.125) | 0.757 |
| Patient/parent VAS         | 42 | 0.886 (0.549-1.400) | 0.619 |
| Oral steroid               | 40 | 1.002 (0.777-1.293) | 0.987 |

Table 1 (abstract P225). Factors Affecting on the Duration of Achieving Remission Period

- **PMP, pulse methylprednisolone**
- **DMARDs, disease modifying anti-rheumatic drugs**

**References**

1. Minoia F, Bosis F, Davas S, Home A, Fischbach M, Frosch M, et al. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2019;78(10):1357-1362.

2. Fardet L, Gallicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.

3. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2019;78(10):1357-1362.

4. Fardet L, Gallicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.

**Disclosure of Interest:** None declared
Introduction: Still's disease, including both systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD), is a rare systemic auto-inflammatory disorder associated with an activated IL-1 pathway.

Objectives: To build on earlier evidence and evaluate in a controlled setting the efficacy and safety of anakinra, an IL-1 receptor antagonist, in patients with active, newly diagnosed Still's disease across all age groups.

Methods: The anastaDDS study (anakinra in Still's disease) was a randomized, double-blind, placebo-controlled, 12-week study including patients with active and newly diagnosed Still's disease (adapted ILAR criteria if <16 years of age, Yamaguchi criteria if ≥16 years of age at disease onset). Patients were randomized to anakinra 2 mg/kg (max 100 mg/day), 4 mg/kg (max 200 mg/day) or placebo. The primary objective was to demonstrate the efficacy of anakinra versus placebo as assessed by ACR30 response with an absence of fever at Week 2. Secondary objectives included: early onset of efficacy, sustained efficacy, time to study drug discontinuation, safety, pharmacokinetics (PK), clinical signs and biomarkers.

Results: Twelve patients were randomized and received study treatment: 6 to anakinra (2 mg/kg n=2, 4 mg/kg n=4) and 6 to placebo. Due to slow recruitment the study was terminated early. One patient was excluded from the efficacy analyses since he/she was later diagnosed with lymphoma, not Still's disease. 11 patients were analyzed for efficacy (anakinra n=6, placebo n=5). 8 children (median [range] age=4.0 [1-11] years) and 3 adults (median [range] age=32.0 [25-51] years). 55% were male and the mean (range) symptom duration was 74.2 (12-222) days. All patients on anakinra but none on placebo achieved ACR30 response with absence of fever at Week 2 (p-value=0.0022). The efficacy of anakinra was supported by superiority to placebo in ACR50/70/90 responses with absence of fever at Week 2. All placebo patients discontinued the study within 6 weeks, 2 due to progressive disease, 2 due to lack of efficacy and 1 due to withdrawal by the patient. A numerically greater proportion of patients in the anakinra group had early onset of efficacy (Week 1) compared to placebo, as assessed by ACR50. ACR30/50/70/90 responses in anakinra-treated patients were sustained throughout the study period. No unexpected safety findings were observed. Based on serum anakinra concentrations Week 12, Cmax was 2920 mg/mL at 4.0 hours (dose: 41 mg/kg) in a 1-year-old patient, and Cmax was 1060 mg/mL at 2.1 hours (dose: 1.5 mg/kg) in a 6-year-old patient.

ACR response with absence of fever at Week 2

| Primary & secondary endpoints | Response (Anakinra) n (%) | Response (Placebo) n (%) | Difference (Anakinra-Placebo) | 95% CI for exact difference | Fisher’s exact test p-value |
|-----------------------------|-------------------------|-------------------------|-----------------------------|----------------------------|----------------------------|
| ACR30*                      | 6 (100.0)               | 0 (0.0)                 | 1.00                        | 0.42, 1.00                 | 0.0022                     |
| ACR50*                      | 6 (100.0)               | 0 (0.0)                 | 1.00                        | 0.42, 1.00                 | 0.0022                     |
| ACR70*                      | 6 (100.0)               | 0 (0.0)                 | 1.00                        | 0.42, 1.00                 | 0.0022                     |
| ACR90*                      | 5 (83.3)                | 0 (0.0)                 | 0.83                        | 0.24, 1.00                 | 0.0152                     |

*With absence of fever at Week 2

Conclusion: Anakinra is superior to placebo in the treatment of Still's disease. The safety and PK results are consistent with previous anakinra experience. These results confirm the benefits of anakinra treatment in patients with active, newly diagnosed Still's disease across ages.

Trial registration identifying number: NCT03265132

Disclosure of Interest: L. Schanberg Consultant for: Sobi, P. Nigrovic Consultant for: Novartis, BMS, Pfizer, Sobi, Miach Orthopedics, Simcere, XBiotech, Quench Bio, Siglion, Cerecor, A. Cooper: None declared, W. Chatham Consultant for: Sobi, A. Kuchler: None declared, N. Singh: None declared, E. Rabinovich: None declared, A. Thataiyatkom: None declared, A. Taxter: None declared, J. Hausmann Consultant for: Novartis, M. Zdravkovic: Shareholder of: Sobi, Employee of: Sobi, S. Ohlman Shareholder of: Sobi, Employee of: Former employee of Sobi, H. Andersson Employee of: Sobi, C. Edemmer Holm Shareholder of: Sobi, Employee of: Sobi, G. Huledal Employee of: Sobi, R. Schneider Consultant for: Novartis, Novimmune, Sobi, F. De Benedetti Speaker Bureau of: AbbVie, Novartis, Roche and Sobi

P228

Canakinumab as first- or second-line DMARD in systemic-onset Juvenile Idiopathic Arthritis (sJIA) - data from the German biker registry

R. Heidebrecht1, A. Klein1, X. Minden2, F. Dressler3, G. Horneff1
1Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, 2Charité University Hospital Berlin, Berlin, 3Hannover Medical School, Hannover, Germany

Correspondence: R. Heidebrecht

Pediatric Rheumatology 2020, 18(Suppl 2):P228

Introduction

Early inhibition of IL-1 is discussed to play an important role in the disease course of sJIA1. Assuming that pretreatment with other DMARDs leads to a later start of therapy with canakinumab, this analysis evaluates the effectiveness of canakinumab as first-line vs. second-line DMARD.

Objectives

To evaluate the effectiveness of canakinumab as first used biological DMARD in sJIA compared to canakinumab in sJIA-patients pretreated with other DMARDs.

Methods

sJIA-patients documented in the German Biologic Registry for Pediatric Rheumatology (BiKeR), who were exposed to canakinumab, were identified. For the first-line (FL) group DMARD naïve patients were selected, prior treatment with corticosteroids and/or NSAIDs was allowed. Patients receiving any DMARD prior to canakinumab entered the second-line (SL) group. Both groups were compared in a retrospective intention-to-treat-analysis. Effectiveness was determined by analyzing JIA American College of Rheumatology (ACR) Inactive Disease (defined by Wallace et al.1, 10-joint Juvenile Arthritis Disease Activity Score Remission (JADAS-10-Remission) and JADAS-10-Minimal Disease Activity (-MDA). Safety was analyzed based on adverse event (AE) reports.

Results

Altogether 60 patients with sJIA were included. 13 patients (21.7%) in the FL-group, 47 (78.3%) in the SL-group. Mean disease duration until baseline was 10.3±22.9 months in the FL- and 35.7±46.7 months in the SL-group (p=0.0647). Patients in the FL-group had significantly higher scores for CRP (FL 76.7±56.8 mg/l, SL 27.2±46.5 mg/l, p=0.002) and JADAS-10-mean (FL 17.7±7.0, SL 10.5±8.5, p=0.0073) at baseline than patients in the SL-group. In both groups a significant improvement in the number of patients reaching JADAS-10-MDA, JADAS-10-Remission and ACR-Inactive-Disease was achieved from month 0 to month 3. Significantly more patients in the FL-group reached ACR-Inactive-Disease (FL 81.8%, SL 40.0%, p=0.0351) at month 6 than in the SL-group. 122 adverse events (AE) were reported, 22 of them were serious (SAEs). Most events were classified as infections and infestations (49 AEs, 5 SAEs).

|                | First Line (n=13) | Second Line (n=47) | P-Value |
|----------------|------------------|--------------------|--------|
| ACR-Inactive Disease, n (%) | Mo | Mo | 0.00 | 7 (14.9) | 0.3288 |
|                | 0 (0.0) | 6 (60.0) | 18 (64.3) | 1.000 |
|                | 9 (81.8) | 14 (40.0) | 0.0351 |
| JADAS-10-Remission, n (%) | Mo | Mo | 0.00 | 11 (23.4) | 0.0998 |
|                | 0 (0.0) | 8 (80.0) | 16 (57.1) | 0.2685 |
|                | 3 (23.1) | 9 (81.8) | 17 (48.6) | 0.0821 |

Conclusion

Canakinumab treatment showed good effectiveness in sJIA both as first- and second-line DMARD. After 6 months the use of canakinumab as first-line DMARD is associated with higher response rates compared to second-line use. Our data support the hypothesis that early
treatment with canakinumab is associated with good therapeutic response and a positive effect on the disease course of SJIA.

References

[1] Topkut N, Blazina S, Avćin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Devel Ther. 2018 Jun 8;12:1633-1643. doi: 10.2147/DDDT.S114532. PMID: 29920383; PMCID: PMC5996857.

[2] Wallace C.A. et al. Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care & Research Vol. 63, No. 7, July 2011, pp 929-936.

Disclosure of Interest: R. Heidebrecht: None declared, A. Klein: None declared, K. Minden Speaker Bureau of: AbbVie, GSK, Roche, Sanofi & Biermann, F. Dressler Speaker Bureau of: Novartis, Pfizer & AbbVie, G. Horneff Speaker Bureau of: Pfizer, AbbVie, Novartis, Chugai

P229 Childhood systemic lupus erythematosus: experience from sub- Himalayan region of North West India

Y. Sharma, A. Sharma
Pediatrics, Dr Rajendra Prasad Government Medical College, kangra, India

Correspondence: Y. Sharma
Pediatric Rheumatology 2020, 18(Suppl 2):P229

Introduction: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. Clinical presentation can vary from mere cutaneous involvement to more severe multisystem involvement. SLE usually presents with rash, fatigue and fever but may sometimes present with unusual, non-specific manifestations in children.

Objectives: To describe a cohort of children with SLE from tertiary care centre in a resource limited setting in North west India

Methods: Retrospective case review of all children diagnosed as SLE from July 2017-December 2018 at a single tertiary care hospital in North India was done. Diagnosis of SLE was based on Systemic Lupus International Collaborating Clinics(SLICC) classification criteria.

Results: A total of 11 children (9 girls) with SLE were identified. Median age of symptom onset and diagnosis was 14 years(range 8-17 years) and 11 years respectively. The presenting manifestations were fever(5), oral ulcers(3), alopecia(3), malar rash(4), photosensitivity(5), renal involvement(5), seizures(1) and gastrointestinal complications(1). The disease continued to be in remission in 7 patients. One child (MAS) died during disease course. Disease continues to be in remission in rest.

Conclusion: We found a significant female preponderance in our study group. Renal involvement was the commonest presentation. Some unusual presentations were also seen. Early recognition of SLE is critical for timely initiation of appropriate treatment. This is the first report of a cohort of Pediatric SLE from this part of India.

Disclosure of Interest: None declared

P230 A rare case of mixed type autoimmune hemolytic anemia in a 15-years old adolescent – don’t always blame lupus

C. D. A. S. Faria1, J. A. Guimarães1, L. R. Campos2, K. L. Baptista2, F. P. L. F. Veiga1, T. G. Noronha3, D. P. Balkoli4, R. D. C. Villalta1, A. C. F. Bassani1, C. Pinheiro1, T. R. D. Souza5, B. Cohen4

1Pediatrics; 2Pediatric Rheumatology, Department of Pediatrics; 3Pediatric Nephrology, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói - Rio de Janeiro, Brazil; 4Hematologistas Associados, Rio de Janeiro, Brazil

Correspondence: C. D. A. S. Faria
Pediatric Rheumatology 2020, 18(Suppl 2):P230

Introduction: Autoantibodies in AHAI may be IgG/IgM/IgA. AHAI can be divided into primary or secondary (e.g. SLE, lymphoproliferative diseases, infections, medications). It is also classified based on the temperature at which the antibody reacts to erythrocytes, and can be warm (IgG or IgA) or cold (IgM or C3). In warm AHAI, the antibodies react at temperatures ≥37°C, not activating the complement system and not undergoing agglutination in vitro. In cold AHAI, antibodies react at temperatures below 37°C, activating the complement system with in vitro agglutination.Mixed AHAI (warm and cold) is rare and occurs in <10% of AHAI cases and can occur at any age, but is extremely rare in children. The prevalence of the mixed form is less than 1/1,000,000 patients with AHAI.

Objectives: To report a rare case of mixed AHAI and idiopathic intracranial hypertension(IIH) in a 15-years old female patient with a previous diagnosis of SLE and APS.

Methods: Case report and literature review.

Results: A 15-years old female adolescent previously diagnosed with SLE/APS since 2017 was in remission on hydroxychloroquine(400mg);azathioprine(150mg);aspirin(100mg);vitaminD3(1,000IU);calcium(1g), and sunscreen. In April 2020, she had a relapse presenting with fatigue, myositis, headache, hypocomplementemia, and severe autoimmune hemolytic anemia (Hb of 4g/dL) (SLEDAI-2K=18 points). Mixed AHAI was diagnosed base on a Direct/Indirect Coombs test 4+/+,DirectAntiGlobulinTesting showing anti-IgA(weak),anti-IgM(3+/+),anti-IgG(3+/+),anti-C3c(weak),anti-C3d (3+/+),JgG1/3subclasses with a reaction of 1:100(2+/+).An eleven cell antibody panel positive revealing a cold and warm antibody, and adsorption technique revealing a cold and warm autoantibody. Chest CT showed bibasilar subsegmental atelectasis, head CT/MRI was normal and LP showed a high opening pressure of 45cmH2O with a normal cell count. After the procedure, the patient reported improvement in the pain and was diagnosed with IIH. The patient was screened for secondary causes for AHAI (table 1) due to the unusual mixed type pattern and serology was positive for Chlamydia trachomatis (IgM) and Mycoplasma pneumoniae (indeterminate-IgM/positive-IgG) suggesting a recent infectious trigger causing reactivation of the underlying disease with a probable cross-reactivity. The patient treated with 10-days of clari-thromycin. Before the infectious screening came back negative, AHAI was treated with a single dose of IVIG(1g/kg) and then, with 3-days of methylprednisolone(1g/day). Azathioprine was replaced by mycophenolate mofetil. Due to headache recurrence, acetazolamide(500mg/day) was started, and the patient referred no pain. The patient was discharged with a resolution of the symptoms.

Conclusion: The diagnosis of AHAI should alert pediatricians for the possibility of underlying causes other such as infectious, autoimmune diseases or neoplasms. In this case, SLE reactivation was a clear cause of AHAI but the mixed type is not what usually occurs in SLE. AHAI in SLE presents with a warm type(IgG). The presence of a cold antibody(IgM) is usually associated with infectious diseases such as Mycoplasma pneumoniae. This could contribute to the disease relapse. Atypical patterns of AHAI should be investigated for other causes even if a clear cause such as SLE is identified.

Disclosure of Interest: None declared

P231 Autoimmune hemolytic anemia: a case report

T. G. Noronha1, D. P. Balkoli1, T. R. D. Souza2, B. Cohen3

1Pediatrics; 2Pediatric Rheumatology, Department of Pediatrics; 3Pediatric Nephrology, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói - Rio de Janeiro, Brazil

Correspondence: T. G. Noronha
Pediatric Rheumatology 2020, 18(Suppl 2):P231

Introduction: Autoimmune hemolytic anemia (AIHA) can be divided into primary or secondary (e.g. SLE, lymphoproliferative diseases, infections, medications). AIHA may present with rash, fatigue and fever but may sometimes present with unusual, non-specific manifestations in children.

Objectives: To describe a cohort of children with SLE from tertiary care centre in a resource limited setting in North west India

Methods: Retrospective case review of all children diagnosed as SLE from July 2017-December 2018 at a single tertiary care hospital in North India was done. Diagnosis of SLE was based on Systemic Lupus International Collaborating Clinics(SLICC) classification criteria.

Results: A total of 11 children (9 girls) with SLE were identified. Median age of symptom onset and diagnosis was 14 years(range 8-17 years) and 11 years respectively. The presenting manifestations were fever(5), oral ulcers(3), alopecia(3), malar rash(4), photosensitivity(5), renal involvement(5), seizures(1) and gastrointestinal complaints(1) apart from some unusual manifestations of isolated peripheral arthritis(1), isolated bilateral pleural effusion(1), macrophage activation syndrome(2).

Laboratory investigations: Hemogram revealed anemia in 8 children and thrombocytopenia in 5. Urine examination showed nephrotic range proteinuria in 1 child and subnephrotic proteinuria in 2. Microscopic hematuria was noted in 2 pateints. Renal function tests were deranged in 2 cases. ANA, Anti dsDNA positivity and hypocomplementemia were present in all. Renal biopsy was done in 4 patients, 2 had class IV, one class III and one had class V lupus nephritis. All patients were initiated on hydroxychloroquine and photoprotection. Children with renal involvement were given pulse methylprednisolone followed by tapering doses of oral prednisolone and intravenous, monthly cyclophosphamide. Azathioprine was used as maintenance therapy in all. Subcutaneous weekly methotrexate was used in 2 patients. One child (MAS) died during disease course. Disease continues to be in remission in rest.

Conclusion: We found a significant female preponderance in our study group. Renal involvement was the commonest presentation. Some unusual presentations were also seen. Early recognition of SLE is critical for timely initiation of appropriate treatment. This is the first report of a cohort of Pediatric SLE from this part of India.

Disclosure of Interest: None declared
**P231**  
Bickerstaff encephalitis with overlapping Guillain-Barré syndrome: a case report  
A. Koryllou1, M. Mejbri2, S. Garcia-Tarodo2, P. Parvex3, E. Gonzalez Nguyen Tang4, C. M. Koff2, M. Hofer1  
1Pediatric Immuno-Rheumatology Unit, Lausanne University Hospital (CHUV), Lausanne; 2Pediatric Neurology Unit, 3Pediatric Nephrology Unit, University Hospitals of Geneva, Geneva, Switzerland  
**Correspondence:** A. Koryllou  
Pediatric Rheumatology 2020, 18(Suppl 2):P231  

**Introduction:** Pediatric systemic lupus erythematosus (pSLE) is an autoimmune disease with multisystemic involvement. More than 50% of the patients present neurological or psychiatric manifestations, with 43.9% of them presenting these symptoms at the time of diagnosis (REF). Rarely, Guillain-Barré syndrome (GBS) and its subtypes have been described in association with active SLE. Bickerstaff’s brainstem encephalitis (BBE) is a rare immune-mediated disorder characterized by ophthalmoplegia, ataxia and disturbance of consciousness, which symptoms may overlap with GBS.  

**Objectives:** To our knowledge, the association of GBS and BBE has been described in adults only.  

**Methods:** We here describe a child presenting at SLE disease-onset with an overlap of peripheral (GBS) and central (BBE) nervous system manifestations, highlighting the possible association between these two entities in children.  

**Results:** An 11-year-old healthy girl presented with acute ataxia, ophthalmoplegia and altered level of consciousness, rapidly followed by areflexia, facial paresis, swallowing difficulties, sensory deficits, paroxysms in all four limbs and respiratory insufficiency. These symptoms were accompanied by pleuro-pericardial serositis, proteinuria and hyperension. Immunological investigations revealed the presence of positive ANA and ds-DNA antibodies. The renal biopsy showed a stage III lupus nephritis. Hence, the clinical, laboratory findings and biopsy report led to the diagnosis of pSLE. Brain and spine MRI did not show any abnormalities; diffuse slowing compatible with nonspecific encephalopathy was seen on EEG. Nerve conduction studies (NCS) confirmed the clinical suspicion of acute polyradiculoneuropathy with proximal interruption of motor nerve conduction, compatible with Guillain-Barré-like syndrome. CSF analysis (performed twice) remained normal. The patient was treated with glucocorticoids, intra-venous immunoglobulins, cyclophosphamide as well as plasmapheresis. The neurological and physical symptoms improved gradually with complete neurological recovery four months after onset.  

**Conclusion:** Overlapping forms of BBE/GBS have never been described in association to SLE in children. Our patient’s presentation and evolution fulfilled the criteria for such an overlap, occurring at pSLE onset. Although SLE and BBE/GBS are rare entities, our case suggests that there may be a common underlying immune background. This association should be recognized early for rapid and appropriate treatment initiation.  

**Disclosure of Interest:** None declared  

**P232**  
Infantile antiphospholipid antibody syndrome: acquired and de novo APL appearance in four infants  
T. Giani1, G. Ferrara2, A. Mauro3, R. Cimaz4  
1Department of Medical Biotechnology, University of Siena, Siena; 2Department of Pediatric, ASL 10, Florence; 3Pediatric Emergency Department, Santobono Children Hospital, Napoli; 4Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy  
**Correspondence:** T. Giani  
Pediatric Rheumatology 2020, 18(Suppl 2):P232  

**Introduction:** Antiphospholipid syndrome (APS) is a rare condition in the neonatal age. In most cases it is considered a passively acquired autoimmune disease, due to a transplacental passage of maternal antiphospholipid antibodies (aPL). Exceedingly unusual is the de novo production of aPL in newborns and infants.  

**Objectives:** To describe four infants who developed an early brain stroke with increased and persistent levels of aPL, even after six months of life.  

**Methods:** We reviewed the clinical charts of four such infants, followed from diagnosis up to two years after the disappearance of aPL.  

**Results:** Four babies (3 F and 1M) came to our attention at 5, 7, 9 and 22 months of life, respectively, because of perinatal stroke and presence of aPL. Clinical and laboratory data of mother-infant pairs are described in the table. Three out of 4 children (cases 1-2-3) had only IgG antibodies. One mother had both aCL and anti-beta2GPI IgM and IgG. In the first 3 cases antibodies disappeared within 2 years of life (6, 16 e 20 months respectively), in the last case at 26 months of life. Two cases (1 and 3) had genetic pro-thrombotic factors and received baby aspirin until the disappearance of aPL. Case 4 had a persistable risk factor and was the only one to have positive aPL IgM.  

**Table:**  
| Case | Perinatal risk factors | Type of delivery | Age of symptoms onset | Laboratory | Disappearance of aPL | Outcome |
|------|------------------------|-----------------|----------------------|------------|----------------------|---------|
| 1    | Gestational diabetes   | Vaginal         | 5 months             | ANA 1:80   | 16 months            | Heteroplasia |
| 2    | Gestational diabetes   | Vaginal         | 5 months             | ANA 1:80   | 16 months            | Heteroplasia |
| 3    | Elective caesarian     | Vaginal         | 5 months             | ANA 1:80   | 16 months            | Heteroplasia |
| 4    | Dichorionic-diamniotic twin pregnancy | Cesarean         | 5 months             | ANA 1:80   | 16 months            | Heteroplasia |

**Conclusion:** Common characteristics of these four children are the development of brain stroke and the increased and persistent aPL levels even after six months of life. This opens the window on a gray zone related to the origin of these antibodies (maternal or neonatal) and on their role in the pathogenesis of the infantile brain stroke.  

**Disclosure of Interest:** None declared  

**P233**  
Spectrum of childhood-onset systemic lupus erythematosus and its clinical course  
P. Morán Álvarez1, A. Boteanu2, M. Vázquez Diaz2  
1Rheumatology; 2Hospital Ramón y Cajal, Madrid, Spain  
**Correspondence:** P. Morán Álvarez  
Pediatric Rheumatology 2020, 18(Suppl 2):P233  

**Introduction:** Childhood systemic lupus erythematosus (cSLE) is an autoimmune systemic disease diagnosed in children under the age of 18 years old, leading to an important morbidity and mortality. Typically in the literature, cSLE is described in the literature with a more severe clinical course compared to adult-onset.  

**Objectives:** To analyze clinical manifestations within the first year after the diagnosis of cSLE and its subsequent clinical course.
Methods: A descriptive, observational, cross-sectional study was carried out. Inclusion criteria: all patients with diagnosis of cSLE based on 1997 updated American College of Rheumatology (ACR) criteria or 2012 Systemic International Collaborating Clinics (SLICC), in a tertiary hospital. Exclusion criteria: patients with a diagnosis of cSLE in another center, as data of the onset of the disease was not available. Demographic, clinical and analytical data were collected.

Results: 42 patients were included, 38 (90.5%) girls and 4 (9.5%) boys. 39 (92.9%) were Caucasians. Mean age at diagnosis was 13.3 years (range: 7-18). Clinical manifestations within the first year of cSLE and complementary tests are shown in Table 1. 31 (73.8%) children developed a major organ involvement within the first year of the disease. Renal impairment was the most frequent manifestation (20 patients, 47.6%); followed by neurological (8 patients, 19%), lung (2 patients, 4.8%), and cardiac (1 patient, 2.4%) involvement.

Class IV lupus nephritis, based on 2003 International Society of Nephrology and the Renal Pathology Society (ISN/RPS) classification, was the most frequent (50%). The most common neurological manifestations were the presence of seizures (4 patients, 9.5%), followed by: 1) pseudotumor (2.4%), 1) chorea (2.4%), 1) asptic meningitis (2.4%), 1) peripheral nervous system (2.4%) and 2) lupus psychosis (2.4%). Regarding lung disorders, 2 (4.8%) lupus pneumonitis were registered; and within cardiac involvement, 1 (2.4%) tamponade. Following the first year of the onset (maximum follow-up period: 46 years), just 6 (14.2%) patients suffered from major organ involvement, with a mean time of 29.5 months (range 12 months – 17 years). 20 (47.6%) children required a strong immunosuppressant drug as mycophenolate, cyclophosphamide, azathioprine or biologic therapy –

Introduction: The Lupus Checklist is designed for use in a Paediatric Rheumatology Clinic to help doctors keep track of the monitoring of patients with Juvenile Systemic Lupus Erythematosus, a complex, multi-organ condition which requires rigorous and regular monitoring.1 Juvenile Systemic Lupus Erythematosus (JSLE) patients in South Africa are at high risk of poor outcomes, so stringent monitoring of disease activity, vaccination, and medication safety are important.2

Objectives: The two objectives of this audit were, firstly, to determine if the appropriate level of rigorous monitoring (as set out by the Lupus Checklist) for each patient was completed and secondly, to determine whether the Lupus Checklist was useful in assisting doctors in monitoring their patients’ condition.

Methods: All patients treated in the Paediatric Rheumatology Clinic at the Red Cross War Memorial Children’s Hospital, Cape Town with JSLE were included (20 patients). Patient notes and laboratory records were used to determine if the appropriate monitoring checks, as laid out by the Lupus Checklist, had been completed.

Results: Overall 37.7% of audited checks were completed. 19 patients had over 20% of their monitoring completed but only 2 had over 80%. Aspects of monitoring that were more time intensive or were required less regularly were most frequently overlooked. There was a statistically significant increase in the percentage of completed monitoring in those patients for whom the Lupus Checklist was used compared to patients where a checklist was not used (p=0.00).

Conclusion: There is significant room for improvement in the monitoring of these patients with JSLE in the rheumatology clinic. This audit illustrates that more diligent use of the Lupus Checklist and an overall improvement in sustained use of the checklist will help to improve monitoring of these patients. Evidence suggests that checklists are underutilised in medicine and wider implementation of this simple tool could improve patient outcomes.3,4 Interventions such as in person or electronic reminders, or audits with feedback to physicians could improve usage over time. The application of the Lupus Checklist or a similar document in other paediatric clinics is important for comprehensive monitoring of a condition as complex as JSLE and has the potential to prevent ongoing damage and medication toxicity in this high-risk population.

References
1. Morgan TA, Watson L, McCann LJ, Beresford MW. Children and adolescents with SLE not just little adults. Lupus 2013; 22: 1309-1319.
2. Lewandowski LB, Schanberg LE, Thielman N, Phuti A, Kalla AA, Okpechi I, et al. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. Lupus. 2017;26(2):186-94.
3. Gavande, A. The Checklist Manifesto: How to Get Things Right. New York: Metropolitan Books, 2010
4. Winters BD, Gurses AP, Lehmann H, Sexton B, Rampersad CJ, Pronovost PJ. Clinical review: Checklists – translating evidence into practice. Crit Care 2009; 13: 210-219.
5. Alnaib M, Samaraee AA, Bhattacharya V. The WHO surgical safety checklist: a review. J Perioper Pract 2012; 22(9): 289-292.

Disclosure of Interest: None declared

Table 1 (abstract P234). Clinical manifestations and complementary tests within the first year of cSLE. ANA: antinuclear antibodies (>1:80); ESR: erythrocyte sedimentation rate; PCR: protein-C reactive

| Joint | 34 (81%) |
|-------|----------|
| Mucocutaneous | 31 (73.8%) |
| Hematological | 29 (69%) |
| Renal | 20 (47.6%) |
| Systemic | 19 (45.2%) |
| Neurological | 8 (19%) |
| Serositis | 6 (14.3%) |
| Pulmonary | 5 (11.9%) |
| Cardiac | 4 (9.5%) |
| Raynaud's phenomenon | 2 (4.8%) |

P234

The use of ‘the lupus checklist’ in consultations with paediatric patients with systemic lupus erythematosus in improving patient monitoring outcomes

K. A. Alexander,1, C. Scott,1, L. B. Lewandowski3

1Western General Hospital, Edinburgh, United Kingdom; 2Department of Paediatric Rheumatology, Red Cross War Memorial Children's Hospital and University of Cape Town, Cape Town, South Africa; 3National Institute of Arthritis, Musculoskeletal and Skin Diseases, Bethesda, United States

Correspondence: K. A. Alexander
Pediatric Rheumatology 2020, 18(Suppl 2):P234

Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that may cause morbidity and mortality by affecting multiple systems. The 10-20% of patients have
Objectives: To report two patients with systemic autoimmune diseases and severe hypophosphatemia secondary to FGF23 level increase.

Methods: The first patient was diagnosed with an early-onset Sjögren syndrome at 4 years old with anti-SSa and SSb antibody positivity and focal lymphocytic sialadenitis with a focus score of ≥1 foci/4 mm², as well as joint, parotid, hepatic, hematological and neurological involvement. During a disease flare, hypophosphatemia occurred (0.51 mmol/L (Normal value=1.3-1.85)) with intact FGF23 level at 215 ng/mL (N=23.2 – 95.3) associated with hyperphosphaturia with a normal renal function. FGF23 level normalized at 62.4 ng/mL, and phosphatemia went back up at 1.19 mmol/L after intensification of immunosuppressive drugs. The second patient suffers from systemic erythematous lupus diagnosed at age of 10 year, with cutaneous, joint, and hematological involvement, positive anti-Sm, anti-SSA, anti-RNP, anti-DNA antibodies. She developed hypophosphatemia at 0.35 mmol/L with a 70% phosphate reabsorption rate, resulting from a renal phosphate leak. An elevation of intact FGF23 to 135.7 ng / L without renal dysfunction was demonstrated. The level of intact FGF23 then normalized with the intensification of immunosuppression.

Conclusion: We report for the first time the occurrence of severe hypophosphatemia secondary to an increase of intact FGF23 level in two patients with systemic autoimmune disease. Correlation between disease activity and the level of FGF23 suggests that this secretion may be secondary to an activating autoimmune mechanism.

Disclosure of Interest: None declared

P237
Longitudinal evaluation of executive functions in patients with childhood-onset systemic lupus erythematosus

J. C. de Amorim1, C. L. Elorza1, B. Bellini1, P. T. Fernandes2, R. Marini3, S. Appenzeller4

1Child and Adolescente Graduate Program; 2Sports Psychology; 3Pediatrics; 4Medicine, UNICAMP, Campinas, Brazil

Correspondence: S. Appenzeller

Pediatric Rheumatology 2020, 18(Suppl 2):P237

Introduction: Among the neuropsychiatric manifestations of Childhood-onset Systemic Lupus Erythematosus, cognitive losses are frequent.

Objectives: To analyze the fluctuation of executive functions these patients in treatment at a tertiary hospital rheumatology outpatient clinic.

Methods: This is a longitudinal study with application of validated instruments: Coding subtest, Picture Arrangement, Block Design, Vocabulary and Picture Completion in patients with confirmed diagnosis of Childhood-onset SLE. In this study 24 patients were included, with a mean of 16.83 years, of whom 23 were women and 1 was man. The subjects were evaluated in two different periods with mean separation time of 9.5 months.

Results: The Coding subtest showed the largest difference between the scoring means, with the first being 58.8 ± 15.18 (mean ± SD) and the second 55.20 ± 20.63, followed by the arrangement of figures, with 22.87 ± 12.69 and 20.5 ± 8.88, and Block Design with 42.37 ± 13.73 and 41.62 ± 13.66. On the other hand, when analyzing the substandard Vocabulary and Picture Completion, there is an increase in the mean between evaluations, the first one being from 26 ± 3.21 to 26.41 ± 6.48, and the second from 22.79 ± 3.28 to 23.95 ± 9.03. When performed the T-test for paired samples, with a 95% confidence interval, it was not possible to prove the statistical significance when comparing the data obtained in the two evaluations. The Block Design subtest was closest to significance, with a result of 0.328, followed by Coding with 0.524.

Conclusion: Although the data analyzed do not have statistical significance it’s possible to realize a tendency in the decrease of the ability to perform tasks. In this way, the study provides an indication of impairment in spatial visualization capabilities, selective and focused
Introduction: SLE is a complex autoimmune disorder, characterized by multisystem involvement including the nervous system, juvenile onset SLE has more aggressive clinical course in comparison with adult-onset SLE. Neuro Psychiatric (NP) symptoms may be the initial presentation of SLE in children. The mortality rate is relatively low, but morbidity may be significant and permanent damage can occur. Early recognition of symptoms is crucial in preventing permanent neurological sequelae and patients’ quality of life.

Objectives: The aim of the work is to study the neurological manifestations of pediatric SLE in a sample of Egyptian children.

Methods: We studied 54 children and adolescents <18 years old who were undergoing treatment or follow-up at the paediatric neurology unit, neurology department at Al-Azhar University Hospitals (Al-Hussein and Bab-Al-Shaaria), and children referred from rheumatology department from June 2018 to November 2018. All patients fulfilled the new EULAR/ACR SLE classification criteria 2017.

Patients were excluded from the study when their NP manifestations were secondary to other causes, such as hypertensive encephalopathy or congenital or acquired CNS disease not related to SLE.

Results: Out of 54 children with SLE, 30 (55.6%) had neuropsychiatric (NP) manifestations, the mean age at onset of the disease was 13.6 years. The mean period between onset of SLE and NP manifestations was 15.5 months. NP manifestations were the presenting feature in 3 patients. Headache was the initial symptom of central nervous system (CNS) involvement in 35% of patients seizures was the most frequent CNS finding seen in 7(23.3%) patients, 6 (20%) patients had convulsive impairment, 6(20%) patient had cognitive impairment, 6(20%) patients had CVA, 2(6.7%) had chorea, 2(6.7%) had psychosis, 2(6.7%) had depression, 1(3.3) had cerebritis, 1(3.3%) had peripheral neuropathy. Lupus anticoagulant was high in patients with chorea, seizures or cerebrovascular accidents (CVA). Electroencephalogram (EEG) was abnormal in 30% of patients presented by seizures and rarely helpful in patients with diffuse NP symptoms. Magnetic resonance imaging (MRI) was abnormal in 13 cases, long term outcome was good, 3 patients had significant persistent CNS deficits, the majority of patients (90%) had excellent recovery from neuropsychiatric SLE.

Conclusion: NPSLE is one of the most common serious complications of pediatric SLE, so early recognition and management are of paramount importance. CNS involvement was observed in 55% of our pediatric patients with SLE, 76% of whom developed symptoms during the first year of onset of the disease. Headache and seizures were the most common neurological manifestations of pediatric SLE, followed by Cerebro Vascular Accident CVA and intellectual disability. Psychosis, depression and chorea were less frequent in our study group, while peripheral neuropathy and cerebritis were rare. Neuromyelitis optica were generally unhelpful in patients with diffuse CNS disease, in contrast, it was more helpful in patients with focal neurological findings such as CVA. Patients with CVA or chorea, usually had positive lupus anticoagulant (LAC) antibody, and all of these patients should be investigated thoroughly for the presence of antiphospholipid antibodies. Thus, the clinicians should make a reasonable prediction of individual patients to reduce morbidity and mortality of SLE in children and improve patients’ outcome.

Disclosure of Interest: None declared

P238 Neurological manifestations of pediatric systemic lupus erythematosus
Y. Gazar1, S. Y. Mostafa2, H. M. Emam2, S. S. Rashed2
1Rheumatology, 2Neurology, Al-Azhar University, Cairo, Egypt

Introduction: Lupus manifestations in children with primary immunodeficiency diseases: phenotypic and genetic features and outcome
S. M. Al-Mayouf1, 2, H. Alreefi1, T. Alsinan1, G. Alsalmi2, A. AlRowais5, W. Al-Herz6, A. Alsonbul8, H. Al-Mousa4
1Pediatric Rheumatology, King Faisal Specialist Hospital and Research Center; 2Pediatric Rheumatology, 3Alfaisal University; 4King Faisal Specialist Hospital; 5Prince Sultan Military Medical City, Riyadh, Saudi Arabia; 6Al-Sabah Hospital, Kuwait, Kuwait

Introduction: Systemic lupus erythematosus (SLE) is a complex systemic inflammatory disease with a wide spectrum of clinical and laboratory features. Increasing evidence has shown a strong association between autoimmune diseases and primary immunodeficiency diseases (PIDs).

Objectives: To report the phenotypic features, underlying genetic defects and outcome of patients with SLE and SLE-like associated with PIDs.

Methods: Data retrospectively collected on patients with lupus manifestations and clinically/or genetically proven PIDs seen between 1998 to 2019. The collected data comprised the clinical findings and diagnostic evaluation including genetic testing, the response to therapeutic intervention and the accrual damage related to SLE.

Results: A total of 40 patients (22 female) with a median age of 13 (range of 2-24) years were reviewed. Thirty-four patients had SLE and 6 with SLE-like. Genetic analysis was performed in 23 patients, all had positive results for monogenic PIDs. Complement deficiency was the most frequent PIDs; 26 patients were C1q deficient, 3 patients had C3 deficiency, 2 patients had C4 deficiency and one patient with heterozygous C6b variant. The other 8 patients had different PIDs genetic defects that include severe combined immunodeficiency caused by PNP deficiency, chronic granulomatous disease, common variable immunodeficiency (CVID), IL-2RB mutation, DNase II deficiency, STAT1 mutation and Griscelli syndrome type 3, in addition to a possible novel genetic defect in FGL2. Mucocutaneous lesions, arthritis and lung involvement were the main clinical features. Most of the patients (84.2%) experienced recurrent infections. Complement-deficient patients were younger and more likely to have a familial disease with severe mucocutaneous lesions. All patients treated with corticosteroid and immunosuppressive medications. Seven patients received biologic agents, either rituximab or belimumab. The mean accrual damage was 2.7 ± 2.2. There were 5 deaths because of infection.

Conclusion: This study showed a variable pectrum of SLE associated with heterogeneous group of PIDs. Our data suggest that SLE patients with early onset disease, family history of SLE or recurrent infections should undergo immunological work-up and genetic testing to rule out PIDs.

Disclosure of Interest: None declared

P240 Ofatumumab use in juvenile systemic lupus erythematosus: a single centre experience
O. Kul Cinar1, 2, M. Marla1, 3, M. Al-Obaidi1, F. I. Cheng1, 3, K. Tullus2, P. Brogan2, 4, 5, E. Moraitis1, 6
1Paediatric Rheumatology, 2Paediatric Nephrology, 3Paediatric Immunology, 4Pharmacy, Great Ormond Street Hospital for Children NHS Trust; 5Infection, Immunity and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom

Introduction: Ofatumumab is a fully humanized anti-CD20 monoclonal antibody (mAb) which has been licensed for use in haematological malignancies, rheumatoid arthritis and paediatric nephrotic syndrome. There are limited data on the off-label use of Ofatumumab as an alternative B-cell depletion agent for patients with
A novel mutation in the C1qA gene in a toddler with C1q deficiency associated with monogenic lupus and recurrent infection

S. Darwish1, S. Bout tabaku2, B. Al Adsba 3

1 Paediatric 2 Paediatric Rheumatology, Sidra Medicine , Doha, Qatar

Correspondence: S. Darwish
Pediatric Rheumatology 2020, 18(Suppl 2):P241

Introduction: C1q deficiency is a rare hereditary disorder, which is strongly associated with Systemic Lupus Erythematosus (SLE). To date, more than 60 cases of C1q deficiency have been published with various mutations.

Objectives: We are reporting a novel homozygous mutation in the C1qA gene in a two year old girl who presented with SLE.

Methods: Chart review of clinical data, laboratory data and molecular analysis.

Results: A two year old girl of consanguineous parents presented to hospital at 13 months of age with fever and erythematous macular rash on her cheeks which spread to her nose, chin, and ears. The rash started a month prior, and progressed over her entire body. A skin swab grew staphylococcus aureus but the rash didn’t respond to topical antibiotics. Review of systems was unremarkable except for longstanding oral thrush and diaper rash. Birth and family history were unremarkable. On exam she had a diffuse, erythematous, morbilliform eruption over her face and body. She had facial swelling, orbital edema and vasculitic oral ulcers. She had leukopenia mainly neutropenia, low hemoglobin, with normal platelets. Her liver enzymes and erythrocyte sedimentation rate (ESR) were high while C-reactive protein, immunoglobulins, C3 and C4 were normal. Cultures were negative, however she was positive for adenovirus, mycoplasma and EBV (EBV load was 6000 IU/ml).Autoimmune hepatitis work up was negative. The direct coombs test, antinuclear antibodies (1:64), Ro, RNP and SmD were positive. CH50 came low as well as C1q level of 4 mg/dL (normal range 12-22 mg/dL). Lymphocyte subsets showed reduced CD4 and NK cells. Bone marrow aspiration showed active marrow. Skin biopsy showed chronic non-specific inflammation (immunofluorescence and electron microscopy were not available). Echocardiogram showed dilatation of the left coronaries. She was treated with intravenous immunoglobulin (IVIG) for Kawasaki disease with no improvement. Therefore pulse steroid 30mg/kg followed by 2 mg/kg was initiated. Her rash, facial swelling and abnormal blood counts improved dramatically. Whole Exome sequence showed homozygous variant c.469G>T p.G157C at the C1qA gene. While tapering steroids she flared so subcutaneous methotrexate was started. Unfortunately, she continued to have rash, leukopenia and high liver enzymes, so treatment was switched to mycophenolate mofetil and hydroxychloroquine. However she did not improve and started to have recurrent bacterial and viral infections that included cellulitis, gastroenteritis and upper respiratory tract infection. We started her on regular IVIG, which helped with infections and allowed for weaning of steroids. However she developed alopecia and lower limb spasticity with delayed walking. MRI brain and spine was normal. Upon reanalysis of the WES, two other homozygous mutations at KIF1C and APG7 were identified and associated with spastic paraplegia, but reported as variants of unknown significant. Fresh frozen plasma (FFP) transfusions were started, initially weekly, then every two weeks and subsequently every four weeks. The rash disappeared, leukopenia and ESR improved and we were able to discontinue steroids.

Conclusion: Early-onset SLE with a severe course of disease raises the possibility of a genetic etiology. We are reporting, for the first time, a rare missense mutation G>T in exon 3 of the C1qA gene that resulted in an amino acid substitution that is pathogenic. Interestingly, she had other mutations associated with neurological manifestation that never reported together before and altered her phenotype. She has responded well to FFP as has been reported in a few case reports.

Disclosure of Interest: None declared
P242
How do not to miss the systemic lupus erythematosus in patients with juvenile idiopathic arthritis: preliminary results of a retrospective study
A. Kupreeva, E. Kuchinskaya1, L. Sorokina3, M. Dubko1, A. Mazing4, O. Tkachenko1, S. Lapin1, M. Kostik1,2
1Saint-Petersburg State Pediatric Medical University; 2Almazov National Medical Research Centre; 3Leningrad’s Regional Children’s Clinical Hospital; 4Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation

Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease with a multisystem lesion. In some cases, mild SLE may resemble juvenile idiopathic arthritis (JIA), leading to misdiagnosis. Both diseases have common features, such as arthritis and antinuclear antibodies (ANA) seropositivity.

Objectives: To conduct a comparative study analysis of patients with SLE and JIA, to develop discriminating criteria for both conditions.

Methods: In a retrospective study, ANA-positive children (≥1/160) from laboratory reports (n=281) selected. We chose patients meeting the criteria for SLE (n = 55) aged 4-18 years and selected RF-negative ANA-positive polyarticular JIA patients (n = 52) of the same age. We exclude patients with other reasons for ANA-positivity. Clinical and laboratory characteristics compared using descriptive statistics, Mann-Whitney test, χ² test, AUC-ROC analysis, calculation of odds ratio (OR), analysis of sensitivity (Se) and specificity (Sp). Univariate, multivariate, and logistic regression analysis applied.

Results: The results of comparison of studied groups in the table. The cut-offs of continued variables and their OR associated with SLE are: onset age>9.5 years (OR=9.0 [95% CI: 3.6; 22.6], Se=89.3, Sp=63.3, p=0.000001), ANA≥1280 (OR=4.2 [95% CI: 1.5; 11.7], Se=48.2, Sp=81.8, p=0.005); platelets ≥267x10⁹/l (OR=7.3 [95% CI: 2.6; 20.4], Se=89.3, Sp=46.8, p=0.00004) and active joints<7 (OR=3.7 [95% CI: 1.6; 8.5], Se=61.8, Sp=69.6, p=0.002). In univariate, multivariate, and logistic regression analysis, only onset age>9.5 years (p=0.00002) and active joints<7 (p=0.009) were independent discriminators between SLE and JIA. In logistic regression onset age>9.5 years (OR=9.1 [95% CI: 2.8; 29.8], p=0.0002) and active joints<7 (OR=5.4 [95% CI: 1.4; 20.1], p=0.012) increase the probability of SLE in JIA-like cohort. The presence of 2 mentioned above criteria has Se=75.0, Sp=87.5, OR=18.0 (95% CI: 6.6; 49.1) for discrimination of SLE from JIA.

Discussion of Interest: None declared

Table 1 (abstract P242). Comparison SLE and JIA patients

| Parameter               | SLE (n=49) | JIA (n=56) | p       |
|-------------------------|-----------|-----------|---------|
| Onset age, year         | 12.3 (10.1;14) | 8.0 (6.2;11.0) | 0.00004 |
| ANA (titer)             | 1/1280 (1/640; 1/5120) | 1/1280 (1/640; 1/1280) | 0.007   |
| Active joints, n        | 0.5 (0.3; 3.5) | 5.0 (1.0; 10.0) | 0.00009 |
| CRP, mg/l               | 1.0 (0.3; 3.9) | 1.4 (0.5; 4.5) | 0.345   |
| ESR, mm/h               | 10.5 (5; 20.5) | 8.0 (4.0; 18.0) | 0.282   |
| WBC x10⁹/l              | 6.0 (4.4; 8.2) | 6.7 (5.7; 8.1) | 0.164   |
| Platelets x10⁹/l        | 245.5 (217.5; 333.0) | 298.0 (251.0; 363.0) | 0.015   |
| Hemoglobin, g/d         | 1215 (113.0; 131.0) | 1240 (118.0; 130.0) | 0.256   |
| Absolute lymphocyte count, x10⁹/l | 1845.8 (1320.5; 2549.0) | 2046.0 (1711.0; 2557.8) | 0.137   |

P243
Hypocomplementemic urticarial vasculitis in pediatric systemic lupus erythematosus
R. Abdwani
Child Health, SQUH, Muscat, Oman

Introduction: Urticarial vasculitis (UV) is a clinico-pathologic entity typified by recurrent episodes of urticaria that have the histopathologic features of leukocytoclastic vasculitis. In addition, patients with hypocomplementemic urticarial vasculitis (HU) exhibit systemic manifestations, including constitutional symptoms, arthralgia or arthritis, serositis, glomerulonephritis, conjunctivitis and recurrent abdominal pain.

An association between HUV and SLE is hypothesized as both share similar clinical anf pathological features. Low serum complement measurements ( C3, C4 and C1q ) as well as anti C1q autoantibodies are also observed in both conditions. Some authors suggest the possible progression of HUV to SLE and others have defined HUV as an SLE subtype. HUV is present in 7-8% of SLE patients and 54% of HUV patients are diagnosed with SLE upon follow-up.

Objectives: To determine the prevalence HUV in pediatric systemic lupus erythematosus (pSLE) cohort of Arab ethnicity from Oman and to describe their demographic, clinical and laboratory features.

Methods: We conducted a retrospective multicenter study among pediatric rheumatology centers in Oman over a 10-year period from 2008-2018. Analyses were performed using univariate statistics.

Results: A total of 148 pSLE under the age of 13 years were included, 30% (n = 44) were males. The overall mean age at diagnosis was 7.6 ± 3.5 years and median disease duration was 9.5 (5-13) years. HUV was diagnosed in 34.5% (n = 51) of pSLE cohort. pSLE with UV were more likely to be males (57% vs 15%; P < 0.001), diagnosed at a younger age (5.9 vs 8.5 years; P < 0.001), have a family history of SLE (53% vs 36%; P = 0.044) and have conjunctivitis more frequently (32% vs 5.3%; P < 0.001) than pSLE without UV. pSLE with UV were also less likely to have CNS involvement (7.6% vs 20%; P = 0.045) and hematological manifestations such as leukopenia (9.4% vs 24%; P = 0.028) and thrombocytopenia (5.7% vs 18%; P = 0.045). In addition, pSLE with UV were more likely to be associated with low C3 complement count (94% vs 66%; P < 0.001) and positive cytoplasmic ANCA (11% vs 0%; P = 0.022). However, the pSLE with UV cohort were less likely to be associated with ANA (65% vs 83%; P = 0.016), DsDNA (56% vs 72%; P = 0.042) and perinuclear anti-neutrophil cytoplasmic antibodies (33% vs 55%; P = 0.047).

Conclusion: We report a high occurrence of HUV in pSLE cohort (34.3%) associated with unique demographic, clinical features and laboratory features. The debate regarding whether HUV is a rare subset or unusual type of SLE, or is a separate entity altogether, continues. However, the overlap in clinical, laboratory and genetic mutation supports the notion that HUV and SLE fall into the same spectrum of autoimmune disease with similar disease pathogenesis. However, further studies are needed to reach clear conclusions regarding the relationship between HUV and SLE.

Disclosure of Interest: None declared
Introduction: Juvenile-onset Systemic Lupus Erythematosus (JSLE) is a rare multisystem, autoimmune/inflammatory disease with onset before the age of 18, that accounts for 15-20% of all SLE patients. Clinical manifestations are extremely heterogeneous and disease course is unpredictable, varying from mild to life-threatening disease. JSLE has been associated with a worse prognosis than adult-onset disease and can be a lifelong disease. However, long term outcomes are poorly described.

Objectives: The aim of this study was to describe clinical features and long-term outcome of a cohort of adult patients diagnosed with JSLE and to evaluate their long-term outcome.

Methods: Charts of adult patients diagnosed with JSLE in two tertiary centres in Milan were analyzed. Data regarding clinical features, laboratory findings, treatments, long-term complications and long-term outcome were recorded retrospectively.

Results: In total, 183 patients with JSLE were included, 88% were female. Mean age at diagnosis was 12.3 years, while median disease duration at last clinical evaluation was 26 years. At the time of diagnosis 102 patients (55.7%) presented cutaneous involvement, 115 patients (62.8%) showed hematologic manifestations, while renal disease was described in 59 patients (32.2%); neurologic involvement was less frequently observed (14.2%). We reported deaths in nine patients: two patients died due to infectious complications, one of kidney failure; two of myocardial infarctions and two of malignancies. Corticosteroids were used in 74 patients (40.4%); 62.8% of patients received hydroxychloroquine, 35.3% azathioprine, 9.2% cyclosporine A and 30.6% cyclophosphamide. Four patients required the use of biologic agents (2 Rituximab and 2 Belimumab).

Major long term complications were hypercorticism due to long use of corticosteroids and infections.

Conclusion: In our cohort of patients, hematologic, cutaneous and renal involvement were the most common clinical features, while neurologic manifestations were rarer. Our patients showed active disease also during adulthood confirming that JSLE is a lifelong multisystem disease with an important impact on health-related quality of life. Moreover treatment strategies contribute to the development of irreversible damage, determining hypercorticism and higher risk of infections.

References
Amaral B, Murphy G, Ioannou Y, Isenberg DA. A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(6):1130-1135. doi:10.1093/rheumatology/ket488
Groot N, Shalhaki D, Teng YKo, et al. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(2):290-301. doi:10.1002/art.40697
Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedricht CM. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274. doi:10.1016/j.clim.2019.108274

Disclosure of Interest: None declared

P245
Genetic ancestry and its contribution to complex traits in childhood-onset systemic lupus erythematosus
F. B. Barbosa,1 L. de Oliveira2, N. A. Sincicato2, R. Marini2, V. L. Gil-da-Silva-Lopes2, S. Appenzeller2
1Laboratory of Recognition Biology, Center of Biosciences and Biotechnology, State University of North Fluminense, Rio de janeiro; 2Medical: 1Pediatrics; 2Genetics, UNICAMP, Campinas, Brazil
Correspondence: S. Appenzeller
Pediatric Rheumatology 2020, 18(Suppl 2):P245

Introduction: Several studies have shown that ancestry influences the susceptibility and development of systemic lupus erythematosus (SLE). However, determining ancestry in an admixture population like Brazilians is difficult.

Objectives: To evaluated the role of admixture in clinical manifestations of childhood-onset systemic lupus erythematosus (cSLE) in a tri-hybrid population.

Methods: The genome-wide human Cytoscan HD array was applied to genotype 2.6K markers in 107 cSLE Brazilian patients and 110 healthy controls. Quality control of the chip was carried out using Chromosome Analysis Suite software. A panel of 345 ancestry informative markers (AIMs) based on SNP data from Cytoscan HD array was used to infer the proportion of European, African and Amerindian ancestries of each cSLE and control subjects. The individual ancestral composition based on the SNP-AIMs set was estimated using Admixture. Statistical analyses to associate the genetic ancestry with different clinical traits were performed using the computing environment R.

Results: Ancestral composition analysis revealed that the main component of patients and control group was European (66.9% and 80.2%), followed by African (21.6% and 11.5%) and Amerindian (11.5% and 8.4%). Comparisons using the proportions of each ancestral component showed significant differences in European (p = 4.7 x 10-11, 95% CI -0.18 – 0.10), African (p = 4.1 x 10-9, 95% CI 0.05 – 0.12) and Amerindian (p = 1.9 x 10-6, 95% CI -0.03 – 0.06) ancestries between cSLE and control groups. A higher proportion of Amerindian ancestry in cSLE was associated to development of photosensitivity (p = 0.035) and hematologic alterations (p = 0.025).

Otherwise, a higher African component was protective against hypocomplementemia (p = 0.021).

Conclusion: Results described here show novel associations to clinical manifestations in cSLE according to the ancestry profile. The deeper investigation of its relation to the pathogenesis may contribute to the understanding of the genetic basis of the disease.

Disclosure of Interest: None declared

P246
Reliable detection of subtypes of nailfold capillary haemorrhages in childhood-onset systemic lupus erythematosus
S. C. Bergkamp1, D. Schonenberg-Meijema2 on behalf of EULAR study group on Microcirculation in Rheumatic Diseases, A. Nassar-Shelikh Rashid1, K. Melsen2,3 on behalf of EULAR study group on Microcirculation in Rheumatic Diseases, A. Vanhaecke1 on behalf of EULAR study group on Microcirculation in Rheumatic Diseases, M. J. Bournaud1, P. C. Hissink Müller1, T. W. Kuijpers1, J. M. van den Berg1, V. Smith2,3 on behalf of EULAR Study Group on Microcirculation in Rheumatic Diseases
1Department of Paediatric Immunology, Rheumatology and Infectious diseases, Amsterdam University Medical Centers, Amsterdam, Netherlands; 2Department of Rheumatology, Ghent University Hospital, Faculty of Internal Medicine, Ghent University, Ghent, Belgium; 3Department of Rheumatology, Maxima Medical Centre, Eindhoven; 4Department of Paediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands; 5Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (RIC), Ghent, Belgium
Correspondence: S. C. Bergkamp
Pediatric Rheumatology 2020, 18(Suppl 2):P246

Introduction: Systemic Lupus Erythematosus (SLE) is a severe chronic disease for which it is necessary to obtain more indicators of disease severity that predict disease damage. Nailfold capillary abnormalities could be such an indicator or biomarker in SLE. Nailfold capillary haemorrhages have been observed in adults and children with SLE as an abnormality that was significantly correlated with disease activity. Recently, different subtypes of capillary haemorrhages have been described in a cross-sectional case-control study of childhood-onset (cSLE)

Objectives: The aim of this current study was to evaluate the inter- and intra-observer reliability for detection of different subtypes of capillary haemorrhages, as identified by nailfold videocapillaroscopy (NVC) in cSLE patients.

Methods: Five raters from three different centres blindly evaluated 140 NVC images from 35 cSLE patients, diagnosed according to the Systemic Lupus International Collaborating Clinics (SLICC) criteria. The raters assessed the anonymized NVC images qualitatively (present or absent) and quantitatively (total number) on four different subtypes of haemorrhages:
1) punctate extravasations; point-shaped, localized around, or in the apical centre of capillary loop  
2) perivascular haemorrhage; as 1) but in grouped/confluent aspect  
3) large confluent haemorrhage; migrating in line with the capillary to distal towards the cuticle  
4) non-definable; not matching criteria 1-3

As punctate extravasations and perivascular haemorrhages were interpreted as a continuous spectrum, an analysis with groups 1-2 merged (mean) kappa/ICC was also calculated as one sub-group. For qualitative data, Fleiss’ and Cohen’s kappa analyses were calculated. For quantitative data, the intra-class correlation coefficient (ICC) was calculated.

Results:

|                         | Fleiss’ kappa | ICC    |
|-------------------------|--------------|--------|
| Inter-rater scores      | 0.78         | 0.72   |
|                          | 0.76         | 0.84   |
|                          | 0.76         | 0.84   |
|                          | 0.95         | 0.95   |

Conclusion: This is the first study on intra- and inter-rater reliability for different subtypes of nailfold capillary haemorrhages in cSLE. Our findings show that different subtypes of capillary haemorrhages in cSLE-patients can be reproduced with a good inter- and intrarater reliability. This confirms our recent observation of two haemorrhage-subtypes in a cross-sectional case-control study. Thus, it also indicates the potential diagnostic value for NVC in cSLE. Future observational studies should elucidate whether the different subtypes of capillary haemorrhages are specific for (c)SLE compared to (juvenile) dermatomyositis and (juvenile) systemic sclerosis. Longitudinal studies are needed to investigate the role of capillary haemorrhages as a prognostic biomarker for disease damage in (c)SLE.

Disclosure of Interest: None declared

P247  
The performances of different classification criteria in pediatric systemic lupus erythematosus  
E. D. Batu¹, U. Kaya Akca³, A. Pac Kisaarslan², E. Sag¹, F. Demir³, S. Demir², S. Ozdemir Cicek³, H. Poyrazoglu², B. Sozen³, Y. Bilginer¹, S. Ozen³  
¹Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara; ²Department of Pediatrics, Division of Rheumatology, Erciyes University Faculty of Medicine, Kayseri; ³Department of Pediatrics, Division of Rheumatology, Umranli Training and Research Center, University of Health Sciences, Istanbul, Turkey

Correspondence: E. D. Batu

Pediatric Rheumatology 2020, 18(Suppl 2):P247

Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. The three available classification criteria for SLE are ACR 1997, SLICC 2012, and EULAR/ACR 2019 all of which are formed based on data mainly derived from adult SLE cohorts. Objectives: We aimed to test the performances of ACR 1997, SLICC 2012, and EULAR/ACR 2019 SLE criteria among pediatric SLE patients. Methods: One hundred and eleven SLE patients from Hacettepe University, Ankara; 102 from Erciyes University, Kayseri; and 49 SLE patients from Umranli Training and Research Hospital, Istanbul, Turkey were included. As controls, 172 children with different rheumatic diseases (including mixed connective tissue disease and juvenile dermatomyositis) who had ANA test were included. The disease onset was before 18 years of age in all patients. The sensitivity and specificity of the ACR 1997, SLICC 2012, and EULAR/ACR 2019 criteria were evaluated based on the features of the patients at the time of diagnosis. The gold standard for the diagnosis of SLE was expert opinion at each center. Results: In total, 262 SLE (80.9% female) and 172 control patients were included. The sensitivities of ACR 1997, SLICC 2012, and EULAR/ACR 2019 criteria were 68.7%, 95.4%, and 92%, respectively. The specificities of ACR 1997, SLICC 2012, and EULAR/ACR 2019 criteria were 94.8%, 89.5%, and 87.8%, respectively. There were 17 SLE patients who met SLICC criteria but not fulfilling ACR/EULAR 2019 criteria. Among these patients, hematologic involvement was prominent (12/17; 70.6%). On the other hand, there were 8 SLE patients fulfilling ACR/EULAR 2019 criteria but not SLICC 2012 criteria. In these patients, joint involvement was prominent (6/8; 75%). The characteristics of these patients are presented in Table 1.

Table 1 (abstract P247): SLE (systemic lupus erythematosus) patients who met either one of the SLICC 2012 or EULAR/ACR 2019 criteria but not the other

| Characteristics, n (%) | SLE patients who met SLICC 2012 but not EULAR/ACR 2019 (n=17) | SLE patients who met EULAR/ACR 2019 but not SLICC 2012 (n=8) |
|------------------------|------------------------------------------------------------|-------------------------------------------------------------|
| Joint involvement      | 3 (17.6)                                                   | 6 (75)                                                      |
| Oral ulcers            | 8 (42)                                                     | 0 (0)                                                       |
| Hematologic involvement| 12 (70.6)                                                  | 1 (12.5)                                                    |
| ANA positivity (21/80) | 15 (88.2)                                                  | 8 (100)                                                     |
| Anti-cardiolipin antibodies | 6 (35.3)                                            | 0 (0)                                                       |
| Anti-β2 glycoprotein   | 3 (17.6)                                                   | 0 (0)                                                       |
| Lupus anticoagulant    | 4 (23.5)                                                   | 0 (0)                                                       |
| Renal biopsy           | 2 (11.8) class I lupus nephritis                           | 0 (0)                                                       |
| SLE according to the ACR 1997 criteria | 7 (41.2)                                        | 2 (25)                                                      |

Conclusion: In our study, the sensitivity of SLICC 2012 criteria was the best, while the best specificity was that of ACR 1997 criteria. SLICC 2012 criteria performed better than EULAR/ACR 2019 criteria with higher sensitivity and specificity. Separation of different hematological manifestations in SLICC 2012 criteria might have contributed to the higher performance of this criteria set.

Disclosure of Interest: None declared

P248  
Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erythematosus in a Mexican pediatric population  
R. E. Loor, E. Faugier  
Reumatología Pediátrica, HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ, México, Mexico

Correspondence: R. E. Loor

Pediatric Rheumatology 2020, 18(Suppl 2):P248
Introduction: Systemic Lupus Erythematosus (SLE) is the prototype autoimmune disease, characterized by the presence of multiple autoantibodies with the consequent formation and deposition of immunocomplexes, and other immune processes, causing a multisystemic disease. Over the years, various classification criteria have been published with variable performance. In 2019 the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) developed a set of criteria, which the validity has not been studied so far in the pediatric population with juvenile Systemic Lupus Erythematosus (SLEj).

Objectives: To determine the sensitivity, specificity, positive predictive value and negative predictive value of the 2019 EULAR / ACR criteria for SLE in children who attended in the pediatric rheumatology service of the Hospital Infantil de México Federico Gómez and compare them with the ACR criteria of 1997 and the International Collaborating Clinics of Systemic Lupus (SLICC) 2012.

Methods: Retrospective collection of clinical and paraclinical data during the first month of illness in patients with SLEj and control group with rheumatologic disease other than SLE who have a positive determination of antinuclear antibodies. The ACR 1997, SLICC 2012 and 2019 EULAR / ACR classification criteria were applied to each patient to determine the sensitivity, specificity, positive predictive value and negative predictive value for each classification criteria.

Results: A total of 100 patients with LESj diagnosis and 100 patients in the control group were included. 88% of the cases and 76% of the controls were female. The average age at diagnosis was 10.5 ± 3.78 years (2 - 17 years). When comparing the criteria proposed by 2019 EULAR-ACR, ACR 1997 and SLICC 21012, greater sensitivity, specificity, positive predictive value and negative predictive value were obtained in the 2019 EULAR-ACR criteria (98%, 100%, 100% and 98% respectively) as reflected in Table 1.

Conclusion: It is the first study in pediatric population where a comparison of the three groups of classification criteria is performed and reveals a sensitivity of 98% and specificity of 100% for the 2019 EULAR-ACR criteria, demonstrating greater sensitivity and specificity in comparison with the criteria of ACR 1997 and SLICC 2012. The report identifies the applicability of the 2019 EULAR / ACR criteria and sets a guideline for future studies.

Disclosure of Interest: None declared

Table 1 (abstract P248). Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value of the Classification Criteria of the European League Against Rheumatism and the American College of Rheumatology of 2019, American College of Rheumatology 1997 and the group of International Collaborating Clinics of Systemic Lupus from 2012

| Criteria       | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|----------------|-----------------|-----------------|---------|---------|
| 2019 EULAR-ACR | 98              | 100             | 100     | 98      |
| ACR 1997      | 91              | 98              | 98      | 92      |
| SLICC 2012    | 88              | 97              | 97      | 89      |

P249

Molecular findings in patients with systemic lupus erythematosus from Sakha Republic (Yakutia)

E. Suspsipts1,2, M. Kosmin1, V. Argunova1, A. Kossmin2, E. Kuchinskaya1

1 St.-Petersburg State Pediatric Medical University, 2. N.N. Petrov Scientific Research Center of Oncology, Almazov National Medical Research Center, St.-Petersburg, 1 Republic Hospital №1, National Center of Medicine, Yaktursk, Russian Federation

Correspondence: E. Suspsipts

Pediatric Rheumatology 2020, 18(Suppl 2):P249

Introduction: In the last few years, many monogenic defects leading to a lupus-like phenotype have been described. Sakha Republic (Yakutia) is a large north – eastern region of Russia where an increased incidence of systemic lupus erythematosus (SLE) is reported. In general, like the native Americans from Alyaska, the Yakutia aborigi- nals have a load of autoimmune diseases, especially HLA-B27-associated conditions.

Objectives: Yakut population of 500000 has peculiar genetic background and high level of consanguinity; thus, we expected to reveal specific lupus - associated genes and founder variants characteristic for this ethnic group.

Methods: We performed clinical exome sequencing of 14 Yakut SLE patients (9 – 18 years old) primarily focusing on analysis of the 51 genes currently associated with monogenic lupus and lupus – like conditions.

Results: Likely causative variants of SLE-associated genes were detected in 7 of 14 patients. Rare variants of RNASEH2B, TREC1, PTPN22, DNASE1L3, TMEM173 and SAMHD1 including some recurrent alleles have been revealed. It is also of interest that TNFRSF13C c.62C>G (p.P21R) polymorphism having reported frequency of 1 – 7% in different world populations was apparently overrepresented in the group of SLE patients.

Conclusion: Genetic defects may be detected in a substantial fraction of non-early onset Yakut SLE thus making this population worthy of further analysis. This pilot study extends existing data on spectrum of genetic variants associated with SLE. This work was supported by the RSF grant № 20-45-01005

Disclosure of Interest: None declared

P250

Withdrawn

P251

Rates of tuberculosis infection in patients with Juvenile Idiopathic Arthritis preceding anti-tfn therapy for more than 2 years: a single-center observational study

N. Tsunkova1, E. Ligoostaeva1, V. Avdeenko1, N. Kobzeva1, I. Tsiganok1, O. Lagunova2

1 Rostov Regional Children Hospital; 2 Rostov Regional Phthisiological Dispensary, Rostov-on-Don, Russian Federation

Correspondence: N. Tsunkova

Pediatric Rheumatology 2020, 18(Suppl 2):P251

Introduction: Currently, the assessment of the incidence of tuberculosis infection in patients with juvenile idiopathic arthritis (JIA) receiving therapy with TNF-alpha inhibitors remains relevant.

Objectives: To evaluate the incidence of tuberculosis infection in patients with JIA receiving anti-TNF therapy (Adalimumab (ADA), Etanercept (ETA)) for 2 years or more.

Methods: This was a retrospective study that included JIA patients treated with anti-TNF therapy for more than 2 years. 48 JIA patients with current age 9.2±4.0 years, mean disease duration of 3.4±1.8 years were included. All patients received a single anti-TNF therapy: 28(58%) patients were treated with etanercept, 20(42%) patients were treated with adalimumab. All patients were screened for latent tuberculosis infection (LTBI) prior to anti-TNF therapy using tuberculin skin test (TST), chest computer tomography (CT) and history of exposure to tuberculosis. Patients were regularly followed at 6-month intervals. Before patients started receive anti-TNF therapy, LTBI screening (solely TST-positive) was positive in 8(16.6%) patients: 5 patients in group of ETA and 3 in group of ADA, no one had active tuberculosis (TB) or history of TB exposure.

Results: After 2 years of therapy with ADA latent tuberculosis infection (LTBI) was diagnosed in 6(12.5%) patients (10.3/100 patient-years); spontaneously cured primary tuberculosis was diagnosed in 1(2%) patient (1.7/100 patient-years); pulmonary tuberculosis (positive TST and changes on chest CT) was diagnosed in 1(2%) patient (1.7/100 patient-years).

After 2 years of ETA therapy LTBI was diagnosed in 4(8.3%) patients (4.6/100 patient-years); spontaneously cured primary tuberculosis developed in 1(2%) patient (1.1/100 patient-years).

Conclusion: According to the obtained data it can be concluded that the risk of developing tuberculosis infection among patients receiving anti-TNF therapy remains. Our observation shows that the
Introduction: Disease-modifying antirheumatic drugs (DMARDs), are widely used for the treatment of rheumatologic diseases including juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), enthesitis related arthropitis (ERA), systemic sclerosis (SSc), systemic lupus erythematous (SLE), and Sjögren syndrome (SS), juvenile dermatomyositis, Behçet disease. We aimed to study the hypersensitivity reaction findings associated with the commonly used conventional DMARDs include methotrexate, leflunomide, hydroxychloroquine and sulfasalazine.

Objectives: We aimed to study the hypersensitivity reaction findings associated with the commonly used conventional DMARDs in addition to methotrexate, leflunomide, hydroxychloroquine and sulfasalazine.

Methods: We evaluated the patients followed up between January 2019 and January 2020 in Department of Pediatric Rheumatology in Hacettepe University, Ankara, Turkey. 128 pediatric patients used DMARDs were accommodated in the study. The demographics, disease course, atopy history, familial history of atopy and drug allergies were analysed.

Results: 128 pediatric rheumatology patients including 46 juvenile idiopathic arthritis, 23 familial mediane rheumatic fever patients, 19 polyarthritis nodosa, 17 systemic lupus erythematous, 7 Behçet’s disease, 5 juvenile dermatomyositis, 5 enthesitis-related arthropitis, 4 scleroderma, and 2 psoriatic arthritis were the subject of this study. Drug allergy was found in 14 patients: 7 against to antibiotics, 4 against to biologic agents and 3 to DMARDs. The use of DMARDs agents among the group were: 62 patients (48%) using methotrexate, 38 patients (29%) colchicine, 18 patients (14%) hydroxychloroquine, 18 patients (14%) mycophenolate mofetil, 12 patients (9%) cyclosporine A, 19 patients (14.8%) AZA, 2 patients sulfasalazine. No allergic reactions to MTX, AZA, MMF were detected. On the other hand, 1 patient developed a hypersensitivity reaction against hydroxychloroquine similar to erythroderma, and another patient developed allergic reactions to sulfasalazine, one to infliximab, one to colchicine and one to rituximab.

Conclusion: DMARDs are commonly used agents in rheumatology departments, hypesensitivity reactions against them are seldom reported. It is usually known that the subcutaneous form results in more allergic reactions than the oral form, however it is discovered that oral forms of DMARDs is very likely to lead to allergic reactions.

Key words: childhood, DMARDs, hypersensitivity reactions, rheumatologic disease, methotrexate

Disclosure of Interest: None declared

P252

Hypersensitivity reactions with DMARDs

M. Kasap Cuceoglu,1 E. Sag1, S. Demir1, U. Yaya Akca1, E. Atalay1, O. Uysal Soyer1, E. D. Batu1, Y. Bilginer1, S. Ozen1

1Pediatric Rheumatology; 2Pediatric Allergy, Hacettepe University, Ankara, Turkey

Correspondence: M. Kasap Cuceoglu

Pediatric Rheumatology 2020, 18(Suppl 2)P252

Disclosure of Interest: None declared

P253

Drug survival and safety of biological therapies in patients with Juvenile Idiopathic Arthritis

A. Boteanu1, A. Briñez Figueroa1, L. Calvo Sanz1, Á. Andreu Suarez1, A. García Fernández1

1Rheumatology, Ramon y Cajal University Hospital; 2Rheumatology, Ramón y Cajal University Hospital, Madrid, Spain

Correspondence: A. Boteanu

Pediatric Rheumatology 2020, 18(Suppl 2)P253

Disclosure of Interest: None declared

P254

Revising the who essential medicines list for paediatric rheumatology

C. Scott1, N. Smith2, R. James3, B. Whitehead1, R. Green4, H. Foster2 on behalf of on behalf of the Paediatric Global MSK Task Force

1Department of Paediatrics, University of Cape Town, Cape Town, South Africa; 2Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom; 3Paediatric Rheumatology, Pharmacy, Queensland Children’s Hospital, Brisbane, Queensland, Australia

Correspondence: C. Scott

Pediatric Rheumatology 2020, 18(Suppl 2)P254

Disclosure of Interest: None declared
Introduction: The World Health Organisation (WHO) Essential Medicines List (EML) informs countries about the minimum medicine items necessary to meet priority health needs of the population (both adults and children). The EMLs guide national and institutional medicine lists, especially in Low and Middle Resource Income Countries. The current EML for paediatric rheumatology does not reflect current best practice (Faster and Scott 2020 Nature Reviews Rheumatology). The Paediatric Global Musculoskeletal Health Task Force (TF) is working to revise the WHO EML.

Objectives: To explore which drugs are considered ‘essential’ and ‘ideal’ for listing in the EML under paediatric rheumatic diseases.

Methods: Healthcare professionals working in paediatric rheumatology and who are TF members were invited to take part in an anonymous online survey. We had 97 responses from 43 countries (across all continents), with 1-35 years of clinical practice including: consultant grade paediatric rheumatologists (n=77), consultant general paediatricians with interest in rheumatology (n=13), paediatric rheumatology trainees (n=3), adult rheumatologists (n=3) and a nurse working in paediatric rheumatology (n=1). The survey data was analysed applying descriptive statistics and free-text comments using qualitative techniques.

Results: Most respondents (n=70/97, 72%) reported that a revised EML would improve access to medicines in their country, improve drug provision and accessibility within their clinical practice, provide assistance when negotiating with healthcare agencies, funding bodies or insurance companies and inform paediatric trainees and adult rheumatologists about paediatric rheumatology issues. They deemed that the EML should list the following drugs (Table 1).

Conclusion: Respondents confirmed the need to update the WHO EML and anticipate considerable impact on clinical practice in many countries around the world. More than 80% of respondents identified 5 agents as ‘essential’ (oral, intra-articular and intravenous steroids, NSAIDS, Hydroxychloroquine and Methotrexate [oral and subcutaneous]) and indicated that the EML should include a wide range of synthetic and biologic DMARDS as well as other immunosuppressive agents used in the management of rheumatic diseases in children. This data will form the basis of the TF application to the WHO to revise the EML with submission planned for 2020.

Disclosure of Interest: None declared

Table 1 (abstract P254). Rheumatic disease drug inclusion within the WHO EML

| Drug                      | Essential | Ideal   | Essential | Ideal   | Essential | Ideal   | Essential | Ideal   | Essential | Ideal   |
|---------------------------|-----------|---------|-----------|---------|-----------|---------|-----------|---------|-----------|---------|
| Prednisolone              | 98%       | 65%     | 94%       | 63%     | 98%       | 52%     | 91%       | 71%     | 98%       | 52%     |
| Cyclophosphamide          | 94%       | 67%     | 91%       | 71%     | 98%       | 52%     |           |         |           |         |
| Methotrexide (oral)       | 94%       | 68%     | 91%       | 71%     | 98%       | 52%     | 91%       | 71%     | 98%       | 52%     |
| Methotrexide (i.a)        | 94%       | 68%     | 91%       | 71%     | 98%       | 52%     |           |         |           |         |
| Methotrexide (i.v)        | 94%       | 68%     | 91%       | 71%     | 98%       | 52%     |           |         |           |         |
| Methotrexide (i.v)        | 94%       | 68%     | 91%       | 71%     | 98%       | 52%     |           |         |           |         |
| Methotrexide (i.v)        | 94%       | 68%     | 91%       | 71%     | 98%       | 52%     |           |         |           |         |
| Methotrexide (i.v)        | 94%       | 68%     | 91%       | 71%     | 98%       | 52%     |           |         |           |         |
| Methotrexide (i.v)        | 94%       | 68%     | 91%       | 71%     | 98%       | 52%     |           |         |           |         |
| Methotrexide (i.v)        | 94%       | 68%     | 91%       | 71%     | 98%       | 52%     |           |         |           |         |

P255

The range of biological drugs used in patients with juvenile idiopathic arthritis, saratov region example

Y. M. Spivakovskiy, A. Y. Spivakovskaya, Y. V. Cheremnov
Department of Hospitality Pediatrics, SARATOV STATE MEDICAL UNIVERSITY, Saratov, Russian Federation

Correspondence: A. Y. Spivakovskaya
Pediatric Rheumatology 2020, 18(Suppl 2):P255

Introduction: The last decade has brought a lot to the approaches to the diagnosis and treatment of juvenile arthritis. In Russia, the actualization of the problem of diagnosis and treatment of JIA required the development of federal standards, which provide the most detailed algorithms for medical care, both at the stage of inpatient and outpatient care. In the regions of the Russian Federation, the effective use of these documents required a whole range of additional educational activities, both with students of medical universities, as well as with the medical and nursing community, in addition, a set of work was carried out to create a regional regulatory framework. The first genetically engineering drug with children’s indications in the Russian Federation was registered at the end of 2009. Over the past decade, the range of biological agents used in pediatrics has expanded significantly and requires constant replenishment of the level of knowledge of doctors.

Objectives: To analyze the structure of biological therapy in patients with juvenile idiopathic arthritis living in the Saratov region of the Russian Federation.

Methods: The study included generalized information on 253 patients aged 1-17 years with a diagnosis of JIA verified by the ILAR criteria and living in the Saratov Region on January 1, 2019.

Results: According to medical statistics in the region, a diagnosis of JIA has been made in 253 children and adolescents. A significant increase is noted annually in children receiving biological therapy, so in 2014 there were 30 patients, which accounted for 9.3% of the total number of patients with JIA, at the beginning of 2019 the figure was 19% (n = 48), and by the end of 2019 – 22.1% (n = 56). In the total biological therapy pool, 67% of patients receive TNF-alpha inhibitors, antibodies to IL-6 receive 27% of patients, antibodies to IL-1 – 6,25%. It is worth noting that when using biological agents in 60% of cases, the criterion of an inactive disease was achieved by 4-5 months, which was characterized by the absence of acute inflammatory symptoms, normalization of ESR and CRP. Monitoring of patients with JIA receiving biological agents required the conduct of a number of educational activities for medical personnel, the creation of an additional methodological base. For further training of young specialists at the regional medical university, a program of an additional educational course in pediatric rheumatology was developed and introduced. A regional patient organization was established and also required a set of information activities by the medical community.

Conclusion: In the Saratov region of the Russian Federation, about 20% of patients with JIA receive biological therapy, which corresponds to the average indicators according to the literature. In the structure of the biological drugs used, the group of TNF-alpha inhibitors is preserved - 67%. The introduction of modern methods of treatment using biological agents in JIA has significantly increased the effectiveness of treatment, but it required the organization of additional information support for medical personnel.

Disclosure of Interest: None declared
Introduction: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of pediatric diseases. Different response to biological treatment (BT) has been reported according to disease subtype. Objectives: to analyze the prescription and withdrawal of BT in JIA patients with focus on JIA category.

Methods: A retrospective observational study was conducted on JIA patients followed in a referral hospital and who had received at least one BT between 1999 and 2019.

Results: 130 JIA patients were analyzed: 29 (22.4%) were Oligoarticular Persistent (OligP), 22 (16.9%) Enthesitis related Arthritis (ERA), 20 (15.4%) Systemic (sJIA), 19 (14.6%) Polyarticular RF- (PolyRF-), 14 (10.8%) Polyarticular RF+ (PolyRF+), 13 (10%) Oligoarticular-Extended (OligE), 11 (8.4%) Psoriatic Arthritis (APso) and 2 (1.5%) Undifferentiated (Und).

The main characteristics are summarized in table 1. The first line BT most frequently indicated was Etanercept up to 40% in all the categories except for ERA, where the most frequent BT was Adalimumab and sJIA, where the most frequent BT was Anakirna. The time between diagnosis and start of BT was different among the categories (p=0.007). In the Und category, the time until BT was the shortest (median: 1 month), since both patients had coxitis, followed by APso median: 9 months IQR(1-57) and sJIA median: 17.5 months IQR(0.3-146.8).

The survival of the first BT was different among the categories (p=0.006): 94.7% of the ERA continue receiving the first BT, followed by 76.2% of OligP and 50% of PolyRF+ and APso. Only 42% of sJIA continue on the first BT prescribed [up to 53.3% were TNF inhibitors (TNFI)]. The categories with less retention of the first BT were: OligE (25%); PolyRF- (27.3%) and Und (0%). The most frequent cause of discontinuation, among these categories, was secondary failure. In the survival analysis between categories, there were differences on OligP (p=0.004), OligE (p=0.042) and PolyRF- (p=0.017). Tocilizumab and Adalimumab were the BT with highest differences on OligP (p=0.004), OligE (p=0.042) and PolyRF- (p=0.017). In the survival analysis, the category with the highest retention of the first BT was ERA. Und patients started sooner BT due to the presence of coxitis. In sJIA, IL1 inhibitors and IL6 inhibitors were superior to TNFi in the survival analysis, as reported in existing literature.

Disclosure of Interest: None declared.
least one allele of MEFV gene (93%). The median duration for CD treatment was higher than that for CO. The mean dosage of CO was higher (1.71 ± 0.44 mg/day) than CD (1.49 ± 0.41 mg/day), and the difference was statistically significant (p<0.001). Besides, usage of CO (significantly higher dosage than CD) showed beneficial effects on number and duration of attacks, VAS for pain and EILP scores, also on FMF severity scores, statistically significantly (p<0.05 for each parameters) (Table 1).

Usage of colchicine opocalcium was successful also in terms of controlling gastrointenstinal symptoms. Bristol stool chart questionnaire scores decreased from 5.62 ± 1.56 to 4.15 ± 1.73 points, and scores of daily stool number decreased from 0.46 ± 0.894 points to 0.03 ± 0.118. Decrease in gastrointestinal complaints were statistically significant (p<0.05) (Table 1).

There were 12 patients in which colchicine dose remained the same. We further analyzed this group separately to see if there was a bias in terms of change of dosage. The results were similar to the whole group analysis. There was a significant decrease of the clinical findings such as number of attacks at the last six months, average duration of attacks, FMF severity score and VAS scores of EILP (p<0.05). Also, the laboratory findings such as NLR, ESR and CRP values were decreased following switch.

Conclusion: The patients with FMF in pediatric age group who have active disease and/or gastrointestinal complications during the use of colchicine disper, may benefit from colchicine opocalcium. It might be a valuable treatment option before considering biological agents.

Disclosure of Interest
None declared

Table 1 (abstract P258). Comparison of clinical results for both preparations (n=29).

| Duration of treatment (months) | Colchicum | Colchicine | p value |
|--------------------------------|-----------|------------|---------|
| Disper                        | 59.54 ± 36.43 | 26.39 ± 16.64 | <0.001 |
| Opocalcium                    | 1.49 ± 0.41  | 1.71 ± 0.44  | <0.001 |
| Number of attacks at the last 6 months | 4.83 ± 2.1   | 1.89 ± 1.50 | <0.001 |
| Average duration of FMF attacks (hours) | 63.98 ± 25.84 | 44.41 ± 21.81 | <0.001 |
| EILP (attack-free period)     | 7.36 ± 1.43  | 2.84 ± 1.77  | <0.001 |
| FMF severity score            | 8.88 ± 2.08  | 6.52 ± 1.83  | <0.001 |
| Bristol stool scale           | 5.62 ± 1.56  | 4.15 ± 1.73  | 0.044  |
| Number of stools/24 h         | 0.46 ± 0.894 | 0.03 ± 0.118 | <0.001 |

P259
Anti-adalimumab antibodies detection using a novel peptide-based assay in a cohort of pediatric patients with chronic rheumatic disorders: a pilot study
E. Marrani1, H. Rusche2, F. Terzani3, E. Peroni2, F. Real-Fernandez4, O. Monasson2, R. Ponti3, G. Simonini6, A. M. Papini3, P. Rovero4
1Rheumatology Unit, Anna Meyer Children Hospital, Firenze, Italy; 2Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, Cergy-Pontoise, France; 3PeptLab, Dep. Chemistry, University of Florence, sesto fiorentino; 4PeptLab, Dep. NEUROFARBA, University of Florence, firenze; 5Pediatric Department, University of Udine, Udine; 6Rheumatology Unit, AOUMeyer, NEUROFARBA, University of Florence, firenze, Italy
Correspondence: E. Marrani
Pediatric Rheumatology 2020, 18(Suppl 2):P259

Introduction:
Immunogenicity and development of anti-drug antibodies have been associated with treatment failure and adverse events during biologic treatment. Anti-drug antibodies (ADAs) have been reported in 21% of Juvenile Idiopathic Arthritis patients treated with Adalimumab. However, their role in reducing adalimumab efficacy is still debated due to conflicting results. No study has been directed toward identification of neutralizing ADAs in paediatric rheumatic disorders.

Objectives: Aim of our study was to detect ADAs, along with their clinical relevance, using a new theranostic peptide-base assay in a cohort of children with inflammatory chronic diseases on Adalimumab treatment.

Methods: Six candidate Adalimumab derived peptide antigens (HC-CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, LC CDR3) have been developed and optimized to be tested. Their performance has been compared with commercial ELISA kit and a SPR-based optical assay (Biacore®). Assays have been performed in sera of a cohort of children receiving Adalimumab due to an inflammatory chronic disease. Mean age, disease duration, concomitant treatment with methotrexate (MTX), ANA positivity, disease activity parameters and scores at the time of ADA determination have been recorded. Chi-square, and Fisher exact test were used to compare data. Pearson’s and Spearman’s correlation tests were used to determine correlation coefficients for entered variables.

Results: Eighteen (14 F, median age 12.6, range 3.8-16, yrs) patients were enrolled: 16 affected by Juvenile Idiopathic Arthritis, 7 of whom complicated by JIA -associated chronic uveitis, and 2 patients affected by chronic idiopathic uveitis. Peptide assay revealed ADAs in 8 children, Biacore in 6, commercial Elisa in 5. Of note, we found total concordance among the 3 tests just in 2 patients. No significant correlation has been proven among the 3 ADA determinations. Biacore and ELISA determination showed significant concordance (r2: 0.72, p<0.006). The presence of HC CDR3 and LC CDR 3 resulted significantly correlated with disease activity (r2: 0.57, p<0.05), and, inversely, with disease remission on treatment (r2=-0.523, p<0.05).

No patient experienced severe adverse events and no correlation with ADAs has been revealed.

Conclusion: In chronic rheumatic disorders, novel reliable methods are urgently required to guide clinical decision and support decisions about switching within or between drugs in refractory children. The 3 different methods, based on different antigenic probes, detect different antibody populations. The present peptide-based assays might contribute to identify neutralizing ADAs in patients treated with Adalimumab. Further validation in larger cohort is required.

Disclosure of Interest
None declared

P260
TNF-inhibitors therapy in 13 patients with non-bacterial multifocal osteomyelitis: lessons from real clinical practice of the single center
I. Nikishina, S. V. Arsenyeva, M. Kaleda, D. Alekseev, T. Pachkoria, O. Kostareva, O. Borodacheva, S. Salugina
Paediatric, V.A. Nasonova Scientific Research Institute of Rheumatology, Moscow, Russian Federation
Correspondence: I. Nikishina
Pediatric Rheumatology 2020, 18(Suppl 2):P260

Introduction:
Non-bacterial multifocal osteomyelitis (NBO) is a rare polygenic autoimmune inflammatory disease, which is difficult to diagnose and treat. Because of combination of bone lesions with arthritis and/or axial skeleton damage in most cases the diagnosis of juvenile idiopathic arthritis (JIA) or juvenile ankylosing spondylitis (JAS) may be established as a concurrent diagnosis, so this allows to legal use of Biologics (BA) for the treatment.
Objectives: To analyze the single center experience of clinical and laboratory features of multifocal NBO in patients (pts) who were treated by BA for the last 8 years.

Methods: The study involved a retrospective cohort of multifocal NBO pts treated by different BA in our clinic from 2013 to 2020. All of them underwent standard rheumatological examination. In order to examine all localizations of the bone damage, a scintigraphy and/or "whole body" MRI scan was performed.

Results: Among the whole group of pts with NBO (n=40) we identified 13 pts treated by BA (TNF-inhibitors only). The majority were girls (n=9, 69 %). Age at disease onset was 10.2 years in average (Me 10.2 range 0.3-8.1). There were 2 cases of withdrawals. Due to inefficacy of TNF inhibitors were administrated: etanercept in 10 pts, adalimumab in 4 pts, sulfasalazine (6 pts, but it was withdrawn in all pts), bisphosphonates (1 pt), prednisolone (3 pts). Because of high activity of NBO with appearance of new bone lesions and persistent arthritis TNF inhibitors were administered: etanercept in 10 pts, adalimumab – 4 (2 as first line, 2 – second line), golimumab – 1. At the start of BA the average age was 13.7 years (range 7.2-17.9); mean disease duration was 3.4 years (range 0.3-8.1). There were 2 cases of withdrawals. Due to inefficacy etanercept was switched to adalimumab. Disease activity decreasing was reached in the most of the patients (12 from 13). Among them 2 pts developed the whole remission with resolving of active arthritis and bone marrow edema spots. Skin lesions (psoriasis pustulosis and acnae conglobate) were significantly improved. There were no adverse events during the TNF therapy.

Conclusion: Our experience of the therapy with TNF inhibitors in patients with high NBO activity has shown that this is a good and safe therapeutic option that is expected to prevent progression and bone destruction.

Disclosure of Interest
None declared

P261
Safety on the use of bisphosphonates in paediatrics
S. Odorico1, E. Jeziorski2, F. Rivier3, T.-A. Tran1
1Pediatrics, Nimes University Hospital, Nimes; 2Pediatrics; 3Pediatric Neurology, Montpellier University Hospital, Montpellier, France
Correspondence: T.-A. Tran
Pediatric Rheumatology 2020, 18(Suppl 2):P261

Introduction: The use of bisphosphonates in rheumatology has increased significantly over the last 5 years and has resulted in considerable cost savings.

Objectives: To assess the effectiveness and tolerability of the Adalimumab biosimilar ABP 501 in patients with JIA.

Methods: A database of patients prescribed Adalimumab in our service has been screened to identify patients with JIA, who switched from the originator to the biosimilar. Only patients who had a clinical review since they had started the biosimilar were included. A paired-samples t-test was conducted to compare the number of active joints at the clinic appointment before and after the initiation of the biosimilar treatment. The frequency and type of side effects, the clinical response and the number of patients who switched back to the originator have been collected.

Results: Sixty-one patients who switched to the biosimilar ABP 501 between February 2019 and February 2020 were included. They were comprised of 30 enthesitis-related arthritis (ERA), 13 polyarthritis, 9 oligoarthritis, 6 psoriatic and 3 systemic JIA patients. Their baseline characteristics and outcomes are summarised in Table. The mean duration of follow-up after the switch to biosimilar was 10 months (range 2-23). Eleven patients (18%) reported side effects; the most common side effect (n=7, 63.6%) was injection site reactions and the remaining 4 consisted of anaphylaxis, drug-induced lupus, dizziness and bone pain, respectively. Seven patients (11.5%) reverted to the Adalimumab originator, 4 as a result of side effects, 3 because of ineffectiveness and 1 patient for both reasons. In addition, 3 patients were changed to a different biologic, one patient due to allergy to both the originator and biosimilar and the other two patients had active disease on the originator and biosimilar Adalimumab. Two patients stopped the biosimilar and remained off any biologic, in the first case this was due to a side effect and in the second case it was patient's choice. On the whole, 78.7% of patients had remained on ABP 501 at their last visit. There was no significant difference in the active joint count before the biosimilar was started (mean 0.55±1.11) and after the switch (mean 0.6±1.59), (p=0.85).

Disclosure of Interest
None declared
Results: Based on adverse events (AE) reports.

JADAS10, joint counts and functional status. Safety assessments were matched control cohort using alternative TNF inhibitors or activity and safety parameters were compared to a contemporary 1:2 registry.

Baseline demographics, clinical characteristics, disease activity was lower at baseline. Pts in the GOL cohort used had a longer disease duration (p<0.0001) and use of GOL was significantly more often second line (84.6% vs 22.3%, p<0.0001) and thus disease activity was lower at baseline. Pts in the GOL cohort used less corticosteroids, otherwise patients were comparable with pts treated with other TNFi (Table 1).

In GOL treated pts a marked clinical response was noted at 6 months and beyond, indicating the effectiveness of GOL in the treatment of pJIA. A significant decrease of the mean JADAS 10 11.3 to 5.3 (p=0.0008) after 6 months of treatment was observed, as well as JIA ACR 30/50/70/90 response rates of 61/59/42/29%. JADAS remission and minimal disease activity was observed in 27% and 53.7% after 6 months and in 39% and 54% after 12 months of treatment.

Rates of AE, SAE and infectious AE were comparable in the GOL cohort (87.5/100PY, 3.4/100PY and 11.1/100PY), the alternative TNFi cohort (92.3/100PY, 2.9/100PY and 9.7/100PY) and the MTX only cohort (121.2/100PY, 2.1/100PY and 18.5/100PY). SAE reported in the GOL cohort were flares of uveitis and of JIA (each 1) and fibromyalgia syndrome (1). SAE reported in the alternative TNF cohort was two serious infections (both influenza), one knee ligament injury, one flare of arthritis and one hyperventilation. No case of pregnancy, malignancy or death was reported.

Conclusion: Golimumab seems an effective in treatment of pJIA.

Tolerability was acceptable and comparable to alternative TNFi or MTX. Recruitment to the project is ongoing.

Trial registration identifying number: EUPAS20781

Disclosure of interest
None declared

P263

Matched controlled surveillance of golimumab treatment for polyarticular Juvenile Idiopathic Arthritis–an interim analysis

A. Klein1, A. Zimmer1, K. Minden2, A. Hospach3, F. Weller-Heinemann4, J. Kuemmerle-Deschner5, M. Faschhauer5, I. Foeldvari6, M. Hufnagel6, D. Foell7, P. T. Oommen8, N. Hofmann8, F. Dressler9, A. Helling-Bakki10, H. E. Koessel14, S. Mrusek15, D. Windschall16, N. Brueck17, G. Horneff1

1ASKLEPIOS, Sankt Augustin; 2DRFZ, Berlin; 3Olgahospital, Stuttgart; 4Prof. Hess Kinderklinik, Bremen; 5University, Tuebingen, Tuebingen; 6St Georg, Leipzig; 7Centre of ped. Rheumatology, Hamburg; 8University, Freiburg; 9University, Muenster; 10University, Duesseldorf; 11klinikum Bamberg, Bamberg; 12MHF, Hannover; 13University, Heidelberg; 14Klinikum Brandenburg, Brandenburg; 15Private office, Baden-Baden; 16St Josef Stift, Sendenhorst; 17University, Dresden, Germany

Correspondence: G. Horneff

Pediatric Rheumatology 2020, 18(Suppl 2):P263

Introduction: Golimumab (GOL) is approved for polyarticular juvenile idiopathic arthritis (pJIA) in patients of ≥2years but long-term safety data are limited.

Objectives: Prospective monitoring of long-term safety and effectiveness of GOL in routine care using the BIKER-registry.

Methods: Baseline demographics, clinical characteristics, disease activity and safety parameters were compared to a contemporary 1:2 matched control cohort using alternative TNF inhibitors or methotrexate without exposure to a biologic. Efficacy outcomes were JADAS10, joint counts and functional status. Safety assessments were based on adverse events (AE) reports.

Results: In this ongoing study, 65 pts initiating GOL were matched to 130 with alternative TNFi and 65 biologic-naive pts. Pts starting GOL had a longer disease duration (p<0.0001) and use of GOL was significantly more often second line (84.6% vs 22.3%, p<0.0001) and thus disease activity was lower at baseline. Pts in the GOL cohort used less corticosteroids, otherwise patients were comparable with pts treated with other TNFi (Table 1).

In GOL treated pts a marked clinical response was noted at 6 months and beyond, indicating the effectiveness of GOL in the treatment of pJIA. A significant decrease of the mean JADAS 10 11.3 to 5.3 (p=0.0008) after 6 months of treatment was observed, as well as JIA ACR 30/50/70/90 response rates of 61/59/42/29%. JADAS remission and minimal disease activity was observed in 27% and 53.7% after 6 months and in 39% and 54% after 12 months of treatment.

Rates of AE, SAE and infectious AE were comparable in the GOL cohort (87.5/100PY, 3.4/100PY and 11.1/100PY), the alternative TNFi cohort (92.3/100PY, 2.9/100PY and 9.7/100PY) and the MTX only cohort (121.2/100PY, 2.1/100PY and 18.5/100PY). SAE reported in the GOL cohort were flares of uveitis and of JIA (each 1) and fibromyalgia syndrome (1). SAE reported in the alternative TNF cohort was two serious infections (both influenza), one knee ligament injury, one flare of arthritis and one hyperventilation. No case of pregnancy, malignancy or death was reported.

Conclusion: Golimumab seems an effective in treatment of pJIA.

Tolerability was acceptable and comparable to alternative TNFi or MTX. Recruitment to the project is ongoing.

Trial registration identifying number: EUPAS20781

Disclosure of interest
None declared

Table 1 (abstract P263). Baseline parameters and adverse events. Comparison of GOL cohort with 1st Other TNFi cohort and 2nd MTX cohort. # t-test or c2-test as appropriate. SD standard deviation, RF rheumatoid factor, bDMARD biologic disease modifying antirheumatic drug

| Patient-reported reduced effectiveness, n (%) | Switched back to originator | Changed to different biologic | Not on biologic | Remained on biosimilar |
|----------------------------------------------|-----------------------------|-------------------------------|-----------------|----------------------|
| GOL n=130                                    | 6 (9.8%)                    | 3 (50%)                       | 3 (50%)         |                      |
| Matched control n=65                        | 2 (3.2%)                    | 1 (1.6%)                      | 2 (3.2%)        |                      |

Conclusion: During a mean follow-up period of 10 months, 78.7% of JIA patients who switched to the Adalimumab biosimilar have remained on treatment with no significant difference in their disease activity. Overall, the tolerability and effectiveness of the Adalimumab biosimilar is acceptable, but 11.5% of patients required to be switched back to the originator.

Disclosur of Interest
None declared

| Disease duration, mean (SD), years | GOL N=65 | Other TNFi N=130 | MTX N=65 | p# GOL vs TNFi/GOL vs. MTX |
|-----------------------------------|----------|------------------|----------|--------------------------|
| 7.0(4.4)                          | 4.2(3.8) | 1.2(2.2)         |          | <0.001                   |
| 32(49.2)/69.2/3(0.3)              | 63(48.5)/20(15.4)/1(2.1) | 43(66.2)/12(18.5)/9(13.8) | ns        |                   |
| 24(36.9)/34(6.4)                 | 44(33.8)/32.3/9(13.8) | 11.5(11.5) |  | ns/0.001                |
| Pretreatment bDMARD n(%)/Concomitant steroids, n(%)/Active joints, mean (SD)/JADAS10, mean (SD)/AE,n (rate/100PY)/SAE, n (rate/100PY)/Serious infections, n (rate/100PY): | 56(86.2)/9(13.8)/4.3(3.8)/11.3(5.6)/71(87.5)/3(3.4)/0 | 29(22.3)/33(25.4)/5.2(5.8)/12.2(6.0)/161(92.3)/5(2.9)/2 (1.0;3.4-14.6) | 0/32(49.2)/69.2/3(0.3)/3(3.4)/71(87.5)/3(3.4)/0 | <0.001/0.001 |

Table 1 (abstract P263). Baseline parameters and adverse events. Comparison of GOL cohort with 1st Other TNFi cohort and 2nd MTX cohort. # t-test or c2-test as appropriate. SD standard deviation, RF rheumatoid factor, bDMARD biologic disease modifying antirheumatic drug

Disclosure of interest
None declared
P264
Methotrexate intolerance: children vs adults
U. Kaya Akca1, B. Faisogullari1, G. K. Yardimci2, S. Demir3, E. Sag1, E. Atalay1, M. Kasap Cuceoglu1, L. Kiliç1, S. Ozen1, Y. Bilginer1
1Division of Pediatric Rheumatology, Department of Pediatrics; 2Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
Correspondence: U. Kaya Akca
Pediatric Rheumatology 2020, 18(Suppl 2):P264

Introduction: Methotrexate (MTX) is one of the most commonly used disease-modifying anti-therapeutic drug in rheumatologic practice. It has some side effects that can impair quality of life. The most common of them is associated with the gastrointestinal tract.

Objectives: The aim of the study is to evaluate and compare the frequency of methotrexate intolerance in adult and pediatric patients.

Methods: Patients with rheumatologic diseases followed in Hacettepe University Pediatric Rheumatology and Rheumatology departments who used oral or parenteral methotrexate for at least 3 months were included in the study. Methotrexate intolerance was assessed using ‘Methotrexate Intolerance Severity Score (MISS)’ questionnaire. The MISS questionnaire consisted of 5 parts: abdominal pain, nausea, vomiting, fatigue and behavioral symptoms. The patients scored the severity of each symptom separately; 0: no symptoms, 1: mild symptoms, 2: moderate symptoms, 3: severe symptoms. A total score of 6 or more was defined as MTX intolerance. Visual analogue scale (VAS) ranging from 0 cm to 10 cm was performed to each patient concurrently with the MISS questionnaire. In the pediatric patient group, MISS questionnaire and VAS assessment were applied to both patients and families.

Results: A total of 100 patients, 50 of whom were children, enrolled in the study. The mean age for children and adults was 11.7± (± 3.4) and 52.9 (± 11.8) respectively. The most frequent diagnosis of patients was juvenile idiopathic arthritis (78.0%) in children and rheumatoid arthritis in adults (68.0%). The mean MTX dose in adults and pediatric group was 12.5 (±3) mg vs 14.5 (± 3.6) mg (p: 0.004). The prevalence of MTX intolerance in children and adults were 66.0% (n:33) and 14.0% (n:7) respectively. The mean MISS score in the pediatric group was higher compared with the adults (12.4±9.4 vs 18.4±4.5, p<0.001). Similarly, the mean VAS scores were higher in pediatric group (1.2±2.4 vs 4.2±3.2 (p<0.001)). There was a strong correlation between MISS and VAS scores between family and child evaluations (p <0.01, r = 0.95 / p <0.01, r = 0.94).

Abdominal pain, nausea, vomiting and behavioral symptoms were observed more frequently in children compared to adults. The rate of subcutaneous use of MTX was 74.0% in pediatric patients and 4.0% in adult patients. Of 61 patients receiving oral MTX, 17 (27.8%) experienced MTX intolerance, whereas 23 (58.9%) of 39 patients receiving parenteral MTX experienced intolerance to the drug symptoms (p=0.001). Complaints were started after the first dose in 2/7 in adults and 8/33 in children. MTX intolerance decreased with increasing folic acid dose (r = -0.26, p = 0.007).

MTX intolerance developed in 16 of 21 pediatric patients who were informed about side effects of drug by their families. In addition, 17 of 45 patients (37.7%) who read the drug prospectus had MTX intolerance.

Conclusion: Methotrexate intolerance was higher in childhood. Folic acid supplementation should be recommended for patients taking MTX treatment.

Disclosure of Interest
None declared

P265
Rates of psoriasis de-novo in patients with Juvenile Idiopathic Arthritis preceding anti-TNF therapy: a single-center observational study
N. Tsurikova, E. Ligostaeva, V. Avdeenko, N. Kobzeva, I. Tsiganok
Rostov Regional Children Hospital, Rostov-on-don, Russian Federation
Correspondence: N. Tsurikova
Pediatric Rheumatology 2020, 18(Suppl 2):P265

Introduction: Nowadays many patients who are suffering from juvenile idiopathic arthritis (JIA) are treated with TNF-alpha inhibitors. The question of the duration of therapy with TNF-alpha inhibitors in children receiving TNF-alpha inhibitors and achieving remission on it is relevant.

Objectives: To evaluate the efficacy of therapy with TNF-alpha inhibitors in children suffering from JIA on different therapy regimens after 2 years of treatment with TNF-alpha inhibitors and having a remission for at least one year, which was achieved after prescribing TNF-alpha inhibitors.

Methods: This single-center observational study included 44 children suffering from JIA receiving anti-TNF therapy for 2 consecutive years in standard dose and standard scheme and reached remission on it (average age 9.6±1.7, average disease duration 5.2±1.4); 20(45%) children were treated with adalimumab(ADA), 24(55%) – etanercept(Eta); all children received methotrexate (the average duration of methotrexate therapy was 4.7±0.4). The first group included children...
who after 2 years of therapy with TNF-alpha inhibitors, was continued this therapy at the standard dose and standard scheme (10 children treated with ADA and 10 children treated with ETA). The comparison group included children who after 2 years of therapy with TNF-alpha inhibitors was continued this therapy at the standard dose. But the intervals between injections of TNF-alpha inhibitors were doubled (this group included 10 children treated with ADA and 14 children treated with ETA). Effectiveness was determined by using the Pediatric American College of Rheumatology Criteria (PedACR) and the Juvenile Disease Activity Score 27 (JADAS-27) at the time of inclusion in the study and after 12, 24, 36 and 52 weeks of therapy. The criteria for exclusion from the study was absent 30% improvement according to PedACR.

Results: In both groups at the time of inclusion all patients had a 90% improvement according to PedACR criteria, JADAS 27 less than 1. After 12 weeks in the first group and in the comparison group JADAS 27-0.75(0.1; 1.5) and 0.7(0.2; 1.5), respectively. 100% of children in the first group had 90% improvement according to PedACR criteria, in the comparison group - 42(84%); 10 children (1 were treated with ADA, 1 – ETA) didn’t reached 30% improvement according to the PedACR criteria, in the comparison group - 2(28%) children didn’t achieve 30% improvement according to the PedACR criteria (1 child was treated with ADA, 1-ETA); Tocilizumab (TOC) was approved for treatment of polyarticular Juvenile Idiopathic Arthritis (JIA). Data out of clinical practice are limited. Tocilizumab (TOC) is approved for treatment of polyarticular Juvenile Idiopathic Arthritis (JIA). Effectiveness was determined by using the Pediatric American College of Rheumatology Criteria (PedACR) and the Juvenile Disease Activity Score 27 (JADAS-27) at the time of inclusion in the study and after 12, 24, 36 and 52 weeks of therapy. The criteria for exclusion from the study was absent 30% improvement according to PedACR.

Methods: Efficacy

Correspondence: G. Horneff

Disclosure of Interest

None declared, R. Berendes: None declared, P. Oommen: None declared, F. Weller-Heinemann: None declared, J. Kuemmerle-Deschner: None declared, A. Hospach: None declared, A. Klein: None declared, R. Trauzeddel: None declared, M. Hufnagel: None declared, D. Foell: None declared, A. Helling-Bakki declared, A. Klein.

Introduction: Tocilizumab (TOC) is approved for treatment of polyarticular JIA. Data out of clinical practice are limited. Objectives: Long-term surveillance of patients newly initiating TOC treatment for at least 5 years compared to a cohort of patients newly initiating a comparator biologic using the BIKER-registry. Methods: Baseline demographics, clinical characteristics and disease activity, efficacy and safety parameters were compared. Efficacy outcomes were JADAS10, joint counts and functional status Safety was assessed by adverse events (AE) reports.

Results: 161 patients with 161 matched controls have been recruited. Patients starting on TOC were older at treatment start (12.1 vs. 10.1 years; p<0.0001) and had a longer disease duration (p<0.0001). TOC was significantly more often a second line biologic (p<0.0001). Baseline JADAS10 (17+/−10 vs 15+/−6), CHAQ-DI (0.63+/−0.63 vs 0.65+/−0.64), ESR 18+/−15 mm/h vs. 21+/−21 mm/h and active joint counts (7+/−7 vs. 6+/−5) were comparable.

Upon TOC a substantial response with a significant reduction in JADAS 10 from 16.8 to 3.4 (p<0.0001) after 12 months of treatment was observed. There were no significant differences between patients from the TOC cohort and their matched controls in the JIA ACR 30/50/70/90 criteria, JADAS 10, JADAS remission and minimal disease activity was reached by comparable numbers (TOC 37% and 58%; control cohort 37% and 60%). The total number of AE was comparable (TOC cohort n=201 AE; (77/100PY); control cohort n=207; (65/100PY); RR 1.2, 95%CI 0.99-1.4).

More serious AE (SAE) were reported with TOC. Serious infections were documented at lower frequency with TOC. Uveitis events were documented at significantly higher frequency with TNF inhibitors most likely due to a selection bias(Table 1). SAE with TOC were depression (n=3) in 2 with suicidal intent, exacerbation of JIA (n=2), septic arthritis, gastrointestinal infection, abdominal pain, colitis, paronychia and fracture. SAE in the control cohort were depression, osteomyelitis, gastrointestinal infection and disease flare. No significant differences regarding cytophenias and elevated transaminases were observed. No gastrointestinal perforation, no vascular events and no deaths occurred.

| TCZ mono | Matched controls | p   |
|----------|-----------------|-----|
| N=161    | N=161           |     |
| RF neg/ Poly/ Poly/ ext.Oligo n (%) | 110 (60/15/9/62) | 97 (60/19/12/45/28) | n.s. |
| Pretreatment with biologics, n(%) | 127 (83.5) | 20 (13.2) | <0.0001 |
| Efficacy Month 12 | | | |
| N=87 | N=105 |
| JADAS MDA/REM, n (%) | 50 (57.5)/32 (36.8) | 63 (60.0)/39/37.1 | n.s. |
| JIA ACR 30/50/70/90, % | 80/75/61/53 | 86/84/70/56 | 0.34/0.15/0.17/0.66 |
| AE, Nirate/100PY/95%(CI) | Observation: 260 PY | Observation: 312 PY | RR (95%(CI); p |
| Serious AE (SAE) | 13 (5; 3-9) | 4 (1.3; 1-3) | 3.9 (1.3-12.0); 0.02 |
| SAE infection | 3 (1.2; 0.4-3.6) | 6 (1.9; 0.8-4.2) | 0.6 (0.2-2.4); n.s. |
| Uveitis event | 2 (0.8; 0.2-3.1) | 12 (3.8; 2.2-6.8) | 0.2 (0.04-0.9); 0.03 |

*Number and rate of patients are given # t-test or c2-test as appropriate

Conclusion: TOC was effective and comparable to treatment with alternative biologics. Tolerability was acceptable. As TOC was given as a second-line biologic in the vast majority of patients comparisons between the 2 cohorts have to be interpreted carefully. Observation is ongoing.

Disclosure of Interest: G. Horneff Speaker Bureau of: Pfizer, Abbvie, Novartis, Chugai, A. Hospach: None declared, F. Weller-Heinemann: None declared, J. Kuemmerle-Deschner: None declared, A. Hospach: None declared, A. Klein: None declared, R. Trauzeddel: None declared, M. Hufnagel: None declared, D. Foell: None declared, A. Helling-Bakki: None declared, A. Klein.

Correspondence: G. Horneff

Disclosure of Interest: G. Horneff Speaker Bureau of: Pfizer, Abbvie, Novartis, Chugai, A. Hospach: None declared, F. Weller-Heinemann: None declared, J. Kuemmerle-Deschner: None declared, M. Hufnagel: None declared, D. Foell: None declared, A. Helling-Bakki: None declared, A. Klein: None declared, R. Trauzeddel: None declared, M. Hufnagel: None declared, D. Foell: None declared, R. Berendes: None declared, P. Oommen: None declared, F. Weller-Heinemann: None declared, J. Kuemmerle-Deschner: None declared.
P268
Secukinumab efficacy and safety in Juvenile Idiopathic Arthritis
I. Kruliun1, E. Alexeeva1, T. Dvoryakovskaya1, R. Denisova1, A. Fetsisa1, A. Mamutova1, K. Iayeva1, A. Chomahidze1, O. Lomakina1, K. Chibisova1, M. Gautier1, D. Vankova1, E. Krekhova1, M. Shingarova1,2
1Rheumatology, National Medical Research Center for Children’s Health; 2Sechenov First Moscow State Medical University, Moscow, Russian Federation

Correspondence: E. Alexeeva
Pediatric Rheumatology 2020, 18(Suppl 2)p268

Introduction: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children, characterized by chronic inflammation of synovium, cartilage and bones destruction and wide spectrum of extra-articular manifestations. Often JIA is associated with eye damage –uveitis. Rheumatoid uveitis is the most common extra-articular JIA manifestation. Currently there is a large number of biological monoclonal antibodies therapy for the treatment of JIA. Monoclonal antibodies now represent an important series of options in the treatment of rheumatoid arthritis. However, some patients do not respond to standard biologic therapy. However, in some cases there is no response to standard therapy. Secukinumab is a human anti-interleukin-17A monoclonal antibody, which is used in JIA. Secukinumab is being used off-label in Russia for JIA, so it is important to evaluate efficacy and safety in children.

Objectives: To evaluate efficacy and safety of Secukinumab in children with JIA.

Methods: 25 children (13 boys (52%) and 12 girls (48%)) with JIA who received Secukinumab in the rheumatological department of the National Medical Research Center for Children’s health of Ministry of health were included. Efficacy of therapy was evaluated by uveitis activity, joint inflammation activity according to pediatric criteria of the American College of rheumatologists (ACRpedi), juvenile arthritis disease activity score (JADAS).

Results: Secukinumab was used in children with following types of JIA: enthesitis-related arthritis – 9 (36%), oligoarthritis – 4 (16%), RF(-) polyarthritis – 6 (24%), psoriatic arthritis – 4 (16%), undifferentiated arthritis – 2 (8%). Among these patients 4 (16%) children had rheumatoid uveitis and 15 (60%) children were HLA-B27 positive. We consider important to notice that 17 (68%) patients were switched on Secukinumab from another biologic agents, the average number of switches was 1.3 [min 0; max 3]. Secukinumab demonstrated high efficacy in treatment of JIA and rheumatoid uveitis. Average treatment duration was 17.6 months [min 0; max 28.5]. From 20 patients who received Secukinumab more than 6 months after six months 20% improvements in ACRpedi and 8 (40%) children reached remission. 5 (20%) patients achieved remission. 92 days after RTX infusion (IQR 62–113) Rituximab concentrations in plasma were measured in 28 patients after a median of 152.3 days. Median RTX level was 41.0 [IQR 113.5–92.0] µg/ml. Rituximab serum concentrations were determined, from frozen rest material, by radio-immunoassay and enzyme-linked immunosorbent assay, respectively. ADA presence was defined as a titer above 12 AU/ml. Patient charts were screened for infusion-related reactions.

Conclusion: High efficiency and safety of Secukinumab in patients with JIA was demonstrated and we consider Secukinumab can be used as first-line therapy for JIA, associated with HLA-B 27 gene and as an alternative therapy when standard biologic anti-TNF therapy is ineffective. Only one serious adverse effect was reported.

Disclosure of Interest
I. Kruliun: None declared, E. Alexeeva: Speaker Bureau of: Novartis, Pfizer, MSD and Roche, T. Dvoryakovskaya: Speaker Bureau of: Novartis, Pfizer, MSD and Roche, R. Denisova: None declared, A. Fetsisa: None declared, A. Mamutova: Speaker Bureau of: Novartis, K. Iayeva: None declared, A. Chomahidze: None declared, O. Lomakina: None declared, K. Chibisova: None declared, M. Gautier: None declared, D. Vankova: None declared, E. Krekhova: None declared, M. Shingarova: None declared

P269
Neutralizing anti-rituximab antibodies in children with immune mediated diseases
I. Oomen1, A. Nassar-Shiekh Rashid1, A. H. Bouts2, S. C. Gouw3, T. W. Kuipers1, T. Rispens4, A. de Vries5, G. Wolbink6, J. M. van den Berg1, D. Schonenberg-Meijer1
1Department of Pediatric Immunology, Rheumatology and Infectious diseases; 2Department of Pediatric Nephrology; 3Department of Pediatric Hematology, Amsterdam University Medical Centers; 4Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands
Correspondence: I. Oomen
Pediatric Rheumatology 2020, 18(Suppl 2)p269

Introduction: Rituximab is frequently used as a therapeutic drug in different B-cell mediated autoimmune diseases and leads to B cell depletion. Different treatment responses have been observed in patients with B-cell mediated diseases. It has been suggested that a lack of efficacy may be related to the formation of anti-drug antibodies (ADA). The presence of ADA has been correlated with the failure of B cell depletion as well as the occurrence of infusion-related reactions. It is unknown if these ADA neutralize in-vivo rituximab levels.

Objectives: The primary objective of this study is to determine if ADA neutralize rituximab levels and if a specific patient-group has a higher susceptibility for developing ADA. The secondary objective is to correlate ADA with B-cell depletion and infusion-related reactions.

Methods: Retrospectively, children with different B-cell mediated diseases, treated with rituximab between December 2006 and November 2019, were included. Plasma samples for B-cell measurements had been collected at standard clinical visits every three months until six months after rituximab treatment. Rituximab-specific ADA levels and rituximab serum concentrations were determined, from frozen rest material, by radio-immunoassay and enzyme-linked immunosorbent assay, respectively. ADA presence was defined as a titer above 12 AU/ml. Patient charts were screened for infusion-related reactions.

Results: ADA levels were measured in 29 patients (n=9 nephrotic syndrome, n=8 Systemic Lupus Erythematosus (SLE), n=2 systemic vasculitis, n=2 pulmonary hemosiderosis, n=2 juvenile systemic sclerosis, n=2 other renal disease, n=1 juvenile dermatomyositis, n=3 other). Of these, 35.4% (n=10/29) tested ADA-positive, after a median of 93 days after RTX infusion (IQR 127.5 – 108.5). Median ADA-titer was 345.0 AU/ml.

RTX concentrations were measured in 28 patients after a median of 92 days after RTX infusion (IQR 62–113). Rituximab concentrations in seven ADA-positive patients were measured and all (n=7) showed undetectable low RTX-concentrations. These RTX-levels differed significantly when compared to ADA-negative patients (p<0.005). Three autoantibodies were significantly more present in ADA-positive patients (anti-ds-DNA (OR 12.5, p=0.045), anti-RNP (OR 14.7, p=0.038) and anti-Sm (only present in ADA-positive patients, p=0.036)). Five ADA-positive patients (n=5/8, 62.5%) did not show B-cell depletion after RTX-treatment, compared to one of 19 (5.3%) ADA-negative patients (p=0.002; OR 26.7; 95% CI, 2.24–317.25).

Severe anaphylaxis during rituximab infusion occurred only in the ADA-positive patients.

Conclusion: In this retrospective cohort study in pediatric patients on RTX-treatment, we found undetectable low drug levels in ADA-positive patients, indicative for their neutralizing capacity. Consequently, the lack of B-cell depletion leads to reduced treatment efficacy. Patients with SLE seem more susceptible to develop ADA. If ADA are detected, continuation of treatment seems non-effective and changing medication is advised. Certainly when considering that, in this study, anaphylactic reactions only occurred in ADA-positive patients.

Disclosure of Interest
None declared
P270
Switching from reference to biosimilars does not reduce efficacy and safety in Juvenile Idiopathic Arthritis

I. Maccora1, G. Simonini1, A. Bettolo2, I. Paglini2, N. Lombardi3, V. Maniscalco1, G. Crescioli1, E. Marrani1, R. Bonaiti2, M. V. Mastroli2, C. Ravaldi2, A. Vannacci1

1Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence; 2Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence; 3Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence;

Objective: To evaluate the long-term efficacy and safety of switching from the etanercept (ETA) and adalimumab (ADA) originators to their biosimilars, in children with JIA.

Methods: Medical charts of JIA children who switched from ETA or ADA originators to the biosimilars were retrospectively evaluated. Efficacy of anti-TNF therapy was evaluated at last follow-up during the originator therapy and at 3, 6 and 12 months following the switch to biosimilar, assessing number of inflamed joints, CRP, ESR, Juvenile Arthritis Disease Activity Score (JADAS 10), Visual Analog Scale (VAS) and Childhood Health Assessment Questionnaire (CHAQ). Occurrence of adverse event (AE) during treatment was evaluated. Continuous variables were reported as median value and interquartile range (IQR) and compared using the Wilcoxon test for paired data, and c² analysis.

Results: 43 children (31 Female, median age at onset 65 months (IQR 31-125) received originator ETA (n=14) or ADA (n=29), as first-line anti-TNF treatment for refractory JIA. Due to healthcare politics, patients have been switched to the biosimilar: Benepali®(n=13), Erelzi® (n=1) for ETA; Imraldi® (n=24). Amgevita® (n=5) for ADA, after 40.5 months (IQR 19.1-73.8) duration of originator treatment. At time of switch, 10/14 patients on ETA and 19/29 on ADA were on complete disease remission. No significance difference of entered parameters has been found at 3, 6 and 12 months thereafter the switch. Nine patients discontinued biosimilars, due to disease remission (5), to family willing (2), to occurrence of burning at injection site (2, on Benepali). The number of patients who experienced an AE was not different in different frame follow-up when comparing exposure to the originator and that to biosimilar, respectively: during 0-3 months, 15/42 (35.7%) vs 7/37 (18.9%), c²: 2.76; during 3-6 months, 16/40 (40.0%) vs 17/31 (54.8%), c²: 1.54; during 6-12 months, 15/39 (38.5%) vs 11/24 (45.8%), c²: 0.33 . Most frequent AEs were upper respiratory tract infections (31) and injection site reactions (7).

|     | 0 Time of switch | 3 months | 6 months | 12 months |
|-----|------------------|----------|----------|----------|
| Amgevita (N=5) | n | 5 | 5 | 3 | 2 |
| Number of active joints | 0 (0-0) | 0 (0-0) | 0 (0-0) | 0 (0-0) |
| JADAS10 | 0 (0-0.1) | 0 (0-1) | 0 (0-0) | 0.1 (0-0.2) |
| Benepalı (N=13) | n | 13 | 11 | 9 | 10 |
| Number of active joints | 0 (0-0) | 0 (0-0) | 0 (0-0) | 0 (0-0) |
| JADAS10 | 0 (0-0) | 0 (0-0.8) | 0 (0-0.4) | 0 (0-0.8) |
| Imraldi (N=24) | n | 24 | 20 | 19 | 12 |
| Number of active joints | 0 (0-0.5) | 0 (0-0) | 0 (0-0) | 0 (0-0) |

Conclusion: Data from this small, retrospective inception cohort, showed similar efficacy and safety of the originator and a type of ETA and ADA biosimilars in JIA.

Disclosure of Interest
None declared

P271
Long term treatment with adalimumab in Juvenile Idiopathic Arthritis associated uveitis - our experience

D. S. Lazarevic1,2, M. Jakovljevic2, J. Vojinovic2,3

1Faculty of Medicine, University of Nis; 2Pediatric Rheumatology, CLINIC OF PEDIATRICS, CLINICAL CENTER NIS; 3Faculty of Medicine, University of Niš, Niš, Serbia

Correspondence: D. S. Lazarevic

Pediatric Rheumatology 2020, 18(Suppl 2):P271

Introduction: Juvenile idiopathic arthritis (JIA) associated uveitis is one of the most severe extra-articular manifestations in JIA. Delayed diagnose time and inadequate treatment could lead to serious structural consequences. In the last years new treatment novelties and TNF inhibitors have shown excellent control of ocular inflammation.

Objectives: The aim of this study was to evaluate retrospectively the long-term efficacy and safety of adalimumab in patients with JIA-associated uveitis.

Methods: We have retrospectively analysed nineteen JIA patients data with associated uveitis from our centre registry between 2010 and 2020, treated with adalimumab after failure of treatment with corticosteroids and metotrexate. Demographic data and blood samples were collected at different time points while uveitis activity was evaluated by slit-lamp biomicroscopy. Adverse events were recorded.

Results: Registry records provided 10 years follow up of 19 JIA patients data with associated uveitis. Eleven patients were females (57.90 %) diagnosed as oligo/extended oligoarticular JIA while eight (42.10 %) were males diagnosed as enthesitis related arthritis (ERA). Before adalimumab was prescribed, all patients were previously treated with metotrexate during 3.5 years in average dose of 10 mg/m² weekly. The mean uveitis duration, before adalimumab administration was 9 months. Ten years long follow up period have showed that there were no new relapsis of uveitis while patients were receiving adalimumab and metotrexate. All of our patients were able to gradually taper and stop treatment with topical steroids two months after adalimumab commencing. Seven patients were able to stop biological treatment after 4.3 years of adalimumab usage. Uveitis relapsed three months after the adalimumab discontinuation only in one patient. Two patient were lost to follow up during the transitional period. No serious adverse events were recorded.

Conclusion: During the long term follow up period adalimumab have shown good efficacy and safety profile in JIA patients with active inflammatory ocular disease.

Disclosure of Interest
None declared
**Introduction:** Juvenile Idiopathic Arthritis (JIA) is the most common extra-ocular disease and is associated with chronic anterior uveitis during childhood. JIA-associated uveitis (JIAU) is a serious, sight-threatening disease with multiple complications and even blindness if untreated. Although most treatments used improve simultaneously both arthritis and uveitis, there is low correlation between the activity and damage for both conditions.

**Objectives:** To determine the association between the occurrence of uveitis flares in patients with Juvenile Idiopathic Arthritis (JIA) and the de-intensification of immunosuppressive treatment.

**Methods:** We conducted a retrospective longitudinal cohort study, including a single-centre consecutive cohort of patients diagnosed with oligoarticular JIA antinuclear antibody (ANA) positive, who had had at least one uveitis flare during their follow-up up to 19.5 years. Patients with the same JIA category, ANA positive, with no history of uveitis flare were considered controls. Epidemiological data, age of first uveitis flare, number of previous episodes, treatments prescribed at the time of the flare and time since the last treatment modification were recorded. Treatment tapering was defined as a reduction in dose or increase in the inter-doses period, according to datasheet of the corresponding treatment. The relative risk (RR) for the development of uveitis flare and treatment tapering were determined by contingency tables.

**Results:** We included 68 patients of which 22 had had uveitis flares during their follow-up, and 46 controls. The mean age of patients at JIA diagnosis was 3.56 ± 2.17 years. A total of 107 uveitis flares were recorded with an average of 4.54 ± 4.70 episodes per patient. The first uveitis flare was registered at an average age of 6.57 ± 5.79 years. Four patients (18.1%) had had only one episode. Among patients with more than one flare, the inter-flare period was 17.84 ± 21.8 months. Thirty flares (27%) were registered in patients without immunosuppressive treatment. Twenty patients (90%) required the initiation of biological therapy specific for uveitis. Adalimumab (ADA) was chosen in 19 (86.3%) patient and avoided further uveitis flares in 15 (68%) cases. Treatment with Tocilizumab (TCZ) was used in 6 (27.3%) cases and avoided further uveitis flares in 5 (27.3%). Thirty-three episodes (33.1%) were registered in patients with Methotrexate (MTX) of which, 8 (7.5%) were receiving doses below datasheet (<10mg/m2). Forty-four uveitis flares (41%) took place in patients on biological treatment, of which 27 were receiving ADA (25.3%), 2 (1.9%) TCZ and 15 (14%) other therapies. Thirty-seven flares (32.1%) took place in patients on tapered treatments and 11 (10.3%) after non-scheduled withdrawal. In terms of risk of developing a new uveitis flare, tapering had a RR of 2.79 (CI 2.01-3.7; P<0.05) while therapy withdrawal had a RR of 5.91 (CI 3.23-10.8; P<0.05). MTX tapering had a RR of 12.5 (CI 6.4-24.5; P<0.05). Patients with ADA had a RR of 0.88 (CI 0.4-1.6; P=0.84) of developing uveitis flares, with TCZ a RR of 4,65 (CI 1.2-17.8; P=0.05) and with other biological therapy (Etanercept, Infliximab, Abatacept) a RR of 3.56 (CI 2.05-6.2; P<0.05).

**Conclusion:** Tapering immunosuppressive treatment in oligoarticular JIA ANA positive patients, increases the risk of developing uveitis flares.
Objectives: To understand the current medication tapering practice patterns of pediatric rheumatologists and pediatric ophthalmologists specialized in children with JIAU.

Methods: We surveyed via email international pediatric rheumatologists: 1. Multinational Interdisciplinary Working Group for Uveitis in Childhood (MWUGC), 2. Pediatric Rheumatologic Email-Listserve, 3. CARRA uveitis workgroup, and international ophthalmologic specialized in children with JIAU. Survey questions focused on the definition of remission, duration of remission prior to initiation of medication tapering, and method of tapering. Specific medications included methotrexate (MTX), adalimumab (ADA), infliximab (IFX), abatacept (ABA), and tocilizumab (TOC).

Results: Of 45 responses, 88% were from pediatric rheumatologists with a mean work experience of 18 years. The regional distribution was 31 from Europa, 9 from North-America, 3 from South-America and 2 from Asia. The responding colleagues managed a mean number of 43 JIAU patients. Remission on medication was defined as no cells in the anterior chamber (78%), followed by no need for eye drops (36%), and no uveitis flares (32%). Tapering practices were described for MTX monotherapy (100%) ADA (100%), IFX (80%), TOC (56% [25% s.c.]) and ABA (46% [30% s.c.]). Standardized protocol for tapering exists in 32% of centers for MTX, 56% [25% s.c.] and ABA (46% [30% s.c.]).

Methods: in the retrospective study 225 pediatric autoimmune uveitis included. The onset age ranged from 1 to 16 years, 144 girls (64%) and 81 boys (36%). ANA positivity was in 106/180 (58.9%), HLA B27 was in 23/107 (21.4%). JIA-associated uveitis was in 90% (59.2% - oligoarthritis, 21.6% - polyarthritis, 9.2% enthesitis-related arthritis) and 10% of the patients had uveitis solely. The distribution of uveitis types: anterior 78%, peripheral and posterior uveitis in 2.8% each, and panuveitis in 16.4%. Unilateral uveitis at onset was in 34.7% and bilateral in 65.3%.

Results: uveitis de-novo occurred in 12 (5.3%) patients of all uveitis in 1-48 months (median=26 months, 25%-75%: 17-41 months) after start of biologic. Gender distribution: 4 boys (33.3%) and 8 girls (66.7%). Anterior uveitis was in 11/12 (91.7%) patients and 1/12 (8.3%) had panuveitis; unilateral involvement in 5 (41.7%) and bilateral in 7 patients (58.3%). HLA B27 antigen was in 3/10 (30%) in uveitis de-novo and in 20/98 (20.4%) in other uveitis (p=0.366), ANA positivity in 4/12 (33.3%) in uveitis de-novo and in 102/171 (59.7%) in other uveitis (p=0.366). The main features in both studied groups are in the table 1. All cases of the uveitis de-novo developed under etanercept (100%) and 4 of them (33.3%) discontinued methotrexate before uveitis. Before uveitis 10/12 (83.3%) had remission in arthritis. All patient discontinued etanercept and 10 patients switched etanercept on adalimumab: eight patients with methotrexate and 2 patients – adalimumab monotherapy. In two remaining patients, one only discontinued etanercept and continue methotrexate with mild flares and using the topical steroids, and second patient discontinued etanercept and restarted methotrexate. Remission in uveitis achieved in 6/10 (60%) who switched etanercept on adalimumab, 4/10 (40%) experienced flares despite adalimumab treatment with methotrexate (n=3).

| Parameter               | Uveitis de-novo (n=12) | Other uveitis (n=213) | p     |
|------------------------|------------------------|-----------------------|-------|
| JIA category           |                        |                       |       |
| OA                     | 2 (16.7)               | 127 (69.5)            | 0.002 |
| PA                     | 6 (50)                 | 40 (21.9)             |       |
| ERA                    | 4 (33.3)               | 16 (8.6)              |       |
| ESR, mm/h              | 30 (19; 57)            | 20 (7; 28)            | 0.03  |
| Arthritis before uveitis, n (%) | 12 (100)              | 123/202 (60.9)        | 0.007 |
| Biologics for uveitis treatment, n (%) | 10 (83.3)            | 113/206 (54.9)        | 0.042 |
| Time before uveitis, years | 3.5 (2.4; 4.9)       | 0.2 (0.1; 0.6)        | 0.000008 |
| Time before biologics treatment (indication: uveitis), years | 2.1 (0.8) | 4.9 | 0.002 |

Conclusion: uveitis de-novo is a challenging problem, associated with biologic treatment. Further investigation required for finding the predictors of this condition.

Trial registration identifying number: This work supported by the Russian Foundation for Basic Research (grant № 18-515-57001)

Disclosure of Interest
None declared
Introduction: Childhood uveitis is a sight-threatening condition and it may lead to ocular complications. In the last 15 years the biologic therapy, specifically anti-TNF, has revolutionised the management of uveitis refractory to conventional immunomodulatory approaches.

Objectives: To summarize evidence regarding efficacy of anti-tumour necrosis factor-α (anti-TNFα) in childhood autoimmune chronic uveitis (CACU), refractory to common disease modifying antirheumatic drugs (DMARDs).

Methods: An updated systematic search was conducted between November 2012 and January 2020. Studies investigating the efficacy of anti-TNFα therapy, in children ages <16 years, as the first biologic treatment for CACU, refractory to topical and/or systemic steroid and at least one DMARD, were eligible for inclusion. The primary outcome measure was the improvement of intraocular inflammation according to Standardization of Uveitis Nomenclature Working Group criteria. A combined estimate of the proportion of children responding to etanercept (ETA), infliximab (INF), and adalimumab (ADA) was determined.

Results: We identified 1677 articles and 37 articles were eligible. Three were randomized clinical trials (RCTs), one on ETA and 2 on ADA, and were excluded from pooled analysis. From the observational studies, a total of 487 children were identified: 226 received ADA, 213 INF and 48 ETA. The proportion of responding children was 86% (95% CI 76–95%) for ADA, 68% (95% CI 50–86%) for INF, and 36% (95% CI 9–67%) for ETA. Pooled analysis showed clear differences ($\chi^2$= 32.2, p<0.0001): ADA and INF were both significantly superior to ETA ($\chi^2$ =26.8, p<0.0001, and $\chi^2$= 7.41, p<0.006 respectively), ADA significantly superior to INF ($\chi^2$= 13.4, p<0.0002).

Conclusion: This metaanalysis, consistent with recent RCT data, suggests the efficacy of ADA and INF in CACU treatment. However, ADA results superior to INF in this clinical setting.

Disclosure of Interest
None declared

P277

Drug survival of the infliximab biosimilar (CT-P13) in pediatric patients with non-infectious uveitis

B. Sozeri1, E. Kardes2, F. demir1, E. Sali3, D. cakir3

1pediatric rheumatology; 2Ophtalmalogy; 3pediatric infectious disease, Istanbul, Turkey

Correspondence: B. Sozeri
Pediatric Rheumatology 2020, 18(Suppl 2):P277

Introduction: Uveitis is uncommon in the children, accounting for 2 to 14% of all uveitis cases Pediatric non-infectious uveitis (NIU) is an important cause of significant long term complications and blindness in children.Biosimilar drugs are reproductions of their originator counterparts, are usually less expensive

Objectives: In this report, we studied children with uveitis who had Infliximab Biosimilar (CT-P13) therapy focusing on demographics, anatomic distribution, etiologies, outcome, and complications.

Methods: This non-interventional, retrospective, single center analysis collected medical record data for pediatric patients with non-infectious uveitis who received CT-P13 treatment at the referral center for pediatric rheumatology between January 2016 and January 2020.

Results: Forty six eyes of twenty six patients were enrolled in this study. The gender distribution was equal. The mean age at presentation was 9.7 years. The mean age of IQA diagnosis of uveitis was 9.41 (5-12.3) years, the median age at primary diagnosis was 7.8 years and the median age at the beginning of the symptoms was 6.6 years. The median time between primary diagnosis and uveitis was 1 months. The mean number of uveitis episodes was 5±2.75. Bilaterally was more commonly encountered in the older age group, p = 0.32. Anterior uveitis was the most common site of inflammation followed by panuveitis then posterior and finally intermediate uveitis. Of the 26 patients evaluated, the primary diagnosis of 16 was JIA, 3 was Behçet disease, 6 were idiopathic and 1 was sarcoidosis. In the patients with BD, the mean age (IQR) at diagnosis was 17.7 (12.9-17.7) years and the mean age (IQR) at diagnosis was 8.2 (7.3-12.3) years in patients with idiopathic uveitis. Both the age at uveitis and primary diagnosis were detected younger in JIA groups than others (p=0.04). While the rate of patients with controlled uveitis was 80.7%, disease control was not achieved in 7 patients with INF treatment. At presentation, there was good VA (LogMAR VA <0.3, >20/40) in sixty percent of the eyes and significant improvement in VA during follow-up in most eyes (81%). Overall, all patients were treated with CT-P13 (22 patients infliximab-naïve; 4 switched from adalimumab). Drug survival was similar in naive and switched patients. Treatment-emergent adverse events (TEAEs) occurred in 26.9%.

Conclusion: In our present study, we report the 4-year follow up results on the safety and efficacy of biosimilar infliximab of pediatric non-infectious uveitis. This is first report about biosimilar infliximab (CT-P13) efficacy and safety in pediatric patients with uveitis. IFX biosimilar (CT-P13) is remarkably safe and effective for long-term treatment of non-infectious pediatric uveitis. Higher dosage and shorter intervals may be necessary to achieve successful control in a greater percentage of patients.

Disclosure of Interest
None declared

P278

Morbidity of JIA-associated uveitis: half of patients despite systemic treatment still show ocular damage during a long-term follow-up

G. B. Beretta1, L. Marelli2, V. Casotto1, M. Romano3, E. Misericocchi2, C. Magelli1, A. Petaccia1, S. Lanni1, I. Pontikakis2, F. Minola1, R. Cimaz3

1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; 2San Giuseppe Hospital, IRCCS Multimedica; 3ASST Gaetano Pini-CTO Institute, Milan, Italy

Correspondence: G. B. Beretta
Pediatric Rheumatology 2020, 18(Suppl 2):P278

Introduction: Uveitis is the most common extra-articular complication of juvenile idiopathic arthritis (JIA). Due to its typical indolent and chronic course, children with this condition are at risk for ocular morbidity with a significant impact on their quality of life.

Objectives: To describe demographic and clinical features, treatment approaches and outcome of a population of patients with JIA-associated uveitis.

Methods: Charts of patients with JIA-associated uveitis, followed in two tertiary Pediatric Rheumatology Centres were retrospectively reviewed with regard to clinical features, therapeutic choices and outcome.

Results: Data from 162 JIA patients with uveitis were analysed (81.5% female), with a mean follow up of 8.9 years (SD ± 2.56). Mean age at JIA onset was 3.6 years (SD± 3.1) and the mean JIA duration at uveitis onset was 2.5 years (SD ± 4.3). Uveitis was diagnosed at JIA onset in 9.9% of patients. The most frequent JIA category was oligoarthritis (88.9%), which was persistent in 72.8% of cases, followed by RF- polyarthritis (9.3%). No systemic JIA was reported. Uveitis was predominantly anterior (96.9%) and reported bilateral in 65.4% of cases. In almost all patients (87.6%) antinuclear antibodies (ANA) were positive. Systemic medications were required in 134 (82.7 %) patients. Methotrexate and cyclosporine were used in 66.0% and 7.4% of cases, respectively, while 86 patients (53.1%) required biologic therapy, mainly adalimumab (34.6%), followed by infliximab (10.5%) and tocilizumab (3.7%). In 28.4% of cases more than 1 biologic was needed. Mean recurrence rate in our cohort was 1.3 per year (SD ±1.1). In 79 patients (49.8%) uveitis was complicated by ocular damage, which is summarized in Table 1. A best-corrected visual acuity (BCVA) ≤ 0.4 and ≤ 0.1 were observed in 14.2% and 10.5% of patients, respectively. Clinical remission at last follow-up was reached in 26 (70.3%)/37 patients with available data.
Table 1 (abstract P278). See text for description.

| Ocular damage, n (%) | JIA patients with uveitis N 162 |
|----------------------|---------------------------------|
| Synechiae            | 56 (34.6%)                      |
| Glaucoma             | 9 (5.6%)                        |
| Cataract             | 29 (17.9%)                      |
| Band keratopathy     | 32 (19.8%)                      |
| Cystoid macular edema| 7 (4.3%)                        |
| Any surgery          | 28 (17.3%)                      |
| Cataract             | 24 (14.8%)                      |
| Synechiotomy         | 2 (1.2%)                        |
| Other (band keratopathy, glaucoma) | 2 (1.2%) |

Conclusion: Despite continue improvement in therapeutic options, uveits remains a high morbidity complication of JIA. Clinical predictors and biomarkers are needed to identify patients at higher risk of unfavourable outcome. Careful monitoring and follow-up are crucial for timely detection of ocular inflammation and prevention of damage.

Disclosure of Interest
None declared

P279
Assessing s100 proteins and cytokines in tears as potential biomarkers for uveitis diagnosis and activity in JIA patients
J. Rodriguez-Smith1, V. Miraldi Utz2, S. Thornton3, G. Schueltet4, A. Sproles1, N. Mwase3, T. Hennard5, A. A. Grom6, M. Altaye7, S. T. Angeles-Han1

Introduction: JIA-associated uveitis (JIA-U) occurs in 10-20% of children with Juvenile Idiopathic Arthritis (JIA) and typically asymptomatic, and sight-threatening complications occur in 50% of children, (i.e. cataracts, vision loss). Frequent ophtalmic examinations are important for early diagnosis and monitoring of uveitis activity. Even after uveitis is controlled, risk of disease exacerbation still exists. Therefore, frequent ophtalmic screening and monitoring is important for detection and management of JIA-associated uveitis (JIA-U). S100 proteins, cytokines, and chemokines detected in aqueous humor of patients with uveitis are also detected in tears. Biomarker discovery using tears is promising since collection is noninvasive, feasible, well-tolerated, and close to the target organ.

Objectives: We aim to determine if S100 proteins, cytokines, and chemokines levels differ in tears of children with JIA and JIA-U and in children with JIA-U by uveitis activity.

Methods: Tears were collected using Schirmer strips from children ≥5 years old with oligo- or polyarticular RF negative JIA with (JIA-U) and without uveitis (JIA-no-U), and in children with JIA-U at time of active and inactive eye disease. Activity was defined by Standardization of Uveitis Nomenclature (SUN) criteria. Active uveitis was anterior chamber inflammation grade ≥1. S100A8, A9, and A12 were measured by ELISA, and IL-18, IL-8, IP-10, MCP-1, RANTES, and sICAM-1 by Lumienx assays. Biomarker levels were compared in children with JIA-no-U (n=8) to active JIA-U (n=8), and 2) JIA-U (n=8) at time of active and inactive uveitis.

Results: Children with JIA-no-U and JIA-U were matched by JIA subtype and arthritis activity. They had primarily oligoarticular JIA (63%), active arthritis (25%), and were on systemic medication (75%). At time of active uveitis, 75% had grade 0.5+, and 25% had 1+ and mean interval between time of active and inactive disease was 11 months. We found that levels of biomarkers in tears of children with JIA-no-U compared to active JIA-U were similar. Although not statistically significant, levels of S100A12 (mean difference 12,190 pg/ML [95% CI -4847 to 29,227], P=0.14) and sICAM-1 (5329 pg/ML [95% CI -5372 to 16,031], P=0.28) were higher when uveitis was active compared to inactive.

Conclusion: Our results suggest that S100A12 and sICAM-1 are potential biomarkers of uveitis activity in JIA-U, but not uveitis diagnosis. Thus, neutrophils may play a role in the pathogenesis of anterior uveitis which has been reported in an animal model of acute anterior uveitis. Identifying biomarkers using tears provides a noninvasive and objective method of monitoring uveitis. Limitations are our heterogeneous cohort that varied by arthritis severity and immunosuppression, and minimally active uveitis. We were underpowered to detect statistically significant differences and continue to collect tears prospectively in children with JIA-U with goal of n=28. Despite low uveitis activity, we were still able to detect differences. Further studies in larger and diverse cohorts are necessary to assess the role of S100A12 and sICAM-1 in JIA-U.

Disclosure of Interest
J. Rodriguez-Smith: None declared, V. Miraldi Utz: None declared, S. Thornton: None declared, G. Schueltet: Consultant for: Novartis, SOBI, A. Sproles: None declared, N. Mwase: None declared, T. Hennard: None declared, A. Grom Consultant for: AB2Bio, Novartis, SOBI, M. Altaye: None declared, S. Angeles-Han: None declared

P280
Case report of acute digital ischaemia in a 12 year old boy with granulomatosis with polyangiitis
K. Gallagher, S. Deepak, S. Rangaraj, K. Warner
Nottingham Children’s Hospital, Nottingham, United Kingdom

Correspondence: K. Gallagher
Pediatric Rheumatology 2020, 18(Suppl 2):P280

Introduction: Granulomatosis with polyangiitis(GPA) is a rare vasculitis involving medium and small arteries, affecting predominantly upper and lower respiratory tracts, often with glomerulonephritis. Typically it is characterised by necrotising granulomatous inflammation and the presence of anti-neutrophil cytoplasmic antibodies(ANCA).

Objectives: To report an extremely rare presentation of GPA in a 12 year old with acute digital ischemia.

Methods: A 12 year old boy, with a background of poorly controlled type 1 diabetes and hypothyroidism, initially presented to hospital unwell with diabetic ketoacidosis. Treatment was initiated promptly with good response. Furthermore, he was found to have weight loss, productive cough and hearing loss over the past 3 months. He was haemodynamically stable, but very pale and cachectic. He had reduced air entry and crackles on the right. There was hypertonia and clonus in his lower limbs. Blood tests showed microcytic hypochromic anaemia (Hb 82g/L), normal white cell count, thrombocytosis and raised inflammatory markers (CRP 138mg/L and ESR 68 mm/hr). His chest x-ray showed enlargement of the right hilum with consolidation/atelectasis extending into the middle and lower lobes. MRI scans of head and spine were normal apart from fluid opacification in the paranasal sinuses. He was screened for infections including Tuberculosis and started on intravenous antibiotics.

On day 13, he developed painful bluish discoloration of his left hand, particularly his thumb, index and middle fingers. His left radial and brachial pulses weren’t palpable. A heparin infusion was started. A Doppler scan showed occlusion of radial and ulnar arteries proximal to the wrist with no clear thrombus. He had a CT thoracic aorta with contrast which showed proximal left radial artery occlusion and distal ulnar artery occlusion with no evidence of proximal embolic source or vasculitis. It showed multiple perihilar masses (lymph nodes) in the right lung and peripheral parenchymal masses in both lungs, suggestive of atypical infection or connective tissue disease.

Blood tests still showed raised inflammatory markers(CRP 107mg/L, ESR 86 mm/hr and platelets 658 10⁹/L). An autoantibody screen showed positive ANCA with strongly positive anti PR3(>100 U/ml);
other autoantibodies, including ANA, ds DNA and anti-phospholipid antibodies, were negative. He developed further ischaemia with bluish, painful discoloration of his right foot, especially right great toe, with a weakly palpable dorsalis pedis pulse. Doppler scan revealed occlusion/narrowing of the posterior tibial artery 6cm proximal to the ankle. Following vascular team advice, he was started on ilioioprost infusion to aid re-perfusion of the extremities involved, with good results.

Based on clinical and lab features of systemic inflammation, evidence of upper airway involvement(bilateral conductive hearing loss and sinusitis on MRI scan), parenchymal lesions on CT chest and strong PR3 positivity, a diagnosis of GPA was made.

**Results:** Our patient responded well to therapy including multiple pulses of high dose methylprednisolone and cyclophosphamide, with improvement of all organs involved and no further digital ischemia.

**Conclusion:** Although GPA is very rare in children, it is associated with high morbidity and mortality. Many studies show that the spectrum of paediatric GPA is not vastly different from adults, except for higher gender bias towards female, more constitutional and musculoskeletal symptoms and higher risk of subglottic stenosis. Although there are a handful of case reports of digital ischaemia in adults with GPA, to our knowledge this is the first case report of acute digital ischaemia in paediatric GPA. Early diagnosis and prompt treatment with a multidisciplinary team approach is paramount for good outcome.

**Disclosure of Interest**
None declared

---

**P281**

**Childhood polyarteritis nodosa – diagnosis using selective visceral angiography**

T. Hospach, F. Blankenburg, F. Głowatzki, C. Stirnkorb, A. Heinkele, T. von Kalle, U. Schweigmann, F. Uhlemann

Olgahospital, Stuttgart, Germany

**Correspondence:** T. Hospach

Pediatric Rheumatology 2020, 18(Suppl 2):P281

**Introduction:** To diagnose polyarteritis nodosa (PAN), either histopathological or imaging evidence of vasculitis is necessary. In our case, the diagnosis could not be confirmed either by histology or by angiography MRI. It was only when conventional selective visceral angiography was carried out that the decisive evidence about the diagnosis was made.

**Objectives:** To report on the difficulties in diagnosing childhood PAN.

**Methods:** Case report: This 10 year old girl with parents of Turkish origin presented with fever up to 40 °C over 14 days, distinct myalgia and cutaneous efflorescences. The general condition was massively impaired, the girl could not turn around in bed without foreign help. The CRP was 24 mg/dl, the ESR 100 mm/h. The girl had microscopic hematuria, the blood pressure was intermittently greater than 95th centile for height. The MRI showed distinct increased signal intensity in the muscles of the lower limbs. Under the suspected diagnosis of PAN, a deep muscle biopsy in the area of the signal intense muscles was performed. However, no arteries were detectable in the biopsy, so that a diagnosis could not be made. The angiography MRI performed afterwards was normal. It was only through conventional selective visceral angiography that the diagnosis could be confirmed by detecting multiple aneurysms.

**Results:** Discussion: To ensure the diagnosis of a PAN, all diagnostic options - including conventional selective visceral angiography - should be consistently exhausted. Therefore a close cooperation between the involved different disciplines is recommended.

**Disclosure of Interest**
None declared
Conclusion: We presented two siblings from a consanguineous marriage with different clinical presentations of DADA2. Further, we emphasize that genetic testing should be repeated in the presence of clinical suspicion.

Disclosure of Interest
None declared

P283
Gastrointestinal Henoch-Schönlein purpura treated with mycophenolate mofetil: description of two case reports
M. F. Gicchino, D. Iafusco, M. M. Marrapodi, R. Melone, G. Cuomo, A. Zaffardino, E. Miraglia del Giudice, A. N. Olivieri
University of the Study of Campania Luigi Vanvitelli, Naples, Italy
Correspondence: M. F. Gicchino
Pediatric Rheumatology 2020, 18(Suppl 2) P283

Introduction: Henoch Schönlein purpura (HSP) is the most common vasculitis in children. HSP prognosis is generally good, recurrence is common among children. Morbidity and mortality are associated with gastrointestinal erosions and nephritis. Treatment is supportive, with control of pain with analgesics. There are retrospective studies that suggest a benefit of steroids to treat abdominal/renal involvement and severe orchitis. Immunosuppressive treatment of HSP nephritis is used in patients with severe renal involvement. There are few data in literature about immunosuppressive treatment of recurrent HSP without kidney involvement.

Objectives: We report the successful use of Mycophenolate Mofetil (MMF) in two patients affected from recurrent gastrointestinal HSP

Methods: Case 1: A 15 years old girl after a pharyngitis presented rash, so she was hospitalized, vasculitis was diagnosed, and steroids treatment was started. At steroids suspension patient presented hematemesis and purpuric lesions, so underwent both to an esophagogastroduodenoscopy that was negative and to a skin biopsy, suggestive of leukocytoclastic vasculitis with IgA deposition. HSP was confirmed and oral prednisone was prescribed. At steroids reduction purpuric lesions, hematemesis, abdominal pain came again, so she came to our observation. She presented purpuric lesions and abdominal pain. Blood tests were unremarkable for: complete blood count, ANA, ENA, ANCA, RF, immunoglobulins, complement C3 and C4. Factor XIII activity was reduced. Virological screening showed IgA deposition. Oral prednisone was prescribed, with initial improvement of symptoms. After few days she presented new purpuric lesions and abdominal pain. Due to the recurrent nature of her symptoms and the lack of a sustained response to steroids, MMF was started and prednisone was gradually tapered in a month.

Case 2: After a respiratory tract infection a 13 years old boy presented purpuric lesions on the limbs with spontaneous resolution in 3 days. After a week purpuric lesions and abdominal pain came again so he was evaluated in emergency department. Abdominal ultrasound was normal, urinalysis revealed proteinuria. HSP was diagnosed, but no treatment was prescribed. Due to the persistence of vasculitic lesions, abdominal pain and the onset of gastrointestinal bleeding patient was hospitalized to our Department. On examination purpuric lesions were detected. Patient referred both abdominal and testis pain. Blood tests were unremarkable for: complete blood count, ERS, CRP, ANA, ENA, ANCA, RF, immunoglobulins, complement C3 and C4. Factor XIII activity was reduced. Virological screening showed IgA deposition. Oral prednisone was administered for three days, then oral prednisone was started. Purpuric lesions, abdominal pain persisted, so we decided to add MMF (600mg/m²/day) and prednisone was tapered in a month.

Results: Thanks to MMF vasculitis lesions and abdominal symptoms disappeared in few days. MMF was continued for a month, tapered in 6 months. There was no evidence of relapse in a 6 months follow up. All clinical manifestations resolved. Multicenter clinical trials with long-term follow up to confirm the efficacy of MMF in the treatment of HSP with gastrointestinal involvement are needed.

Disclosure of Interest
None declared

P284
Henoch-Schönlein purpura complicated by calculus cholecystitis
A. A. Abushaiwia, M. A. Zletni, A. Ateeq, A. Alwaddan, A. Malek
1 pediatric Rheumatology, Tripoli faculty of medicine; 2 pediatric rheumatology, Tripoli university Faculty of Medicine; 3 pediatric department, Tripoli Faculty of Medicine; 4 pediatric department, Tripoli children’s hospital, Tripoli, Libya
Correspondence: A. A. Abushaiwia
Pediatric Rheumatology 2020, 18(Suppl 2) P284

Introduction: Henoch–Schönlein purpura (HSP), the most common childhood vasculitis. Choledocholithiasis is extremely rare in patients with HSP. This is the first case of a Libyan child presenting with HSP complicated by calculus cholecystitis HSP nephritis.

Objectives: Our aim is to present an unusual case of gall bladder involvement in an 8-year-old Libyan female affected by HSP.

Methods: A case reports study

Results: We report an unusual case of gall bladder involvement in an 8-year-old Libyan female with HSP. She was referred to a rheumatology clinic due to HSP with chronic calculus cholecystitis and distended small bowel with fluid-like fecal material with no evidence of intussusception on an abdominal ultrasound.

The patient had a one-month history of abdominal pain, purpuric lesion on lower limbs and swelling in both feet. She was admitted 3 times to another hospital before being referred to the rheumatology clinic. An abdominal sonography revealed a distended small bowel with fluid-like fecal material with no evidence of intussusception and chronic calculus cholecystitis; they treated her with Urosoxycylic acid tab at 250mg per day and ibuprofen syrup. Then referred to our rheumatology clinic. After 40 days, she showed a purpuric rash over her lower extremities, mainly over her thighs and buttocks, microscopic hematuria, no arthritis, no fever, no abdominal pain; her blood pressure was normal at 90/55mmHg, and she had normal laboratory tests (CBC, WBC 7.7, HGB 10.8, Platelets 252 ESR 20ml/hour, CRP 1mg/dl was negative, C4 was 150mg/dl within normal range 90-180mg/dl, C4 was 35.4 mg/dl within normal range 10-40, ANCA, ANA, as well AntidsDNA Ab yielded negative, Antistreptolysin-O (ASO) titer was 250 TdU, LFT included total bilirubin , direct , indirect GPT, GOT, U/E, creatinine ) except urine routine showed mild microscopic hematuria RBC 100 HFP , protein was Nil . Urine for protein/creatinine ratio was 0.16 normal range <0.5 ). An abdominal sonography showed multiple stones, with faint acoustic shadow, the largest of which were 7mm, no signs of acute inflammation. We initially treated her with oral prednisolone tab at 1mg/kg/day and endolipir tal 2.5mg once per day. All clinical manifestations resolved within one week, including normal gallbladder sonography finding, besides microscopic hematuria RBS was 80-85HPF; she had nephrotic syndrome urine protein/creatinine ratio was 1.99 (normal range is <0.5) in spite of taking prednisolone tab for 4 weeks. The treatment with MMF 30 mg/kg/day commenced and the oral prednisolone (2 mg/kg/every other day for 2 months only) after treatment with MMF for two months, microscopic hematuria continued for 3 months and recovery from nephrotic syndrome within 2 weeks. After six months, MMF was discontinued and there was no clinical or laboratory abnormalities. The patient achieved complete remission at the end and after discontinuation of the therapy. There was no evidence of recurrence over one-year follow-up.

Conclusion: Physicians should be aware that HSP might present initially as calculus cholecystitis. Repeat abdominal ultrasonography
is essential in order to detect complications in patients with HSP. MMF was found to be a useful immune-suppressant and effective for maintenance of remission in HSP patients.

Disclosure of Interest
None declared

P285
Inflammatory bowel disease and takayasu arteritis: a case report
R. L. Pybus1, J. Sims2, M. Wood3, N. Tahiri2, V. Zarnvar1
1Paediatric Gastroenterology, Leeds Teaching Hospitals Trust, Leeds;
2Paediatrics, Bradford Teaching Hospitals Trust, Bradford; 3Paediatric Rheumatology; 4Paediatric Radiology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
Correspondence: R. L. Pybus
Pediatric Rheumatology 2020, 18(Suppl 2):P285

Introduction: Takayasu’s arteritis (TA) is extremely rare, especially in childhood, and its occurrence with inflammatory bowel disease (IBD) is even rarer. There have been suspected associations between TA and IBD in adult literature, but only a few paediatric case reports.

Objectives: We describe a case of a girl (X) with Pakistani origin, diagnosed with indeterminate pan colitis, age 4 following her presentation with abdominal pain, weight loss, blood and mucus per rectum. Recapping 2 years later, as steroid dependant, confirmed ulcerative colitis and she subsequently went into remission with Sulfasalazine and Azathioprine. Age 12, X presented with 3 months history of right sided neck pain, fatigue, pain in her lower limbs, intermittent fevers, night sweats and weight loss but no changes in her bowel symptoms. On examination she was pale, tachycardic at 135 bpm, BP 101/61 mmHg with no discrepancy between limbs. She had right sided torticollis despite full range of neck movements.

Methods: X was admitted for pain management and noted to have raised inflammatory markers, anaemia and thrombocytosis. She had a neck ultrasound which revealed evidence of large vessel arteritis. CT angiogram showed arteritis of the thoracic aorta with aneurysmal change with involvement of the proximal arch vessels and proximal superior mesenteric artery; consistent with a diagnosis of Takayasu arteritis. MRI confirmed the findings. X was started on IV pulsed Methylprednisolone 30mg/kg for 3 days followed by weaning dose of oral Prednisolone, weekly SC Methotrexate and low dose Aspirin therapy. Treatment was switched to Mypocenolate Mofetil and later Tocilizumab, due to inadequate control of TA with SC Methotrexate, suggested by blood tests and serial US of large artery walls. Her disease remains stable and Prednisolone has been weaned to 5mg daily.

Results: The exact causative mechanism for both IBD and TA is unclear; however there may be genetic markers which link both diseases. A significantly higher proportion of patients with IBD and TA were HLA-B52 positive compared to TA alone. Other genetic markers including HLA-DR2 and IL-12B have also been shown to be present in both diseases. There are reports that Infliximab has been effective to treat combined IBD and TA; this could support the theory that TNF-alpha may have a role in both conditions leading to mucosal and vessel inflammation. There is currently no NHS England funding pathway for anti-TNF alpha medications for TA, however Tocilizumab can be used.

Conclusion: TA and IBD is extremely rare and requires a high degree of suspicion. Ongoing symptoms of pain, weight loss, fever and high inflammatory markers, in patients with otherwise well controlled IBD, should raise suspicion of alternative pathologies such as Takayasu arteritis. Neck and back pain in this child aided the journey to a diagnosis of TA due to direct pressure effects of enlarged arteries, but these symptoms are unusual. Early diagnosis and prompt treatment are likely to reduce morbidity and mortality in these patients who already suffer a high disease burden.

Disclosure of Interest
None declared

P286
Kawasaki disease in early infancy - case series
K. Rücklová1,2, S. Fingerhutová3, P. Doležalová4
1Faculty Hospital Královské Vinohrady; 2General University Hospital, Prague, Czech Republic
Correspondence: K. Rücklová
Pediatric Rheumatology 2020, 18(Suppl 2):P286

Introduction: Kawasaki disease in infants typically presents as an incomplete or atypical form, which often results in delayed diagnosis and treatment thereby increasing the risk of coronary artery involvement.

Objectives: To draw attention to diagnostic and therapeutic challenges posed by patients with Kawasaki disease manifesting at very early age.

Methods: Medical reports and laboratory and echocardiographic findings of three infants treated at our centre for Kawasaki disease presenting below four months of age were analyzed retrospectively.

Results: The first patient presented at the age of almost four months with fever and shock that required inotropes and artificial ventilation. Due to the atypical presentation the diagnosis was delayed until day seventeen of the illness when the patient developed giant coronary aneurysms and severe mitral valve insufficiency. Another patient manifested at three months of age and fulfilled most of the clinical criteria and received appropriate treatment already on the fifth day of the illness. He exhibited multiple risk factors for an adverse outcome including low age, very high CRP, thrombocytopenia, hyponatremia and hypalbuminemia with pronounced vascular leakage. After administration of IVIG and corticosteroids his clinical condition improved significantly. He was afebrile but his CRP remained mildly elevated and he experienced another flare of the disease within four weeks after the initial treatment with newly formed giant coronary aneurysms. He received adalimumab and pulsed methylprednisolone that finally terminated the inflammation. The last patient manifested at two months with a complete form of Kawasaki disease that prompted timely IVIG treatment. Despite repeated administration of IVIG only partial improvement was achieved and the patient developed giant coronary aneurysms during the second week of illness. Further therapeutic decision was complicated by the patient’s concurrent primary CMV infection.

Conclusion: The first case demonstrates a diagnostic challenge posed by patients presenting with Kawasaki disease shock syndrome. The second patient shows the need for very close follow-up of high risk patients. Even though our patient was afebrile after the initial treatment, his CRP remained elevated and the inflammatory process continued requiring biological therapy and escalation of antiaggregation to anticoagulation. The last patient emphasizes the importance of treating both Kawasaki and the concurrent illness that may potentiate the vasculitis as a trigger.

Supported by Ministry of Health of the Czech Republic, grant nr. NV18-02-00237.

Disclosure of Interest
None declared
Kawasaki disease complicated by macrophage activation syndrome and parvovirus b19 infection: which relationship?

M. G. Magnolia, S. Martelossi, C. Stefanì, L. Da Dalt, G. Martini

1 Pediatric and Neonatologic Unit, “Santa Maria della Stella” Hospital, Orvieto, 2 Pediatric Unit, “Ca’ Foncello Hospital”, 3 Pediatric Unit, “Ca’ Foncello” Hospital, Treviso, 4 Pediatric Emergency Unit, 5 Pediatric Rheumatology Unit, Department of Woman and Child Health, Padova, Italy

Correspondence: G. Martini
Pediatric Rheumatology 2020, 18(Suppl 2):P287

Introduction: Macrophage activation syndrome (MAS) is characterized by massive production of cytokines leading to macrophage activation and haemophagocytosis presenting with prolonged fever, rash, hepatosplenomegaly, pancytopenia, liver dysfunction, hypertriglyceridemia, hyperferritinemia and coagulopathy that can complicate rheumatic conditions such as Systemic Juvenile Idiopathic Arthritis (SJIA) and Systemic Lupus Erythematosus (SLE). Incidence of MAS in Kawasaki Disease (KD) has been estimated in about 1.1% patients but subclinical MAS may be detected in 30-40% of KD.

Objectives: Case description

Methods: A previously healthy 10 years-old girl presented high grade fever for 4 days, pharyngitis and vomiting. After 24 hours, she developed diffuse maculo-papular rash and oedema on extremities. She presented progressive worsening of general conditions and bilateral bulbar conjunctivitis, mucositis with strawberry-like tongue and left cervical lymph nodes enlargement. On admission remarkable laboratory tests were increased C reactive protein (CRP), neutrophilic leucocytosis, low sodium and albumin, increased gGT and gallbladder hydrops on abdominal ultrasound. Suspecting Kawasaki disease 2 g/r kg IVIG were administered with salicylic acid (50 mg/kg/day). Nevertheless, she presented persistent remitting fever, low consciousness, diffuse vasculitic rash, worsening of mucositis and pericardial and pleural effusion. Lab tests showed low haemoglobin, platelets and fibrinogen (9.3 g/L, 65,000/ml and 1.05 g/L, respectively), ferritin 16,492 g/L, SGOT 487 U/L, SGT 351 U/L, triglycerides 345 mg/dl, D-dimers 10.353 microgr/L and soluble interleukin-2 receptor (sIL-2R), 16.492 g/L, SGOT 487 U/L, SGT 351 U/L, triglycerides 345 mg/dl, D-dimers 10.353 microgr/L and soluble interleukin-2 receptor (sIL-2R), 16.492 g/L, SGOT 487 U/L, SGT 351 U/L, triglycerides 345 mg/dl, D-dimers 10.353 microgr/L and soluble interleukin-2 receptor (sIL-2R), 16.492 g/L, SGOT 487 U/L, SGT 351 U/L, triglycerides 345 mg/dl, D-dimers 10.353 microgr/L and soluble interleukin-2 receptor (sIL-2R), 16.492 g/L, SGOT 487 U/L, SGT 351 U/L, triglycerides 345 mg/dl, D-dimers 10.353 microgr/L and soluble interleukin-2 receptor (sIL-2R), 16.492 g/L, SGOT 487 U/L, SGT 351 U/L, triglycerides 345 mg/dl, D-dimers 10.353 microgr/L and soluble interleukin-2 receptor (sIL-2R), 16.492 g/L, SGOT 487 U/L, SGT 351 U/L, triglycerides 345 mg/dl, D-dimers 10.353 microgr/L and soluble interleukin-2 receptor (sIL-2R), 16.492 g/L, SGOT 487 U/L, SGT 351 U/L, triglycerides 345 mg/dl, D-dimers 10.353 microgr/L and soluble interleukin-2 receptor (sIL-2R)

demand of fever, oedema of extremities and skin rash and after 6 days of disease onset. Her blood tests slowly improved and normal values were achieved on day 23. Echocardiogram did not show any coronary aneurism or dilatation, while cerebral MRI was normal and neurological impairment gradually disappeared. The most common vasculitis in our cohort is Kawasaki disease. The number of incomplete KD patients was almost same as complete KD. Almost all our KD patients responded to IV Ig. None of the children with KD developed coronary artery abnormalities. Gastrointestinal complications were seen to be associated with four patients of IgA vasculitis at onset. Two children with IgA vasculitis developed renal complication within 3 months of disease onset.

Trial registration identifying number

1. Review.Indian J Pediatr2010 Sep;77(9):993-6. doi: 10.1007/s12098-010-0134-x. Epub 2010 Sep 3.

The Place of Pediatric Rheumatology in India

1. PratapKumarPatra, ManishKumar
Department of Pediatrics, All Institute of Medical Sciences, Patna, Bihar, India

2. Journal of Natural science,Biology & Medicine-2018
Clinico-epidemiological profile of pediatric rheumatology disorders in Eastern India

Disclosure of Interest
None declared
Table 1 (abstract P288), showed detailed analysis of children with Vasculitis at Dev Children’s Hospital

| Parameter                                 | No (%) of children fulfilled a respective parameter |
|-------------------------------------------|---------------------------------------------------|
| Age < 3 months                            | 1 (33.3%)                                         |
| 3 months- 2 years                         | 8 (29.5%)                                         |
| 2 years-5 years                           | 9 (33.5%)                                         |
| >5 years                                  | 9 (33.5%)                                         |
| Sex: Male                                 | 18 (66.6%)                                        |
| Female                                    | 9 (33.5%)                                         |
| Incomplete Kawasaki disease (KD)          | 8 (29.5%)                                         |
| Complete Kawasaki disease                 | 9 (33.5%)                                         |
| IgA Vasculitis (IgA-V)                    | 10 (37%)                                          |
| Coronary artery involvement in KD patients at onset | None                                               |
| Renal involvement in IgA-V patients at onset | 1 (10%)                                           |
| Gastrointestinal complications in IgA-V patients | 4 (40%)                                           |
| Echocardiography findings at diagnosis in KD | 7 (44%)                                           |
| Pericarditis                              | 15 (88%)                                          |
| Treatment (IV Ig within 12 days of fever in all KD patients) | 2 (12%)                                             |
| Intravenous Immunoglobulin Infusion (IV Ig) – single dose | 2 (KD and IgA-V patient each)                     |
| IV Ig – two doses                         | 9 (IgA-V patients)                                |
| IV methyl prednisolone                    | 0                                                |
| Oral steroids                             | 1 (10%)                                           |
| Coronary artery involvement in KD patients at 2.46 weeks | 1,2,3 months                                      |
| Renal involvement in IgA-V patients at 1,2,3 months | 1,2,3 months                                      |

P289
Autoimmune diseases as non-cardiogenic complications of Kawasaki disease

V. Osterman1, T. Avramoska1, M. Bizjak2, G. Markelj2, M. Pokorn3,4, T. Avčin2,4
1Department of Infectious diseases, University Medical Centre Ljubljana; 2Department of Allergology, Rheumatology and Clinical Immunology; 3University Children’s Hospital, 4Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Correspondence: V. Osterman
Pediatric Rheumatology 2020, 18(Suppl 2):P289

Introduction: Kawasaki disease (KD) is an acute, immune-mediated multisystem vasculitis of unknown etiology that most frequently affects infants and young children. Immunological abnormalities during the acute phase of KD have been described extensively and coronary artery aneurysms (CAA) identified as a main long term complication. The occurrence of non-cardiac, autoimmune complications in patients with history of KD was rarely reported.

Objectives: Our aim was to evaluate the presence of autoimmune diseases (AID) in patients after KD diagnosis and to compare clinical, demographic and laboratory characteristics between patients who developed AID (group 1) and patients who did not (group 2).

Methods: A single-center, retrospective cohort study with longitudinal follow-up of all children newly diagnosed with KD between June 2006 and December 2018 was performed. In total, 151 children (91 males and 60 females, median age 3.4 years) with KD were enrolled. Range of follow up was from 1 to 13 years after KD (mean follow-up 16.8 months).

Results: Of 151 children with KD, 16 (10.6%) developed AID after KD including: 6 juvenile idiopathic arthritis (JIA), 6 macrophage activation syndrome (MAS), 3 coeliac diseases, 1 ulcerative colitis, 1 psoriasis, 1 hypothyroidism and 1 demyelination. Three patients presented with more than one AID. The mean time interval between diagnosis of KD and diagnosis of AID was 30.5 months (range 0.2 – 149 months). We found no difference in age distribution, clinical characteristics and incidence of CAA between the two groups. Group 1 had significantly lower median serum sodium (135 vs 137 mmol/L, p = 0.002), lower median platelet count (262 vs 363 x109/L, p = 0.026) and higher neutrophil to lymphocyte ratio (9.4 vs 4, p = 0.009). There was also significantly higher percentage of IVIG resistance in group 1 (37.5% vs 12.6%, p = 0.022). Moreover, we found that children with KD had twice as many AID compared to CAA on long term follow-up (10.6% and 5.3% respectively).

Conclusion: In our cohort, children with KD had twice as many AID when compared to CAA on long term follow up. Monitoring of children after KD for AID should be considered, especially in patients who were resistant to IVIG treatment. Additional studies are necessary to clarify the possible role of sodium, platelet count and neutrophil to lymphocyte ratio for risk stratification of AID after KD.

Disclosure of Interest
None declared

P290
Clinical features and therapy in children who have granulomatosis with polyangiitis (Wegener’s) in one Russian center

E. Alexeeva1,2, R. Denisova1, T. Dvorovskovskaya1,2, A. Mamutova1, K. Isayeva1, A. Chomahidze1, A. Fettisova1, O. Lornakina1, V. Chibisova1, M. Gautier1, D. Vankova1, L. Krivulin1, E. Krekhova1,2, M. Shingarova1,2
1Rheumatology, National Medical Research Center for Children’s Health; 2Sechenov First Moscow State Medical University, Moscow, Russian Federation

Correspondence: E. Alexeeva
Pediatric Rheumatology 2020, 18(Suppl 2):P290

Introduction: The clinical presentation of Granulomatosis With Polyangiitis (GPA) is often heterogeneous, with frequent involvement of the respiratory tract, the kidney, the skin and the joints. GPA vasculitis is rare in childhood but cohort studies performed during the last decade have clarified their phenotype, patterns of renal involvement and their prognostic implications, and outcome. We provided preliminary data on demographic characteristics and organ manifestations of Russian cohort in one center.

Objectives: To describe demographic characteristics, presenting clinical features, and initial treatments in patients with granulomatosis with polyangiitis (Wegener’s) (GPA).

Methods: The European Medicines Agency (EMA) classification algorithm was applied. The EMA algorithm was used to uniquely distinguish children with GPA from children with other vasculitides, whose diagnoses had been classified according to both adult- and pediatric-specific criteria. Descriptive statistics were used for comparisons.

Results: In total, 15 patients (67% female) fulfilled the classification criteria for GPA (n = 15). The median time to diagnosis was 3.5 months (ranging to 24 and 46 months, respectively). The median age was 13 years. Pulmonary manifestations were in 53 % (n=8) of patients (alveolar hemorrhage (n=2), dyspnea (n=5), chronic cough (n=4), pleural effusion (n=1), lung nodules or cavity (n=3), lung infiltration (n=6). Renal pathologic features were found in 53% (n=8). Eye involvement was in 33% (n=5), ENT involvement was in 67% (n=10), cutaneous involvement was in 26% (n=4). CNS involvement was in 6% (n=1), cardiovascular involvement was in 60% (n=6), musculoskeletal involvement was in 60% (n=9), gastrointestinal involvement was in 13% (n=2), fever, fatigue were in 87% (n=13). All patients with GPA for induction remission received combination therapy with corticosteroids plus immunosuppressive agents
cyclophosphamide (n=4), mycophenolate (n=10), rituximab (n=6), tocolizumab (n=1)), for maintenance therapy - combination therapy with corticosteroids plus immunosuppressive agents (azathioprine (n=5), mycophenolate (n=10), rituximab (n=2)).

Conclusion: GPA is rare disease in childhood. Their clinical presentation is often similar to that adult patients, although some differences exist. Renal involvement drives the prognosis of pediatric GPA. The treatment of pediatric GPA still relies on the studies performed in adults.

Disclosure of Interest
E. Aleseva Speaker Bureau of: Novartis, Pfizer, Sanofi, MSD and Roche, R. Denisova Speaker Bureau of: Novartis, MSD and Roche, T. Dvoryakovskaya Speaker Bureau of: Novartis, Pfizer, MSD and Roche, A. Mamutova Speaker Bureau of: Novartis, K. Itayeva: None declared, A. Chomahidze: None declared, A. Fetisova: None declared, O. Lomakina: None declared, K. Chibisova: None declared, M. Gautier: None declared, D. Vankova: None declared, I. Kirilin: None declared, E. Vrekhova: None declared, M. Shingarova: None declared

P291 Erythrocyte glutathione S-transferase activity in children with Henoch-Schönlein purpura
M. Frkovic1, A. Milarici, S. Srlen, A. Arogao, S. Huljev Frkovic, D. Rogic, M. Jelu
1Department of pediatrics, 2Department for laboratory diagnostics, UHC ZAGREB, Zagreb; 3Department of pediatrics, UHC Split, Split;

Introduction: Henoch-Schönlein purpura (HSP) is the most common vasculitis of the childhood. Among all possible symptoms / complications, nephritis (HSPN) is the main and almost only cause of morbidity and mortality in HSP.

Objectives: The aim of this study was to investigate the value of erythrocyte glutathione S-transferase (e-GST) activity as an early predictor of nephritis development in HSP.

Methods: Ninety-seven children with HSP were enrolled into the study. The control group consisted of 52 children without clinical and laboratory signs of inflammation. In all patients e-GST activity was determined spectrometrically for three times during six-month period and correlated with clinical characteristics of the disease, routine blood and urine laboratory findings as well as with e-GST activity in healthy children.

Results: At the beginning of the disease the e-GST activity values were significantly higher in the group of HSP patients who developed proteinuria above 0.15 g/dU and/or hematuria above 5 E/mm3 were significantly higher in the group of HSP patients who developed proteinuria above 0.15 g/dU and/or hematuria above 5 E/mm3 compared to 5,70 U/g Hb (4,38-7,50 U/g Hb) vs. 3,13 U/g Hb (1,91-4,20 U/g Hb); P<0,001. Similar results were obtained after the comparison of the patients with HSPN and control group: 5,70 U/gHb (4,38-7,50 U/gHb) vs. 3,13 U/gHb (1,91-4,20 U/gHb); P<0,001. There were no statistically significant differences between the group of HSP patients without nephritis and a control group (P=0,837). After the period of three and six months, a decrease of e-GST activity was observed in the HSPN patients, but it was still significantly higher compared to the group of HSP patients without nephritis (P<0,001 / P<0,001).

In the ROC analysis of the e-GST activity determination value in the prediction of HSP nephritis, for the e-GST values >4,1 U/gHb a significant area under the curve (AUC) of 91.1% (P < 0.001) and sensitivity of 90.5% and specificity of 72.7% was found at the beginning of the study. The sensitivity of the nephritis detection tests decreased, and the specificity increased during the follow-up period. No significant correlation between e-GST activity and severity of skin changes, abdominal pain and arthralgia/arthritis, or used therapy was found. Among the routine laboratory tests, a consistent, statistically significant, positive correlation was found only between e-GST activity and the number of erythrocytes per mm3 in urine samples.

Conclusion: e-GST activity is a reliable, independent marker of early nephritis risk assessment in children with HSP. As a sensitive and specific, feasible and inexpensive laboratory test, it has potential practical utility in the diagnostic algorithm and monitoring of the children with HSP.

Disclosure of Interest
None declared

P292 Gastrointestinal manifestations and their association with the risk for renal disease in patients with henoch-schönlein’s purpura
M. Sestan1, N. Kifer1, S. Srsen, A. Arogao, S. Huljev Frkovic, D. Rogic, M. Jelu
1University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb; 2University Hospital Centre Split, University of Split School of Medicine, Split; 3University Hospital Centre Rijeka, University of Rijeka School of Medicine, Rijeka; 4University Hospital Centre Osijek, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek; 5University Hospital Centre Osijek, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek, Faculty of Dental Medicine and Health, Osijek; 6Children’s Hospital Zagreb, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek, Zagreb, Croatia
Correspondence: M. Sestan
Pediatric Rheumatology 2020, 18(Suppl 2):P291

Introduction: Henoch-Schönlein’s purpura (HSP) is the most frequent systemic vasculitis in childhood. Although the disease is most often self-limiting, more than 50% of children may develop gastrointestinal (GI) symptoms, most commonly manifested by nausea, vomiting, and blood in the stool, while in about 10-20% of patients serious complications such as intussusception, bowel perforation, and massive bleeding occur.

Objectives: The aim of this research was to analyze clinical and biochemical parameters in patients with HSP and GI manifestations.

Methods: This retrospective study included children with HSP reviewed in five Croatian University Centers for pediatric rheumatology in the period 2009 to 2019. Differences between categorical variables were examined using the χ² and Fisher exact test, and among the numerical using the Mann Whitney U test.

Results: Out of 611 children with HSP, 320 were males and 291 were females. The overall GI prevalence was 45.9% with a 95% CI of 41.9 to 50% and the median (range) age at diagnosis was 6.42 (4.5-8.83) years. Among patients with GI symptoms there were 1.44 times more males (N = 166) than females (N = 115), which was statistically significant (p = 0.003), higher proportion of patients came from the Mediterranean area (54% vs. 42%, p = 0.007). Patients with GI symptoms had less predramatic infections before the appearance of purpura (59.8% vs. 70.9%, p = 0.005) and less respiratory infections (35.6% vs. 45.2%, p < 0.001), while regarding intestinal infections there was no difference. Patients with GI symptoms were 1.68 times more likely to develop renal symptoms, and if GI symptoms occurred before other symptoms of HSP, then this probability was 3.55 times higher. There was no difference in involvement of the joints and central nervous system, whereas patients suffering from HSP with GI symptoms were found to be significantly more likely to have rash distributed on the trunk (61.9% vs. 48.5%, p = 0.001), and upper extremities (35.2% vs. 24.7%, p = 0.006), as well as generalized rash (38.8% vs. 28.3%, p = 0.008). These patients also had statistically significant higher values of C-reactive protein, leukocyte count, erythrocytes and platelets, hemoglobin, hematocrit and D-dimer concentrations and lower levels of IgG and IgM. In our cohort 42 out of 281
children (14.9%) had the most severe GI manifestations (intussusception and/or massive GI bleeding) with statistically significantly higher values of 24-hour urine protein levels and D-dimer concentrations and lower total serum protein, albumin, IgG, IgM and C3 levels in comparison with children whose GI manifestations were less severe (abdominal pain, vomiting, and blood in the stool).

Conclusion: We detected a group of patients with HSP and GI symptoms that differed in their demographic, clinical, and biochemical characteristics from patients without GI symptoms. This group of patients was found to be significantly more likely to develop renal disease and thus cumulatively have a higher risk of acute and chronic complications of HSP.

Disclosure of Interest
None declared

P293
Does the patients with Kawasaki disease diagnosed before one year of age have distinct presentations?
N. Aktay Ayaz, F. Çakmak, S. G. Karadağ, A. Tanatar, H. E. Sönmez, M. Çakar, F. Demir, B. Sözeri
Pediatric Rheumatology, Istanbul University Medical School; Pediatric Rheumatology, Kanuni Sultan Süleyman Research and Training Hospital, University of Health Sciences; Pediatric Rheumatology, Umraniye Research and Training Hospital, University of Health Sciences, Istanbul, Turkey

Introduction: Kawasaki disease (KD) is one of the most common vasculitidis of childhood. It may present at an early age with atypical findings and even more severe course.

Objectives: In this study, we aimed to examine the clinical and laboratory features of patients diagnosed with KD below one year of age and compare the data with KD patients diagnosed over one year of age.

Methods: The demographic data, clinical features, laboratory findings and treatment modalities of patients diagnosed with KD between January 2009 and January 2019 were reviewed retrospectively. Patients were grouped according to age of presentation as group 1 (diagnosed before 1 year of age) and group 2 (diagnosed after 1 year of age).

Results: The study included 68 patients (37 boys / 31 girls) below one year of age and 97 (60 boys / 37 girls) patients over one year of age. The mean age of diagnosis was 7 months (1-12) in patients under one year and 50 months (12-119) in patients over one year of age. Twenty-six of all patients (41.2%) were atypical KD; 18 of these children were below one year and 8 were over one year of age (p= 0.001). Fifty-eight of all patients (%86.5) were diagnosed with incomplete KD; 34 of these children were in group 1 and 24 were in group 2 (p<0.001). Unilateral cervical lymphadenopathy was obviously more common in group 2 (p<0.001), while aseptic meningitis and BCG scar erythema was significantly more common in group 1. Coronary artery involvement was present in 27 of 68 patients (%39.7) in group 1 and in 15 of 97 patients (%15.4) in group 2 (p<0.001). IVIG resistance was detected in 23/165 (%13.9) of the patients, 12 of whom were in group 1 (p=0.178). In addition to IVIG treatment, steroid therapy was commenced to 17 patients in group 1 and 12 patients in group 2 (p=0.30). Aspirin was started to all patients (40-80 mg / kg / day) and salicylism findings were observed in 3 patients in group 1 and 3 patients in group 2.

We applied Kobayashi, Harada, Egami and Formosa risk score systems for each of the two groups and analyzed the accuracy of each score in detecting high risk patients for coronary artery aneurysms and IVIG resistance. None of the scores could predict high risk patients in both of the groups. When we use Harada score to predict coronary artery involvement it was statistically high in both groups that had CALs (p=0.001).

Conclusion: In our cohort, incomplete KD, atypical KD and cardiac involvement were more common in children diagnosed before one year of age. So, while evaluating patients under 1 year of age, physicians should be aware of the distinctive features of presentation, severe course of disease and follow these patients accordingly.

Disclosure of Interest
None declared

P294
Is Kawasaki disease or systemic juvenile idiopathic arthritis in children with fever without a source?
B. Sozeri1, F. Demir1, T. Metiner1, M. Karacan1
1Pediatric Rheumatology, 2Pediatrics, 3Pediatric cardiology, Health Sciences University, Umraniye Training and Research Hospital, Istanbul, Turkey

Correspondence: B. Sozeri
Pediatric Rheumatology 2020, 18(Suppl 2):P294

Introduction: Fever without a source (FWS) is caused by various diseases, making differential diagnosis difficult. Clinical similarities between Kawasaki disease (KD) and systemic Juvenile Idiopathic Arthritis (sJIA) are well known. Kawasaki disease (KD), a self-limiting systemic vasculitis, remains of unknown etiology and can cause irreversible coronary artery aneurysms (CAAs). SoJIA is sometimes confused with incomplete KD because both diseases have overlapping clinical features and can be accompanied with CAAs and/or sJIA with macrophage activation syndrome (MAS).

Objectives: In this study, the frequency of both KD and sJIA among the patients evaluated with FWS and the clinical features of patients diagnosed with Kawasaki disease.

Methods: Medical records of patients who first visited our department between January 2016 and December 2019 were reviewed

Results: A total of 107 patients were enrolled in this study, including 43 patients (40.2%, 23 males) who fulfilled the criteria of Kawasaki disease and 64 patients (59.8%, 39 males) who did not fulfill them. In patients who fulfilled the criteria of classical FWS, 36(33.6%, 20 males) patients were diagnosed with systemic juvenile idiopathic arthritis. The mean age of the patients with Kawasaki disease was 30.0±20.4 months (median 25 months), the mean age of other patients was 52.6±40 months (median 39.5 months). The mean age of the patients with sJIA patients was 87.6±49.8 (median 80 months). Kawasaki patients were younger than others (p<0.01). There was no difference in gender between groups.

Conclusion: The clinical features of patients with FWS reveal that Kawasaki disease and sJIA can overlap. The most common feature at diagnosis was fever (100%) followed by conjunctival congestion and mucosal changes (69%). The last two findings are more significant in Kawasaki patients than others (p<0.00). Twenty-six (59%) patients had completed KD while 25% had incomplete KD. 7 (16%) patients had atypical KD. The mean fever duration was longer in sJIA patients than KD and others (median 14.8 and 7 days, p<0.00). All patients with KD received IVIG (2 g/kg, infusion in 12 h) and aspirin (60 mg/kg/day). 13.6% of the patients also received oral corticosteroids because of IVIG resistance. Thirty-one patients (72.1%) responded to IVIG treatment, whereas 12 (6 female, 6 male) were IVIG resistant. CAl was detected in echocardiography at diagnosis in 10 (22.7%) (6 female; 4 male) patients. We also detected 4 patients pericarditis with /without CIA.

Conclusion: The clinical presentations of KD and sJIA are quite similar with fever, rash, hepatomegaly, and lymphadenopathy. All 2 entities may provide clues to potentially shared immunopathology.

Disclosure of Interest
None declared
P295
Japanese predictive scores in Slovenian population of children with Kawasaki disease
T. Avramoska1, V. Osterman1, M. Bizjak2, G. Markelj3, T. Avcin3, M. Pokorni3
1Department of Infectious diseases; 2Children’s University Hospital; 3Department of Rheumatology, Children’s University Hospital, University Medical Centre, Ljubljana, Slovenia
Correspondence: T. Avramoska
Pediatric Rheumatology 2020, 18(Suppl 2)P295
Introduction: There are several scoring systems developed in Japan that are clinically used to stratify high risk KD patients and to identify the ones that may benefit from early adjunctive therapy. There are increasing reports from all over the world on poor performance of these scores in other ethnic populations.
Objectives: The aim of our study was to evaluate the Kobayashi, Egami, Sano and Kawamura scores in our population which is homogenous Caucasian.
Methods: Hospital database was retrospectively searched for code M30.3 of the International Classification of Diseases, 10th Revision, Clinical Modification Code: Mucocutaneous lymph node syndrome [Kawasaki], over the period from January 2006 to December 2019. All patients who were seen in this period for the first time for complete or incomplete Kawasaki disease, as defined by the American Heart Association were included.
We applied IVIG resistance prediction scores (Kobayashi, Sano, Egami and Kawamura scores) to our cohort. Only patients who received 2g/ kg IVIG within the first 10 days of the disease were included in this analysis. The scores of prediction models were calculated for each patient and patients were assigned to high- or low-risk group accordingly.
Results: During the study period a total of 169 children were diagnosed with KD (61.5 % males, median age 3.28 years). All of them were Caucasian except one child who was biracial (Caucasian and African American). Among them, 158 children were hospitalized in the acute phase of the disease and 11 children were seen in the subacute phase of the disease. 151 children were followed-up for at least one year to evaluate persistent coronary artery aneurysms (CAA), which were observed in 8 (5.3 %) patients. Among them, 2 were not treated with IVIG and 2 received IVIG after 10 days of illness. 125 patients were treated with IVIG within first 10 days of illness and were included in the calculation of IVIG resistance prediction scores. 24 (19.2 %) were IVIG resistant.
Sensitivity of Kobayashi, Sano, Egami and Kawamura scores were 0.53, 0.47, 0.61 and 0.58, respectively. Specificity of those scores were 0.77, 0.87, 0.75 and 0.58, respectively. We found no difference in demographic or clinical characteristics between IVIG resistant and IVIG responsive patients. Patients with IVIG resistance had significantly higher ALT (p = 0.025), neutrophil-to-lymphocyte ratio (p = 0.036) and lower serum sodium (p = 0.009).
Conclusion: By applying the Japanese scores to our population, we were able to identify most of the low-risk, but missed many of the high-risk patients. Our results are consistent with Caucasian based population studies available to date.
Disclosure of Interest
None declared

P296
Long term outcome of post-varicella arteriopathy in children
S. Signa1, M. Bertamino2, M. Veneruso3, G. Prato3, R. Caorsi1, M. Di Rocco2, G. Losurdo5, A. Zanetti2, D. Tortora7, S. Volpi1, A. Rossi1, P. Morreti4, A. Ravello1, M. Gattorno1, M. Severino7
1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey; 2Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey; 3Department of Rheumatology, Children’s University Hospital, University Medical Centre, Ljubljana, Slovenia; 4Division of Pediatric Rheumatology, Department of Pediatrics, ‘1Division of Pediatric Rheumatology, Department of Pediatrics; 2Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey
Correspondence: U. Kaya Akca
Pediatric Rheumatology 2020, 18(Suppl 2)P296
Introduction: Varicella zoster virus (VZV) related arterial ischemic stroke (AIS) has been described in literature in pediatric age. However, the long-term course of post-VZV vasculopathy need to be inquired: clear information about prevalence of recurrence and severity of clinical outcome are lacking, even if a favorable evolution was initially described, and therapeutic protocols are not currently standardized.
Objectives: We aimed to describe the clinical, laboratory and neuroradiologic features of children affected by AIS due to post-VZV referred to our Institute and to present our experience in their therapeutic management.
Methods: We selected 22 pediatric patients (6 females) with AIS and a CNS confirmed VZV reactivation and/or with a VZV history in the previous 12 months. Other causes of pediatric stroke (systemic disease, cardiac disease, trauma, major thrombophilia) were excluded. Clinical, neuroimaging, laboratory and treatment data were reviewed, focusing on pediatric score outcome measure (PSOM) and executive functions final outcome.
Results: Average age of AIS onset, VZV primary infection and interval between infection and AIS were: 4 years 10mo (range: 1 year and 8 mo-9 years and 11 months), 4 years and 5 months (range 8 months-9.4 years), and 7 months (range 10days-34 months), respectively. The AIS involved the nucleo-capular region in 18 cases, the cerebral cortex in 9 cases, the thalamus in 4 cases, and the caudate in 3 subjects. Seventeen patients had inflammatory focal cerebral arteriopathy (iFCA). Virological confirmation (VZV-DNA or anti-VZV IgG in the cerebrospinal fluid) was obtained in 11 patients. Three patients were treated with trombectomy and one with rTPA. Thirteen patients were treated with antiviral agents associated with steroids in 8 cases, with different administration schedules. Only in one case steroid treatment was given without association with antiviral agents. One patient received a short course of steroid and antiviral treatment at the time of the stroke and then a more prolonged course after six months at the time of the virological diagnosis. Prophylactic antitaggregants were administered to all patients. Mean follow-up was 2 years and 5 months (range 6 mo -10 years) ; iFCA was persistent in 12 cases and transient in 5 subjects. Four patients presented a recurrence of post VZV arteriopathy, two of them presenting new stroke events. Twelve patients presented a variable motor deficit at last follow up. The mean PSOM score of the cohort at the last visit was 1 (range 0-2). Executive functions were evaluated at last follow up in twelve patients, showing no deficit in seven patients, a mild deficit in two patients and a severe deficit in the last three.
Conclusion: Albeit a favourable evolution was initially described, our experience suggests that VZV-related AIS may result in persistent FCA and significant neurological impairment in the majority of cases. Therapeutic approach, particularly involving steroid administration, still need to be validated.
Disclosure of Interest
None declared

P297
Can we predict coronary artery involvement in Kawasaki disease?
U. Kaya Akca1, O. Serin2, E. Arslangolu Aydin2, E. Sag1, S. Demir1, E. Atalay1, M. Kasap Cuceoglu1, E. D. Batu1, Y. Bilginer1, S. Ozen1
1Division of Pediatric Rheumatology, Department of Pediatrics; 2Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey
Correspondence: U. Kaya Akca
Pediatric Rheumatology 2020, 18(Suppl 2)P297
Introduction: Coronary artery involvement is the most important complication of Kawasaki disease (KD). While 25% of the untreated patients develop coronary artery aneurysms, this rate decreases to 3-5% in patients who started treatment rapidly.
Objectives: We aimed to evaluate the clinical and laboratory features that could predict coronary artery involvement in these patients.
Methods: This study included retrospective analysis of patients who diagnosed with Kawasaki disease at the Hacettepe University Children’s Hospital between June 2007 and September 2019. Complete and incomplete KD patients were included in the study.

Results: A total of 129 patients, 79 boys (61.2%), with a median age 36 (IQR 19.5-57.0) months were included in the study. The median duration of fever was 7.0 (IQR 5-10) days. Compleat KD was diagnosed in 87 patients (67.4%). The number of patients with IVIG resistance were 16 (12.4%). Coronary artery involvement was detected in 44 of 129 patients (34.1%). There were coronary artery dilatation (Z score > 2.5) in 14 patients, small aneurysm (Z score > 2.5 to <3) in 18 patients, medium aneurysm (Z score >2 to <1) and maximum dimensional <8 mm in 7 patients, and giant aneurysm (Z score >10, or absolute dimension >8 mm) in 5 patients. Patients with extremity changes had more common coronary artery involvement (p=0.04). We observed a significant association with young age, male gender, high levels of white blood cell count, high lymphocyte count and high lymphocyte percentage. In univariate analysis, male gender, age under 1 year, changes in extremities, and high lymphocyte counts were associated with the coronary involvement (OR: 0.39; 95%CI: 0.176-0.879; p=0.023, OR: 3.873; 95%CI: 1.303-11.507; p=0.015, OR: 0.176; 95%CI: 1.008-6.313; p=0.048, and OR: 1.239; 95%CI: 1.046-1.452; p=0.023, respectively).

Conclusion: Children under 1 year of age and high lymphocyte count as independent risk factors for coronary involvement. Further multivariate analysis identified young age (<1 year of age), male gender, changes in extremities, and high lymphocyte counts had more common coronary artery involvement (p=0.04). We observed a significant association with young age, male gender, high levels of white blood cell count, high lymphocyte count and high lymphocyte percentage. In univariate analysis, male gender, age under 1 year, changes in extremities, and high lymphocyte counts were associated with the coronary involvement (OR: 0.39; 95%CI: 0.176-0.879; p=0.023, OR: 3.873; 95%CI: 1.303-11.507; p=0.015, OR: 0.176; 95%CI: 1.008-6.313; p=0.048, and OR: 1.239; 95%CI: 1.046-1.452; p=0.023, respectively).

Disclosure of interest
None declared
Introduction: Henoch Schonlein purpura or IgA vasculitis (IgAV) is the most common childhood vasculitis which is characterized by nonthrombocytopenic purpura of the skin, gastrointestinal, renal and joint involvement. Skin symptoms can be localized on legs, affecting the glutes, or rarely presented atypically, affecting the head and neck area. In the most severe cases, ulcerations and necroses can be seen.

Methods: In this retrospective study patients with IgAV referred to five tertiary teaching hospitals between 2009 and 2019 were included in the study. The severity and distribution of skin symptoms were classified into four categories: localized only to legs, extended to the gluteal region, generalized, and severe skin symptoms with ulcerations and necrosis.

Results: 611 patients, of which 320 boys and 291 girls with a median age of 6.42 (4.42 - 8.92) years were included in the study. All patients had skin involvements. In 205 (33.72%) patients, only legs were affected, in 207 (34.05%) the gluteal region was affected besides the legs, in 181 (29.77%) the rash was generalized, and 15 patients (2.47%) had the most severe skin symptoms which included ulcerations and necroses.

Patients with generalized (27.68%), and severe skin (28.57%) involvement had almost twice as much relapses compared to patients with legs (16.08%), legs and gluteal (16.1%) affection (p= 0.011).

Patients with more severe skin symptoms had significantly more gastrointestinal symptoms (generalized: 53.59%, necroses and ulcerations: 66.67%, legs only: 36.1%, legs and glutes: 47.83%; p= 0.002), joint involvements (generalized, necroses and ulcerations: 29.08%, legs only: 16.59%, legs and glutes: 21.27%, p=0.01), renal involvement (generalized: 28.18%, necroses and ulcerations: 46.67%, legs only: 21.46%, legs and glutes: 21.46%; p<0.001)

Regarding the treatment, patients with more severe skin involvement needed more corticosteroids (generalized: 52.78%, necroses and ulcerations: 93.33%, legs only: 21.11%, legs and glutes: 34.15%; p<0.001), and immunosuppressants (generalized: 22.2%, necroses and ulcerations: 20%, legs only: 1.97%, legs and glutes: 1.97%; p=0.017).

Conclusion: The prevalence of generalized skin symptoms, as well as the most severe forms in childhood IgAV is much less than the classical findings. However, the more severe the skin symptoms are, the more severe the course of the disease is, and aggressive treatment will be needed.

Support: Croatian Science Foundation project IP-2019-04882.

Disclosure of interest
None declared

P300
Venous wall thickness in Behçet’s disease: can it be a finding supporting our diagnosis?
E. Atalay1, B. Oguz1, E. Sag1, S. Demir1, U. K. Akca1, M. K. Cuceoglu1, E. D. Batu1, Y. Bilginer1, S. Ozen1
1Pediatric Rheumatology, 2Radiology, Hacettepe University, Ankara, Turkey
Correspondence: E. Atalay
Pediatric Rheumatology 2020, 18(Suppl 2):P300

Introduction: Behçet’s Disease (BD) is a systemic inflammatory disease that can involve both the arteries and veins. The lower extremity venous wall thickness (VWT) of patients who were followed with the diagnosis of Behçet’s disease increased significantly compared to healthy controls in two studies conducted in adults.

Objectives: The aim of this prospective study was to investigate the lower extremity VWT in childhood Behçet’s patients and in incomplete BD.

Methods: Pediatric patients classified according to the 2015 international pediatric BD criteria in Hacettepe University Department of Pediatric Rheumatology were included in the study. The control group was age and gender matched healthy children. VWT measurements of the lower extremity veins including common femoral vein (CFV), superficial femoral vein (SFV), vena saphena magna (VSM), vena saphena parva (VSP) and popliteal vein (PV) were recorded.

Results: Venous wall thickness was measured in 20 patients (70% male) and 5 healthy controls (60% male). Eight of 20 patients fully met the criteria for the diagnosis of BD. The remaining 12 had incomplete BD. The median age was 18 (range 9.5-24) years in the BD group and 16 (range 12-17) in the control group. The median VWT values of BD patients were significantly higher than the control group in the right CFV, right superficial FV, right VSM, right PV, left CFV, left superficial FV and left PV (Table 1). Vascular involvement was present in 5 (25%) patients. Of those; sagittal vein thrombus was detected in two patients, thrombus in deep lower extremity veins in two patients and superficial thrombophlebitis in one patient. Venous wall thickness of the right CFV, right FV, left CFV and left FV in patients with vascular involvement were higher than those without vascular involvement. However, the difference was not statistically significant.

Conclusion: The majority of pediatric patients do not meet the full criteria, and are followed with a diagnosis of incomplete Behçet’s Disease. Increased venous wall thickness might serve as a biomarker supporting the diagnosis of Behçet’s disease.

References
Koné-Paut I, Shahram F, Darce-Bello M, et al. Consensus classification criteria for paediatric Behçet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis Published Online First doi:10.1136/annrheumdis-2015-20849
Onfer FA, Ergelen R, Mutsi A et al. Venous vessel wall thickness in lower extremity is increased in male patients with Behcet’s disease. Clinical Rheumatology 2019 https://doi.org/10.1007/s10067-019-04470-z
Seyahi E, Gjoni M, Durmaz ES et al. Increased vein wall thickness in Behçet disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders Volume 7, Issue 5, September 2019, Pages 677-684.e2

Disclosure of interest
None declared

Table 1 (abstract P300). Behçet’s patients (n=20) VWT values (median and IQR) vs healthy controls (n=5) VWT values (median and IQR) respectively.

| Vein Type                  | Median (IQR) VWT | P=       |
|---------------------------|-----------------|----------|
| Right Common Femoral Vein | 0.77 (0.70-0.88)| =0.003   |
| Right Superficial Femoral Vein | 0.67 (0.60-0.75) | <0.02    |
| Right Vena Saphena Magna  | 0.58 (0.46-0.62) | =0.038   |
| Right Vena Saphena Parva | 0.45 (0.38-0.57) | =0.31    |
| Right Popliteal Vein      | 0.65 (0.56-0.74) | =0.025   |
| Left Common Femoral Vein  | 0.78 (0.68-0.86) | =0.025   |
| Left Superficial Femoral Vein | 0.65 (0.55-0.75) | =0.035   |
| Left Vena Saphena Magna   | 0.50 (0.42-0.64) | =0.057   |
| Left Vena Saphena Parva   | 0.40 (0.33-0.58) | =0.185   |
| Left Popliteal Vein       | 0.66 (0.51-0.81) | =0.012   |
P301
The changing epidemiology of kawasaki disease in Eastern India
P. Pal, N. Ahmed
Pediatric Rheumatology, Institute of Child Health Kolkata, Kolkata
700019, India
Correspondence: P. Pal
Pediatric Rheumatology 2020, 18(Suppl 2):P301
Introduction: Kawasaki disease(KD) is an emerging disease in India. Though there is an overall agreement that the disease is on the rise but there is no nation wide data. Publications from Northern India show an overall increase in disease incidence, Institute of Child Health Kolkata is a tertiary care pediatric hospital in eastern India with dedicated pediatric rheumatology services. In this study we have attempted to analyse data of KD patients from the Pediatric Rheumatology Unit of our hospital from April 2009 to April 2020.
Objectives: To evaluate the epidemiology of KD in Eastern India.
Methods: Medical records of 266 children admitted with KD during the study period was evaluated for annual incidence, complete and incomplete KD, incidence of coronary artery abnormalities and IVIG resistance.
Results: 1. A significant rise in the overall incidence of the disease was observed with number of cases doubling over the last 10 years; from 18 in 2009 to 35 in 2018 & 40 in 2019. In 2020, 13 cases have been diagnosed till April.
2. Majority (80%) of the children presented with complete form of KD.
3. Till 2017 the incidence of coronary artery aneurysms (CAA) was 12 to 15%. A rise in the CAA was observed over the last 2 years with 6 cases in 2018 (17%) & 13(32.5%) in 2019. It is interesting to note that majority of the 13 patients in 2019 was diagnosed and administered IVIG within 10 days of disease onset. In the current year, 3 of the 13 children had CAA at diagnosis.
4. There has been a significant increase in IVIG resistant KD. 12 patients with IVIG resistance were recorded from 2009 to 2017. However, in 2018 there were 7 cases (20%) and 8 (20%) in 2019. 5. 10 children over the last 4 years have developed giant aneurysms (z score> 10) inspite of timely initiation of IVIG. 4 of them had persistent ballooning even after Infliximab administration post IVIG.
Conclusion: 1. The number of patients diagnosed with KD has doubled over the last 10 years. Whether it is a true increase in incidence or because of increased detection remains speculative.
2. It seems that the disease is behaving more aggressively with higher incidence of coronary aneurysms and IVIG unresponsiveness inspite of timely IVIG administration.
Disclosure of Interest
None declared

P302
Predictive biomarkers of i IgA vasculitis with nephritis by metabolomic analysis
S. Demir1, M. CELEBİER2, O. KAPLAN1, E. SAG1, Y. BİLGİNER3, I. LAY3, S. OZEN2
1Department of Pediatric Rheumatology; 2 Department of Analytical Chemistry; 3 Department of Pediatric Rheumatology, Department of Biochemistry, Hacettepe University Medical Faculty, Ankara, Turkey
Correspondence: S. Demir
Pediatric Rheumatology 2020, 18(Suppl 2):P302
Introduction: IgA vasculitis/ Henoch Schönlein Purpura (IgAV/HSP) is the most common vasculitis of childhood and renal involvement is the most serious long-term complication. A better understanding of the pathophysiology of the progression to kidney disease is required for better treatment to be achieved and current biomarkers of Ig A vasculitis with nephritis (IgAVN) lack the predictive value.
Objectives: In this study, an untargeted metabolomics approach was performed to reveal the underlying molecular mechanism of disease pathogenesis and to find potential biomarkers of plasma samples from patients with IgAV and IgAVN.
Methods: IgAV was diagnosed according to the Ankara criteria in 2008 (1). Forty-five patients, including 39 active IgAV patients (H), 6 IgAVN (N), and 6 age- and gender- matched healthy controls (C), were enrolled in the study. Plasma samples from subjects were collected on the same day of IgAV(HSP) diagnosis and before steroid or other immunosuppressive treatment initiated. This study has utilized liquid chromatography-mass spectrometry (LC-MS/ Q-TOF) to investigate the alterations in plasma metabolomic profiles. Three separate pools, health controls, active IgAV , and IgAVN were created. Peak picking, grouping, and comparison parts were performed (metabolite profiling) via XCMS (https://xcmsonline.scripps.edu/) software.
Results: Totally 2618 peaks were detected for group H, N and C. Among them 355 peaks were found to be statistically significant and reliable (p<0.05) and 155 of these peaks were found to be changed (fold change >1.5) between the groups C and H. On the other hand, 66 peaks were found to be changed (fold change >1.5) between the groups H and N. The number of the peaks on the intersection of the peaks found to be changed between the groups (C and H) and (H and N) was 39. Based on putative identification results, 15 peaks were matched with 11 metabolites. We found an up-regulated level of DHAP(18:0), prostaglandin D2/I2, 5-methyltetrahydrofolic acid, porphobilinogen and N-Acetyl-4-O-acetylenuraminic acid/N-Acetyl-7-O-acetylenuraminic acid, 5-Aminopentanamide /5-Aminopentanoic acid, Glycocholic acid, Saccharopine, N2-Succinyl-L-ornithine, gamma Tocopherol, and Galactosylsphingosine /Glucoylsphingosine in IgAV patients.
Conclusion: In conclusion, we have identified a number of metabolites that may be associated with the pathogenesis of IgAV. We also suggest that DHAP (18:0), prostaglandin D2/I2, porphobilinogen, 5-methyltetrahydrofolic acid and N-Acetyl-4-O-acetylenuraminic acid/N-Acetyl-7-O-acetylenuraminic acid may serve as biomarkers for predicting kidney disease since they were increased only in the patients who developed renal involvement at follow-up.
Grant Support: This work was supported by Hacettepe University Scientific Research Coordination Unit
Disclosure of Interest
None declared

P303
Spatial analysis of childhood IgA-vasculitis in Croatia – a pilot study
M. Sapina1, M. Frukovic2, M. Sestan3, S. Srsen4, A. Ovuka5, M. Batnozic Varga5, N. Kifer5, K. Kramaric6, D. Brdaric7, K. Milas8, A. Gagro8, M. Jelusic2
1University Hospital Centre Osijek, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek, Faculty of Dental Medicine and Health, Osijek; 2University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb; 3University Hospital Centre Split, University of Split School of Medicine, Split; 4University Hospital Centre Rijeka, University of Rijeka School of Medicine, Rijeka; 5University Hospital Centre Osijek, Josip Juraj Strossmayer University of Osijek, Medical Faculty; 6University Hospital Centre Osijek, Josip Juraj Strossmayer University of Osijek, Faculty of Dental Medicine and Health Osijek; 7Children’s Hospital Zagreb, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek, Zagreb, Croatia
Correspondence: M. Sapina
Pediatric Rheumatology 2020, 18(Suppl 2):P303
Introduction: Henoch-Schönlein purpura or IgA vasculitis (IgAV) is the most common childhood vasculitis. Although the etiology of IgAV is still unclear, however, it seems that a combination of genetic and environmental factors may contribute. Spatial analyses have previously been used in the analysis of infectious diseases spreading, and several researches showed promising applications in non-communicable diseases.
Objectives: To estimate the incidence and describe the spatial distribution of the incidence of IgAV in Croatia.
Methods: In this retrospective pilot study patient’s data were collected over a six-year period between 2013 and 2019 in five
tertiary hospitals in Croatia. The average annual incidence of IgAV was calculated with the population census data from 2011 as the denominator. To investigate the spatial distributions of IgAV, a choropleth map was created based on the raw and Bayesian adjusted incidence data.

Results: A total of 402 domestic patients were included in the study, of which 223 (55.47%) were male, and 179 (44.53%) were female, with a median age of 6.42 (4.5 to 9.08) years. The estimated average annual incidence was 8.4 with a 95% confidence interval between 6.51 to 10.66 per 100 000 children. As expected, the raw data showed that the highest number of cases was detected in administrative areas with a higher population. A statistically significant higher percentage of patients came from the continental (69.15%), when compared to the Mediterranean part (30.85%), p < 0.001. Box maps and standard deviation maps showed with incidences higher (hot-spots) and lower (cold-spots) than the average annual incidence. However, when the standardized average annual incidence was plotted, the spatial distribution correlates with the location of higher incidence levels. Therefore, the spatial distribution pattern showed the existing of hot-spot clusters with higher incidences around large cities both in the continental, and Mediterranean part of Croatia.

Conclusion: This pilot study investigated the usefulness in expanding the epidemiological toolbox with applying spatial analyses. The results of this study suggested that the IgAV incidence might be clustered in space. However, for a more definitive conclusion, a geostatistical analytical approach is needed to evaluate the significance of observed clusters.

SUPPORT: Croatian Science Foundation project IP-2019-04-8822.

Disclosure of Interest
None declared

**P304**
Eleven children with primary angiitis of the central nervous system: the experience of a single center
T. Giani1,2, G. Abbati3, M. Mortilla3, G. Simonini3, A. Rosati4
1Rheumatology Unit, AOUMeyer, Florence; 2Department of Medical Biotechnology, University of Siena, Siena; 3Radiology Unit; 4Neurosurgery Unit, AOUMeyer, Florence, Italy
Corespondence: T. Giani
Pediatric Rheumatology 2020, 18(Suppl 2):P304

Introduction: Childhood primary angiitis of the central nervous system (cPACNS) is a rare condition, whose clinical presentation may embrace a large, but non-specific range of manifestations. To investigate the spatial distributions of IgAV, a choropleth map was created based on the raw and Bayesian adjusted incidence data.

Results: A total of 402 domestic patients were included in the study, of which 223 (55.47%) were male, and 179 (44.53%) were female, with a median age of 6.42 (4.5 to 9.08) years. The estimated average annual incidence was 8.4 with a 95% confidence interval between 6.51 to 10.66 per 100 000 children. As expected, the raw data showed that the highest number of cases was detected in administrative areas with a higher population. A statistically significant higher percentage of patients came from the continental (69.15%), when compared to the Mediterranean part (30.85%), p < 0.001. Box maps and standard deviation maps showed with incidences higher (hot-spots) and lower (cold-spots) than the average annual incidence. However, when the standardized average annual incidence was plotted, the spatial distribution correlates with the location of higher incidence levels. Therefore, the spatial distribution pattern showed the existing of hot-spot clusters with higher incidences around large cities both in the continental, and Mediterranean part of Croatia.

Conclusion: This pilot study investigated the usefulness in expanding the epidemiological toolbox with applying spatial analyses. The results of this study suggested that the IgAV incidence might be clustered in space. However, for a more definitive conclusion, a geostatistical analytical approach is needed to evaluate the significance of observed clusters.

SUPPORT: Croatian Science Foundation project IP-2019-04-8822.

Disclosure of Interest
None declared

**P305**
Infliximab in Kawasaki disease: sharing an experience over 4 years
P. Pal, M. Roy
Pediatric Rheumatology, Institute of Child Health Kolkata, Kolkata 700017, India
Correspondence: P. Pal
Pediatric Rheumatology 2020, 18(Suppl 2):P305

Introduction: Tumor Necrosis Factor (TNF-α) blocker Infliximab (IFX) is emerging as an important drug in management of Kawasaki Disease (KD). This study was undertaken to evaluate the effectiveness of IFX in severe KD on 33 children over a period of 4 years (2015 to 2019).

Objectives: 1. Determine effectiveness of IFX in IVIG resistant KD.
2. Evaluate response on developing/ increasing coronary artery aneurysms (CAAs).

Methods: The study was carried out in the pediatric Rheumatology Unit of the Institute of Child Health Kolkata, India. 33 children aged between 6 weeks to 7 years with KD were included who received IFX after 1-2 doses of IVIG due to persistent fever/ increasing CAA or developing new CAA. Patients were analyzed for response in terms of achievement of defervescence in hours, normalization of CRP and improvement in echocardiographical findings specially CAAs. Children with severe CAAs were followed up by echocardiography weekly upto 6 weeks, monthly upto 3 months, and then 6 monthly.

Results: IFX was used in 1) IVIG resistant fever(23/33) and 2) increasing CAAs post IVIG (15/33). Overlapping indications ie. IVIG resistance with increasing CAAs were also present (7/33) IFX was administered at 5mg/kg and defervescence was achieved within 24 hours in all of the 23 resistant cases along with normalization/ drastic fall in CRP. 2 children whose fever persisted was later diagnosed as Systemic Arthritis and hence excluded from the study.

Diminution in size of aneurysm was seen in 80 % (12 out of 15) cases on follow up, giant aneurysms being converted to medium or small sized aneurysms over 6 to 18 months. Interestingly 50% reduction in the aneurysm size was noted in 60% (n=9) within first 6 months of administration.

**P306**
Diminution in size of aneurysm in Kawasaki disease
P. Pal, M. Roy
Pediatric Rheumatology, Institute of Child Health Kolkata, Kolkata 700017, India
Correspondence: P. Pal
Pediatric Rheumatology 2020, 18(Suppl 2):P306

Introduction: Tumor Necrosis Factor (TNF-α) blocker Infliximab (IFX) is emerging as an important drug in management of Kawasaki Disease (KD). This study was undertaken to evaluate the effectiveness of IFX in severe KD on 33 children over a period of 4 years (2015 to 2019). Objectives: 1. Determine effectiveness of IFX in IVIG resistant KD. 2. Evaluate response on developing/ increasing coronary artery aneurysms (CAAs).

Methods: The study was carried out in the pediatric Rheumatology Unit of the Institute of Child Health Kolkata, India. 33 children aged between 6 weeks to 7 years with KD were included who received IFX after 1-2 doses of IVIG due to persistent fever/ increasing CAA or developing new CAA. Patients were analyzed for response in terms of achievement of defervescence in hours, normalization of CRP and improvement in echocardiographical findings specially CAAs. Children with severe CAAs were followed up by echocardiography weekly upto 6 weeks, monthly upto 3 months, and then 6 monthly.

Results: IFX was used in 1) IVIG resistant fever(23/33) and 2) increasing CAAs post IVIG (15/33). Overlapping indications ie. IVIG resistance with increasing CAAs were also present (7/33) IFX was administered at 5mg/kg and defervescence was achieved within 24 hours in all of the 23 resistant cases along with normalization/ drastic fall in CRP. 2 children whose fever persisted was later diagnosed as Systemic Arthritis and hence excluded from the study.

Diminution in size of aneurysm was seen in 80 % (12 out of 15) cases on follow up, giant aneurysms being converted to medium or small sized aneurysms over 6 to 18 months. Interestingly 50% reduction in the aneurysm size was noted in 60% (n=9) within first 6 months of administration.
Conclusion: 1. IFX showed remarkable success in rapidly lowering the inflammation (fever and CRP) in IVIG resistant patients. Superiority over 2nd dose IVIG cannot be commented though 2 patients were enrolled who had failed to respond to the 2nd dose IVIG. 2. Majority of patients with developing or increasing aneurysms receiving IFX post IVIG showed diminution in size on follow up.

Limitations:
1. The number of patients is relatively small and there was no control arm.
2. Coronary angiographic corroboration of the echocardiographic findings could be performed in only 2 of the patients.

Disclosure of Interest
None declared

P306
Systematic review of childhood-onset polyarteritis nodosa and DADA2
M. Kasap Cuceoglu, S. Demir, E. Sag, U. Kaya Akca, E. Atalay, E. D. Batu, Y. Bilginer, S. Ozen
Pediatric Rheumatology, Hacettepe University, Ankara, Turkey

Introduction: Polyarteritis nodosa (PAN) is a vasculitic disease characterized primarily by necrotizing vasculitis that may present with fever, weight loss, severe muscle and joint pains, and abdominal pain. Effective treatment is now available for PAN.1

Objective: We aimed at assessing the characteristics of childhood-onset PAN in our center in the last ten years along with a systematic review.

Methods: We reviewed the charts of all pediatric PAN patients from 2010 onwards, in the Department of Pediatric Rheumatology in Hacettepe University, Ankara, Turkey. 47 pediatric patients who had fulfilled the Ankara 2008 for PAN, were included in the study.2 The demographics, clinical findings and treatment were evaluated. A systematic literature review was conducted by using keywords ‘Polyarteritis Nodosa’ and ‘childhood’ in PubMed databases in the English literature.

Results: 12 children had cutaneous PAN, 18 patients had systemic PAN. After 2014, 17 patients who we had originally classified as PAN, were diagnosed as DADA2. Skin involvement (86%) was the most common feature of PAN, followed by abdominal pain (73%), arthralgia/arthritis, weight loss, renal and neurologic involvement. Cutaneous PAN patients were treated with corticosteroids. In systemic PAN both IV cyclophosphamide and mycophenolate mofetil were used for the induction phase. None of the patients died. All patients were ANCA negative. MEFV mutations were screened among 20 patients, 17 of them had mutations in at least one allele. Biopsy was performed in 21 patients and angiography was performed in 33 patients.

The literature review yielded 937 articles about PAN, 170 articles in childhood.

Conclusion: Early recognition and treatment accounts for a good prognosis in childhood PAN. A careful attention must be given to DADA2 in the differential diagnosis, since the DADA2 patients also meet both the Ankara 2008 and ACR criteria for PAN and have mimicking features.

References
1. De Virgilio A, Greco A, Magliulo G, et al. Polyarteritis nodosa: A contemporary overview. Autoimmun Rev. 2016;15(6):564-570.10.1016/j.autrev.2016.02.015
2. Ozen S, Pistorio A, Iusan SM, et al. EULAR / PRINTO / PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis : Ankara 2008. Part II : Final classifi cation criteria. 2010(1):798-806. doi:10.1136/ ard.2009.116657

Disclosure of Interest
None declared

P307
PRES vasculitis working party annual report for 2020 year
M. Jelusic, on behalf of the PRES Vasulitis Working Party, D. Elefteriou1, T. Giani1, E. D. Batu, N. Martin2, M. Sestan3, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia; 2 UCL Great Ormond St Institute of Child Health, London, United Kingdom; 3 Anna Meyer Children's Hospital, Florence, Italy; 4 Ankara Training and Research Hospital, Ankara, Turkey; 5 Royal Hospital for Children, Glasgow, United Kingdom

Correspondence: M. Jelusic

Pediatric Rheumatology 2020, 18(Suppl 2):P307

Introduction: The PRES Vasulitis Working Party is an international group of clinicians, scientists and trainees with about 50 members, and its main goal is to facilitate translational research in the field of vasculitis of the young. This encompasses basic science with potential to improve patient care, molecular genetics, clinical trials (investigator led and industry sponsored) and clinical guidelines.

Objectives: Current activities of this Working Party are divided into three areas: educational activities, activities for clinical care and activities in science and research.

The main educational activity includes endorsement of the First European Congress on Kawasaki Disease EURO – KDs Congress from 14 to 16 January 2021 in Paris, France. A two-day main meeting aimed to update on clinical innovation, recommendations, basic science and sharing clinical experiences. We have applied for the PReS Educational Course ‘Vasculitis in paediatric age’, which is planned to be held in Barcelona in March 2022.

Activities for clinical care include: implementation of existing diagnostic and treatment recommendations into clinical practice and development of new recommendations with translations to other languages; encouraging the application of clinical questionnaires in assessing the quality of life and disease activity; encouraging the issuance and use of brochures and educational materials for patients and their family members that will be available online; connection with organizations of patients to better understand their needs; developing web-based platform for healthcare professionals with virtual panels in order to discuss difficult cases in the field of vasculitis with the possibility of sharing medical imaging.

Currently there are three ongoing scientific projects. The first project entitled "Comparison of pediatric criteria with adult classification criteria in granulomatosis with polyangiitis" is a multicentre study which will include at least 2 patients with granulomatosis with polyangiitis per center, and 2 controls (patients with other primary systemic vasculitis or mimicks such as sarcoidosis) per 1 granulomatosis with polyangiitis patient. For further information please contact principal investigator of the project, Prof. Seza Ozen (sezaozen@gmail.com). The second project entitled "Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms in Kawasaki disease" is a multicentre European study (funding already approved) to establish the efficacy and safety of added corticosteroids to IVIG and aspirin for treatment of Kawasaki disease. It aims to recruit 262 children over 30 months from around 40 centres in 12 countries. Chief investigators of the project are Dr. Despina Elefteriou (d.elefteriou@ucl.ac.uk) and Prof. Paul Brogan (p.brogan@ucl.ac.uk). The third project entitled "Histological predictors of outcome in patients with Henoch-Schönlein purpura and nephritis" is a multicenter, multinational study which aims to compare the International Study of Kidney Disease in Children, Haas, Oxford and modified semiquantitative classification for their ability to predict the clinical outcomes in Henoch-Schönlein purpura and to establish which variables of each histological classification most significantly predict renal outcome/have the strongest association with unfavorable outcome. The principal investigator of this project is Prof. Marija Jelusic (marija.jelic@gmail.com).

Disclosure of Interest
None declared
AB001  
A case of myositis in a patient with possible familial Mediterranean fever, successfully treated with colchicine  
S. Arikanosyan1, A. Alyazyan2  
1Rheumatology, Yerevan State Medical University; 2Internal Medicine, Muratyan clinic, Yerevan, Armenia  
Correspondence: S. Arikanosyan  
Pediatric Rheumatology 2020, 18(Suppl 2):AB001

Introduction: Although Myalgia in FMF is quite common, reported cases of Myositis in FMF are rare.  
Objectives: To report an unusual clinical presentation of possible FMF.  
Methods: A 18 year old, male patient was admitted to the clinic, complaining of severe bilateral calf muscle pain. No edema or erythema was visible. No chest or abdominal pain was mentioned. Peripheral joints were not swollen, range of motion was preserved. His parents mentioned that this was his second episode of calf muscle pain, but no documented evidence was present. Body temperature was 37.5°C. On laboratory tests - CRP: 50 mg/L, ESR: 30 mm/h, transient mild proteinuria, Creatine phosphokinase 1995 U/L. A number of viruses (AIDS, Hep.B, C, etc.) was excluded. On EMG - definite pathological myopathy-like changes were visible. Muscle biopsy was not performed due to technical problems. Genetics - his uncle has definite diagnosis of FMF, MEFV gene mutation test revealed M604V/N genotype.  
A possible diagnosis of FMF by Tel-Hashomer criteria was made. Colchicine 1 mg/day was prescribed.  
Results: A total clinicolaboratory remission on Colchicine 1mg/day was achieved.  
Conclusion: Several types of Myalgia can occur in FMF patients. Exertional, spontaneous and protracted febrile myalgia syndrome are quite common. In all these cases CPK level and EMG are normal. So, we report an unusual case of Myositis in possible FMF, treated by Colchicine.

Disclosure of Interest  
None declared

AB002  
Abdominal syndrome in a monogenic autoinflammatory disease - not only a familial Mediterranean fever  
S. Salugina, E. Fedorov  
V. A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation  
Correspondence: S. Salugina  
Pediatric Rheumatology 2020, 18(Suppl 2):AB002

Introduction: Manifestations of the gastrointestinal tract (GIT) (abdominal pain, nausea, vomiting, diarrhea) are frequent symptoms of autoinflammatory diseases (AID). Acute abdominal pain occurs in 95% of patients with FMF and not rarely leads to unreasonable surgical interventions. This symptom is included in the diagnostic criteria for FMF. However, abdominal pain may be a serious symptom in patients with TRAPS, leading to occurrence of severe complications (peritonitis, peritoneal commissures, intestinal perforation) and emergency surgeries. The core targeted drug in the treatment of TRAPS is IL-1 inhibitor - Canakinumab, that prevents development of organ-lesions, including gastrointestinal disorders.  
Objectives: To present a female patient with genetically confirmed TRAPS, suffering in addition to standard manifestations (fever, rash, periorbital edema, arthritis, acute phase markers), from profound abdominal pain during seizures, formation of severe adhesive disease, which led to perforation of the intestine and an emergency surgical intervention.  
Methods: Case report  
Results: A female patient P., aged 13, for the first time was admitted to the Federal Rheumatology Center in March 2015 with complaints of intermittent episodes of fever, rash, periorbital edema, arthritis, and abdominal pain lasting for 10-20 days every 2-3 weeks. From the disease anamnesis: she has been sick almost from the birth, as episodes of a macular rash began to occur. From the age of 3 months, monthly fever up to 39.6-40.4°C, lasting for 10 days (sometimes even up to 20 days), accompanied by a confluent macular and annular rash, myalgia, arthralgia, conjunctivitis, periorbital erythema, a significant increase in acute phase markers (ESR, CRP), ANA, RF, negative. During the hospitalization period, 2 disease recurrences were noted, with febrile fever up to 40.4°C, erythematous rash, conjunctival hyperemia, periorbital erythema, myalgia, arthritis, profound abdominal pains. ESR: 43 mm/h, leuk: 23.5, CRP: 211 mg/l (normal ≤ 5). The use of pulse therapy of GS by a single intravenous administration interrupted the attack. The patient's condition between the attacks is relatively satisfactory. A molecular-genetic study was conducted: by the direct sequencing method a partial analysis of the TNFRSF1A gene was performed. In exon 3, a single nucleotide substitution c295T>C (pCys99Arg) in a heterozygous state was detected. The TRAPS diagnosis was confirmed. Canakinumab was prescribed in a dosage of 150 mg once every 4 weeks, which led to relief of the disease main manifestations and improvement of lab tests. An increase in the interval up to 8 weeks and interruptions in treatment resulted in acute exacerbations with fever, rash, increase CRP, ESR, diarrhea, nausea, vomiting, abdominal pains. In November 2018: an acute exacerbation, acute abdominal pains, increase in ESR level up to 82 mm/h, CRP up to 31 mg/dl (normal ≤ 0.5), Hb – 8.7 g/dl. In December 2018, an emergency laparotomy was performed - perforation of the transverse colon, widespread serofibrinous peritonitis, massive adhesion process in the abdominal cavity were diagnosed. Treatment with Canakinumab re-initiation starting from January 2019 led to a complete relief of clinical manifestations, abdominal symptoms and normalization of ESR, CRP.  
Conclusion: Treating patients suffering from severe gastrointestinal manifestations during seizures, it is necessary to consider not only FMF, but also other autoinflammatory diseases, including TRAPS. Well-timed prescribed targeted therapy, strict adherence to the dosage and intervals between drug administrations, as well as a proper monitoring may help prevent severe gastrointestinal disorders and eliminate them in a prompt manner.

Disclosure of Interest  
None declared

AB003  
Severe glomerulonephritis complicating traps syndrome  
P. Mesa-Del-Castillo B1, M. J. Lorente Sánchez2, J. A. Piñero2, C. Vicente Calderón2, J. M. de la Peña Moral1  
1Pediatric Rheumatology; 2Pediatric Nephrology; 3Pathology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain  
Correspondence: P. Mesa-Del-Castillo B  
Pediatric Rheumatology 2020, 18(Suppl 2):AB003

Introduction: TRAPS is an autosomal dominant autoinflammatory disease. To date no severe inflammatory glomerular lesions leading to renal failure have been described associated to disease or its treatment. We present a case of severe glomerulonephritis in a TRAPS patient in treatment with IL-1 blocker canakinumab.

Objectives: To describe the clinical features, treatment and outcome of an acute renal failure due to glomerulonephritis in a 5 year old toddler who was under treatment with IL-1 blocker canakinumab.  
Methods: A retrospective chart review was conducted to extract clinical, laboratory, histology and evolutive data of the patient.  
Results: A previously steady 5 year old male in chronic treatment with canakinumab 4 mg/Kg for a TRAPS due to an heterozygotic de novo mutation in TNFRSF1A p.(Cys43Tyr), presents in emergency room with a 12 hour macrohematuric oligoanuria and generalized oedema. He referred an auto limited febrile spike two weeks before, and a few days vomiting and nausea previous to consultation. Initial exams showed renal injury with urea 227 mg/dl and creatinin 4.24 mg/dl, hematuria, leucocituria and nephrotic range proteinuria (3.7 mg/Cr mg) with normal seric albumin, compatible with acute glomerulonephritis. Autoimmunity, lupus anticoagulant, and rheumatoïd factor were negative, serology was normal apart from antistreptolysin O titres of 1663 UI/L. Levels of C4 were normal and...
A 12-year-old female patient, whose parents refer for recurrent episodes of fever (38-39.5ºC), that are accompanied with diffuse joint disease, skin rash and abdominal pain. The fever episodes have a duration of 4-6 days, they begin from the first year of life and appear periodically throughout the whole life. The mutation in the HIDS leads to a decrease in the activity of mevalonate kinase, an enzyme important for cholesterol synthesis, and febrile episodes can further decrease this activity. Thus, during these episodes high levels of mevalonic acid can be found on blood serum and urine.

Objectives: Case presentation, a child with HIDS

Methods: A 12-year-old female patient, whose parents refer for recurrent episodes of fever (38-39.5ºC), that are accompanied with diffuse joint disease, skin rash, oral aphthous lesions and abdominal pain. The episodes had begun nearly at 18-months-old with a duration of 3-5 days up to 6-years-old. Then again at 11-years-old. The fever episodes did not improve with the use of antibiotics, NSAIDs, CS or antipyretics. The mother had a normal pregnancy, the child was born on term and the psycho-motor development was conform the age.

Results: In the examination performed during the febrile episodes the patient did have joint pain on pressure, non itchy skin rash in the abdomen and inferior limbs, appearing during the fever but that endure even outside the febrile episodes. Aphthous lesions can be seen on tongue and soft palate. Moreover, on painful, mobile nodules of 1-1.5 cm can be palpated in the cervical, axillary and inguinal area. Spleen at the level of iliac crest. In the laboratory evaluation: inflammatory anemia in the blood test and a mild leukocytosis, (WBC 14x10³, RBC 3.12x10⁶, HgB 10.7 mg/dL) with an ESR of 67 mm/h and a CRP of 0.95 mg/dL. First day after admission a drug refractory hypertensive, metabolic acidosis and hyperpotasemia developed, requiring admission in intensive care unit for veno-venous continuous hemofiltration (HDFVC). Metil prednisolone bolus (1g/1.73 m²) every 48 hours were initiated and a renal biopsy performed, showing generalized endocapillary proliferation with neutrophil infiltration and exclusive abundant mesangial pseudodinole deposits of C3 on immunofluorescence, no signs of amyloidosis. After five days of HDFVFC and two metilprednisolone bolus, oral prednisone (2mg/Kg) was initiated and a 10 day course of amoxiciline administered. Evolution was satisfactory thereafter, at two months follow-up visit only minimal hematuria (5-10 ertroctes/field) persisted, with normal renal function, complement levels, prednisone 2.5 mg every 48 hour and no hypertensive drugs required; canakinumab was reinitiated 8 weeks after renal failure, no further major events occurred up to date.

Conclusion: We present a case of acute severe postinfectious glomerulonephritis in a TRAPs patient, presumably poststreptococcal. This is to our best knowledge the first case reported and questions arise on the possible association of this severe event to TRAPs syndrome, ongoing treatment or just an unfortunate coincidence. Differential diagnosis was mandatory to discard a rapidly progressive glomerulonephritis and renal amyloidosis in this context. Mild and generally transient proteinuria and creatinine clearance reduction have been reported in association with canakinumab treatment but to no acute glomerulonephritis has been previously described.

Disclosure of Interest
None declared
9.7mg/dl, MCV 86 fl, ESR 40mm/h). The biochemical profile within range. In the blood and urine culture no pathogenic increase were found. Febrile infectious antigens were negative. Bone marrow examination was normal. Immunological evaluation: FR neg, AAN neg, ENA neg, ANCAp/c neg, C3-C4 within the range, PCR 9.6(<5UI/ml). Protein electrophoresis revealed an increase in α1. Immunoelectrophoresis revealed an increase in IgD 350UI/ml(100UI/ml). Blood ferritin level was 60mg/dl (20-50mg/dl). Head MRI was normal. In the abdominal CT with contrast infusion, cervical, axillary and inguinal nodules of 1-2 cm can be seen, liver of 16 cm without any visible lesions and homogenous spleen of 13.4 cm. The data of lymphocyte immunophenotyping of peripheral and central blood within the range, no pathological lymphocytic populations were found. Nothing abnormal was found during node biopsy, HLA-B27 neg, HLA-B51 neg. The level of mevalonic acid in urine resulted 130.8 mmol/ml (<69mmol/ml).

Discussion: For the case the diagnostic differentiation between several diseases was made, including lymphoproiferative disorders (the data of bone marrow examination, biopsy and lymphocyte immunophenotyping did not support the diagnosis), infectious diseases (the data of febrile antigens were negative and febrile episodes were not affected by use of antibiotics), JRA- Still’s disease (blood ferritin slightly increased and recurrent febrile episodes that resolve by themselves), inflammatory connective tissue disease (FR, AAN, ENA, HLA-B27, HLA-B51 neg).

Conclusion: Since all other diseases were ruled out and both the level of IgD in blood and the level of mevalonic acid in urine were found to be elevated, besides the periodic febrile episodes and clinical symptoms, the patient was diagnosed with HIDS. In all patients with periodic febrile episodes the electrophoresis of immunoglobulins should be performed and also the evaluation of mevalonic acid both in blood and urine.

Disclosure of Interest
None declared

AB006
The evaluation of calcium metabolism and bone mineral density in patients with CAPS
S. Kılıç, S. S. Kılıç
1Pediatric Immunology and Rheumatology, Uludağ University Faculty of Medicine; 2Uludağ University Faculty of Medicine, Pediatric Immunology and Rheumatology, Bursa, Turkey
Correspondence: S. S. Kılıç
Pediatric Rheumatology 2020, 18(Suppl 2):AB006

Introduction: Cryopyrin-associated periodic syndrome (CAPS) includes a group of genetic conditions, caused by dominantly inherited mutations in the NLRP3 gene in Muckle-Wells syndrome (MWS) and familial cold autoinflammatory syndrome (FCAS), and de novo mutations in the NLRP3 gene in Muckle-Wells syndrome (MWS) and de novo mutations in the NLRP3 gene in Muckle-Wells syndrome (MWS) and de novo mutations in the NLRP3 gene in Muckle-Wells syndrome (MWS)

Methods: Eight patients with MWS were included in the study. The clinical data were obtained from the file records of patients, retrospectively. Calcium (Ca), Phosphorus (P), Magnesium (Mg), Alkaline Phosphatase (ALP), 25 OH vitamin D, and bone mineral densimetry (BMD) tests were performed in all cases, but parathyroid hormone (PTH) levels were in 7 cases.

Results: The female to male ratio was 5/3 and their ages ranged from 13.5 to 70 years. Most patients had had a history of cold-induced urticaria (88.8%) and arthritis (100%) since their early childhood. Hearing loss was detected in 3 out of 8 (55.5%). Alkaline Phosphatase levels ranged between 57-271 U / L, Ca 9-9.6 mg / dl, Mg 2.3 mg / dl, P 2.6-4.4 mg / dl, 25-OH vitamin D 3.7-20.2 µg / L and PTH 28.8-162.7 mg / L. Vitamin D level was low in 7 out of 8 cases (87.5%). The results of BMD tests showed that 2 cases were normal, 5 cases had osteopenia and 1 had osteoporosis. T scores of lumbar spine were between -2.4-0.5 in adult patients, the z score was -0.5 of the pediatric case. Six patients were treated with canakinumab and 2 patients with anakinra.

Conclusion: It is known that excessive production of IL-1β can cause inflammatory bone loss and abnormality. Vitamin D deficiency and osteopenia/ osteoporosis may cause additional musculoskeletal problems besides arthritis and joint destruction in CAPS. We think that Ca metabolism and bone mineral density measurements should be a part of routine controls in patients with CAPS.

Disclosure of Interest
None declared

AB007
Clinical and genetic features of patients with periodic syndrome associated with mutation of the tumor necrosis factor receptor gene and juvenile arthritis having mutations in TNFRSF1A gene and juvenile arthritis having mutations in TNFRSF1A gene
M. Shingarova1,2, E. Alexeeva1,2, T. Dvoryakovskaya1,2, A. Mamutova1, K. Isayeva1, R. Denisova1, A. Chomahidze1, A. Fetsiova1, O. Lombakina1, K. Chibisova1, M. Gautier1, D. Vankova1, L. Knulin2, E. Krokhova1, A. Pushkov2, K. Savostyanov3
1Rheumatology, National Medical Research Center for Children’s Health; 2Sechenov First Moscow State Medical University; 3Genetic, National Medical Research Center for Children’s Health, Moscow, Russian Federation
Correspondence: E. Alexeeva
Pediatric Rheumatology 2020, 18(Suppl 2):AB007

Introduction: The use of a new generation of sequencing allows us to evaluate the genetic characteristics of patients with JIA in the Russian Federation, as well as to optimize the treatment strategy for JIA and TRAPS.

Objectives: To reveal the clinical and genetic features of JIA and TRAPS in patients with a genotypically confirmed nucleotide variant in the TNFRSF1A gene.

Methods: Retrospective analysis of 21 case histories of patients with JIA-12 and TRAPS-9 observed, of which 14 girls, median age-14.1, median debut age-4.7. All children underwent molecular genetic research by Next Generation Sequencing and revealed nucleotide variants of the TNFRSF1A gene.

Results: An analysis of clinical symptoms and laboratory activity in children with TRAPS was performed: in the onset of the disease, systemic manifestations were observed in 8/9: fever in 8/9, maculopapular rash in 5/9, hepatosplenomegaly occurred in 5/9, and lymphadenopathy in 4/9. High laboratory activity was recorded in 7/9. Active arthritis in 8/9, it was poly in 2, oligo in 6. When assessing the clinical symptoms and laboratory activity of patients with JIA, it was revealed that in the onset of the disease, systemic manifestations were observed in 8/12: fever in 8/12, rash in 4/12, hepatosplenomegaly in 5/12, pneumonia in 2/12, carditis in 1/12 and lymphadenopathy in 5/12.

High laboratory activity was recorded in 11/12. Active arthritis in 10/12, it was poly in 4, oligo in 6. In all 100% of patients, the nucleotide variants of the TNFRSF1A gene were identified in the study. 9/21 of patients were diagnosed with TRAPS. The most frequent heterozygous variant of TNFRSF1A gene with nucleotide substitution of c.362G>A was found in 7/9 of patients, in 1/9 of patients it was found homozygous variant with nucleotide substitution of c.362G>A, in 1/9 of children it was found heterozygous variant with deletion of c.337_339del. All of these variants are pathogenic. 12/21 of patients were diagnosed with JA: juvenile arthritis with a systemic onset was in 7/12, pauciarticular arthritis was in 2/12, it was poly RF- and in 1/12 it was psoriatic arthritis. It is worth noting to note that in 6/12 a heterozygous version of the TNFRSF1A gene was detected with a nucleotide substitution of c.362G>A, however, considering the absence of clinical manifestations of auto-inflammatory disease and active articular syndrome in these patients, children were diagnosed with JA. In addition, in 2/12 a heterozygous variant with a nucleotide substitution c.1110C>T was detected, which is an undetermined value variant; in 2/12 a heterozygous variant with a nucleotide substitution c.43C>T was detected, in 1/12 heterozygous variant c.374G>A was detected, and 1/12 heterozygous variant c.306C>T was detected.
Conclusion: Systemic manifestations were more prevalent in patients with TRAPS - 91.6%, and active articular syndrome was approximately the same in patients with JIA and TRAPS. In patients with TRAPS, the most common was the heterozygous version of the TNFRSF1A gene with the nucleotide substitution c.362G>A. Despite the fact that in 57.1% of JIA patients, variants of TNFRSF1A gene were identified, it is not possible to establish a diagnosis of auto-inflammatory syndrome in such patients. It is necessary to correctly interpret the results of molecular genetic research in accordance with the severity of the course of the disease, clinical manifestations.

Disclosure of Interest
M. Shingarova: None declared, E. Alexeeva Speaker Bureau of: Novartis, Pfizer, Sanofi, MSD and Roche, T. Dvoryakovskyaya: None declared, A. Mamutova Speaker Bureau of: Novartis, K. Isayeva: None declared, R. Denisova Speaker Bureau of: Novartis, MSD and Roche, A. Chomahidze: None declared, A. Fetsisova: None declared, O. Lomakina: None declared, K. Chibsova: None declared, M. Gautier: None declared, D. Vankova: None declared, I. Kriulin: None declared, E. Krekhova: None declared, A. Pushkov: None declared, K. Savostyanov: None declared

AB008
Does corona virus cause a specific inflammatory toe abnormality
N. Hasson
THE PORTLAND HOSPITAL, London, United Kingdom
Pediatric Rheumatology 2020, 18(Suppl 2):AB008

Introduction: During the recent coronavirus pandemic there was a description of inflammation of toes possibly related to Covid 19 infection. I have seen 4 patients present with inflamed toes.

Objectives: To ascertain if Covid-19 causes a specific toe inflammation or is this due to another problem

Methods: I reviewed the 3 patients who presented with toe inflammation doing a full rheumatological examination. They were all seen via Skype.

Results: None of the 4 patients had had any symptoms of Covid 19 and all had self isolated. Examination of the toes revealed chilblain type lesions and all 3 patients had evidence of Raynaud’s syndrome with markedly delayed capillary refill times in the feet of around 10 seconds. 2 of the patients had had a previous diagnosis of Primary Raynaud’s and the two were new patients both with Primary Raynauds and no underlying rheumatological disease. Hands were much less affected in the patients than feet with slight prolongation of CRT in hands compared to feet.

Conclusion: I think that although the weather was warm in the UK at the time of lockdown, indoor temperatures are significantly lower than outdoors. I think due to decreased exercise, lack of wearing socks and shoes indoors and cooler temperatures indoors these patients had suffered from acute Raynaud’s syndrome with chilblains rather than immune mediated vasculitic type illness causing their toe problems. I question if ‘Covid Toes’ as it was described is actually a condition or a manifestation of lockdown and Raynaud’s with chilblains. Once the patients wore socks and shoes and kept warm no further lesions occurred.

Disclosure of Interest
None declared

AB009
COVID-19 and relapsing Kawasaki disease: a case report during the pandemic
M. C. Maggio1, S. Giordano2, M. C. Failla2, A. Alaimo3, C. Gicé4, G. Sireci3
1PROMISE "G. D’Alessandro", University of Palermo; 2U.O.C. of Paediatric Infectious Diseases, Paediatric COVID Center, Children Hospital “G. Di Cristina”; 3U.O.C. of Paediatric Cardiology, Children Hospital “G. Di Cristina”; 4B U.O.C. of Paediatric Infectious Diseases, Paediatric COVID Center, Children Hospital “G. Di Cristina”, ARNAS, Palermo; 5CLADIBIOR, University of Palermo, Palermo, Italy
Correspondence: M. C. Maggio
Pediatric Rheumatology 2020, 18(Suppl 2):AB009

Introduction: The pandemic of COVID-19 remains a global health alarm with high incidence of lethality, especially in older age groups who suffer from underlying medical conditions. However, children are less likely to manifest severe conditions.

Objectives: COVID-19 was correlated to a higher incidence and a suspected increased risk of Kawasaki Disease (KD) in children.

Methods: We describe the case of a 2.2-year-old infant admitted for fever (>5 days; > 39°C), pharyngitis, chelitis, arthralgia, feet oedema, rash, perineal and scrotal region erythema, bilateral lymphadenopathy of the neck, cough, rhinorrhea. He was extremely irritable. Heart rate: 140/min; capillary saturation 99 % in air. Laboratory tests showed: leukocytes 13.4 x 10^9/l (neutrophils: 7.4 x 10^9/l); platelets 502 x 10^9/l; haemoglobin 11.1 g/dl; increased inflammatory markers, with C-reactive protein (CRP) of 14.7 mg/dl (n. < 0.5); hyponatremia (133 mmEq/l). The nasal swab for respiratory viruses, IgM and IgG anti-EBV, CMV, Parvovirus, Mycoplasma, Chlamydia were negative. Anamnestic records revealed a previous KD, without coronary artery lesions (CAL), 1 year before.

Results: He was treated with antibiotics, intravenous infusion of Immunoglobulins (IVIG) (2 gr/kg), acetylsalicylic acid (ASA) (50 mg/Kg in 4 doses and 4 times/day) and reached defervescence into 2 days. Echocardiography excluded CAL. The nasopharyngeal swab for SARS-COV-2 was doubt. The second throat swab done the day after IVIG infusion, was negative; however, the third nasopharyngeal swab for SARS-COV-2, done 4 days after IVIG infusion, was positive. Chest X-ray showed a significant lung interstitial thickening. IL-6 levels were < 6.25 pg/ml (n. < 6.25 pg/ml).

He continued treatment with antibiotics, ASA (5 mg/Kg/day), with the progressive resolution of the clinical symptoms and of the normalization of laboratory findings.

Conclusion: The peculiar outcome of the patient is the correlation of COVID-19 with KD, recently reported as associated. KD is considered as a multifactorial autoinflammatory disease, induced by a cytokine hypersecretion with a systemic vasculitis. COVID-19 is considered a cytokine storm syndrome, with a severe systemic vasculitis. SARS-COV-2 infection could be the trigger that could lead to hyperinflammation of KD. The IVIG infusion could explain the transient negative swab for SARS-COV-2, with the successive positive relieve lasting 7 days, and the normal levels of IL-6, detected after IVIG infusion. Relapsing KD is rare (1.7-3.5%); in our patient this event could be triggered by the documented SARS-COV-2 infection.

Disclosure of Interest
None declared

AB010
Management of children with rheumatic diseases in covid-19 outbreak in the tertiary pediatric rheumatology center in Iran
V. Javadi Parvaneh, R. Samet, M. H. Vaseghi, M. Abdollahi
Pediatric rheumatology, shahid beheshti university of medical sciences, tehran, Iran, Islamic Republic Of
Correspondence: V. Javadi Parvaneh
Pediatric Rheumatology 2020, 18(Suppl 2):AB010

Introduction: The COVID-19 disease identified and reported from Wuhan, Hubei, China. At the time being, the disease is a pandemic and has involved the entire world.

Objectives: The aim of this study is reporting the planning and actions after the COVID-19 epidemic for prevention of spread of the disease, supporting patients, and managing the disease at our center’s outpatient clinic as a referral center for children suffering rheumatic diseases.

Methods: Since the first report of disease, we tried to reply to the patients’ questions in a virtual social network. We were following lab data, radiograms, sonograms, CT scans, and MRI results in this network and provided solutions for the management of the children’s problems without need to encountering.

Results: In cases that were controlled and their diseases were in remission, we invited one of the patient’s parents to come and receive the prescription. We put some instructive short films about COVID-19 in the virtual network and in LED screens of our outpatient hospital clinic to provide useful information. About the turn rating system (queueing system) we omitted manual turn-taking stands to prevent virus transmission. In the peak of the epidemic, we stopped outpatient
clinics for three weeks. After that, we started clinics with the least number of patients and the most standard protection measures for physicians, patients, and other staff. All people were triaged in the hospital yard before entering the waiting hall of the clinic by taking their temperature and screening questions. If they didn’t have a fever and symptoms compatible with the disease, we let the patient and only one companion enter the clinic hall with giving a free three-layer surgical mask to each of them. We requested the physicians to increase the time of their clinics to distance the appointments of the patients and to prevent overcrowding in the clinic. Each clinic was held with the presence of the attending physician and only one fellow physician. Gowns, protective glasses and face shields, surgical masks, and latex gloves were provided for secretaries and the other staff in the clinic. In the first eight weeks, daily disinfection was performed for all the surfaces of the clinic and after that, a disinfecting tunnel at the door of the clinic was added. With the screening of about 100 staff in the clinic, we found only one IgM positive person for COVID-19 during the first eight weeks who was one of the secretaries without any signs and symptoms and were quarantined at home. Among the physicians, 6 of them (8 percent) developed COVID-19 disease with laboratory confirmation. All of the involved physicians were working in the private section as well as a state-run system. From about 200 patients with different rheumatic diseases came to the clinic in eight weeks, 11 of them (5.5%) were in the relapse of their disease which in comparison to the same time in the last year, 26 from 760 patients (3%), a remarkable increase (almost double) is seen for which different causes can be considered. Most of the patients who came to the clinic in the COVID-19 outbreak were those who had to come due to the severity of their disease. In the patients who came before the epidemic, the most causes were musculoskeletal pains such as hypermobility and skeletal benign reasons and rheumatic diseases were in the next rank but in the epidemic outbreak, the presence of COVID-19 disease in a lower number. Follow up on the patients after the epidemic will reveal this matter better.

**Conclusion:** Employing personal and patient protective equipments, patients’ triage, postponement of face-to-face appointments, social distancing, telemedicine, and using the virtual social networks may be effective policies in outpatient clinics in the COVID-19 outbreak.

**Disclosure of Interest**
None declared

**AB01**

Severe cardiac involvement with myocardial dysfunction and arrhythmias in SARS-COV-2 related Kawasaki-like disease

M. E. Pinto, G. Di Salvo, E. Reffo, G. Gendron, A. Menegheli, F. Zulian, G. Martin

1Pediatric Rheumatology; 2Pediatric Cardiology, University-Hospital of Padua, Padua, Italy

**Correspondence:** M. E. Pinto

Pediatric Rheumatology 2020, 18(Suppl 2):AB01

**Introduction:** During SARS-COV-2 pandemic, different reports have been published regarding children who developed hyperinflammatory syndrome with certain or probable relationship with SARS-COV-2. These patients presented incomplete or atypical manifestations of Kawasaki disease (KD), particularly abdominal pain, myocarditis and macrophage activation syndrome features.

**Objectives:** To report a case of SARS-COV-2 related Kawasaki-like disease with severe cardiac involvement.

**Methods:** case report description.

**Results:** A 10-year-old previously healthy girl presented progressively worsening abdominal pain, high grade fever for 3 days and vomiting. Lab tests showed WBC 11680/mmíc, N 9370/mmíc, C-reactive protein (CRP) 329 mg/L, procalcitonin (PCT) 0.74 ug/L, PT-INR 1.35 and elevated D-dimer and fibrinogen levels (817 ug/L and 9.45 g/L respectively). Abdominal ultrasound revealed lymphadenopathies and hypoechoic mesentery in the right lower quadrant, although the appendix was not visualized. She underwent laparoscopy showing moderate quantity of free fluid and appendectomy was performed. Thereafter she continued to complain of high-grade fever, abdominal pain and diarrhoea, despite broad-spectrum antibiotics. Blood, urine and stool cultures were negative. Bilateral non-exudative conjunctivitis was present. Moreover, the lab tests showed persistent marked elevation of CRP (370 mg/L), WBC 15506/mmíc, N 14070/mmíc, hypoalbuminemia (23 g/L), elevated ferritin and triglycerides (458 ug/L and 221 mg/dL). By taking into consideration the concomitant SARS-COV-2 pandemic, nasopharyngeal and rectal swabs were taken with negative results. Conversely, serological test showed anti-SARS-COV-2 IgG antibodies and absence of IgM. The family medical history showed that the mother had presented fever, cough, ageusia and anosmia one month before, preceded by a contact with a SARS-COV-2 positive case, while the patient was asymptomatic at that time. Suspecting a KD-like disease she was referred to our Paediatric Rheumatology Unit: cardiological assessment revealed negative T-waves in V4-V5-V6 on EKG while standard and advanced echocardiography showed mild mitral and tricuspid insufficiencies, mild dilatation of the left main coronary artery (LMCA, z score +2), normal global function (FEVS 2D 58%) but reduced longitudinal strain (GLS -16%). Lab tests confirmed myocardial injury with troponin (Tnl) 100.1 ng/L and brain natriuretic peptide (BNP) 593 ng/L.

A single infusion of intravenous immunoglobulin 2 g/kg associated with methylprednisolone (1 mg/kg/day) led to a rapid clinical improvement with apyrexia and resolution of abdominal pain and conjunctivitis. Blood test confirmed gradual normalization of inflammatory markers, ferritin, troponin and BNP and EKG showed positive T-waves. Shortly after the discharge, while she was on prednisone 0.5 mg/kg/day and acetylsalicylic acid 100 mg/day, she referred some episodes of heart pounding, lasting about ten minutes with spontaneous resolution. Three weeks after onset, cardiac MRI was normal, however, speckle tracking echocardiography showed persistent dilatation of LMCA and reduction of global longitudinal strain (GLS -14%). 24-hour EKG-Holter detected episodes of supraventricular tachycardia and several ventricular and supraventricular extrasystoles. Thus, oral atenolol therapy was started.

**Conclusion:** In our patient SARS-COV-2 induced a possible post-infectious antibody or immune-complex mediated reaction that led to KD-like disease with acute surgical abdomen presentation and persistent myocardial damage and arrhythmias. Speckle tracking echocardiography appears more reliable than MRI in early detection of myocardial damage in patients with preserved left ventricular ejection fraction.

**Disclosure of Interest**
None declared

**AB012**

Spectrum of systemic inflammatory syndrome in children during COVID 19 pandemic in India

D. B. Pandya, on behalf of Dr Harsh Dobariya, Dr Vinod Bhadukia, Dr Rakesh Patel, Dr Hitesh Bhambhani and Dr Sameer Dhami, Paediatric Rheumatology & Immunology, Dev Children’s Hospital, Rajkot, India

**Correspondence:** D. B. Pandya

Pediatric Rheumatology 2020, 18(Suppl 2):AB012

**Introduction**
Recently reports from Europe and North America have described clusters of children and adolescents with a multisystem inflammatory condition with some features similar to those of incomplete Kawasaki disease. 1-3

**Objectives**
To unveil characteristics of systemic inflammatory syndrome (SIS) in children during COVID-19 pandemic in India

**Methods**
This is a case series which included three such pediatric patients who were evaluated between April 2020 and May 2020 at five different hospitals from an Indian state of Gujarat. Our electronic data included demographics, clinical presentation, laboratory results and follow up.
Results

Table 1 (abstract AB012). showed characteristics of SIS in children during COVID-19 pandemic in India

| Age (years) / Sex (M/F) | 3 / M | 7.7 / M | 7 / F |
|------------------------|-------|---------|-------|
| Fever (duration)       | 2 weeks | 11 days | 11 days |
| Containment Zone       | Yes   | No      | Yes   |
| Rash                   | +     | +       | + (evanescent) |
| Red eyes               | +     | +       | -     |
| Red Tongue             | -     | +       | -     |
| Pharyngeal congestion  | +     | -       | -     |
| Distal edema           | +     | -       | -     |
| Skin exfoliation       | -     | +       | -     |
| Swollen lips           | +     | -       | -     |
| Joint involvement      | +     | +       | +     |
| Serositis              | +     | +       | -     |
| Orgonomegaly           | +     | -       | -     |
| GI symptoms            | +     | +       | +     |
| Respiratory symptoms   | +     | +       | -     |
| Chest X-Ray findings   | +     | -       | -     |
| Shock or Hypotension   | -     | -       | -     |
| 2d Echo findings       | -     | -       | -     |
| HB                     | 7.2   | 9.1     | 96    |
| TLC                    | 7800  | 19,700  | 23,230 |
| Platelets              | 46,000 | 5,20,000 | 5,57,000 |
| Blood C/S              | Negative | Negative | Negative |
| ESR                    | 68    | 110     | 120   |
| CRP                    | 234   | 44.7    | 226   |
| Ferritin               | 125.4 | 122     | 6235  |
| Procalcitonin (<0.15 ng/mL) | 3.84 | Not done | 7.14  |
| Triglycerides (35-138mg/dL) | 333  | Not done | Not done |
| Fibrinogen (150-400 mg/dL) | 209.5  | Not done | Not done |
| LDH (24-59 IU/L)       | 663   | Not done | Not done |
| PT, aPTT               | Mild derangements | Not done | Not done |
| COVID-19 RT PCR        | Negative | Negative | Not done |
| Treatment              | IV antibiotics | IV Ig | Oral naproxen |
|                        | Oral Azithromycin | Oral aspirin | Oral steroids |
|                        | IV albumin  |
| Last follow up         | better | better | better |

($ = IV albumin infusion was given in view of progressive generalized edema and hypalbuminemia)

Conclusion
Above three cases reemphasize the need for a high index of suspicion for COVID 19 (coronavirus) as a possible culprit in a child with unexplained multisystem inflammatory syndrome.

Trial registration identifying number
1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020. Epub 2020/05/11.
2. DeBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J, et al. Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region. J Pediatr. 2020.
3. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Bradley Segal J, et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hosp Pediatr. 2020. Epub 2020/04/09

Disclosure of Interest
None declared

AB013
A child with a severe multi-system inflammatory syndrome following COVID-19 infection

A. Mauro1, L. Zienzi1, N. Improda1, T. Gagliardo1, C. Granato1, C. D’Anna1, I. Parente1, I. R. Schiavone1, M. Oreste1, R. Sottile2, V. Tipo1
1Emergency department, “pediatrics, AORN Santobono-Pausilipon, Naples, Italy
2Correspondence: A. Mauro
Pediatric Rheumatology 2020, 18(Suppl 2):AB013

Introduction: Despite the mild clinical course during the acute phase of COVID-19 infection in children, latest ongoing researches are pointing the attention towards a hyperinflammatory shock in pediatric patients as a possible consequence to COVID-19 exposure.

Objectives: We report the case of a child with a severe systemic inflammatory syndrome following an asymptomatic COVID-19 infection.

Methods: A 9-year-old male was admitted to the Pediatric Emergency Unit due to fever and abdominal pain. Symptoms started 7 days before admission, with fever, vomiting and non-bloody-diarrhea. Family history revealed that the father had been admitted to a COVID-19 Sub-Intensive Unit with bilateral interstitial pneumonia until 7 days before the onset of symptoms in the child. On the basis of familial history and because of the presence of fever, patient entered the COVID-19 pathway and was isolated. He had no chronic underlying disease nor history of previous hospitalization. At admission, he appeared stable. Body temperature was 38.1°C, O2 saturation was 98% in ambient area, blood pressure was 106/60 mm Hg, heart rate was 140 bpm, respiratory rate was 21 breaths per minute. On examination he was alert, there were no cough, runny nose or other respiratory symptoms. No conjunctivitis, rash or peripheral edema was detected. He had mild hepatomegaly.

Results: The patient underwent blood and microbiological exams including blood specimens for cultures and nasopharyngeal swabs for SARS-COV2 nucleic acid (by RT-PCR assay). At baseline, leukocytosis with neutrophilia and relative lymphopenia were found. Hemoglobin was below the normal range, while platelets count was normal. Inflammatory markers were strongly elevated, particularly CRP(420.8 mg/L), ferritin(4488 ng/mL), D-dimer (5106 ng/mL). Several significantly altered parameters suggested liver function abnormality, with hypertransaminasemia, acute renal injury, with elevated blood urea nitrogen and serum creatinine, and myocardial injury, with elevated high sensitivity cardiac troponin (434 ng/L) and brain natriuretic peptide (825 pg/mL). Lymphocyte subsets were within the normal range, while NK cells were slightly reduced. Patient was also tested for respiratory syncytial virus (RSV) and for influenza viruses A and B, resulted all negative. Bacteria and fungi blood cultures were sterile, as well as urine and stool cultures. He was tested for COVID-19 antibodies which showed positivity of both IgG and IgM (qualitative test), confirmed by a quantitative analysis which showed a high level of IgG (5066 AU/mL) and a weak positivity of IgM (0.532 AU/mL). Echocardiography showed no ventricular dysfunction, no dilated coronary or pericoronary ipecochogenicity. Chest CT on the 2nd day showed two small bilateral areas of atelectasis associated to minimal pleural effusion more evident on the right side. The diagnosis of Hyperinflammatory syndrome COVID-19 related was made.

Conclusion: Because of the high levels of BNP and troponin, IV methylprednisolone (5 mg/kg/day) and subcutaneous heparin (100 U/kg/day) were started after 24 hours since admission. Search for COVID-19 on nasopharyngeal swabs collected for 3 consecutive days resulted negative, The patient gradually recovered and fever disappeared after 48 hours. He presented no vomiting or diarrhea during the hospital stay, nor respiratory symptoms. Laboratory exams dramatically improved. According to his clinical and
laboratoristic improvement, methylprednisolone was tapered to 3mg/kg/day and he started oral prednisone 1.25 mg/kg/day four days after. He was discharged with steroid and heparin therapy and a close follow-up was planned.

Disclosure of Interest
None declared

AB014
Camptodactyly-Arthopathy – Coxarava-Pericarditis (CACP) syndrome in a Libyan female child
A. B. Malek1, A. M. Abushahwa4, M. A. Zletni2, A. J. Ateeq2, F. Bencheikh 2
1Pediatrics, 2Rheumatology, 3Tripoli children Hospital, 4Tripoli, Libya
Correspondence: A. B. Malek
Pediatric Rheumatology 2020, 18(Suppl 2):AB014

Introduction: Camptodactyly-arthritis – coxarava-pericarditis (CACP) syndrome is a rare autosomal recessive disorder caused by a mutation in the gene proteoglycan 4 (PRG4) affecting lubricin production, which is an essential protein for joint function. We present this case to describe the clinical, laboratory and radiological findings of CACP syndrome that should help in differentiation of CACP syndrome from other childhood inflammatory arthritis.

Objectives: To increase the awareness of this familial condition to prevent confusion with other inflammatory conditions

Methods: A case report

Results: An 8-year-old female patient was referred to the Rheumatology clinic with complaints of joint deformities of her fingers namely camptodactyly was noticed through the first year of life that treated surgically, while other joint involvement at age 3 was starting to have multiple joints swelling, she was the products of 3rd degree consanguineous marriage and other 2 siblings are healthy, she was referred as a case of poly juvenile idiopathic arthritis. She has normal intelligence with normal school performance, she

Conclusion: CACP syndrome should be considered in juvenile patients presenting with non-inflammatory arthropathy. We hope that this report will increase the awareness of this familial arthropathy condition and the clinical characteristics and the radiological findings will facilitate the differentiation from the common childhood rheumatic diseases.

Disclosure of Interest
None declared

AB015
Relationship of Raynaud’s phenomenon on qualitative and quantitative videocapillaroscopy evaluation of pediatric patients with rheumatic diseases
S. Jiménez H., K. Jiron, A. V. Villareal T., F. García R., M. De la O C., N. Rubio P.
Reumatología Pediátrica, Hospital Universitario “Dr. José Eleuterio González”, Monterrey, Mexico
Correspondence: S. Jiménez H
Pediatric Rheumatology 2020, 18(Suppl 2):AB015

Introduction: Capillaroscopy is a tool that helps to assess microcirculation (MC) by observing the shape, density, structure, and alterations in the capillaries of the nailfold. MC has an important association with rheumatic diseases (RD), which is why it has become an important tool in rheumatology, and is considered a low-cost, non-invasive method. Raynaud’s phenomenon (RP), a clinical condition commonly found in patients with RD, requires capillaroscopic evaluation to differentiate primary RP from the secondary, and it also helps to monitor the activity of the disease, assess response to treatment and prognosis. To date, there are no standardized capillaroscopic patterns in pediatric populations.

Objectives: Describe qualitative and quantitative capillaroscopic differences between pediatric RD patients with RP and those without RP.

Methods: Patients from the pediatric rheumatology department of a tertiary center in Monterrey, Nuevo León, Mexico from July 2017 to March 2020 were included. Eight fingers, excluding the thumb, taking for analysis the most representative 1 mm image of each finger with x200 videocapillaroscopy (Optilia), all measurements were taken by the same observer. Demographic data captured to describe the diagnosis, age, and RP presence. Capillaroscopy data, qualitative data: pattern, density, abnormal shapes, microbleedings and edema; for quantitative characteristics length, width, inter capillary distance, afferent diameter and efferent diameter were obtained.

Results: Sixteen patients were included, of which 13 (81.2%) were female, the mean age was 12 years, RP was present in 12 (75%) patients. Regarding the diagnoses in the RP group, we found Systemic Lupus Erythematosus (5/12), Juvenile Idiopathic Arthritis (3/12), undifferentiated connective tissue disease (1/12), systemic sclerosis (1/12), IgA vasculitis (1/12) and primary RP (1/12); in the group without RP the diagnosis were psoriatic arthritis (1/4), psoriasis (1/4), localized scleroderma (1/4) and polymyositis (1/4). Among the quantitative characteristics, we found a greater length in R2, R4, RS, L4 and LS of the patients with RP. Similarly, we observed a difference in the afferent diameter of R3, R4, RS, L2, L3, L4 and LS, being bigger in patients with RP. In L4 we found a difference in length, afferent and efferent diameter, being greater in those patients with RP, on the contrary, the width is usually smaller.

Conclusion: We found both qualitative and quantitative differences in patients with RP versus those without RP, mainly in afferent diameter for all fingers, and in L4 we found a difference in most of the measurements. This study shows the quantitative data of the videocapillaroscopic analysis, and therefore it is proposed as a possible tool for the diagnosis and monitoring of RD in pediatric patients. Despite finding capillaroscopic alterations in both, the sample size in this cohort is small, so studies with a greater sample must be done, as well as studies with controls on healthy children, to make more conclusions.

Disclosure of Interest
None declared

AB016
Relationship of Raynaud’s phenomenon on qualitative and quantitative videocapillaroscopy evaluation of pediatric patients with rheumatic diseases
S. Jiménez H., K. Jiron, A. V. Villareal T., F. García R., M. De la O C., N. Rubio P.
Reumatología Pediátrica, Hospital Universitario “Dr. José Eleuterio González”, Monterrey, Mexico
Correspondence: S. Jiménez H
Pediatric Rheumatology 2020, 18(Suppl 2):AB015

Introduction: Capillaroscopy is a tool that helps to assess microcirculation (MC) by observing the shape, density, structure, and alterations in the capillaries of the nailfold. MC has an important association with rheumatic diseases (RD), which is why it has become an important tool in rheumatology, and is considered a low-cost, non-invasive method. Raynaud’s phenomenon (RP), a clinical condition commonly found in patients with RD, requires capillaroscopic evaluation to differentiate primary RP from the secondary, and it also helps to monitor the activity of the disease, assess response to treatment and prognosis. To date, there are no standardized capillaroscopic patterns in pediatric populations.

Objectives: Describe qualitative and quantitative capillaroscopic differences between pediatric RD patients with RP and those without RP.

Methods: Patients from the pediatric rheumatology department of a tertiary center in Monterrey, Nuevo León, Mexico from July 2017 to March 2020 were included. Eight fingers, excluding the thumb, taking for analysis the most representative 1 mm image of each finger with x200 videocapillaroscopy (Optilia), all measurements were taken by the same observer. Demographic data captured to describe the diagnosis, age, and RP presence. Capillaroscopy data, qualitative data: pattern, density, abnormal shapes, microbleedings and edema; for quantitative characteristics length, width, inter capillary distance, afferent diameter and efferent diameter were obtained.

Results: Sixteen patients were included, of which 13 (81.2%) were female, the mean age was 12 years, RP was present in 12 (75%) patients. Regarding the diagnoses in the RP group, we found Systemic Lupus Erythematosus (5/12), Juvenile Idiopathic Arthritis (3/12), undifferentiated connective tissue disease (1/12), systemic sclerosis (1/12), IgA vasculitis (1/12) and primary RP (1/12); in the group without RP the diagnosis were psoriatic arthritis (1/4), psoriasis (1/4), localized scleroderma (1/4) and polymyositis (1/4). Among the quantitative characteristics, we found a greater length in R2, R4, RS, L4 and LS of the patients with RP. Similarly, we observed a difference in the afferent diameter of R3, R4, RS, L2, L3, L4 and LS, being bigger in patients with RP. In L4 we found a difference in length, afferent and efferent diameter, being greater in those patients with RP, on the contrary, the width is usually smaller.

Conclusion: We found both qualitative and quantitative differences in patients with RP versus those without RP, mainly in afferent diameter for all fingers, and in L4 we found a difference in most of the measurements. This study shows the quantitative data of the videocapillaroscopic analysis, and therefore it is proposed as a possible tool for the diagnosis and monitoring of RD in pediatric patients. Despite finding capillaroscopic alterations in both, the sample size in this cohort is small, so studies with a greater sample must be done, as well as studies with controls on healthy children, to make more conclusions.

Disclosure of Interest
None declared
Table 1 (abstract AB015). See text for description

| Raynaud's phenomenon | R2 | R3 | R4 | R5 | L2 | L3 | L4 | L5 |
|----------------------|----|----|----|----|----|----|----|----|
| Length (μm)          | Yes| 230.687| 234.351| 234.687| 211.900| 211.920| 215.000| 225.755| 268.188|
| No                   | 253.056| 281.273| 180.906| 203.546| 275.288| 268.120| 160.940| 194.445|
| Width (μm)           | Yes| 54.442| 69.112| 51.100| 51.091| 53.070| 46.854| 51.965| 45.713|
| No                   | 57.606| 54.518| 45.658| 46.696| 52.281| 80.571| 53.020| 42.710|
| Afferent diameter (μm)| No | 18.511| 21.858| 20.718| 18.033| 18.106| 17.241| 18.143| 17.149|
| No                   | 18.075| 19.573| 15.568| 16.319| 15.302| 15.815| 15.239| 15.507|
| Efferent diameter (μm)| No | 25.403| 26.675| 24.918| 24.037| 23.804| 22.895| 25.008| 22.229|
| No                   | 26.463| 27.900| 22.088| 22.763| 30.990| 22.396| 20.140| 18.854|

Right hand finger No. 2 to No. 5 = R2, R3, R4, R5. Left hand finger No.2 to No. 5 = L2, L3, L4, L5.

**AB016**

Is subclinical synovitis assessed by ultrasound able to predict flares in children with Juvenile Idiopathic Arthritis in clinical remission? A systematic review of the literature

**Aim of the present study is to review published articles related to the predictive value for flare of subclinical synovitis assessed by ultrasound in juvenile idiopathic arthritis (JIA) in clinical remission. This could have implications in the practical management both for adjustments in drug treatments and for the timing of clinical surveillance during follow-up.**

**Objectives:**

- To analyze the effectiveness of Etanercept, as well as its tolerance in juvenile idiopathic arthritis (JIA).

**Methods:**

- We carried out a retrospective study of children diagnosed with JIA according to the ILAR classification criteria and treated with Etanercept at the pediatric center of Setif University Hospital since 2015.
- 15 children were included and judged at 3 months, 6 months, 1 year, 2 years, 3 years, 4 years on epidemiological criteria, efficacy criteria (Joint scores, uveitis, SV, CHAQ) and the occurrence of possible Side effects.

**Results:**

- The epidemiological characteristics were as follows: 9 girls and 6 boys, 7 have a polyarticular form, 5 have an oligoarticular form, 2 cases with psoriatic arthritis, and only one case of arthritis-associated enthesitis (ARE).
- ACR 30 is obtained in 75%, 84%, 88% of cases respectively at 3 months, 6 months, 1 year.
- The most marked responses were maintained in the polyarticular, oligoarticular and arthritis-related enthesitis for psoriatic arthritis = 72%.
- Complete remission was maintained in the majority of the patients for varying durations depending on the outcomes.

**Conclusion:**

- Etanercept has a spectacular efficacy in children suffering from juvenile idiopathic arthritis, particularly in polyarticular, oligoarticular forms and IBAs.
- His overall tolerance is very good.

**Disclosure of Interest**

None declared
AB019
Fibroblast growth factor and hepatocyte growth factor in adolescents with Juvenile Idiopathic Arthritis treated with methotrexate
L. Parkhomenko, L. Strashok, O. Pavlova
Department of Adolescent Medicine, Kharkiv medical academy of postgraduate education, Kharkiv, Ukraine
Correspondence: O. Pavlova
Pediatric Rheumatology 2020, 18(Suppl 2):AB019

Introduction: Risk of liver fibrosis development during juvenile idiopathic arthritis (JIA) treatment with methotrexate (MTX) in adolescents remains relevant.

Objectives: To study levels of basic fibroblast growth factor (BFGF) and hepatocyte growth factor (HGF) in adolescents with JIA treated with MTX.

Methods: 68 children were observed, 25 boys (36.8%) and 43 girls (63.2%). The average age of the patients was 13.3 ± 0.3 years. Children were divided into four groups: those with JIA who didn’t receive MTX yet (group 1); those who received MTX within 1 gram during whole treatment (group 2); those who received MTX from 1 to 3 grams (group 3); children, received more than 3 grams of MTX (group 4).

Results: The autoimmune inflammatory process in JIA can cause formation of pathological changes in the liver, even before the start of treatment. It is confirmed by a statistically significant correlation of BFGF level in 1st group with liver steatosis according to ultrasound examination (r = 0.8) and the level of C-reactive protein (r = 0.7). This indicates a close relationship between the intensity of the inflammatory process and collagen synthesis activation, which can further provoke liver fibrosis. Alternative processes in the liver associated with autoimmune inflammation, as evidenced by the presence of a positive correlation between the level of ALT and BFGF (r = 0.5). Upon reaching MTX dose 1 gram and 3 grams, it is possible that compensatory processes in the liver are triggered, as evidenced by the negative correlation between the content of BFGF and HGF (r = -0.6).

Conclusion: The use of modern markers with routine laboratory and instrumental studies is appropriate for the timely determination of the risks of developing irreversible pathological changes in the liver during JIA treatment with MTX.

Disclosure of Interest
None declared

AB020
Predictors of the effectiveness of intra-articular glucocorticoid injections in juvenile hip involvement
L. Nacef, H. Ferjani, L. Ben Ammar, K. Maatallah, D. Kaffel, W. Hamdi
Rheumatology, Mohamed Kassab Hospital, Tunisia, Tunisia
Correspondence: L. Nacef
Pediatric Rheumatology 2020, 18(Suppl 2):AB020

Introduction: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory arthritis in children. Intra-articular glucocorticoids (IAG) are recommended as the first-line therapy for oligoarticular JIA. The safety and the benefits of use of IAG in other subtypes should be more studied.

Objectives: The aim of our study is to evaluate the efficacy of (IAG) injections in hip in children with (JIA) and to assess the factors predicting the improvement of this management.

Methods: This is a retrospective study, between 2006 and 2009, including patients with JIA diagnosed according to the ILAR criteria. The socio-demographic data were collected as well as the parameters of the disease. The activity was evaluated by JADAS. The functional impact was assessed by the Lequesne score. The treatments taken have been specified as well as the infiltrations received. The improvement after infiltration was assessed by JADAS and Lequesne score.

Results: Fourteen patients were included, with mean age 17.21 ±6.8 [6-33]. The mean age at the onset of symptoms was 11 ±0.5 [3-15]. Subtypes of JIA according to The ILAR were: enthesitis-related arthritis in 7 cases, seropositive polyarticular JIA in 2 cases, seronegative polyarticular JIA in 2 cases, oligoarticular JIA in 2 cases and juvenile psoriatic arthritis in one case. All the patients had hip arthritis, inaugural in 90% of the cases. Of these, 92.8% had a flexion deformity and lower limb inequality. The average Lequesne index was 8.5 ±4.6. The treatments taken were Methotrexate in 57.14% of the cases, Sulfasalazine in 14.28% of the cases, and the combination of the two in 21.4% of the cases. Eleven patients underwent hip infiltration, and three of them required more than one. Eighty one percent improved thereafter. The number of infiltrations was not statistically associated with the Lequesne index (p = 0.069). Improvement after infiltration was negatively associated with the prior existence of an inequality of the lower limbs (p = 0.04). The existence of a flexion deformity was not associated with good results after infiltration (p = 0.476, r=-0.624). Ten patients (90%) among those who had an infiltration did not have to resort to surgery.

Conclusion: IAG injection is an adjunct therapy in AJI with hip involvement offering a good results and delay surgery in the majority of cases. The presence of lower limb inequality is associated with less improvement of IAG.

Disclosure of Interest
None declared

AB021
Rice bodies at juvenile idiopathic arthritis onset
P. Mesa-del-Castillo B, M. J. Ponce-Sanchez, L. Barona Garcia, P. Alcarz Rodriguez, P. Castillo Dayer
1Pediatric Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca; 2Pathology, Hospital Universitario Virgen de la Arrixaca; 3Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
Correspondence: P. Mesa-del-Castillo B
Pediatric Rheumatology 2020, 18(Suppl 2):AB021

Introduction: Rice bodies are detached synovial fragments surrounded by fibrine concentric layers, giving them the aspect of a white oval rice grain. The pathologic mechanism is related to synovial hypertrophic growth and has been frequently reported in rheumatoid and tuberculous arthritis. This formations have been scarcely reported in juvenile idiopathic arthritis individual patients.

Objectives: To describe the difficulties and particularities of three cases Juvenile Idiopathic Arthritis in which rice bodies were present at onset.

Methods: Retrospective chart review, collection of clinical, radiological and microscopic images.

Results: CASE 1: A 3 years old girl presenting with five week history of right knee swelling. Two joint punctures with a 21 G needle were unable to completely drain the joint; with a 16 G needle the joint was finally drained and injected with triamcinolone acetonide. Synovial fluid had plenty of white oval shaped bodies. Culture of synovial fluid and mantoux were negative. Pathology showed to be compatible with synovial rice bodies. MRI and ultrasound images show an intense synovial hypertrophy.

CASE 2: A 3 years old girl presenting with an undetermined duration right knee effusion, received an steroid joint injection with good response. One month later she presents a left knee swelling; joint puncture was performed with a 21 G needle obtaining synovial fluid with tiny oval white formations compatible with rice bodies. Culture of synovial fluid and mantoux were negative. Ultrasound images show intense synovial hypertrophy and positive synovial Doppler signal.

CASE 3: A 3 years old girl presenting with a nine week history of right knee swelling. Joint puncture was performed with a 21 G needle obtaining 10 ml of inflammatory fluid ank steroids injected in the joint. After two weeks a second procedure was performed with a 16G needle: giant white oval bodies were obtained but complete drainage of the joint was not achieved. Finaly she underwent arthroscopic surgery for complete clearance of intraarticular loose
bodies. Pathology showed synovial hypertrophy fragments surrounded by fibrous, compatible with rice bodies. Culture of synovial fluid and mantoux were both negative. MRI and ultrasound images show an intense sinovial hypertrophy with suprapatellar recess occupation and positive synovial Doppler signal.

**Table 1 (abstract AB022).** showed characteristics of 27 JIA patients managed at Dev Children’s Hospital.

| Sub-types of JIA | Early-onset JIA | RF positive JIA | SJIA | Enthesitis-related arthritis (ESRA) | Other and unclassified |
|------------------|-----------------|-----------------|------|------------------------------------|-----------------------|
| Total no of Cases 27 | 4 (15%) | 9 (33%) | 7 (26%) | 3 (11%) | 4 (15%) |
| Average age of onset | 3.7 years | 9.4 yrs All females | 5.1 yrs All males | 12.9 yrs M=F | 66 yrs M=F |
| Average number of joints affected | 4.5 | 7 | 3 | 1.6 | 4 |
| Most common affected joint | Knee | Wrist | Knee | Ankle | Knee |
| Eye involvement | None | None | None | One patient | None |
| Drugs used | Naproxen | All | All | All | All |
| Methotrexate | All | All | Five | All | All |
| Steroids | One | All | None | Two | None |
| Tocilizumab | None | One | Two | None | None |

**Conclusion:** Synovial rice bodies are rarely described in juvenile idiopathic arthritis, even less at disease onset. Their presence has not been associated to a worse disease prognosis or joint outcome but awareness of the existence of this particular form of intraarticular loose bodies may encourage the clinician to use lower gauge needle during arthrocentesis procedure; this can prevent arthroscopy, as occurred in our case 1. Arthroscopy may be necessary in some cases to achieve full drainage of the joint. In our series the duration of arthritis correlated with the size of rice bodies and the number and aggressiveness of procedures needed to evacuate them.

**Disclosure of Interest**
None declared

**AB022**
Spectrum of Juvenile Idiopathic Arthritis in 27 patients from a single center in an Indian state of Gujarat

D. B. Pandya, on behalf of Dr Haresh Dobaria, Dr Harshad Takvani, Dr Yogesh Soni, Dr Jay Virani, Dr Rohan Parwani and Dr Akash Mankadia.

Pediatric Rheumatology & Immunology, Dev Children’s Hospital, Rajkot, India

**Correspondence:** D. B. Pandya

Pediatric Rheumatology 2020, 18(Suppl 2):AB022

**Introduction**
There is very limited information and awareness about juvenile idiopathic arthritis (JIA) amongst primary physicians in Gujarat and to make this matter even worse, we are not having a single exclusive pediatric rheumatology center for a population of around 60 million.1,2

**Objectives**
To study characteristics of twenty seven JIA children managed at Dev Children’s Hospital.

**Methods**
I gathered a data of 27 pediatric patients with confirmed diagnosis of JIA who were seen at Dev Children’s Hospital between January 2019 and January 2020. It included demographics, clinical presentation, laboratory results and treatment. All cases were reclassified according to preliminary PRINTO JIA classification.4

**Results**
**Conclusion**
Most common JIA sub-type in our cohort is RF positive JIA. Knee is the most common affected joint irrespective of JIA sub-type. Only one patient showed eye involvement. Most of the patients have been given steroids at onset. One patient with RF positive JIA and two patients with systemic JIA have been given intravenous tocilizumab infusion. Anti-inflammatory diet and yoga were advised for almost all patients of more than 5 years of age.

**Trial registration identifying number**
1. Review.Indian J Pediatr2010 Sep;77(9):993-6.doi: 10.1007/s12098-010-0134-x. Epub 2010 Sep 3.

The Place of Pediatric Rheumatology in India
Sujata Sawhney 1, Prudence Manners

2. Journal of Natural science.Biology & Medicine-2018
Clinico-epidemiological profile of pediatric rheumatology disorders in Eastern India
PratapKumarPatra, ManishKumar
Department of Pediatrics, All Institute of Medical Sciences, Patna, Bihar, India

3. International Journal of Advanced Medical Health & Research (JIPMER)
Pediatric rheumatology: An under-recognized subspecialty in India
Year : 2017 | Volume : 4 | Issue : 2 | Page : 47-53

AkhilaKavirayani1, SomaBalani2
1 Department of Paediatric Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
2 Department of Paediatric Rheumatology, Amrita Institute of Medical Sciences, Kochi, Kerala, India

4. Research Article: Pediatric Rheumatology: Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps
Pediatric Rheumatology International Trials Organization International Consensus
Alberto Martini, Angelo Ravelli, Tadej Avcin, Michael W. Beresford, Ruben Burgos-Vargas, Ruben Cuttica, Norman T. Ilowite, Raju Khubchandani, Ronald M. Laxer, Daniel J. Lovell, Ross E. Petty, Carol A. Wallace, Nico M. Wulfraat, Angela Pistorio, Nicolinoruperto and for the Pediatric Rheumatology International Trials Organization (PRIN TO)
The Journal of Rheumatology February 2019, 46 (2) 190-197; DOI: https://doi.org/10.3899/jrheum.180168

5. Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1777
The impact of yoga, anti inflammatory diet and self monitoring in children with rheumatic diseases
D. B. Pandya1
1Dev Children’s Hospital, Pediatric Department, Rajkot, India

**Disclosure of Interest**
None declared
Introduction: Juvenile dermatomyositis (JDM) is the most recognizable paediatric-onset systemic autoimmune inflammatory myopathy.

Objectives: To confirm the significance of Type I interferon signature as a proven fascinating contributor in the pathogenesis of the disease that strongly correlates with disease measures in JDM.

Methods: An 8 years old female patient, 2nd sibling of non-consanguinous marriage, presented at the age of seven with a two month history of high grade persistent fever, progressive proximal muscle weakness with evolving dysphonia, nasal tone, velopharyngeal dysfunction, dysphagia and severe dyspnea.

Results: On physical examination, patient was average built for age, conscious and alert. Systemic examination revealed evidence of heart failure, generalized muscle weakness more evident in the proximal groups (2 on Manual Muscle Testing Grading System), marked hypotonia and hyporeflexia with no affection of sensation, dermatologic manifestations showed only Gottron’s papules on metacarpophalangeal joints of both hands and no organomegaly/Routine Laboratory evaluation showed a within normal CBC picture, ESR 11 mm/1st hr, CRP 96 mg/dl, elevated AST, ALT, LDH and highly elevated CK (6000 U/L), non significant 24 hrs proteinuria level and negative viral markers. Immunological profile showed a within normal levels serum immunoglobulins assay, CD markers, negative immune markers (ANA, Anti-DNA, ANCA). Echo showed evidence of carditis and EF 38%, pelviabdomial US was free. Patient was diagnosed as a case of juvenile dermatomyositis (JDM), started on pulse steroid therapy (Methylprednisolone; 30mg/kg x 5 days) and IV cyclophosphamide (600 mg/m² planned monthly x 6 doses), patient showed relative improvement and was maintained further on oral full dose steroids (FDS) and corticosteroid inhibitor ruxolitinib (5 mg twice a day, i.e. 0.5 mg/kg/day) with consecutive glucocorticoid (1 mg/6 days a week), allopurinol with a titration of up to 300 mg per day, L-thyroxine 100 mg per day with gradual positive dynamics and good tolerance.

Conclusion: Refractory cutaneous dermatomyositis is a challenging situation. Steroid dependence, limited success of anti-TNF and difficult implementation of rituximab drove to applying JAK inhibitors. Ruxolitinib, as a new anti-inflammatory agent, has a potential to improve clinical outcome, as evidenced by a decrease in muscle pain, improved muscle strength, and improved quality of life.

Disclosure of Interest
None declared
**AB025**

**Rituximab for treatment of resistant Paediatric MCTD**

V. Paisal, S. Compneyrot-Lacassagne
Paediatric Rheumatology, Great Ormond Street Hospital, London, United Kingdom

**Correspondence:** V. Paisal
Pediatric Rheumatology 2020, 18(Suppl 2):AB025

**Introduction:** First described in 1972 by Sharp et al, Mixed Connective Tissue Disease (MCTD) is a rare entity in children. Diagnosis is made by clinical-immunological overlapping features of different Connective tissue diseases. Typical clinical features are Raynaud’s phenomenon, myositis, arthritis, sclerodactyly along with positive anti RNP Antibody. There is a higher risk of interstitial lung disease and pulmonary hypertension. Treatment is tailored to the patient based on features present [1].

**Objectives:** We present a challenging case of Paediatric Mixed Connective Tissue Disease (MCTD) with Sjogren overlap resistant to standard treatment and requiring the addition of Rituximab to control recurrent debilitating parotitis.

**Methods:** We conducted a retrospective case review using electronic patient record.

**Results:** A 15 year old female, first presented at the age of 7 with Raynaud’s phenomenon and a high ANA 1:5120 was referred from local hospital. Double stranded DNA was negative, ENA typing revealed anti U1-RNP positive. She then developed symptoms of Parotitis and arthritis when oral steroids were commenced. A lower lip biopsy revealed periductal lymphocytic infiltrate admixed with scattered plasma cells. USS of parotid glands showed bilateral chronic sialadenitis in submandibular and parotid glands. Increased vascularity in submandibular glands bilaterally may represent acute on chronic inflammation. She did not have dry mouth, pain with swallowing or dry eyes. Her capillary folds were abnormal. She was commenced on Hydroxychloroquine whilst awaiting Biopsy, which was consistent with Sjogren’s syndrome. Methotrexate was added, which soon led to transaminitis and she also continued to have flares and Methotrexate was switched to Azathioprine. This helped with her symptoms but not to Neutropenia. Eventually decision was made to switch to Mycophenolate Mofetil (MMF). Initially MMF helped her with arthritis and energy levels improved but after a year of being on MMF her disease started to flare, requiring oral steroids, and leading to cushingoid facies. Her Lipase was elevated and Amylase was borderline elevated. Due to ongoing disease activity with recurrent and painful parotitis, decision was made to use Rituximab. She gradually recovered from this. Since Rituximab infusion in January 2019 her disease has been continuously in remission and she has recently started to wean MMF down.

**Conclusion:** We report the successful use of rituximab in a difficult to treat patient with Sjogren-MCTD overlap [2]. Rituximab was chosen due to the well-established role of B cell hyperactivity in the immunopathogenesis of primary Sjogren disease [3]. Rituximab has mixed results in the management of primary Sjogren syndrome in adults. There is no evidence of the use of rituximab in paediatric Sjogren but it was successful at controlling paediatric Sjogren syndrome in our patient and allowed weaning of long-term DMARD.

**References**

1. Tani C, Carli L, Vagnani S, Talarico R, Baldini C, Mosca M, Bombardieri S. The diagnosis and classification of mixed connective tissue disease. J Autoimmun. 2014 Feb-Mar;48-49:46-9
2. Deepak S, Werner KC. Mixed connective tissue disease in children - case series. Rheumatol Orthop Med. 2017;2(1-7)
3. Verstappen GM, van Nimwegen FJ, Vissink A, Kroese FGM, Bootma H. The value of Rituximab treatment in primary Sjögren’s syndrome. Clin Immunol. 2017 Sep;182:62-71

**Disclosure of Interest**

None declared

**AB026**

**Juvenile Idiopathic Arthritis a multifaceted approach is essential for robust rehabilitation**

M. Nice1, M. E. Thomsen1, M. S. Jensen2, L. A. Bistrup1, A.-H. Bohr1

1 Paediatrics, 2Physiotherapy, Slagelse Hospital, Slagelse, Denmark

**Correspondence:** M. E. Thomsen
Pediatric Rheumatology 2020, 18(Suppl 2):AB026

**Introduction:** The prognosis for JIA regarding joint destruction and disability has changed significantly during the last two decades due to the emergence of effective anti-inflammatory treatment regimens. However, approximately 50% of the patients will need ongoing medication far into adult life. The prospect of having a long lasting chronic disease requiring continuing medication, with possible side effects, frequent clinical controls and periods of pain, can, by itself, for some patients lead to a passive and inactive lifestyle overshadowing the primary positive effect of the anti-inflammatory medication. In these cases, it can be difficult for the patient (child or adolescent) to resume a normal physically and mentally active lifestyle so important in childhood and youth and of great importance for general health in adulthood.

Recently a Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) was published, and we now have an internationally validated tool for assessment of our patients’ life circumstances and their personal view of the burden of their disease. Using this tool, in combination with structured clarifying talks between nurse and/or physiotherapist and patient (and parents according to age of the patient) we aim to uncover unmet special needs that we may help to fulfil in the municipal system, in schools, in sports clubs or in other institutions. This structured approach may also by itself help the patient and the family to gain constructive insight in their life situation, with a chronically ill member, and find possible hitherto unknown resources.

**Objectives:** The purpose of this project is to investigate the effect of a structured multifaceted treatment of juvenile idiopathic arthritis, focusing on lifestyle and physical activity in parallel with anti-inflammatory medication.

We hypothesize that this strategy will help patients to obtain an early and robust rehabilitation and thus get the full benefits of the effective medicine currently available.

**Methods:** This is a prospective, non-randomized intervention project. A pilot design is chosen with the purpose of early evaluation of practical circumstances.

**Inclusion criteria:**

- Danish speaking patients with JIA, followed in the outpatient clinic at the Pediatric Department at Slagelse Hospital
- having a low objective clinical disease activity and a high subjective burden of disease according to JAMAR

We aim to include 20 patients.

**Intervention:**

- structured clarifying talks between patient (and parents according to age of the patient) and the caregiving nurse or physiotherapist with the purpose of uncovering unmet needs
- special needs are sought fulfilled by individual agreements between patients/families and the municipal system, with schools, with sports clubs or with other institutions. The staff in the rheumatology clinic shall be drivers in this process.

**Endpoints:**

- Change in JAMAR score at 3 and 6 months after inclusion; the patient will serve as his/her own control.

**Results:**

Delayed by the Corona Pandemic
Conclusion: Pending

Disclosure of Interest
None declared

AB027
Autoimmune Hepatitis-SLE overlap syndrome (Lupoid Hepatitis)
A. A. Abushshaiwia, A. Raveli, M. A. Zletni, A. MALEK
1Pediatric Rheumatology, Tripoli Children’s Hospital;2Tripoli Faculty of Medicine; 3head division of Rheumatology, Giannina Gaslini Institute, Giannina Gaslini Institute, Genova, Italy; 4Pediatric Rheumatology, Tripoli Children’s Hospital, Tripoli Faculty of Medicine; 4Radiology department, Tripoli faculty of Medicine, Tripoli, Libya

Correspondence: A. A. Abushshaiwia
Pediatric Rheumatology 2020, 18(Suppl 2):AB027

Introduction: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease classically involving the skin, kidneys, and central nervous system. Several previous reports showed manifestation of AIH in adult lupus patients; however, there are no reports of such an association between AIH and SLE in children. Both AIH and SLE have an autoimmune basis and hence can occur simultaneously or masquerading as presentations of each other. In this case report, we report AIH as the first manifestation of SLE in an 8-year-old girl.

Objectives: We described a case of liver involvement in SLE presenting with emphasis on the differential diagnosis with autoimmune hepatitis.

Methods: case report study

Results: A 8-year-old female patient was referred to the Rheumatology clinic with complaints icteric sclera for 10 months anorexia, malaise, pain in both knees, ankles joints and both wrists accompanied by swelling, and remarkable motion limitations. Laboratory revealed T bilirubin 4.9 mainly direct 3.9 with elevated liver enzymes GOT 401, GPT 189, ALKP 520, high Glutamyl transpeptidase 56U/l her WBC 7.4 HGB 10, PTL 317, except very high ESR 105ml/hr, CRP was positive 190mg/dl, viral screen (HCV, HBsAg, HIV) was normal, serology tests ANA was positive with high titer 1280, anti ds- DNA AB was positive 320, anti Sm was negative, ANTI LKM1 antibodies negative, anti smooth muscle AB negative soluble liver antigen were negative, antimitochondrial AB (M1,M2,M3).

ultrasound abdomen revealed mild enlarged spleen, abnormal diffused increased liver echogenicity with early stage of liver cirrhosis treated by fresh frozen plasma 5 times, VT k 10mg once/day then was referred to rheumatology clinic regarding her serology tests & developmental arthritis of her joints suspected PSL! She was performed liver biopsy showed lesions necrotic inflammatory portal and lobular severe in eosinophilic polymuclear with cirrhosis evolving a syndrome of overlap associating a primary biliary cirrhosis and an autoimmune hepatitis. Laboratory data revealed liver dysfunction and liver biopsy suggesting autoimmune hepatitis, and she underwent treatment for hepatitis (prednisolone with azathioprine), Ursodoxycolic acid with fat-soluble vitamins K, D&A, E. However, with the elimination of jaundice and decreased hepatic enzyme levels, the prednisolone dose was tapered within 2 months and stopped before they were referred to Rheumatology clinic. On her review of systems, she has malar rash, generalized fatigability. On physical examination, we found malar rash, leviadoreticularis of her skin, swelling and limitation of movement in the knees, ankles, wrists joints. There was hepatosplenomegaly. Laboratory data revealed liver treatment for hepatitis, ANA still high titer 1:1280, Antids DAN positive with titer 307 IU/ml, antiSMA was negative. WBC 4.5, HGB 11.8, PLT 268, ESR 60ml/hr. Her ultrasound abdomen: revealed slightly heterogeneous liver with coarse echotexture without focal lesion with liver span 14 cm. These paraclinical results together with the clinical findings strongly suggested systemic lupus erythematosus (SLE) as the definitive diagnosis. Indeed, in this case, AIH was associated with SLE, prednisolone orally for 2 months, after that dose was tapered and continued, rapid clinical improvement in arthritis, malaise, and general condition. Azathioprine was continued. In addition, daily hydroxychloroquine sulfate.

Conclusion: Overlapping of SLE and AIH should be suspected when AIH patients present with a malar or other skin rash. The prompt diagnosis and adjustment of further treatment plans can improve disease outcomes and prevent liver disease progression.

Disclosure of Interest
None declared

AB028
Hematological presentation as the first manifestation of a positive triple marker antiphospholipid syndrome case presentation and literature review
M. C. TERCERO, M. G. E. PLAZA, F. I. E. ROQUE, Y. R. LOYOLA
1PEDIATRIC, 2HOSPITAL DE ESPECIALIDADES DEL NIÑO Y LA MUJER, QUERETARO; 3HOSPITAL DE ESPECIALIDADES DEL NIÑO Y LA MUJER, QUERATRAO, Mexico

Correspondence: M. C. TERCERO
Pediatric Rheumatology 2020, 18(Suppl 2):AB028

Introduction: Pediatric Antiphospholipid syndrome (p-APS) is a rare autoimmune multisystemic syndrome, with a reported incidence around 3% in patients younger than 15 years with a higher prevalence in female : male ratio of 1.2:1. Secondary p-APS is associated with Systemic Erythematosus Lupus in 50% of the cases. The Sapporo criteria require at least 1 clinical criteria, one or more thrombosis events or comorbidities during pregnancy, associated with the finding of antiphospholipid antibodies, positive lupus anticoagulant, IgM or IgG anticardiolipin antibodies, IgM or IgG anti-b2-glycoproteins in two or more determinations separated by 12 weeks. In pediatric patients we take for consideration antiphospholipid antibodies and clinical manifestations, such as hematological (thrombocytopenia, anemia) and neurological (Chorea).

Objectives: To describe the clinical presentation of a 13 yo patient with positive triple marker for antiphospholipid syndrome (APS) secondary to Systemic Erythematosus Lupus (SLE), with hematologic manifestations.

Methods: Thirteen-year-old female patient under hematology department follow up due to pancytopenia, discarding an hematological malignancy. Presenting to our department complaining of anomalous uterine bleeding, clinically with a malar erythema. Routine labs were performed, reporting pancytopenia with Anemia (3.2), Thrombocytopenia (23, 000) and lymphopenia (850). Immunology test with hypocomplementemia (C3 56mg/dl and C4 2.9mg/dl), Positive Anti-DNA antibodies (410U/ml), Positive Antinuclear antibodies with a speckled pattern (1:1280), positive lupus anticoagulant (1:8), IgG anticardiolipin (11.8U/ml), IgM anticardiolipin (37.7 U/ml), IgM anti.b2, glycoprotein (32 U/ml). With triple positive marker for APS and SLE, initiating treatment with methylprednisolone bolus, hydroxychloroquine, acetylsaliclic acid and immunomodulation with Azathioprine. We performed a second determination 12 weeks after with positive IgG Anticardiolipin (10.9U/ml) IgM (56.8 U/l), Positive lupus anticoagulant (1.9), positive anti b2-glycoprotein (40.7U/ml). During follow up as an outpatient without thrombotic events.

Results: Our patient meets the 1997 ACR criteria for SLE and Sapporo criteria for APS. With APS positive triple marker. Clinically with anomalous uterine bleeding and hematological manifestations, persistent thrombocytopenia and lymphopenia, having discarded hematological malignancies.

Conclusion: Pediatric antiphospholipid syndrome is a rare condition, in most cases associated with Systemic Erythematosus Lupus. Triple positive marker increases the risk of thrombotic events significantly. Our patient, at presentation and during follow up, only hematological manifestations were presented as the only clinical symptom associated with pancytopenia, nevertheless the risk of thrombotic events is high during the natural course of APS.

Disclosure of Interest
None declared
**AB029**

**Juvenile SLE and Autism: a case of rare combinations and diagnostic dilemma**

A. Sridhar, C. Devanahalli
Leicester Children’s Hospital, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

**Correspondence:** A. Sridhar
Pediatric Rheumatology 2020, 18(Suppl 2):AB029

**Objectives:**
We present a case of a 7 yr old with severe Autism presenting with 2 week history of facial and bilateral neck swelling with bilateral cervical lymphadenopathy initially thought to be lymphoma but later diagnosed as systemic lupus with nephritis and neuro-lupus. Her initial course was stormy needing admission to intensive care unit and referral to oncology centre for work up of lymphoma. This child had no significant hospitalisations in the past.

**Methods:**
Her initial blood results and CT (Computerised tomography) referral to oncology centre for work up of lymphoma. Initial course was stormy needing admission to intensive care unit and referral to oncology centre for work up of lymphoma. This child had no significant hospitalisations in the past.

**Results:**
Case:
We present a case of a 7 yr old with severe Autism presenting with 2 week history of facial and bilateral neck swelling with bilateral cervical lymphadenopathy initially thought to be lymphoma but later diagnosed as systemic lupus with nephritis and neuro-lupus. Her initial course was stormy needing admission to intensive care unit and referral to oncology centre for work up of lymphoma.

This child had no significant hospitalisations in the past. Her initial blood results and CT (Computerised tomography) chest suggestive of lymphoma with tumor lysis. She was transferred to a local paediatric oncology centre for lymph node and bone marrow testing which showed no evidence of Leukemia or Lymphoma. She developed focal seizure secondary to hypertension and PRES (Posterior reversible encephalopathy), needing intubation and transferred to intensive care unit for 48 hours.

Magnetic resonance (MRI) imaging brain showed signs consisted with cerebral lupus. Autoimmune screen strongly positive for antibodies ANA (Antinuclear), dsDNA antibodies, Anti-Ro, Anti-Smith, RNP, RNP70, low C3(complement) and C4 in keeping with Juvenile SLE. Renal biopsy was not performed as the child remained hypertensive despite being on antihypertensive medications and later due to parental refusal for Renal Biopsy. Echo showed evidence of mild Pericardial effusion, which was managed conservatively. She also had ascites and pleural effusion.

Follow up MRI head shows significant improvement in comparison to her previous images, Echo showed complete resolution of the pericardial effusion and urine examination no evidence of proteinuria or haematuria.

At 1yr follow up she remains clinically stable with complete neurological recovery with no ongoing neurological, cardiac or Renal flare ups. She has been maintained on Oral Mycophenolate (MMF), and Hydroxychloroquine. Her inflammatory markers, complement profile, double stranded DNA levels remain normal and Urine shows no evidence of Haematuria or Proteinuria.

**Conclusion:**
Juvenile SLE with multi-system involvement in an Autistic child can be difficult to diagnose and manage. The case highlights that JSLE is a disease of thousand faces with varied clinical presentations and the need for high index of suspicion. This case also highlights the role of multidisciplinary teams in the management of such complex cases.

**Disclosure of Interest:**
None declared

---

**AB030**

**Juvenile Systemic Lupus Erythematosus, experience of the pediatric center**

K. Okka, B. Bioud
Pediatrics, word, SETIF, Algeria

**Correspondence:** K. Okka
Pediatric Rheumatology 2020, 18(Suppl 2):AB030

**Introduction:**
Juvenile systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multi-visceral involvement with an unpredictable prognosis. The diagnosis is usually made in young women aged between 20 to 40 years, however, it can affect people at any age and it is classified as a juvenile illness when it starts before the age of 16.

**Objectives:**
We are reporting the epidemiological, clinical, therapeutic and evolitional characteristics of a series done in the pediatric Pole in setif with 13 girls and 1 boy.

**Methods:**
The average age of onset is 13 years. The average time limits of the diagnosis is 7 months. The clinical features is done with cutaneous, articular manifestations and fever respectively in 100% 71% and 57% of the cases followed by kidney damage in 42% of the cases,
the cardiac, pulmonary and ophthalmological participations are reported with low percentage. Haematological involvement was detected in 85% of the patients and the inflammatory syndrome was almost constant. A positive titer of anti-nuclear antibodies and anti-DNA is objectified, as well as a reduction in the complement rate. Antibodies anti GP 2 and anti cardiolipine are positive in 57% of cases. Kidney damage was diagnosed in 42% of the cases, and only one case of overlap syndrome with dermatomyositis was reported. Concerning the neurological form it was present in only one addolecent girl, and only one case of familial lupus.

**Results:** The diagnosis is based on the classification of the American College of rheumatology (ACR) 1982 revised on 1997 and the new criteria SLILCS’S ‘Systemic Lupus International Collaborating Clinics’. The clinical characteristics of our series relies on global data of literature with the Predominance of Cutaneous and articular involvement. with however some specific characteristics which are individualized by a more advanced age of onset, 13 years on average in our study versus 10 years and 12 years, the rarity of familial forms (1 case), a lower percentage of kidney damage (42% versus 63% and 80%). The therapeutic management was based on corticosteroid therapy and Hydroxychloroquine in the majority of cases, the use of immunosuppressants has been reserved for severe forms.

**Conclusion:** Lupus is an autoimmune disease with protean clinical manifestations, the prognosis of which is dominated by renal, neurological and thrombotic disorders. Cortisone treatments and immunosuppressants have significantly improved the prognosis for life.

**Trial registration identifying number:** Lupus is an autoimmune disease with protean clinical manifestations, the prognosis of which is dominated by renal, neurological and thrombotic disorders. Cortisone treatments and immunosuppressants have significantly improved the prognosis for life.

**Disclosure of Interest**

None declared

**AB031**

**Systemic lupus erythematous with unusual presentation: a single centre experience from North India**

Y. Sharma, A. Sharma

Pediatrics, Dr Rajendra Prasad Government Medical College, Kangra, India

**Correspondence:** Y. Sharma

Pediatric Rheumatology 2020, 18(Suppl 2):AB031

**Introduction:** Systemic lupus erythematous (SLE) is a multisystem autoimmune disease. SLE mimics many clinical entities and diagnosis may become difficult at times, especially if presentation is atypical.

**Objectives:** To highlight unusual presentation of Pediatric SLE

**Methods:** Retrospective case review of all children diagnosed as SLE from July 2017–November 2018 at a single tertiary care hospital in North India was done. We here describe 4 children who presented with unusual manifestations.

**CASE 1:** 8 years, girl, presented with fever for 1 month and bilateral pleural effusion. She had fever, epistaxis, hepatosplenomegaly and bactycopenia and was managed as tropical infections initially. She was later on diagnosed to have SLE and managed for the same.

**CASE 2:** 11 years, boy, presented with arthritis in multiple small and large joints of body. On evaluation ANA and anti dsDNA was found to be positive. He was started on subcutaneous, weekly methotrexate and responded to treatment. However, he developed lupus nephritis during disease course after 6 months of diagnosis. Renal biopsy revealed Class III/V lupus nephritis. Intravenous Cyclophosphamide pulses were started for induction along with tapering doses of corticosteroids.

**CASE 3:** 8 years, girl, presented with early morning periarticular puffiness and abdominal distension with history of photosensitivity and Raynaud phenomenon. Urine routine examination revealed nephrotic range proteinuria with no hematuria. Clinical possibility of nephrotic syndrome secondary to SLE was kept. Renal biopsy revealed Class V lupus nephritis.

**CASE 4:** 17 years old, girl, presented with high grade fever and pain in bilateral knee joints and malar rash. Investigation were suggestive of SLE with MAS (macrophage activation syndrome). Child was started on iv antibiotics and iv immunoglobulins but died during the disease process.

**ANA positivity,** hypocomplementemia and Anti ds DNA positivity were seen in all the 4 cases.

**Results:** out of 11 children diagnosed to have SLE, 4 presented with unusual manifestations as described above.

**Conclusion:** In this report we present unusual presentations as the predominant manifestation of SLE and emphasize the fact that early recognition and awareness of unusual presentation of SLE help institute timely initiation of appropriate treatment.
onset of inactive and active oligo-JA were not significantly differ. The analysis revealed a correlation between a short phase of beneficial effect after is-iAI of TA and risk of activity disease (with an inactive phase of arthritis less than 3 months, the risk activity was OR = 2.09, p <0.001; with an inactive phase less than 2 months - OR = 9.9, p < 0.001).

Conclusion: Tramcinolone acetonide is an effective and safe treatment in children with oligoarticular juvenile arthritis. Research was revealed that about a third of children with oligo-JA achieved inactive arthritis of average after two intra-articular injections of triamcinolone acetonide. Despite the widespread use of biological treatment should not be neglected topical corticosteroid drugs as the first-line treatment in children with oligo-JIA.

Disclosure of Interest
None declared

AB033
The use of off-label biologics in children with systemic connective tissue diseases
O. A. Oshilianska 1, L. I. Omelchenko 2, O. M. Okhotnitska 3, A. G. Artsyomovich 1.
1Department of Pediatrics № 1, 2Department of connective tissue disorders in children, 1Shupyk National Medical Academy of postgraduate education, 2State Institute of Pediatrics, Obstetrics and Gynecology, Academy of Medical Sciences of Ukraine; "2. Department of connective tissue disorders in children, 2State Institute of Pediatrics, Obstetrics and Gynecology, Academy of Medical Sciences of Ukraine; 3Department of Pediatrics № 1, 1Shupyk National Medical Academy of postgraduate education, Kyiv, Ukraine
Correspondence: O. A. Oshilianska
Pediatric Rheumatology 2020, 18(Suppl 2):AB033

Introduction: Off-label prescribing often occurs in pediatric rheumatology. This is due to insufficient evidence base, the severity and unpredictability of the course of the disease.

Objectives: To analyze the cases of off-label use of biologics among patients with rheumatic diseases.

Methods: Analysis of patient treatment was carried out using data from the registry of children's rheumatological patients: 38 systemic sclerosis (SSD), 47 systemic lupus erythematosus (SLE), 42 juvenile dermatomyositis (JDM), 19 systemic vasculitis (SV), 11 from the registry of children's rheumatological patients: 38 systemic lupus erythematosus (SLE), 42 juvenile dermatomyositis (JDM), 19 systemic vasculitis (SV), 11 unspecified systemic involvement of connective tissue, 8 auto-inflammatory syndromes.

Results: The possibility of providing patients with systemic connective tissue diseases with expensive therapy in Ukraine is absent. Biologics are prescribed only in cases of extremely severe courses of the diseases with the previous ineffectiveness of all other available methods of therapy CS and DMARDs. Biologics were prescribed-off-label 10 times in 8 patients. In case with SLE (SELENA-SLEDAI=60, ESR 30/mm/h) rituximab (RTX) was used after tocilizumab (TCZ). RTX was prescribed in another 4 patients (polyarteritis nodosa VDI=11, ESR 64/mm/h; ANCA+SV VDI=12, ESR 56/mm/h, CRP=18/mg/l, JDM DAS 31, CMAS 4, CK 8000 IO/l; SLE SELENA-SLEDAI=59, ESR 45 mm/h). RTX was administered to patients who had received high-dose CS with 2–3 DMARDs; in all cases combined pulse therapy CS for 2–10 was preliminarily used. RTX 500 mg were applied after 6mo-2y from the debut of the disease. In all cases, its use led to clinical improvement after 1-5 mo with normalization of laboratory activity indicators, in 4 cases a decrease in the level of B cells to 0–0.56 in μl was noted (3 with agammaglobulinemia). After 2 months 3 patients had severe infectious complications, 2 of them ended fatally. 2 another patients had a second stroke. The 1st patient survived, had a kidney allotransplantation, there is no disease activity. The 2nd patient, in connection with the development of the demyelinating process in CNS, attempted to continue therapy using golimumab with IVIG. It led to an increase in the infectious complications, therefore, we decided to refrain from continuing with ITNF as well. The patient died after 2 years from the administration of RTX due to the progression of neurologic disorders. 2 cases with auto-inflammatory syndromes were: chronic infantile neurologic cutaneous and articular syndrome received TCZ; it was unsuccessful (hyperthermia and rash persisted, eye lesions progressed, there were no increase in height), later switched to anakinra. Family mediterranean fever, received adalimumab (ADA). The 1-year-course of ADA led to the disappearance of articular and abdominal syndrome while maintaining persistent increased levels of ESR and CRP and periodic fever. The use of TCZ in 2 patients with SSD was more successful. The first patient received it subcutaneously for 1 year, CS&DMARDs (3 were used) had already been canceled, lung and kidney lesions were contained, blood pressure normalized, ESRG-AI decreased from 7 to 1, MRS decreased from 18 to 14. In the second case, the patient received TCZ for 6 months i/v, decrease of ESRG-AI 6.5 to 1, MRSS 33 to 21 were noted, the dose of CS was halved, he also continued treatment with cyclophosphamide.

Conclusion: The presented experience cannot be called completely positive; maybe this can be improved by earlier prescribing of medicines. An attempt to off-label use of biological cannot be rejected in pediatric rheumatology since sometimes this is the only chance for our patients to survive.

Disclosure of Interest
None declared

AB034
Iatrogenic cushing after local infiltration with triamcinolone acetonate. About two cases
N. Palmou 1, M. Bertholt 2, C. Naranjo 3, H. Ortega 3, A. López 1
1Rheumatology; 2Paediatric Endocrinology; 3Endocrinology;
4Dermatology, Hospital Universitario Marqués de Valdecilla, Santander (Cantabria), Spain
Correspondence: N. Palmou
Pediatric Rheumatology 2020, 18(Suppl 2):AB034

Objectives: To describe two cases of Cushing’s Syndrome secondary to local infiltration with triamcinolone acetonate presented at our Hospital during 2019

Methods: CASE 1: 6-year-old girl referred, for asthenia, polyphagia, weight gain (4kg in 30 days) and progressive face and abdomen oedema, one month in evolution. It associates high TA (129/92mmHg) and frontal headache (without alarm data). The only antecedent: triamcinolone acetonide depot infiltration in ankle’s ganglion (equipotent x4:16mg/m2) one week before starting symptoms. No family history.CASE 2: 7-year-old girl father with psoriasis with joint involvement. Consultation in July 2019 to traumatology for right knee pain with functional impotence after trauma. In ultrasound and MRI, sinalov hypertrophy is visualized, with minimal joint effusion. Referred to Rheumatology, she was diagnosed by Polartycular Juvenile Idiopathic Arthritis. In the analysis, hypochromic microcytic anemia and PCR 3.6 mg/dl stand out. Haematology rules out haematological process and starts treatment with oral iron. She received corticosteroid treatment: Oral prednisolone(equipotential x5:supposes 31.5mg/m2 for 20 days and descending regimen) and intra-articular infiltration (knee and ankles) with Triamcinolone acetonide depot (equipotent x4: supposes 432.4mg/m2). Also, she receives treatment with methotrexate, folic acid, tocilizumab and abatacept. From the start of the corticosteroid treatment, she presented a Cushing phenotype and weight gain (7kg in 4.5 months). She did not have fatigue or any other symptom. It refers to paediatric endocrine

Results: CASE 1 Complementary ambulatory tests: leukocytosis (neutrophilia) and mild reticulocytosis, hypercholesterolemia 232mg/dl (HDL: 104mg/dl), Exploration: Age 6.5 years, height 122.3cm (0.5SDS), weight 27.2kg (0.76SDS), P/T 107.97%, BMI 18.19 (0.46SDS). TAS 121mmHg (p97)/TAD 81mmHg (p89).Cushing phenotype, prepubertal. Complementary tests: Ultrasound without pathological findings. ACTH and cortisol suppressed (ACTH <5pg/ml, cortisol<1μg/dl). Suspecting exogenous Cushing syndrome secondary to local infiltration with corticosteroid. The study was expanded with normal imaging tests (brain MRI, normal bonescan, total-body PET with normal F18-FDG PET/CT) and ACTH test with a suppressed response. In monthly controls, ACTH and suppressed cortisol persist up to five months after the infiltration that initiates analytical recovery of the
adrenal axis. Clinically, phenotype persists. Continue to follow up.

CASE 2 Exploration: Age 8.12 years, TA 99/55mmHg, height 125.1cm (-0.73SDS), Weight 37.4kg (1.28SDS), P/T 138.9%, BMI 23.9 (2.14SDS).

Good general condition, Cushing phenotype (full moonface, globular abdomen, few stretch marks in the inner thighs). Prepubertal.

Complementary tests: ACTH plasma 17 pg/ml, Cortisol serum 10.9 μg/dl. Suppression test with normal dexamethasone. 24-hour cortisoluria decreased.

Conclusion: DISCUSSION: The use of intra-muscular or intra-synovial triamcinolone acetate is approved in children from 6 years. There are few cases described that develop a secondary Cushing syndrome. We found a systematic review describing 18 cases of Cushing after infiltrations and injuries in scars. Although there are no clear recommendations regarding its use in paediatrics, we must be cautious, use the lowest effective dose and adequately monitor these patients.

Disclosure of Interest
None declared

AB035
Successful haplo-identical allogenic bone marrow transplantation in a child with refractory systemic Juvenile Idiopathic Arthritis
G. Morelle, D. Moshous, P. Quartier
Paediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, Paris, France

Correspondence: G. Morelle
Pediatric Rheumatology 2020, 18(Suppl 2):AB035

Introduction: Some patients with systemic juvenile idiopathic arthritis (sJIA) and severe, refractory disease achieved remission through intensive immunosuppressive treatment followed by autologous hematopoietic stem cell transplantation (HSCT). However, disease relapsed in most cases. More recently selected sJIA patients received allogenic HSCT from a HLA-identical sibling or a HLA matched unrelated donor. While most transplanted patients achieved sustained sJIA remission off-treatment, the procedure-related morbidity was high.

Objectives: We try to demonstrate that haplo-identical allogenic HSCT in refractory sJIA can be an alternative treatment for refractory sJIA.

Methods: We report the case of a child who was successfully treated with haplo-identical allogenic HSCT.

Results: A girl presented sJIA since the age of 15 months with a severe disease course. She was refractory to the combination of methotrexate and steroids to anti-interleukin(IL)-1, then anti-IL-6, tumor necrosis factor alpha inhibitors and thalidomide. Therefore allogenic HSCT was considered. In the absence of any possible HLA matched donor, a multidisciplinary team assessed carefully risks and benefits of an alternative graft. Given the high disease burden and treatment related toxicity the indication for a haploidentical HSCT from her mother was validated. The patient was treated with intensive immunosuppression and received a T replete bone marrow graft at the age of 3.7 years. Conditioning contained Rituximab, Alemtuzumab, Busulfan, and Fludarabine, as well as Cyclophosphamide at D+3 and +4 post HSCT for GVHD prophylaxis, followed by Cyclosporine A and Mycophenolate Mofetil. Post HSCT complications included severe infections, grade 3 intestinal graft versus host disease, autoimmune thyroiditis, and immune thrombocytopenia. Three years after HSCT, the child was alive and well, notwithstanding persistent hypothyroidy requiring substitution. Immune thrombocytopenia had resolved. Most importantly, sJIA was in complete remission, off immunosuppressive drugs.

Conclusion: Allogenic HSCT may be a therapeutic option, even with a HLA haplo-identical donor, in patients with inflammatory diseases such as sJIA. Despite increased experience with this treatment, the risk of life-threatening complications restrains its indication to selected patients with severe, refractory disease.

Disclosure of Interest
None declared

AB036
Analysis of published randomized controlled trials in pediatric patients with rheumatic inflammatory diseases treated with biologics
T. Welzel1,2, C. Winklki3, N. Zhang3, A. Woerner2, M. Pfister1,3
1Pediatric Rheumatology and Pharmacometrics, 2Pediatric Rheumatology, University Children’s Hospital Basel (UKBB), University of Basel, Basel, Switzerland; 3Certara, Princeton, New Jersey, United States

Correspondence: T. Welzel
Pediatric Rheumatology 2020, 18(Suppl 2):AB036

Introduction: The same biologic disease modifying antirheumatic drugs (bDMARDs) are prescribed in adult and pediatric rheumatology. Due to age-dependent changes, disease course, and pharmacokinetic (PK) processes pediatric patients with inflammatory rheumatic diseases (PiRD) differ from adult rheumatology patients.

Objectives: A systematic literature review was performed to assess current knowledge about bDMARDs use in PiRD patients by analyzing published randomized controlled trials (RCTs) in this pediatric population.

Methods: A systematic literature search for RCTs in PiRD with bDMARDs intervention such as rituximab, abatacept, anakinra, canakinumab, rilonacept, tocilizumab, ustekinumab, secukinumab, adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, belimumab, baricitinib, tofacitinib, upadacitinib was conducted on Medline, PubMed, EMBASE, the Cochrane Library, the US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov and the EU Clinical Trials Register in March 2020. Abstracts from conferences and relevant studies were added. RCTs were included if (i) patients were aged ≤ 20 years, (ii) patients had a previous defined pediatric rheumatic diagnosis and (iii) RCT met predefined outcomes. Studies were excluded in case of (i) observational or single arm study or (ii) sample size ≤ 5 patients. Study design, location, duration, treatment, population, sample size, age criteria, gender, concomitant treatments and primary outcome was extracted.

Results: Out of 550 screened references, 62 references reporting 35 unique RCTs in PiRD. All 35 RCTs reported efficacy while 34/35 RCTs provided safety outcomes and 15/35 RCTs provided PK data. Ten of 17 reviewed bDMARDs are approved for PiRDs by the Food and Drug Administration (FDA). Of these, seven had ≤ 2 RCTs. The most common intervention was TNF inhibitors (63%), IL-1 inhibitors (17%) and IL-6 inhibitors (8%). No RCTs with published results were identified for rituximab, secukinumab, certolizumab pegol, baricitinib, or upadacitinib. In patients with juvenile idiopathic arthritis (JIA) 26/35 RCTs were conducted. The remaining 9 RCTs were performed in non-JIA patients including plaque psoriasis, Kawasaki Disease (KD), systemic lupus erythematous and idiopathic uveitis. In JIA-RCTs, the control arm was mainly placebo and the concomitant treatments were either methotrexate, NSAID or corticosteroids. Non-JIA patients received mostly NSAIDS. A majority of JIA-RCTs were global studies or otherwise conducted in Europe, the US, or Japan. The non-JIA RCTs took place in North America, Europe or globally and for KD mainly in Asia or the US. Currently three Phase III RCTs are investigating baricitinib and one Phase II global RCT investigating tofacitinib. Further, there are recruiting studies for secukinumab and certolizumab pegol in psoriasis, for adalimumab in JIA-associated uveitis, for abatacept and etanercept in JIA.

Conclusion: Despite the FDA Modernization Act and support of major pediatric rheumatology networks, such as the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Pediatric Rheumatology International Trials Organization (PRINTO), which resulted in bDMARDs approval for PiRD indications, there are limited RCTs in pediatric rheumatology. As bDMARDs therapy response is influenced by age-dependent changes, PK processes and disease course it is important to consider developmental changes in bDMARDs use in PiRD patients. As such it is critical to collaborate and conduct randomized clinical trials in PiRD patients with the goal to appropriately investigate PK, efficacy and safety in bDMARDs used in pediatric rheumatology.
Disclosure of Interest
None declared

AB037
Efficacy and safety on the use of bisphosphonates for secondary osteoporosis in paediatrics
S. Odorico1, E. Jeziorski2, F. Rivier3, T.-A. Tran1
1Pediatrics, Nîmes University Hospital, Nîmes; 2Pediatrics; 3Pediatric Neurology, Montpellier University Hospital, Montpellier, France
Correspondence: T.-A. Tran
Pediatric Rheumatology 2020, 18(Suppl 2):AB037

Introduction: The use of bisphosphonates has increased in paediatrics in the last twenty years.
Objectives: The study describes efficacy and safety of bisphosphonate therapy for secondary osteoporosis in children in Montpellier and Nîmes University Hospitals, France.
Methods: In our retrospective study, all patients treated with bisphosphonates for secondary osteoporosis, between January 2012 and August 2018, were included, using medical files. The main endpoint was efficacy using fracture rate, bone mineral density (BMD) change, and bone pain frequency before and after treatment. Adverse effects were also analysed.
Results: 77 children, median age [IQR 25%>75%] of 14 years [11-15 years], with secondary osteoporosis; immobility (n=63), nutritional diseases (n=5), corticosteroids (n=7), sickle cell anaemia (n=1), growth hormone deficiency (n=1), were included. The median duration of treatment [IQR 25%>75%] was 9 months [1-25 months]: 25 using zoledronate, 52 using pamidronate. Fracture rate significantly decreased from 41.6% to 5.2% and bone pain frequency significantly decreased from 57% to 26% (p<0.01). Lumbar spine BMD Z-score significantly improved by 0.74 (p<0.01). Adverse events were reported for 79.2% of patients: flu-like symptoms (65%), hypocalcaemia (44.2%) and hypophosphataemia (27.3%). Only one serious hyponatremia occurred corresponding to a patient with renal failure before treatment.
Conclusion: Our results were similar to those previously published: bisphosphonates are effective and safe for secondary osteoporosis in children. The use of bisphosphonates beforehand requires dietary measures (vitamin D and calcium supplementation). Growth periods amplify bisphosphonates effects as we have shown with a maximum mean increase in the early years of life: this suggests a better time to start treatment in young people. Further systematic collection on efficacy and safety parameters for each bisphosphonates drug should confirm these data.

Disclosure of Interest
None declared

AB038
Cutaneous or systemic polyarteritis nodosa?
M. Nashawi1, F. Blankenburg1, A. Heinkele1, F. Glowatzki1, C. Strinkorb1, F. Noll1, D. Hübner1, A. Enninger2, S. Dammann1, T. Heigle1, P. Ostendorf1, P. Driesc1, C. Eisenbeis2, T. Hospach1
1Pediatric rheumatology department; 2Pediatric gastroenterology department, Klinikum Stuttgart, Stuttgart, Germany
Correspondence: M. Nashawi
Pediatric Rheumatology 2020, 18(Suppl 2):AB038

Introduction: Polyarteritis nodosa (PAN) is a rare vasculitis of medium and small vessels. There is ongoing controversy about if systemic and cutaneous forms are different diseases or only a spectrum of symptoms
Objectives: Presenting a case of cutaneous polyarteritis nodosa and discussing the possibility evolving to a systemic disease
Methods: We introduce a 13-year-old girl patient who has been admitted to our clinic with suspicion of erythema nodosum. She had painful subcutaneous nodules for 4 weeks, especially on the lower extremities and her face. Macroscopically, central necrotizing skin rashes could be seen. She had frank arthritis of both knee and ankle joints. The comprehensive serological diagnosis (including hepatitis serology and anti-streptolysin titer) were normal except for a slight increase in CRP 0.9 mg/dl and ESR 36 mm/h. The patient also complained of abdominal pain and bloody stools. Calprotectin was 3613 μg/L. A Gastro-colonoscopy revealed a small mariske and a minimal inflammation of the ileocecal valve, without signs of vasculitis or chronic bowel disease. A skin biopsy revealed leukocytoclastic vasculitis of the small arteries. Angiography of the intestinal arteries was rejected by the family. Initially we started a treatment with methylprednisolone pulses followed by oral prednisolone. The patient showed a very good response with quick resolution of the skin symptoms and abdominal pain. The medication could be quickly tapered and discontinued at full remission after one month.

Results: PAN is classified as a cutaneous PAN (cPAN) when there are exclusive skin manifestations, besides arthralgia or arthritis. A systemic PAN must be diagnosed with the involvement of internal organs. However, cutaneous PAN may evolve into systemic PAN. In our patient, the skin and joints were primarily affected. If the existing gastrointestinal complaints are part of a systemic PAN or chronic bowel disease could not be cleared yet, due to refusal of further investigations.

Conclusion: cPAN must be considered as a suspected diagnosis in patients with necrotizing skin nodules. As transition of the cutaneous into the systemic form cannot be predicted regular monitoring is mandatory.

Disclosure of Interest
None declared

AB039
Efficacy of anakinra in reducing giant coronary aneurysms in refractory Kawasaki disease: a case report
M. E. Pinto, A. Meneghel, G. Martini, M. Patti, F. Zulian
Pediatric Rheumatology, University-Hospital of Padua, Padua, Italy
Correspondence: M. E. Pinto
Pediatric Rheumatology 2020, 18(Suppl 2):AB039

Introduction: Coronary artery aneurysms (CAAs) are the most serious complication in Kawasaki Disease (KD). Treatment with intravenous immunoglobulin (IVIG) significantly reduces the risk of CAAs. However, up to 20% of cases are IVIG resistant with a higher risk of cardiovascular complications. Currently several second-line treatments are available for refractory KD. Nonetheless, the existing literature is still unable to identify which treatment is the most effective. Recent studies suggest that a IL-1 receptor antagonist (anakinra) may be an effective therapy in refractory KD.

Objectives: We report the case of a 3 year-old boy diagnosed with KD refractory to conventional treatment, who developed giant CAAs successfully treated with subcutaneous (sc) anakinra.

Methods: Case report.

Results: A 3 year-old boy was referred to our Pediatric Rheumatology Unit 18 days after the onset of a Typical refractory KD. He had been previously treated at a local hospital with two doses of IVIG (2 g/kg), infused respectively 8 and 11 days after the onset of the fever. Afterwards, given the persisting fever, doses of pulse intravenous (IV) methylprednisolone (MPDN 30 mg/kg/day) have been used for 3 days followed by oral prednisone (2 mg/kg/day). Treatment with Acetylsalicylic Acid (60 mg/kg/day q8h) was also started. Following a transient defervescence the day after the first IV pulse MPDN, fever relapsed and the echocardiography showed CAAs of Left Main Coronary Artery (LMCA), Left Anterior Descending (LAD) and Right Coronary Artery (RCA) with z score 7.4, 11.7, 4.1 respectively. Laboratory tests showed a persistent elevation of inflammatory markers (WB 20810/mm3, PMNc: 12860/mm3, CRP 50 mg/L). The patient was then transferred to our Unit. Therapy with sc anakinra (2 mg/kg/day) was started with rapid defervescence and reduction of CRP. Echocardiography was performed 5 days after and it showed a worsening of all
coronary aneurisms, with evidence of giant CAAs (LMCA, LAD, RCA z score: 12.7, 15.1, 10.4). The anakinra dosage was increased to 4 mg/kg/day and anticoagulant therapy with warfarin was started. Echocardiography showed a significant reduction of CAAs (LMCA, LAD, RCA z score: 10.1, 12.29, 7.9) 6 days after, with complete resolution of giant CAA (LMCA, LAD, RCA z score 7.4, 9.4, 7.17) 13 days after. Therapy with subcutaneous Anakinra (4 mg/kg/day) was continued for a month, then it was gradually tapered down and completely stopped after 4 months. Follow up is still ongoing but serial echocardiographies confirmed a persistent positive remodelling of all CAAs.

Conclusion: It has been reported that therapy with Anakinra in refractory KD leads to a rapid and sustained improvement in clinical and biological inflammation. However, its effects on the size of CAAs are still unclear. In our patient with refractory KD, subcutaneous Anakinra was quickly effective in controlling the systemic and laboratory inflammatory aspects of the disease and, at a higher dose, led to a rapid and significant reduction of CAAs with complete resolution of giant aneurisms. No side effects were reported. Therefore, Anakinra can represent a valuable and safe treatment approach in refractory KD patients, reducing cardiovascular damage. Further studies are needed to reach a standardized treatment protocol to better define the optimal dosage, duration and tapering of Anakinra therapy, facilitating improvement and uniformity of care.

References
1) Tremoulet AH et al. Rationale and study design for a phase IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (The ANAKID Trial). Contemp Clin Trials. 2016 May; 48: 70-75.
2) Kone-Paut I et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series. Autoimmun Rev 2018 Aug;17(8):768-774.

Disclosure of Interest
None declared

AB040
Kawasaki disease complicated by acute kidney injury: a case report
A. Mauro, F. Orlando, M. Tardi, R. Bortelli, L. Martemucci, R. Sottile
Pediatrics, AORN SANTOBONO-PAUSILPON, Naples, Italy
Correspondence: A. Mauro
Pediatric Rheumatology 2020, 18(Suppl 2):AB040

Introduction: Kawasaki disease (KD) is a febrile vasculitis that affect young children < 5 years of age. Diagnosis of KD is a clinical challenge, given the wide variety of clinical presentations. There are few reports of acute kidney injury (AKI) in KD, defined as serum creatinine level elevation to more than 1.5 times of baseline level.

Objectives: To describe the case of Kawasaki Disease complicated by AKI

Methods: A 5-year-old female was admitted to our Rheumatology Unit with persistent fever (6 days), widespread polymorphous exanthema, change in lips and in oral mucosa. Family history was unremarkable. She had no chronic underlying disease nor history of previous hospitalization. At admission, she appeared stable. Body temperature was 38.9°C, O2 saturation was 96% in ambient area, blood pressure was 118/75 mm Hg, heart rate was 90 bpm, respiratory rate was 21 breaths per minute. On examination she presented widespread polymorphous exanthema, changes in lips and in oral mucosa, cervical lymphadenopathy and bilateral conjunctival injection.

Results: Exams revealed: white blood cells 11980/μl, Hb 10.4 g/dl, platelets 389.000/μl, albumin 2.5 g/dl, serum sodium 126 mEq/L, serum chloride 90 mEq/L. Transaminases were in normal range. creatinine was 1.5 mg/dl. Fluid balance evidenced oliguria. She underwent echocardiography that showed no dilated coronaries or pericoronary hyperechogenicity. Abdomen ultrasound and Chest-RX were negative. Intravenous Immunoglobulin (IGIV) at the dose of 2 g/Kg and antinflammatory dosage of ASA were started at 7 days of fever. After the first dose of IVIG, fever, conjunctivitis and polymorphous rash disappeared. Blood tests revealed a reduction of inflammatory markers (CRP 89.9 mg/L, ESR 28 mm/1h) and creatinine (0.69 mg/dL). She presented also normalization of fluid balance.

Conclusion: Acute kidney injury (AKI) is rarely been reported in patients with Kawasaki disease (KD). The pathogenic mechanism underlying renal involvement in patients with KD and AKI is unknown. A recent review concluded that patients with KD and AKI had good outcomes. The reported patient presented rapid improvement of clinical and laboratory parameters after only one dose of IGIV.

AB041
Paediatric extra-pulmonary large vessel arteritis, a forme fruste of pediatric Behcet’s disease?
S. A. Ganu1, R. K. Kumar2, S. Balan3
1Department of Clinical Immunology and Rheumatology, 2Dept of Pediatric Cardiology, Amrita Institute of Medical Sciences, Kochin, India
Correspondence: S. A. Ganu
Pediatric Rheumatology 2020, 18(Suppl 2):AB041

Introduction: Prevalence of Behcet’s disease in children is not known, but is probably very low. Extra-pulmonary large vessel arteritis in these cases is even rarer as a presenting manifestation.

Objectives: To report two cases of paediatric extrapulmonary large vessel arteritis with a ‘Behcet like disease’.

Methods: We present case reports of two cases who presented to paediatric rheumatology OPD to our department. Ms. F, a 16 year old girl was referred to us with history of short duration of fever, generalized lymphadenopathy, neutrophilic leukocytosis, thrombocytosis, hyperglobulinaemia and high inflammatory markers. On detailed history and examination she was found to have a healed palatal ulcer and her maternal aunt was found to have a history of recurrent oral ulcer, genital ulcer and enthesitis. Patient’s Montoux test was positive but the gene expert for MTB was negative. MD-CT showed a circumferential thickening of aorta, subclavian and bilateral renal artery with stenosis at origin of both renal arteries indicating a vasculitis. Few necrotic nodes were also noted in lungs. Lymph node biopsy suggested a reactive hyperplasia. Tissue typing showed presence of HLA B 44, B 51. She improved clinically with oral Prednisolone and Mycofenolate Mofetil and had no recurrence till her recent follow up visit. Second case, master FKN an 11 year old child was referred to us with a background of 2 week history of fever, non migratory arthritis, raised inflammatory markers and a symptomatic severe aortic regurgitation with pansiastolic flow reversal on 2D echo. His evaluation showed negative Montoux, normal IGG4 levels and HLA B35 B 51 on tissue typing. His aortic wall thickness resolved with 1 mg/kg oral Prednisolone and Mycofenolate mofetil.

Results: Both these cases have features similar to Behcet’s disease. These cases do not fulfil ISG, ICBD 2014 or ICBD criteria for pediatric Behcet’s disease. However, the aortitis and other clinical features responded well to the treatment in both cases.
Conclusion: Paediatric case with extra-pulmonary Large vessel arteritis that do not meet criteria for Behcet’s disease but have specific clinical or laboratory features do respond well to immunosuppression. Therefore, after ruling out other causes of the large vessel vasculitis, a possibility of form fruste of Behcet’s disease should be under consideration.

Disclosure of Interest: None declared

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this supplement
These abstracts have been published as part of Pediatric Rheumatology, Volume 18, Supplement 2, 2020: Proceedings of the 26th European Paediatric Rheumatology Congress (PReS 2020). The full contents of the supplement are available at https://ped-rheum.biomedcentral.com/articles/supplements/volume-18-supplement-2. Please note that this is part 2 of 2.